,Start Date,Start Price,End Date,End Price,Weekly Returns,Bin Label,News,Basics
0,2023-01-08,279.25,2023-01-15,288.0400085449219,0.031477201593274495,U4,[],"{""assetTurnoverTTM"": 0.4148, ""bookValue"": 13398, ""cashRatio"": 1.044607393828292, ""currentRatio"": 2.9914, ""ebitPerShare"": 4.8136, ""eps"": 3.7854, ""ev"": 42738.9, ""fcfPerShareTTM"": 7.9243, ""grossMargin"": 0.7756, ""inventoryTurnoverTTM"": 1.6901, ""longtermDebtTotalAsset"": 0.2558, ""longtermDebtTotalCapital"": 0.3192, ""longtermDebtTotalEquity"": 0.4688, ""netDebtToTotalCapital"": 0.1454, ""netDebtToTotalEquity"": 0.2136, ""netMargin"": 0.2164, ""operatingMargin"": 0.2751, ""pb"": 2.9763, ""peTTM"": 13.0877, ""pretaxMargin"": 0.2373, ""psTTM"": 3.9197, ""ptbv"": 3.4531, ""quickRatio"": 2.5808, ""receivablesTurnoverTTM"": 4.9651, ""roaTTM"": 0.1242, ""roeTTM"": 0.2473, ""roicTTM"": 0.1595, ""rotcTTM"": 0.2132, ""salesPerShare"": 17.4966, ""sgaToSale"": 0.2244, ""tangibleBookValue"": 11548, ""totalDebtToEquity"": 0.4688, ""totalDebtToTotalAsset"": 0.2558, ""totalDebtToTotalCapital"": 0.3192, ""totalRatio"": 2.201, ""period"": ""2022-12-31""}"
1,2023-01-15,288.0400085449219,2023-01-22,285.7699890136719,-0.007880917455590164,D1,[],"{""assetTurnoverTTM"": 0.4148, ""bookValue"": 13398, ""cashRatio"": 1.044607393828292, ""currentRatio"": 2.9914, ""ebitPerShare"": 4.8136, ""eps"": 3.7854, ""ev"": 42738.9, ""fcfPerShareTTM"": 7.9243, ""grossMargin"": 0.7756, ""inventoryTurnoverTTM"": 1.6901, ""longtermDebtTotalAsset"": 0.2558, ""longtermDebtTotalCapital"": 0.3192, ""longtermDebtTotalEquity"": 0.4688, ""netDebtToTotalCapital"": 0.1454, ""netDebtToTotalEquity"": 0.2136, ""netMargin"": 0.2164, ""operatingMargin"": 0.2751, ""pb"": 2.9763, ""peTTM"": 13.0877, ""pretaxMargin"": 0.2373, ""psTTM"": 3.9197, ""ptbv"": 3.4531, ""quickRatio"": 2.5808, ""receivablesTurnoverTTM"": 4.9651, ""roaTTM"": 0.1242, ""roeTTM"": 0.2473, ""roicTTM"": 0.1595, ""rotcTTM"": 0.2132, ""salesPerShare"": 17.4966, ""sgaToSale"": 0.2244, ""tangibleBookValue"": 11548, ""totalDebtToEquity"": 0.4688, ""totalDebtToTotalAsset"": 0.2558, ""totalDebtToTotalCapital"": 0.3192, ""totalRatio"": 2.201, ""period"": ""2022-12-31""}"
2,2023-01-22,285.7699890136719,2023-01-29,290.0799865722656,0.015082051035063548,U2,"[{""date"": ""20230124060000"", ""headline"": ""ClearBridge Value Equity Strategy Q4 2022 Portfolio Manager Commentary"", ""summary"": ""ClearBridge is a leading global asset manager committed to active management. Find out more here.""}, {""date"": ""20230124121005"", ""headline"": ""Why Biogen Inc. (BIIB) Could Beat Earnings Estimates Again"", ""summary"": ""Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.""}, {""date"": ""20230124180011"", ""headline"": ""Biogen Inc. (BIIB) Stock Moves -0.02%: What You Should Know"", ""summary"": ""In the latest trading session, Biogen Inc. (BIIB) closed at $291.88, marking a -0.02% move from the previous day.""}, {""date"": ""20230125010124"", ""headline"": ""Eagle Pharmaceuticals: Upside Could Be Lying Ahead Very Nicely"", ""summary"": ""Eagle Pharmaceuticals is an interesting opportunity to benefit from volatility in stock markets. Click here to find out why EGRX stock is a Hold.""}, {""date"": ""20230125055700"", ""headline"": ""Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?"", ""summary"": ""Lilly's FDA rejection puts Biogen and its partner Eisai in the driver's seat in the Alzheimer's disease drug market.""}, {""date"": ""20230125103727"", ""headline"": ""12 Cheap Biotech Stocks To Buy"", ""summary"": ""In this article, we will be taking a look at 12 cheap biotech stocks to buy. To skip our detailed analysis of the biotech sector, you can go directly to see 5 Cheap Biotech Stocks To Buy. The biotechnology sector has been on the rise over the past three decades. Several forecasts expect the sector [\u2026]""}, {""date"": ""20230126055425"", ""headline"": ""The Petri Dish: Morphic, J&J part ways; FDA committee to review another Biogen drug"", ""summary"": ""Waltham biotech Morphic Holding Inc. is no longer working with Johnson & Johnson Inc. after the pharma giant elected to terminate a nearly four-year-old collaboration agreement.""}, {""date"": ""20230126073000"", ""headline"": ""Is Biogen Stock a Buy Now?"", ""summary"": ""Moving new medicines to the market can sometimes make biopharmaceutical companies tons of returns.  Biogen (NASDAQ: BIIB) just scored a major new drug approval for an Alzheimer's disease therapy, so investors are understandably rushing to evaluate whether to buy the stock.  One key factor that could drive Biogen's outperformance in the next few years is the launch of a new neurology medicine.""}, {""date"": ""20230126135600"", ""headline"": ""Biogen Alzheimer's Drug Lecanemab Gets EU Marketing Authorization"", ""summary"": ""By Sabela Ojea Biogen Inc. said Thursday that the European Medicines Agency committee has accepted a marketing authorization application for its Alzheimer's...""}, {""date"": ""20230126183000"", ""headline"": ""Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer\u2019s Disease Accepted by European Medicines Agency"", ""summary"": ""TOKYO and CAMBRIDGE, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \""Eisai\"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \""Biogen\"") announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab (Brand Name in the U.S.: LEQEMBI\u2122), an investigational anti-amyloid beta (A\u03b2) protofibril* antibody, for the treatment of""}, {""date"": ""20230126192258"", ""headline"": ""UPDATE 1-EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen"", ""summary"": ""Japanese drugmaker Eisai Co Ltd and Biogen Inc said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug.  The application to the EMA was based on results from a late-stage study that showed the drug slowed down the rate of cognitive decline in patients with early Alzheimer's by 27%, compared with a placebo.  Eisai has also filed for approval of the drug in Japan.""}, {""date"": ""20230126192300"", ""headline"": ""EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen"", ""summary"": ""Japanese drugmaker Eisai Co Ltd and Biogen Inc said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer's disease drug.""}, {""date"": ""20230127095702"", ""headline"": ""Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance"", ""summary"": ""Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.""}, {""date"": ""20230129143538"", ""headline"": ""15 Most Famous Hedge Fund Managers and Their Top Stock Picks"", ""summary"": ""In this article, we discuss 15 most famous hedge fund managers and their top stock picks. If you want to see more hedge fund managers, check out 5 Most Famous Hedge Fund Managers and Their Top Stock Picks. According to data provider Hedge Fund Research (HFR), hedge funds in 2022 reported their worst performance since [\u2026]""}, {""date"": ""20230129183000"", ""headline"": ""LECANEMAB RECEIVES PRIORITY REVIEW STATUS IN JAPAN"", ""summary"": ""Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \""Eisai\"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \""Biogen\"") announced today that an application for manufacturing and marketing approval for lecanemab (generic name, U.S. brand name: LEQEMBI\u2122), an anti-amyloid-\u03b2 (A\u03b2) protofibril* antibody, in Japan has been designated for Priority Review by the Japanese Ministry of Health, Labour and Welfare (MHLW). Priority Review in J""}, {""date"": ""20230129184824"", ""headline"": ""Japan grants priority review status to Alzheimer's treatment from Eisai-Biogen"", ""summary"": ""Japanese drugmaker Eisai Co Ltd and Biogen Inc said on Sunday the Japanese Ministry of Health, Labour and Welfare has given priority review for their Alzheimer's disease drug.""}]",{}
3,2023-01-29,290.0799865722656,2023-02-05,283.6300048828125,-0.022235183356388744,D3,"[{""date"": ""20230129143538"", ""headline"": ""15 Most Famous Hedge Fund Managers and Their Top Stock Picks"", ""summary"": ""In this article, we discuss 15 most famous hedge fund managers and their top stock picks. If you want to see more hedge fund managers, check out 5 Most Famous Hedge Fund Managers and Their Top Stock Picks. According to data provider Hedge Fund Research (HFR), hedge funds in 2022 reported their worst performance since [\u2026]""}, {""date"": ""20230129183000"", ""headline"": ""LECANEMAB RECEIVES PRIORITY REVIEW STATUS IN JAPAN"", ""summary"": ""Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \""Eisai\"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \""Biogen\"") announced today that an application for manufacturing and marketing approval for lecanemab (generic name, U.S. brand name: LEQEMBI\u2122), an anti-amyloid-\u03b2 (A\u03b2) protofibril* antibody, in Japan has been designated for Priority Review by the Japanese Ministry of Health, Labour and Welfare (MHLW). Priority Review in J""}, {""date"": ""20230129184824"", ""headline"": ""Japan grants priority review status to Alzheimer's treatment from Eisai-Biogen"", ""summary"": ""Japanese drugmaker Eisai Co Ltd and Biogen Inc said on Sunday the Japanese Ministry of Health, Labour and Welfare has given priority review for their Alzheimer's disease drug.""}, {""date"": ""20230129194417"", ""headline"": ""UPDATE 1-Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen"", ""summary"": ""Japanese drugmaker Eisai Co Ltd and U.S. biotech firm Biogen Inc said in a joint statement that the Japanese Ministry of Health, Labour and Welfare has granted priority review status to their Alzheimer's disease treatment.  In their Jan. 29 statement, the companies said priority review in Japan is granted to new medicines recognised as having high medical utility for serious diseases.  Once the priority status has been granted, the target total review period is shortened, they said.""}, {""date"": ""20230129194420"", ""headline"": ""Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen"", ""summary"": ""Japanese drugmaker Eisai Co Ltd and U.S. biotech firm Biogen Inc said in a joint statement that the Japanese Ministry of Health, Labour and Welfare has granted priority review status to their Alzheimer's disease treatment.""}, {""date"": ""20230130071354"", ""headline"": ""Approval For Anavex's Blarcamesine Looks Inevitable After Biogen's Leqembi Approved"", ""summary"": ""FDA grants emergency approval of Biogen/Eisai's Leqembi based solely on Phase 2 trial results. Read why approval For Anavex's Blarcamesine looks inevitable.""}, {""date"": ""20230130093803"", ""headline"": ""15 Biggest Neuroscience Companies in the World"", ""summary"": ""In this article, we will discuss the 15 Biggest Neuroscience Companies in the World. You can skip our industry overview and go directly to the 5 Biggest Neuroscience Companies in the World. As the name suggests, neuroscience concerns itself with the development, structure, and functions of the nervous system, intending to enhance neurological health. According [\u2026]""}, {""date"": ""20230130180011"", ""headline"": ""Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know"", ""summary"": ""Biogen Inc. (BIIB) closed at $285.94 in the latest trading session, marking a -1.43% move from the prior day.""}, {""date"": ""20230201095300"", ""headline"": ""Why the FDA's Rejection of Eli Lilly's Alzheimer's Drug Is Actually Great News for the Stock"", ""summary"": ""When the Food and Drug Administration (FDA) rejects a key drug from a healthcare company, it can send the stock spiraling into a sell-off.  In order for the FDA to be confident in a drug's effectiveness, it needs to have a large enough sample size to evaluate it.  Unfortunately, in Eli Lilly's case, it simply didn't have enough data points for the agency to make a positive conclusion about the treatment and grant it accelerated approval.""}, {""date"": ""20230201114000"", ""headline"": ""Biogen Inc. stock rises Wednesday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.24% higher to $291.60 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""20230201161043"", ""headline"": ""The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023"", ""summary"": ""Thanks to the wild events of 2022, discerning investors enjoy plenty of bargains, particularly in the arena of the most undervalued Nasdaq stocks. Given the exchange\u2019s bias toward technology players (including biotech), wagering in this space carries the advantage of relevance. Even if circumstances look shoddy right now, at some point, these enterprises have a shot at upside eventually. Now, a word of caution is in order following the utterances of the last few words above. With the most underv""}, {""date"": ""20230202114000"", ""headline"": ""Biogen Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. slid 1.40% to $287.52 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230203114000"", ""headline"": ""Biogen Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. slid 1.35% to $283.63 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...""}]",{}
4,2023-02-05,283.6300048828125,2023-02-12,286.29998779296875,0.009413612326592213,U1,"[{""date"": ""20230205211257"", ""headline"": ""Biogen: What To Do Ahead Of Q4 2022 Financial Report"", ""summary"": ""Biogen's business focuses on developing and commercializing drugs aimed at treating patients living with neurological and neurodegenerative diseases. Find out why BIIB stock is a Hold.""}, {""date"": ""20230206014900"", ""headline"": ""Biogen, Sage Get FDA Priority Review of Zuranolone >BIIB SAGE"", ""summary"": ""By Colin Kellaher Biogen Inc. and Sage Therapeutics Inc. on Monday said the U.S. Food and Drug Administration granted priority review to the application...""}, {""date"": ""20230206031900"", ""headline"": ""FDA grants Priority Review to depression drug; Sage\u2019s stock rallies"", ""summary"": ""Shares of Sage Therapeutics Inc. gained about 5% in premarket trading on Monday after the company said the experimental treatment for major depressive...""}, {""date"": ""20230206063000"", ""headline"": ""Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression"", ""summary"": ""CAMBRIDGE, Mass., February 06, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an investigational drug being evaluated as a 14-day, rapid-acting, once-daily, oral treatment in adults with MDD and PPD. The application has been granted priority revie""}, {""date"": ""20230206063000"", ""headline"": ""Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression"", ""summary"": ""Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder (MDD) and postpartum depression (PPD)Depression is a public health issue with significant unmet medical need CAMBRIDGE, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatme""}, {""date"": ""20230206114000"", ""headline"": ""Biogen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Biogen Inc. advanced 1.64% to $288.28 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230206121446"", ""headline"": ""Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive'"", ""summary"": ""The FDA has accepted for review a marketing application seeking approval for Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc's (NASDAQ: BIIB) zuranolone for major depressive disorder (MDD) and postpartum depression (PPD). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of August 5, 2023. William Blair views the acceptance as an important milestone for the company. The analyst believes the granting of priority review, though not surprising, is an incremental positive""}, {""date"": ""20230206180011"", ""headline"": ""Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know"", ""summary"": ""Biogen Inc. (BIIB) closed at $288.28 in the latest trading session, marking a +1.64% move from the prior day.""}, {""date"": ""20230207090013"", ""headline"": ""Is Biogen Inc. (NASDAQ:BIIB) Trading At A 24% Discount?"", ""summary"": ""How far off is Biogen Inc. ( NASDAQ:BIIB ) from its intrinsic value? Using the most recent financial data, we'll take a...""}, {""date"": ""20230207101703"", ""headline"": ""Sage and Biogen's NDA for Depression Drug Gets Priority Review"", ""summary"": ""Sage Therapeutics, Inc. (SAGE) and partner, Biogen Inc.'s (BIIB) NDA for zuranolone to treat adults with MDD and PPD accepted by the FDA and granted priority review.""}, {""date"": ""20230207114000"", ""headline"": ""Biogen Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. advanced 1.09% to $291.43 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""20230208094702"", ""headline"": ""Will Biogen (BIIB) Beat Estimates This Earnings Season?"", ""summary"": ""Biogen's (BIIB) sales in the fourth quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.""}, {""date"": ""20230208100003"", ""headline"": ""Biogen Inc. (BIIB) Reports Next Week: Wall Street Expects Earnings Growth"", ""summary"": ""Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.""}, {""date"": ""20230208140000"", ""headline"": ""2 Top Biotech Stocks Defying the Bear Market"", ""summary"": ""The bear market crushed many top healthcare stocks -- from young high-growth players to long-established companies generating billions of dollars in earnings.  Vertex is the worldwide leader in the cystic fibrosis (CF) treatment market.  In fact, last year product revenue climbed 18% to more than $8.9 billion.""}, {""date"": ""20230210134027"", ""headline"": ""25 Biggest Massachusetts Companies and Stocks"", ""summary"": ""In this article, we will be taking a look at the 25 biggest Massachusetts companies and stocks. To skip our detailed analysis, you can go directly to see the 5 biggest Massachusetts companies and stocks. If all U.S. states were countries, Massachusetts would be 32nd largest economy in the world based on a 2021 GDP [\u2026]""}, {""date"": ""20230210224526"", ""headline"": ""IWS: Little Added Value In This Value Index"", ""summary"": ""The iShares Russell Mid-Cap Value ETF tracks the Russell Midcap Value Index. Click here to read why I see little added value in IWS.""}, {""date"": ""20230211070021"", ""headline"": ""With 88% institutional ownership, Biogen Inc. (NASDAQ:BIIB) is a favorite amongst the big guns"", ""summary"": ""Every investor in Biogen Inc. ( NASDAQ:BIIB ) should be aware of the most powerful shareholder groups. We can see that...""}]",{}
5,2023-02-12,286.29998779296875,2023-02-19,278.3800048828125,-0.027663231742375727,D3,"[{""date"": ""20230212215800"", ""headline"": ""Earnings Growth Improves As Investors Ready Themselves For Retailers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230213004500"", ""headline"": ""Investors Are Awaiting The Name Of The New BoJ Governor"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230213114000"", ""headline"": ""Biogen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Biogen Inc. rallied 1.45% to $290.46 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230214010100"", ""headline"": ""Top 5 4th Quarter Trades of SEEYOND"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230214030100"", ""headline"": ""Tamarack Advisers, LP Buys 1, Sells 4 in 4th Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230214044000"", ""headline"": ""Hyperfine could have `interesting` opportunity in Alzheimer`s, says Evercore ISI"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230214054300"", ""headline"": ""All eyes on Biogen Q4 results with focus on future of Alzheimer`s drug Leqembi"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230214055400"", ""headline"": ""Biogen`s Alzheimer`s therapy Aduhelm gets updated warning on brain hemorrhage risk"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230214065600"", ""headline"": ""Notable companies reporting before tomorrow`s open"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230214114000"", ""headline"": ""Biogen Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. shed 0.48% to $289.08 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230214194100"", ""headline"": ""GLOBAL BRIEFING: Stocks called lower ahead of UK inflation figures"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230214223200"", ""headline"": ""What You Missed On Wall Street On Wednesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230215011300"", ""headline"": ""Biogen reports Q4 EPS $4.05, consensus $3.48"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230215011500"", ""headline"": ""Biogen sees FY23 EPS $15.00-$16.00, consensus $15.72"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230215011800"", ""headline"": ""Biogen beats Q4 top and bottom line estimates; initiates FY23 outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230215022000"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Applied DNA Sciences (APDN) and Provention Bio (PRVB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230215023000"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and ChitogenX (OtherCHNXF)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230215024900"", ""headline"": ""7 stocks to watch on Wednesday: Telsa, Airbnb, Krispy Kreme and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230215025600"", ""headline"": ""Fly Intel: Pre-market Movers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230215030020"", ""headline"": ""Airbnb, TripAdvisor, Tesla rise premarket; Barclays, Devon Energy fall"", ""summary"": ""By Peter Nurse""}, {""date"": ""20230215031500"", ""headline"": ""Biogen`s stock gains after company beats Q4 revenue and earnings expectations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230215031541"", ""headline"": ""Stocks making the biggest moves premarket: Kraft Heinz, Paramount, Airbnb, Tripadvisor and more"", ""summary"": ""Here are the companies making headlines before the bell on Monday.""}, {""date"": ""20230215033200"", ""headline"": ""Biogen net income up across 2022, fourth quarter; revenue down"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230215045000"", ""headline"": ""Biogen Beats Q4 Earnings & Sales Estimates, Stock Up"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230215052200"", ""headline"": ""Biogen expects new Alzheimer`s drug to weigh on 2023 outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230215060000"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230215070007"", ""headline"": ""Biogen Inc. (BIIB) Q4 2022 Earnings Call Transcript"", ""summary"": ""Biogen Inc. (NASDAQ:NASDAQ:BIIB) Q4 2022 Results Conference Call February 15, 2023 8:00 AM ETCompany ParticipantsMike Hencke - Head, Investor RelationsChristopher Viehbacher - CEOMichael...""}, {""date"": ""20230215070104"", ""headline"": ""Investors in Biogen (NASDAQ:BIIB) have made a respectable return of 35% over the past year"", ""summary"": ""These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But if you pick...""}, {""date"": ""20230215070107"", ""headline"": ""Biogen earnings beat estimates on boost from muscle disorder drug"", ""summary"": ""Biogen Inc beat Wall Street expectations for quarterly profit and sales on Wednesday, riding on strong demand for its spinal muscular atrophy drug, Spinraza, and forecast modest revenue from its Alzheimer's disease drug this year.""}, {""date"": ""20230215070406"", ""headline"": ""Biogen sees modest 2023 revenue from Alzheimer's disease drug"", ""summary"": ""(Reuters) -Biogen Inc said on Wednesday that Alzheimer's disease drug Leqembi would bring in modest revenue for the year although it might not be enough to offset costs tied to its launch.  The company is banking on Leqembi, which was granted accelerated U.S. approval in January, to drive its sales at a time when many of Biogen's top drugs face increasing competition.  Biogen has a 50% share of U.S. profits on Leqembi, which it developed with lead partner Eisai Co Ltd.""}, {""date"": ""20230215071700"", ""headline"": ""Medicare mulls limiting per month costs for generic drugs at $2"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230215072400"", ""headline"": ""Biogen\u2019s stock gains after company beats Q4 revenue and earnings expectations"", ""summary"": ""Shares of Biogen Inc.  (BIIB)  gained about 1.7% in premarket trading on Wednesday after the company beat revenue and earnings expectations in the fourth quarter.  Biogen had earnings of $550.4 million, or $3.79 per share, in the fourth quarter, up from $368.2 million, or $2.50 per share, in the same three months of 2021.  Adjusted earnings per share were $4.05, against a FactSet consensus of $3.49.""}, {""date"": ""20230215072400"", ""headline"": ""Biogen Tops Profit Expectations as Alzheimer\u2019s and Depression Drugs Remain in Focus"", ""summary"": ""The expected rollouts of both drugs this year are vital to the company's future because its remaining offerings face intense competitive pressure.""}, {""date"": ""20230215075318"", ""headline"": ""UPDATE 2-Biogen CEO bets on Alzheimer's drug, pipeline to return to growth"", ""summary"": ""Biogen Inc Chief Executive Officer Christopher Viehbacher said on Wednesday he is banking on high-profile launches of Alzheimer's disease treatment Leqembi and depression drug zuranolone, as well as deals, to help the company return to revenue growth.  Industry veteran Viehbacher joined the U.S. biotech in November, at a time when sales have been hit by competition for top-selling drugs such as Tecfidera for multiple sclerosis and Spinraza for spinal muscular atrophy.  A controversial approval and problematic launch of previous Alzheimer's disease drug Aduhelm, which like Leqembi was developed with Eisai Co Ltd, have further dented investor sentiment.""}, {""date"": ""20230215082501"", ""headline"": ""Biogen Inc. (BIIB) Q4 Earnings and Revenues Beat Estimates"", ""summary"": ""Biogen Inc. (BIIB) delivered earnings and revenue surprises of 15.38% and 4.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?""}, {""date"": ""20230215085428"", ""headline"": ""Biogen Inches Higher On Quarterly Beat, Guides To 'Modest' Alzheimer's Drug Sales"", ""summary"": ""Biogen stock inched higher Wednesday after the company beat quarterly expectations, but offered disappointing 2023 guidance.""}, {""date"": ""20230215091300"", ""headline"": ""Drugmaker Biogen tops 4Q forecasts despite sales slip"", ""summary"": ""Biogen closed 2022 with a better-than-expected fourth quarter, as more cost cutting helped counter sales declines for some key treatments.  The drugmaker said Wednesday that total cost and expenses fell 17% in the quarter, and Biogen\u2019s bottom line grew nearly 50% to $550.4 million.  Adjusted earnings totaled $4.05 per share.""}, {""date"": ""20230215094759"", ""headline"": ""Why Biogen Stock Is Falling Today"", ""summary"": ""Biogen Inc (NASDAQ: BIIB) posted Q4 sales of $2.54 billion, beating the consensus of $2.44 billion, down 7% Y/Y and 4% at constant currency (CC). Multiple sclerosis revenue of $1.27 billion decreased by 17% (down 14% CC). Multiple sclerosis drug Tysabri sales are down to $488.4 million from $512.7. Spinraza's revenue of $458.8 million increased by 4% at actual currency (increased by 10% at CC). Aduhelm generated sales of $0.3 million in Q4, compared to $1.0 million a year ago. Biosimilars' reven""}, {""date"": ""20230215101201"", ""headline"": ""Biogen CEO bets on Alzheimer's drug, pipeline to return to growth"", ""summary"": ""Biogen Inc Chief Executive Officer Christopher Viehbacher said on Wednesday he is banking on high-profile launches of Alzheimer's disease treatment Leqembi and depression drug zuranolone, as well as deals, to help the company return to revenue growth.""}, {""date"": ""20230215105319"", ""headline"": ""Biogen hints at more cost-cutting under new CEO as revenue falls"", ""summary"": ""Biogen Inc. may see new drug approvals this year \u2014 but first, new CEO Christopher Viehbacher is looking at ways to cut costs as the company continues to struggle with falling revenue.""}, {""date"": ""20230215105703"", ""headline"": ""Biogen (BIIB) Beats Q4 Earnings & Sales Estimates, Stock Up"", ""summary"": ""Biogen (BIIB) beats fourth-quarter estimates for earnings and sales. Stock rises in pre-market.""}, {""date"": ""20230215113600"", ""headline"": ""NEW YORK MARKET CLOSE: Stocks stage late rally to end higher"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230215114000"", ""headline"": ""Biogen Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slipped 3.49% to $278.98 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""20230215114306"", ""headline"": ""Leqembi: Medicare coverage needs \u2018a convincing set of evidence\u2019 for FDA approval, analyst says"", ""summary"": ""William Blair Biotech Equity Research Analyst Myles Minter joins Yahoo Finance Live to discuss his Outperform rating on Biogen stock, Biogen\u2019s Alzheimer and depression treatment drugs, full-year guidance, profit growth, cost-cutting efforts, and the outlook for the company.""}, {""date"": ""20230215115800"", ""headline"": ""Health Care Down as Biogen Weighs -- Health Care Roundup"", ""summary"": ""Health-care companies fell after a selloff in one big biotech. Biogen shares slid after the biotech giant posted a sharp drop in 2022 revenue, and warned of...""}, {""date"": ""20230215122605"", ""headline"": ""Compared to Estimates, Biogen Inc. (BIIB) Q4 Earnings: A Look at Key Metrics"", ""summary"": ""Although the revenue and EPS for Biogen Inc. (BIIB) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.""}, {""date"": ""20230215131600"", ""headline"": ""Biogen Boss Turns Corner on Alzheimer\u2019s Miscues"", ""summary"": ""The biotech company needs to embark on new growth path as former Sanofi CEO Chris Viehbacher takes the helm.""}, {""date"": ""20230215143034"", ""headline"": ""Biogen (BIIB) Q4 2022 Earnings Call Transcript"", ""summary"": ""At this time, I would like to welcome everyone to the Biogen fourth quarter and full year 2022 earnings call and business update.  On today's call, I am joined by our president and chief executive officer, Christopher Viehbacher; Dr. Priya Singhal, head of development; and our CFO, Mike McDonnell.""}, {""date"": ""20230215160328"", ""headline"": ""Biogen Slumps On Limited Alzheimer's Sales Expectations As Pressure Points Mount"", ""summary"": ""Biogen stock was hamstrung Wednesday on mixed 2023 guidance that assumes expenses for its new Alzheimer's drug will outpace sales.""}, {""date"": ""20230215225500"", ""headline"": ""Biogen (BIIB) Gets a Buy from Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230215234500"", ""headline"": ""Bank of America Securities Sticks to Their Hold Rating for Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230216003400"", ""headline"": ""Biogen price target lowered to $310 from $320 at Oppenheimer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230216004300"", ""headline"": ""Biogen price target raised to $351 from $345 at Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230216012600"", ""headline"": ""BMO Capital Gives a Buy Rating to Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230216012600"", ""headline"": ""H.C. Wainwright Reaffirms Their Buy Rating on Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230216013700"", ""headline"": ""Biogen price target raised to $315 from $300 at Cowen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230216015300"", ""headline"": ""GLOBAL BROKER RATINGS: LBBW cuts LVMH; DZ Bank cuts Kering"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230216024000"", ""headline"": ""Analysts` Top Healthcare Picks: Alkermes (ALKS), Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230216030800"", ""headline"": ""Biogen price target lowered to $333 from $359 at RBC Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230216054000"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Amedisys (AMED), Biogen (BIIB) and Waters (WAT)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230216055000"", ""headline"": ""Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), SAGE Therapeutics (SAGE) and Karyopharm Therapeutics (KPTI)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230216114000"", ""headline"": ""Biogen Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. slid 2.67% to $271.53 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230216114804"", ""headline"": ""Biotech Stock Roundup: BIIB's Q4 Results, EBS and BPMC Offer Updates"", ""summary"": ""Earnings results from Biogen (BIIB) and updates from EBS are the key highlights from the biotech sector during the past week.""}, {""date"": ""20230216134158"", ""headline"": ""Biogen has nearly made good on reported plan to cut 1,000 jobs in 2022"", ""summary"": ""In late 2021, the Cambridge drugmaker reportedly began drafting plans to get rid of more than 1,000 positions. Now, it appears to have nearly accomplished that goal.""}, {""date"": ""20230216184950"", ""headline"": ""Biogen Inc. (NASDAQ:BIIB) Q4 2022 Earnings Call Transcript"", ""summary"": ""Biogen Inc. (NASDAQ:BIIB) Q4 2022 Earnings Call Transcript February 15, 2023 Operator: Good morning. My name is Bettina , and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen Fourth Quarter and Full Year 2022 Earnings Call and Business Update. All lines have been placed [\u2026]""}, {""date"": ""20230217010100"", ""headline"": ""RA CAPITAL MANAGEMENT, L.P. Buys 2, Sells 3 in 4th Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230217015900"", ""headline"": ""GLOBAL BROKER RATINGS: Citigroup likes Coca-Cola; DZ cuts Kraft Heinz"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230217022600"", ""headline"": ""Barclays Remains a Hold on Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230217032842"", ""headline"": ""Maker of promising Alzheimer's drug Leqembi expects full FDA approval this summer, expanded Medicare coverage"", ""summary"": ""Even if the FDA grants full approval of the Alzheimer's treatment Leqembi, the rollout will take years. ""}, {""date"": ""20230217040600"", ""headline"": ""Biogen (BIIB) Gets a Buy from SVB Securities"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230217055616"", ""headline"": ""Senators call on Medicare to offer broad coverage of Alzheimer's treatments as public pressure grows"", ""summary"": ""Eighteen Republicans and two Democrats, led by Sens. Susan Collins and Shelley Moore Capito, pushed Medicare to expand coverage for Alzheimer's treatments.""}, {""date"": ""20230217065700"", ""headline"": ""Senators urge swift action to expand Medicare coverage for Alzheimer`s therapies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230217070100"", ""headline"": ""Jeff Auxier Buys 2, Sells 3 in 4th Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230217075313"", ""headline"": ""Stocks making the biggest moves midday: Deere, Airbnb, AutoNation, Moderna and more"", ""summary"": ""Deere shares popped on strong earnings. ""}, {""date"": ""20230217114000"", ""headline"": ""Biogen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Biogen Inc. rallied 2.52% to $278.38 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""20230217211927"", ""headline"": ""Steven Cohen\u2019s Point72 Hedge Fund Backs Salesforce, Broadcom And Meta While Cutting Palo Alto And Workday Stakes"", ""summary"": """"}, {""date"": ""20230219060015"", ""headline"": ""Biogen Inc.'s (NASDAQ:BIIB) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?"", ""summary"": ""It is hard to get excited after looking at Biogen's (NASDAQ:BIIB) recent performance, when its stock has declined 7.7...""}]",{}
6,2023-02-19,278.3800048828125,2023-02-26,270.0199890136719,-0.030030949502497073,D4,"[{""date"": ""20230219060015"", ""headline"": ""Biogen Inc.'s (NASDAQ:BIIB) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?"", ""summary"": ""It is hard to get excited after looking at Biogen's (NASDAQ:BIIB) recent performance, when its stock has declined 7.7...""}, {""date"": ""20230221012310"", ""headline"": ""Sage Therapeutics Looking To FDA Approval Of Zuranolone"", ""summary"": ""Sage Therapeutics specializes in psychiatric drug therapies, and the stock price has fluctuated greatly over the years. Click here to read why SAGE is a Buy.""}, {""date"": ""20230221030100"", ""headline"": ""Jeff Auxier Downloads Adobe, Boosts British American Tobacco"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230221030100"", ""headline"": ""HealthCor Management, L.P. Buys 2, Sells 3 in 4th Quarter"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230221114000"", ""headline"": ""Biogen Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. slid 2.32% to $271.93 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230221223400"", ""headline"": ""Analyst Favorites With Strong Buyback Activity: Biogen Ranks As a Top Pick"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230222001600"", ""headline"": ""Stanley Druckenmiller Buys the Dip on Nvidia, Exits Amazon"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230222052900"", ""headline"": ""May 19th Options Now Available For Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230222114000"", ""headline"": ""Biogen Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.23% higher to $272.55 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P...""}, {""date"": ""20230222210731"", ""headline"": ""UPDATE 1-U.S. Medicare says no change to Alzheimer's drug restrictions"", ""summary"": ""The U.S. government health plan for people over the age of 65  on Wednesday said it would not reconsider strict coverage limits put in place last year for new Alzheimer's treatments, rejecting a request from the Alzheimer's Association.  The Centers for Medicare and Medicaid Services (CMS) reaffirmed its policy allowing coverage for drugs designed to clear amyloid plaques from the brains of Alzheimer's patients only if a medication is approved under the Food and Drug Administration's standard review process, not under its accelerated review program.  The Alzheimer's Association said in a statement it \""is appalled that the Biden Administration is extending its unjust decision to deny access to FDA-approved treatments for people living with Alzheimer's - a fatal disease.\""""}, {""date"": ""20230223005800"", ""headline"": ""Medicare says coverage limits on Alzheimer`s drugs is not under review"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230223025100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP), Medtronic (MDT) and Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230223040900"", ""headline"": ""TG Therapeutics` Briumvi: A Tough Sell For Multiple Sclerosis Treatment Market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230223050322"", ""headline"": ""TG Therapeutics' Briumvi: A Tough Sell For Multiple Sclerosis Treatment Market"", ""summary"": ""TG Therapeutic's Briumvi for MS is unlikely to make the company profitable before its patent expires. Click here to read why TGTX stock is a Strong Sell.""}, {""date"": ""20230223054723"", ""headline"": ""Medicare rejects Alzheimer's Association request for unrestricted coverage of treatments like Leqembi"", ""summary"": ""The Alzheimer's Association, in a statement Wednesday, said it was \""appalled\"" by CMS' decision.""}, {""date"": ""20230223060013"", ""headline"": ""We Think Biogen (NASDAQ:BIIB) Can Stay On Top Of Its Debt"", ""summary"": ""Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...""}, {""date"": ""20230223114000"", ""headline"": ""Biogen Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. dropped 0.22% to $271.95 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""20230224114000"", ""headline"": ""Biogen Inc. stock falls Friday, still outperforms market"", ""summary"": ""Shares of Biogen Inc. shed 0.71% to $270.02 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230225154412"", ""headline"": ""3 Biotech Stocks To Watch Ahead Of March 2023"", ""summary"": ""Do you have these three biotech stocks on your watchlist right now?""}, {""date"": ""20230226180500"", ""headline"": ""Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca"", ""summary"": ""Chengdu Keymed Bio and Lepu Biopharma out-licensed global rights for their partnered Claudin 18.2 antibody drug conjugate to AstraZeneca. Read more here...""}]",{}
7,2023-02-26,270.0199890136719,2023-03-05,270.2699890136719,0.0009258573815709159,U1,"[{""date"": ""20230226180500"", ""headline"": ""Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca"", ""summary"": ""Chengdu Keymed Bio and Lepu Biopharma out-licensed global rights for their partnered Claudin 18.2 antibody drug conjugate to AstraZeneca. Read more here...""}, {""date"": ""20230226201400"", ""headline"": ""Reata in selloff ahead of FDA decision on lead asset as top agency official departs (Update)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230227003200"", ""headline"": ""Biogen license application for lecanemab designated for priority review in China"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230227070900"", ""headline"": ""Reata in selloff ahead of FDA decision on lead asset as top agency official departs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230227080000"", ""headline"": ""Amyloid Gains Converts in Debate Over Alzheimer\u2019s Treatments"", ""summary"": ""The drug\u2019s success has helped quell a dispute over a theory of what causes the disease and how to treat it. However, critics say scientists still aren\u2019t sure how amyloid removal slows down Alzheimer\u2019s.""}, {""date"": ""20230227114000"", ""headline"": ""Biogen Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. slumped 0.30% to $269.20 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""20230227141847"", ""headline"": ""Lightning Round: This is Boeing's time if they don't screw it up"", ""summary"": ""Mad Money host Jim Cramer weighs in on all manner of stocks, including Accenture, Boeing, Biogen, Union Pacific, Meta, Nokia and Enphase Energy.""}, {""date"": ""20230227183000"", ""headline"": ""Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products Administration"", ""summary"": ""TOKYO and CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \""Eisai\"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \""Biogen\"") announced today that the Biologics License Application (BLA) for lecanemab (brand name in the U.S.: LEQEMBI\u2122), an investigational anti-amyloid beta (A\u03b2) protofibril antibody, has been designated for Priority Review by the National Medical Products Ad""}, {""date"": ""20230227191628"", ""headline"": ""Eisai, Biogen say Alzheimer's drug Lecanemab getting priority review in China"", ""summary"": ""Japanese drugmaker Eisai Co Ltd and U.S. biotech firm Biogen Inc said on Tuesday that Chinese authorities have given priority review status to Lecanemab, their jointly-developed Alzheimer's disease treatment drug.""}, {""date"": ""20230227223700"", ""headline"": ""Biogen, Eisai`s Alzheimer`s therapy lecanemab gets priority review in Chinna"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230228114000"", ""headline"": ""Biogen Inc. stock rises Tuesday, outperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.25% higher to $269.86 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...""}, {""date"": ""20230228134145"", ""headline"": ""FDA neurosciences chief Billy Dunn to leave immediately, analysts raise concern"", ""summary"": ""The U.S. Food and Drug Administration neurosciences head Billy Dunn will retire from his role effective immediately, the health regulator told Reuters on Tuesday.  Wall Street analysts said Dunn's departure could impact the regulator's stance on neurological drug decisions in the near term, sending down shares of Reata Pharmaceuticals Inc 30% on Monday when media reports on the exit surfaced.  Texas-based Reata is expecting FDA's decision by Tuesday on its drug to treat a rare neuromuscular disorder called Friedreich's ataxia.""}, {""date"": ""20230228201400"", ""headline"": ""Reata\u2019s stock soars 150% after FDA approves rare-disease drug amid uncertainty about approach to neuroscience treatments"", ""summary"": ""The U.S. Food and Drug Administration on Tuesday approved Reata Pharmaceuticals Inc.\u2019s treatment for Friedreich\u2019s ataxia, a rare inherited disease that causes damage to the nervous system.  Reata\u2019s  (RETA)  stock jumped more than 150% in after-hours trading, after being halted in advance of the FDA\u2019s decision.  The drug, omaveloxolone, is now called Skyclarys and has been approved to treat adults 16 and older with the degenerative disease, which often appears when a patient is a teenager.""}, {""date"": ""20230301025000"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Outset Medical (OM) and Prometheus Biosciences (RXDX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230301065800"", ""headline"": ""Roche`s Genentech sues Biogen over additional patent royalties from Tysabri sales"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230301114000"", ""headline"": ""Biogen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Biogen Inc. inched 0.87% higher to $272.21 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""20230301120402"", ""headline"": ""Genentech sues Biogen for royalties on blockbuster MS drug"", ""summary"": ""Roche's Genentech Inc sued Biogen MA Inc on Tuesday in San Francisco federal court, claiming Biogen owes additional patent royalties from worldwide sales of its blockbuster multiple-sclerosis and Crohn's disease drug Tysabri.  Genentech's lawsuit said Biogen owes royalties for all the Tysabri that was produced using Genentech's patents before the patents expired, even if it was sold later.""}, {""date"": ""20230301144349"", ""headline"": ""UPDATE 1-Genentech sues Biogen for royalties on blockbuster MS drug"", ""summary"": ""Roche's Genentech Inc sued Biogen MA Inc on Tuesday in San Francisco federal court, claiming Biogen owes additional patent royalties from worldwide sales of its blockbuster multiple-sclerosis and Crohn's disease drug Tysabri.  Genentech's lawsuit said Biogen owes royalties for all the Tysabri that was produced using Genentech's patents before the patents expired, even if it was sold later.""}, {""date"": ""20230302114000"", ""headline"": ""Biogen Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slid 1.27% to $268.75 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""20230303000800"", ""headline"": ""Medicare just crushed the hopes of 750,000 Alzheimer`s patients a year"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230303071100"", ""headline"": ""Biotech Stocks Fell on Fear of Less Flexible FDA. This Analyst Isn\u2019t Worried."", ""summary"": ""Investors panicked on Monday in response to the retirement of an official seen as a standard bearer for flexibility on approvals of certain neurological drugs.""}, {""date"": ""20230303114000"", ""headline"": ""Biogen Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.57% higher to $270.27 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""20230305004100"", ""headline"": ""Eisai, Biogen say FDA accepted sBLA for LEQEMBI, granted Priority Review"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230305133000"", ""headline"": ""FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI\u2122 (lecanemab-irmb) for the Treatment of Alzheimer's Disease"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230305183000"", ""headline"": ""FDA Accepts Eisai\u2019s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI\u2122 (lecanemab-irmb) for the Treatment of Alzheimer\u2019s Disease"", ""summary"": ""Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to convert accelerated approval of LEQEMBI to a traditional approval Priority Review accelerates FDA review time with a Prescription Drug User Fee Act (PDUFA) target action on July 6, 2023 TOKYO and CAMBRIDGE, Mass., March 05, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \""Eisai\"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A.""}]",{}
8,2023-03-05,270.2699890136719,2023-03-12,256.55999755859375,-0.0507270211728339,D5+,"[{""date"": ""20230305004100"", ""headline"": ""Eisai, Biogen say FDA accepted sBLA for LEQEMBI, granted Priority Review"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230305133000"", ""headline"": ""FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI\u2122 (lecanemab-irmb) for the Treatment of Alzheimer's Disease"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230305183000"", ""headline"": ""FDA Accepts Eisai\u2019s Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI\u2122 (lecanemab-irmb) for the Treatment of Alzheimer\u2019s Disease"", ""summary"": ""Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to convert accelerated approval of LEQEMBI to a traditional approval Priority Review accelerates FDA review time with a Prescription Drug User Fee Act (PDUFA) target action on July 6, 2023 TOKYO and CAMBRIDGE, Mass., March 05, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \""Eisai\"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A.""}, {""date"": ""20230305191605"", ""headline"": ""Eisai, Biogen say FDA grants priority review for Alzheimer's drug Lecanemab"", ""summary"": ""Japanese drugmaker Eisai Co Ltd and its U.S. partner Biogen Inc said on Monday that the U.S. Food and Drug Administration granted priority review for traditional approval of their Alzheimer's treatment Lecanemab.""}, {""date"": ""20230305205900"", ""headline"": ""US FDA accepts application for traditional Leqembi approval - Biogen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230305223700"", ""headline"": ""Biogen, Eisai`s Alzheimer`s drug Leqembi gets FDA priority review for traditional approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230306041929"", ""headline"": ""FDA will review Eisai and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early July"", ""summary"": ""Medicare has agreed to provide broader coverage once Leqembi receives full FDA approval.""}, {""date"": ""20230306081601"", ""headline"": ""Biogen (BIIB), Eisai Seek Full Nod for Alzheimer Drug Leqembi"", ""summary"": ""The FDA grants priority review to Biogen (BIIB) and Eisai's sBLA seeking traditional approval of Alzheimer's disease drug, Leqembi. The FDA decision is expected on Jul 6, 2023.""}, {""date"": ""20230306113020"", ""headline"": ""Biogen Inc. (BIIB) 43rd Annual Cowen Healthcare Conference (Transcript)"", ""summary"": ""Call Start: 09:50 January 1, 0000 10:21 AM ETBiogen Inc.""}, {""date"": ""20230306113020"", ""headline"": ""Biogen Inc. (BIIB) 43rd Annual Cowen Healthcare Conference Conference (Transcript)"", ""summary"": ""Biogen Inc. (NASDAQ:NASDAQ:BIIB) 43rd Annual Cowen Healthcare Conference Call March 6, 2023 9:50 AM ETCompany ParticipantsChristopher Viehbacher - Chief Executive OfficerConference Call...""}, {""date"": ""20230306113800"", ""headline"": ""FDA Will Weigh Full Approval for Alzheimer\u2019s Drug. Why It Matters for Biogen Stock."", ""summary"": ""The drug already has accelerated approval. Full approval would open the door for Medicare to pay for the treatment for more patients.""}, {""date"": ""20230306114000"", ""headline"": ""Biogen Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. dropped 0.01% to $270.25 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230306124654"", ""headline"": ""Eisai-Biogen Seek Complete FDA Approval For Its Second Alzheimer's Treatment"", ""summary"": ""The FDA has accepted Eisai Co Ltd (OTC: ESALY) and Biogen Inc's (NASDAQ: BIIB) supplemental Biologics License Application (sBLA) for Leqembi (lecanemab-irmb) 100 mg/mL injection, supporting the conversion of the accelerated approval of Leqembi to a traditional approval. The Leqembi application has been granted Priority Review, with a Prescription Drug User Fee Act (PDUFA) action date of July 6, 2023. The FDA plans to hold an Advisory Committee to discuss this application but has not publicly ann""}, {""date"": ""20230306163815"", ""headline"": ""FDA to decide on full approval of Alzheimer's treatment Leqembi in early July"", ""summary"": ""The FDA will decide on July 6 whether to grant full approval to the new Alzheimer's treatment Leqembi, Japanese drugmaker Eisai and its U.S. partner Biogen said.""}, {""date"": ""20230306214750"", ""headline"": ""Biogen Should Resume Strong Growth With Zuranolone Approval"", ""summary"": ""Biogen's revenue will continue to decline if the FDA (or payers) declines to approve both zuranolone and Leqembi. Find out why BIIB stock is a Buy.""}, {""date"": ""20230307013700"", ""headline"": ""Biden to announce plan to keep Medicare solvent beyond 2050"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230307065000"", ""headline"": ""The Data Will Speak Louder Than Powell. Fed Rate Is Veering Toward 6%."", ""summary"": ""China ramps up U.S. tensions, JetBlue merger faces legal action, the return of luxury consumers, and other news to start your day.""}, {""date"": ""20230307114000"", ""headline"": ""Biogen Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slid 1.99% to $264.88 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230307220955"", ""headline"": ""U.S. Wide-Moat Stocks On Sale - The March 2023 Heat Map"", ""summary"": ""We are only interested in those targets that are attractively valued in historical comparison. Click here for our 3-step process that focuses on wide-moat stocks.""}, {""date"": ""20230308003200"", ""headline"": ""Biogen, Sage Therapeutics: FDA has no plans to discuss NDA for zuranolone"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230308010000"", ""headline"": ""FDA to not hold panel meeting for Biogen, Sage`s depression therapy zuranolone"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230308013000"", ""headline"": ""Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230308013500"", ""headline"": ""Biogen elects Dorsa as Chair of the Board of Directors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230308015700"", ""headline"": ""Biogen elects new board chairperson"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230308030000"", ""headline"": ""Biogen Names Dorsa to Succeed Papadopoulos as Chairman >BIIB"", ""summary"": ""By Colin Kellaher Biogen Inc. on Wednesday said it has designated long-time board member Caroline Dorsa to succeed Stelios Papadopoulos as chairman of the...""}, {""date"": ""20230308044100"", ""headline"": ""Elliott Wave Technical Analysis: Biogen Inc. - Wednesday, March 8"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230308073000"", ""headline"": ""Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors"", ""summary"": ""CAMBRIDGE, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced that the Board of Directors has elected Caroline Dorsa as Chair of the Board of Directors, effective immediately following the Company\u2019s 2023 Annual Meeting of Stockholders (the \u201cAnnual Meeting\u201d), scheduled to take place on June 14, 2023. Ms. Dorsa will succeed Stelios Papadopoulos, Ph.D., who announced he would not stand for reelection to the Board at the Annual Meeting. Dr. Papadopoulos said: \u201cThe e""}, {""date"": ""20230308114000"", ""headline"": ""Biogen Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Biogen Inc. shed 0.70% to $263.02 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230308180011"", ""headline"": ""Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know"", ""summary"": ""Biogen Inc. (BIIB) closed the most recent trading day at $263.02, moving -0.7% from the previous trading session.""}, {""date"": ""20230309004900"", ""headline"": ""No ad com suggests positive potential outcome for Sage`s zura, says BofA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230309033600"", ""headline"": ""Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230309070300"", ""headline"": ""Needham healthcare analyst to hold an analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230309093302"", ""headline"": ""Lilly's (LLY) Alzheimer Drug Fails Late-Stage Prevention Study"", ""summary"": ""Data from a late-stage study showed that treatment with Eli Lilly's (LLY) solanezumab did not result in the clearance of brain amyloid plaque in people with preclinical Alzheimer's disease.""}, {""date"": ""20230309093727"", ""headline"": ""Eli Lilly's Decade-Long Effort In Alzheimer's Disease Just Failed"", ""summary"": ""Eli Lilly stock and Biogen stock diverged Thursday after Lilly said a decade-long study of an Alzheimer's treatment definitively failed.""}, {""date"": ""20230309114000"", ""headline"": ""Biogen Inc. stock outperforms market despite losses on the day"", ""summary"": ""Shares of Biogen Inc. slid 1.53% to $258.99 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230310114000"", ""headline"": ""Biogen Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. dropped 0.94% to $256.56 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230312050100"", ""headline"": ""Biosimilars expected to save $180B over next five years as more gain approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
9,2023-03-12,256.55999755859375,2023-03-19,263.1600036621094,0.025725000648272545,U3,"[{""date"": ""20230312050100"", ""headline"": ""Biosimilars expected to save $180B over next five years as more gain approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230312213100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Crinetics Pharmaceuticals (CRNX) and 89bio (ETNB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230312221300"", ""headline"": ""VA to widely cover new Alzheimer`s treatment from Eisai and Biogen, STAT says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230312225000"", ""headline"": ""Biogen `welcomes` VHA recent decision to provide coverage to Leqembi"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230312233700"", ""headline"": ""Biogen Takes Over #202 Spot From Bank of New York Mellon"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230313021000"", ""headline"": ""Biogen price target raised to $350 from $335 at RBC Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230313055900"", ""headline"": ""Sage upgraded to outperform at RBC on greater confidence in zuranolone approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230313124000"", ""headline"": ""Biogen Inc. stock underperforms Monday when compared to competitors despite daily gains"", ""summary"": ""Shares of Biogen Inc. inched 0.78% higher to $258.55 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...""}, {""date"": ""20230313124837"", ""headline"": ""Veterans Health Administration will cover Alzheimer's treatment Leqembi, Eisai says"", ""summary"": ""Veterans with early Alzheimer's who meet certain VHA criteria can get the treatment covered, according to drugmaker Eisai. ""}, {""date"": ""20230313152700"", ""headline"": ""Veterans Affairs to Be First Major Insurer to Cover Alzheimer\u2019s Drug Leqembi"", ""summary"": ""Eisai  \u2019s new Alzheimer\u2019s disease drug Leqembi will be covered by the U.S. Department of Veterans Affairs, the first major insurer to agree to pay for the drug since its approval by U.S. regulators earlier this year.  Eisai said Monday veterans with the early stages of Alzheimer\u2019s would get the drug covered under criteria set by the VA.  An estimated 167,954 veterans receiving care through the VA have Alzheimer\u2019s dementia, according to government estimates.""}, {""date"": ""20230313170158"", ""headline"": ""UPDATE 1-US VA to cover Eisai, Biogen Alzheimer's treatment Leqembi"", ""summary"": ""Eisai Co Ltd and Biogen Inc said on Monday that the U.S. Department of Veteran Affairs (VA) will provide coverage of their Alzheimer's treatment Leqembi to veterans at an early stage of the memory-robbing disease.  The VA did not immediately respond to a request for comment, but a document on its website shows that the agency added Leqembi to its list nonformulary drugs, making it available provided patients request it, receive prior approval, and meet strict inclusion criteria for the drug's use.""}, {""date"": ""20230313170202"", ""headline"": ""US VA to cover Eisai, Biogen Alzheimer's treatment Leqembi"", ""summary"": ""Eisai Co Ltd and Biogen Inc said on Monday that the U.S. Department of Veteran Affairs (VA) will provide coverage of their Alzheimer's treatment Leqembi to veterans at an early stage of the memory-robbing disease.""}, {""date"": ""20230314011100"", ""headline"": ""Analysts` Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Illumina (ILMN) and Arcutis Biotherapeutics (ARQT)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230314023500"", ""headline"": ""Biogen appoints Triano as Head of Investor Relations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230314035900"", ""headline"": ""Veterans Health to cover Eisai, Biogen`s new Alzheimer`s drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230314073000"", ""headline"": ""Biogen Appoints Chuck Triano as Head of Investor Relations"", ""summary"": ""CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced the appointment of Chuck Triano as Senior Vice President, Head of Investor Relations effective 10 April 2023. Mr. Triano will report to Michael McDonnell, Executive Vice President and Chief Financial Officer. \u201cChuck will bring invaluable industry insights and a strong network of relationships to Biogen, and I\u2019m pleased to welcome him to our leadership team,\u201d said Michael McDonnell, Executive Vice Pres""}, {""date"": ""20230314085700"", ""headline"": ""Veterans Health to cover Eisai, Biogen\u2019s new Alzheimer\u2019s drug"", ""summary"": ""Eisai Co. Ltd.  (JP:4523)  said Tuesday that the Veterans Health Administration will cover Leqembi, the Alzheimer\u2019s disease treatment it developed with Biogen Inc.  (BIIB)  that received an accelerated approval in January.  The drug is not broadly covered at this time by the Centers for Medicare and Medicaid Services given its accelerated approval status.  \u201cWe see the VHA decision as the beginning of a potential series of wins on the reimbursement front for Leqembi, with the larger catalyst being the CMS potentially revisiting the currently restrictive [national coverage determination] after full approval,\u201d William Blair analysts told investors on Monday.""}, {""date"": ""20230314102300"", ""headline"": ""1 Reason to Buy Biogen Stock, and 1 Reason to Sell"", ""summary"": ""Biogen (NASDAQ: BIIB) has been one of the more notable names in the biotech industry in the past four years -- and not always for the best of reasons.  U.S. approval of Biogen's Aduhelm for treating Alzheimer's disease (AD) turned out to be a bit of a flop as the medicine isn't generating anywhere near the kinds of sales the drugmaker hoped to see.  Let's consider one reason the answer might be yes, and one reason to be wary of Biogen's future.""}, {""date"": ""20230314105200"", ""headline"": ""The VA Will Pay for Leqembi. It\u2019s a Step in Right Direction for Biogen."", ""summary"": ""The biotech and its partner Eisai are seeking to get Medicare to pay for the new Alzheimer's disease therapy.""}, {""date"": ""20230314124000"", ""headline"": ""Biogen Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. rallied 1.47% to $262.35 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230314181510"", ""headline"": ""Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know"", ""summary"": ""In the latest trading session, Biogen Inc. (BIIB) closed at $262.35, marking a +1.47% move from the previous day.""}, {""date"": ""20230315065500"", ""headline"": ""Needham healthcare analyst to hold an analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230315124000"", ""headline"": ""Biogen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Biogen Inc. inched 0.01% higher to $262.37 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...""}, {""date"": ""20230315180010"", ""headline"": ""Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know"", ""summary"": ""Biogen Inc. (BIIB) closed the most recent trading day at $262.37, moving +0.01% from the previous trading session.""}, {""date"": ""20230316013200"", ""headline"": ""Biogen receives favorable court ruling on TECFIDERA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230316020500"", ""headline"": ""Biogen gets EU court ruling in favor of blocking Tecfidera generic entry"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230316023114"", ""headline"": ""PBE: Healthcare Dashboard For March"", ""summary"": ""Healthcare equipment is the less attractive subsector regarding both valuation and quality. Click here to find out why PBE is a Hold.""}, {""date"": ""20230316030900"", ""headline"": ""Wall Street Breakfast: Credit Suisse`s $54B Lifeline"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230316035000"", ""headline"": ""Biogen And Eisai`s Leqembi: A Dose Of Reality For Alzheimer`s Disease"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230316035738"", ""headline"": ""Wall Street Breakfast: Credit Suisse's $54B Lifeline"", ""summary"": ""Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.""}, {""date"": ""20230316044538"", ""headline"": ""Biogen And Eisai's Leqembi: A Dose Of Reality For Alzheimer's Disease"", ""summary"": ""Biogen and Eisai are confident that the FDA will grant full approval for Leqembi for Alzheimer's disease. Find out why BIIB and ESALY could experience a substantial boost.""}, {""date"": ""20230316063000"", ""headline"": ""Biogen Receives Favorable Decision from Court of Justice of the European Union\u00a0Relating to TECFIDERA\u00ae (dimethyl fumarate) Regulatory Data and Marketing Protection"", ""summary"": ""CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Court of Justice of the European Union decided in favor of Biogen, the European Medicines Agency (EMA), and the European Commission in their appeal of a General Court decision annulling the EMA\u2019s refusal to evaluate a generic version of TECFIDERA\u00ae (dimethyl fumarate) because of TECFIDERA\u2019s regulatory data and marketing protection. With this favorable decision, Biogen believes that TECFIDERA i""}, {""date"": ""20230316084312"", ""headline"": ""Biogen (BIIB) Up 29% in a Year Despite Multiple Challenges"", ""summary"": ""Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, potential new product launches such as Leqembi (Alzheimer's disease) and zuranolone (depression) can help revive growth.""}, {""date"": ""20230316124000"", ""headline"": ""Biogen Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. rose 1.10% to $265.25 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""20230316140051"", ""headline"": ""Alzheimer's Association Launches Grassroots Level Lobbying For Medicare Coverage Of Alzheimer's Treatments"", ""summary"": ""https://cdn.benzinga.com/files/images/story/2023/03/16/dementia-3051832_1920.jpg?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 The Alzheimer's Association has launched a grassroots lobbying campaign while deploying 1,000 people, either patients or caring for someone with the disease, to meet with all 535 members of Congress across the U.S. and urge them to press Medicare program for the drugs starting with Biogen Inc (NASDAQ: BIIB) Leqembi (lecanemab). According to interviews with four Associa""}, {""date"": ""20230317035100"", ""headline"": ""Stifel trims Biogen target, but has more confidence lecanemab `best-in-class`"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230317080019"", ""headline"": ""Is There An Opportunity With Biogen Inc.'s (NASDAQ:BIIB) 27% Undervaluation?"", ""summary"": ""Key Insights The projected fair value for Biogen is US$362 based on 2 Stage Free Cash Flow to Equity Biogen's US$265...""}, {""date"": ""20230317113003"", ""headline"": ""Biogen Inc. (BIIB) Down 2.3% Since Last Earnings Report: Can It Rebound?"", ""summary"": ""Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.""}, {""date"": ""20230317124000"", ""headline"": ""Biogen Inc. stock falls Friday, still outperforms market"", ""summary"": ""Shares of Biogen Inc. dropped 0.79% to $263.16 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230317144500"", ""headline"": ""Sangamo Shares Down 8% After Hours as Novartis, Biogen End Collaborations"", ""summary"": ""By Josh Beckerman Sangamo Therapeutics Inc. shares were down 8% to $1.84 after hours as the company said Novartis AG and Biogen Inc. terminated collaboration...""}, {""date"": ""20230317154400"", ""headline"": ""Stocks to Watch: Credit Suisse, First Republic Bank, Sangamo"", ""summary"": ""By Sabela Ojea Credit Suisse Group AG is in discussions for all or parts of the bank to be taken over by UBS Group AG, the Financial Times reported on...""}, {""date"": ""20230319053000"", ""headline"": ""Should You Buy Biogen Before a Big July Decision?"", ""summary"": ""Over time, Biogen (NASDAQ: BIIB) created a true success story.  Competition for Biogen's MS blockbuster Tecfidera, and for other key products, entered the market.  Now, though, Biogen may have found that new growth source.""}]",{}
10,2023-03-19,263.1600036621094,2023-03-26,270.0299987792969,0.026105772235846203,U3,"[{""date"": ""20230319053000"", ""headline"": ""Should You Buy Biogen Before a Big July Decision?"", ""summary"": ""Over time, Biogen (NASDAQ: BIIB) created a true success story.  Competition for Biogen's MS blockbuster Tecfidera, and for other key products, entered the market.  Now, though, Biogen may have found that new growth source.""}, {""date"": ""20230320020100"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Biogen (BIIB), Sarepta Therapeutics (SRPT) and G1 Therapeutics (GTHX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230320041900"", ""headline"": ""FDA posts briefing document for advisors` review of Biogen`s ALS drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230320055100"", ""headline"": ""FDA scientists weigh potential effect of Biogen ALS drug ahead of advisory meeting"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230320062500"", ""headline"": ""Biogen, Eisai Alzheimer`s drug Leqembi covered by VA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230320095130"", ""headline"": ""UPDATE 2-FDA staff says safety issues with Biogen's ALS drug to not prevent approval"", ""summary"": ""The U.S. health regulator's staff said on Monday safety issues with Biogen Inc's drug to treat an ultra-rare form of amyotrophic lateral sclerosis or ALS, also known as Lou Gehrig's disease, should not prevent its accelerated approval.  A panel of outside advisers to the U.S. Food and Drug Administration on Wednesday will closely scrutinize mixed efficacy data from the drug's late-stage trial and vote on the drug's effectiveness, and if reduction of a key protein related to the disease is enough to conclude that it may benefit ALS patients.""}, {""date"": ""20230320105303"", ""headline"": ""FDA staff says Biogen's ALS drug may have a 'clinical benefit' on a rare form of the disease"", ""summary"": ""The FDA staff on Monday said Biogen's investigational ALS drug tofersen may have a \""clinical benefit\"" on a rare and aggressive form of the disease.""}, {""date"": ""20230320113428"", ""headline"": ""FDA staff says safety issues with Biogen's ALS drug to not prevent approval"", ""summary"": ""The U.S. health regulator's staff said on Monday safety issues with Biogen Inc's drug to treat an ultra-rare form of amyotrophic lateral sclerosis or ALS, also known as Lou Gehrig's disease, should not prevent its accelerated approval.""}, {""date"": ""20230320122522"", ""headline"": ""Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With Sangamo"", ""summary"": ""https://cdn.benzinga.com/files/images/story/2023/03/20/sgmo_logo_light__df15263084666d45f8f072d9581b42da.png?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 Two big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days. On Friday, the company filed an SEC document, Novartis AG (NYSE: NVS) terminated the Collaboration and License Agreement dated July 27, 2020, effective June 11, 2023. The Novartis and Sangamo were engaged in programs to rese""}, {""date"": ""20230321025700"", ""headline"": ""FDA briefing docs suggest FDA in favor of Biogen`s tofersen, says BofA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230321035100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Danaher (DHR) and Blueprint Medicines (BPMC)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230321064600"", ""headline"": ""Wall Street predicts approval for another ALS drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230321074400"", ""headline"": ""Wall Street analysts predict approval for another ALS drug"", ""summary"": ""An FDA advisory committee is set to meet this week to discuss a drug developed by Biogen and Ionis to treat a rare form of Lou Gehrig's disease.""}, {""date"": ""20230321085925"", ""headline"": ""Despite Failed Phase 3 Study, FDA Staff Says Biogen's ALS Drug May Have Clinical Benefit"", ""summary"": ""FDA's Peripheral and Central Nervous System Drugs Advisory Committee will virtually meet on Wednesday, March 22, to discuss Biogen Inc's (NASDAQ: BIIB) ALS drug tofersen. FDA staff, citing a briefing document, said Biogen's investigational ALS drug might have a \""clinical benefit\"" on a rare and aggressive form of the disease, despite failing a broader late-stage clinical trial last year. \""Despite the notable limitations of a failed study and the many post hoc exploratory analyses conducted after""}, {""date"": ""20230321124000"", ""headline"": ""Biogen Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slipped 0.66% to $266.15 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230321161355"", ""headline"": ""7 Healthcare Stocks to Buy for Long-Term Growth and Stability"", ""summary"": ""Stock market investors have been on a rollercoaster ride over the past year. The Federal Reserve continues to be hawkish in controlling inflation. All while the global economic backdrop is marred by China and the Russia/Ukraine War. Therefore, investing in defensive investment options, such as the best healthcare stocks to buy, is perhaps a more prudent strategy now. Healthcare stocks typically exhibit resilience during economic downturns. All thanks to heightened government healthcare spending,""}, {""date"": ""20230321180010"", ""headline"": ""Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know"", ""summary"": ""Biogen Inc. (BIIB) closed the most recent trading day at $266.15, moving -0.66% from the previous trading session.""}, {""date"": ""20230322001000"", ""headline"": ""Biogen ALS drug tofersen wins unanimous FDA panel recommendation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230322010800"", ""headline"": ""Biogen ALS drug tofersen earns mixed voting by FDA advisory panel"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230322021600"", ""headline"": ""Veterans Health Administration will cover new Alzheimer`s drug. Why won`t Medicare?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230322033700"", ""headline"": ""Inozyme appoints Matthew Winton as COO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230322035700"", ""headline"": ""Biogen provides update on AdCom meeting on Tofersen for SOD1-ALS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230322040500"", ""headline"": ""FDA Peripheral/Central Nervous System Drugs Advisory Committee holds meeting"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230322064000"", ""headline"": ""Why won`t Medicare cover the new Alzheimer`s drug?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230322124000"", ""headline"": ""Biogen Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slid 1.85% to $261.22 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230322133636"", ""headline"": ""FDA advisors vote against effectiveness of Biogen's ALS drug for rare and aggressive form of the disease "", ""summary"": ""FDA advisors voted against the effectiveness of Biogen's investigational ALS drug, which could become the first to target a genetic cause of the disease.""}, {""date"": ""20230322142700"", ""headline"": ""Biogen ALS drug considered not effective by FDA advisory panel"", ""summary"": ""Biogen Inc. received a setback late Wednesday after a Food and Drug Administration advisory committee said the biotech drug maker\u2019s proposed amyotrophic...""}, {""date"": ""20230322172919"", ""headline"": ""UPDATE 2-US FDA panel says current data not 'convincing' for Biogen's ALS drug"", ""summary"": ""A panel of advisers to the U.S. health regulator said on Wednesday there was not enough convincing evidence to show the effectiveness of Biogen Inc's experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS).  The U.S. Food and Drug Administration (FDA) panel voted 5 to 3 that the late-stage data for the drug, tofersen, did not show it was an effective treatment for ALS patients with mutations in a specific gene that leads to accumulation of toxic levels of a protein known as superoxide dismutase 1 (SOD1).  One panelist abstained.""}, {""date"": ""20230322183255"", ""headline"": ""US FDA panel says current data not 'convincing' for Biogen's ALS drug"", ""summary"": ""A panel of advisers to the U.S. health regulator said on Wednesday there was not enough convincing evidence to show the effectiveness of Biogen Inc's experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS).""}, {""date"": ""20230322203100"", ""headline"": ""Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS"", ""summary"": ""SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United StatesCAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug Administration\u2019s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational product for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). On the question, \u201cIs the available evidenc""}, {""date"": ""20230323013500"", ""headline"": ""Biogen (BIIB) Receives a Hold from BTIG"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230323013500"", ""headline"": ""Raymond James Sticks to Its Hold Rating for Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230323014000"", ""headline"": ""Analysts` Top Healthcare Picks: Biogen (BIIB), Applied DNA Sciences (APDN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230323033100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Regeneron (REGN) and Alcon (ALC)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230323040300"", ""headline"": ""Elliott Wave Technical Analysis: Biogen Inc. - Thursday, March 23"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230323060938"", ""headline"": ""The Petri Dish: Takeda scores win from Nimbus licensing deal; Biogen exits partnership"", ""summary"": ""Takeda paid Nimbus Therapeutics $4 billion for a psoriasis drug in December. It just met its primary goal in a midstage trial.""}, {""date"": ""20230323064231"", ""headline"": ""US FDA panel backs accelerated approval for Biogen's ALS drug"", ""summary"": ""A panel of advisers to the U.S. drug regulator voted that data on Biogen Inc's experimental treatment for ALS, also known as Lou Gehrig's disease, shows that the drug could work, potentially paving the way for an accelerated approval.""}, {""date"": ""20230323065100"", ""headline"": ""May 5th Options Now Available For Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230323091228"", ""headline"": ""FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder"", ""summary"": ""The FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 9 yes - 0 no, indicating sufficient evidence showing a reduction in plasma neurofilament light chain (NfL) concentration in tofersen-treated patients is reasonably likely to predict the clinical benefit of tofersen for SOD1-ALS patients. Biogen Inc (NASDAQ: BIIB) licensed tofersen from Ionis Pharmaceuticals Inc (NASDAQ: IONS) under a collaborative development and license agreement. Neurofilament light chain (NfL) is a""}, {""date"": ""20230323105302"", ""headline"": ""Biogen (BIIB) Gets Positive FDA Panel Vote for Tofersen NDA"", ""summary"": ""The FDA committee supports an accelerated approval of Biogen's (BIIB) tofersen for treating SOD1-ALS. The committee does not believe the data supports a traditional/standard approval for tofersen.""}, {""date"": ""20230323135105"", ""headline"": ""Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval"", ""summary"": ""Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.""}, {""date"": ""20230323135639"", ""headline"": ""7 Blue-Chip Stocks Sitting in the Sweet Spot"", ""summary"": ""Although blue-chip stocks often carry a reputation for being lumbering giants that might not kill your portfolio but certainly won\u2019t do it any favors, specific stalwarts can get the business done. In other words, these enterprises hit the sweet spot: they\u2019re tied to well-established businesses that also offer double-digit (percentage) upside potential, as determined by Wall Street analysts. Further, adding to the sweet nature of these blue-chip stocks, they\u2019re all undervalued based on earnings m""}, {""date"": ""20230323160326"", ""headline"": ""Biogen Pops \u2014 But Ionis Hands Back Gains \u2014 After ALS Drug Wins A Key Endorsement"", ""summary"": ""Biogen stock jumped \u2014 as Ionis stock gave back early gains \u2014 after a FDA panel offered a mixed view of their ALS treatment.""}, {""date"": ""20230324013300"", ""headline"": ""5 Best Healthcare Stocks to Invest in Now, According to Analysts"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230324124000"", ""headline"": ""Biogen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Biogen Inc. advanced 1.83% to $270.03 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230326090031"", ""headline"": ""Biogen Inc. (NASDAQ:BIIB) is a favorite amongst institutional investors who own 88%"", ""summary"": ""Key Insights Given the large stake in the stock by institutions, Biogen's stock price might be vulnerable to their...""}]",{}
11,2023-03-26,270.0299987792969,2023-04-02,278.0299987792969,0.02962633794824643,U3,"[{""date"": ""20230326090031"", ""headline"": ""Biogen Inc. (NASDAQ:BIIB) is a favorite amongst institutional investors who own 88%"", ""summary"": ""Key Insights Given the large stake in the stock by institutions, Biogen's stock price might be vulnerable to their...""}, {""date"": ""20230327114203"", ""headline"": ""Ionis (IONS) Posts New Upbeat Data From Amyloidosis Drug Study"", ""summary"": ""Ionis (IONS) reports positive long-term phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).""}, {""date"": ""20230327124000"", ""headline"": ""Biogen Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. shed 0.02% to $269.98 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230327181510"", ""headline"": ""Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know"", ""summary"": ""Biogen Inc. (BIIB) closed at $269.98 in the latest trading session, marking a -0.02% move from the prior day.""}, {""date"": ""20230328082200"", ""headline"": """", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230328082600"", ""headline"": ""VRTX, BIIB, or IQV: Which Biotech Stock Could Deliver Best Returns?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230328083500"", ""headline"": ""VRTX, BIIB, or IQV: Which Biotech Stock Could Deliver the Highest Returns?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230328084100"", ""headline"": ""VRTX, BIIB, or IQV: Which Biotech Stock Could Deliver the Highest Return?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230328124000"", ""headline"": ""Biogen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Biogen Inc. inched 0.10% higher to $270.25 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""20230329034900"", ""headline"": ""Ionis Pharmaceuticals` IONIS-MAPTRx shows tau reduction efficacy in Alzheimer`s"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230329035400"", ""headline"": ""Biogen says BIIB080 `substantially reduced` tau protein level in early-stage AD"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230329084500"", ""headline"": ""New Data Presented at AD/PD\u2122 2023 Show Biogen\u2019s BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer\u2019s Disease"", ""summary"": ""The BIIB080 Phase 1b clinical study is the first to show a reduction of this magnitude in tau PET across brain regionsPhase 1b Study of BIIB080 showed dose-dependent and sustained reduction of tau protein (CSF t-tau and p-tau181) in the cerebral spinal fluid (CSF) throughout the open-label long-term extension (LTE)Neurofibrillary tangles in the brain are composed of tau proteins and are a key pathology associated with Alzheimer\u2019s disease1 CAMBRIDGE, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Biog""}, {""date"": ""20230329124000"", ""headline"": ""Biogen Inc. stock rises Wednesday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. advanced 1.39% to $274.01 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""20230329180010"", ""headline"": ""Biogen Inc. (BIIB) Gains But Lags Market: What You Should Know"", ""summary"": ""Biogen Inc. (BIIB) closed at $274.01 in the latest trading session, marking a +1.39% move from the prior day.""}, {""date"": ""20230330023600"", ""headline"": ""Biogen announces detailed analyses from phase 2 study of Lecanemab"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230330062532"", ""headline"": ""15 Cheap Beginner Stocks to Buy"", ""summary"": ""In this article, we will take a look at 15 cheap stocks to buy now for beginners. If you want to explore similar stocks, you can also take a look at 5 Cheap Beginner Stocks to Buy. Morgan Stanley\u2019s Big Bear: \u201cIt\u2019s Just A Much Less Predictable World\u201d On March 27 Morgan Stanley\u2019s chief U.S. [\u2026]""}, {""date"": ""20230330113003"", ""headline"": ""Novavax (NVAX) Down 2.9% Since Last Earnings Report: Can It Rebound?"", ""summary"": ""Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.""}, {""date"": ""20230330124000"", ""headline"": ""Biogen Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.41% higher to $275.13 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""20230330193000"", ""headline"": ""Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD\u2122 2023 Annual Meeting"", ""summary"": ""TOKYO and CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \""Eisai\"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \""Biogen\"") announced today that Eisai presented new analyses on amyloid-related imaging abnormalities (ARIA) with the use of antiplatelet and anticoagulant medications, isolated ARIA-H, and caregiver burden and health-related quality of life (QOL), from the re""}, {""date"": ""20230330193100"", ""headline"": ""ADDITIONAL DETAILED ANALYSES FROM PHASE 2 STUDY 201 OF LECANEMAB PUBLISHED AS THREE PAPERS IN PEER-REVIEWED JOURNALS"", ""summary"": ""Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \""Eisai\"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \""Biogen\"") announced today that three additional detailed analyses from the Phase IIb clinical study (Study 201), evaluating the efficacy and safety of lecanemab for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD), were published in the peer-reviewed journals.""}, {""date"": ""20230331095751"", ""headline"": ""Eisai-Biogen Highlights Additional Data From Recently Approved Alzheimer's Drug"", ""summary"": ""Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) announced that three additional detailed analyses from the Phase IIb clinical study (Study 201) of lecanemab for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD were published in the peer-reviewed journals. In the core 201 study, lecanemab was shown to reduce brain A\u03b2 accumulation measured by amyloid PET in a dose- and time-dependent manner after 12 and 18 months of treatment, and corresponding changes in plasma""}, {""date"": ""20230331124000"", ""headline"": ""Biogen Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. advanced 1.05% to $278.03 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""20230401080014"", ""headline"": ""Do Fundamentals Have Any Role To Play In Driving Biogen Inc.'s (NASDAQ:BIIB) Stock Up Recently?"", ""summary"": ""Biogen's (NASDAQ:BIIB) stock is up by 3.0% over the past week. As most would know, long-term fundamentals have a strong...""}]","{""assetTurnoverTTM"": 0.4079, ""bookValue"": 13796, ""cashRatio"": 0.9611940298507463, ""currentRatio"": 3.2381, ""ebitPerShare"": 3.4966, ""eps"": 2.6715, ""ev"": 43556.344, ""fcfMargin"": 0.1558, ""fcfPerShareTTM"": 9.7993, ""grossMargin"": 0.7309, ""inventoryTurnoverTTM"": 1.7526, ""longtermDebtTotalAsset"": 0.2554, ""longtermDebtTotalCapital"": 0.3129, ""longtermDebtTotalEquity"": 0.4554, ""netDebtToTotalCapital"": 0.1686, ""netDebtToTotalEquity"": 0.2453, ""netMargin"": 0.1575, ""operatingMargin"": 0.2061, ""pb"": 2.9118, ""peTTM"": 12.8302, ""pfcfTTM"": 23.8646, ""pretaxMargin"": 0.178, ""psTTM"": 3.9756, ""ptbv"": 3.3524, ""quickRatio"": 2.8133, ""receivablesTurnoverTTM"": 4.9912, ""roaTTM"": 0.1264, ""roeTTM"": 0.2416, ""roicTTM"": 0.1606, ""rotcTTM"": 0.2036, ""salesPerShare"": 16.9628, ""sgaToSale"": 0.2691, ""tangibleBookValue"": 11983, ""totalDebtToEquity"": 0.4554, ""totalDebtToTotalAsset"": 0.2554, ""totalDebtToTotalCapital"": 0.3129, ""totalRatio"": 2.2772, ""period"": ""2023-03-31""}"
12,2023-04-02,278.0299987792969,2023-04-09,286.79998779296875,0.03154331925395426,U4,"[{""date"": ""20230403021000"", ""headline"": ""US to create Alzheimer`s research database in ~$300M project - report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230403124000"", ""headline"": ""Biogen Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. slid 0.25% to $277.34 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230404023800"", ""headline"": ""Biogen appoints Keeney as Head of Corporate Development"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230404072700"", ""headline"": ""Biogen names Adam Keeney to head corporate development"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230404073000"", ""headline"": ""Biogen Appoints Adam Keeney as Head of Corporate Development"", ""summary"": ""CAMBRIDGE, Mass., April 04, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Adam Keeney, Ph.D., as Executive Vice President, Head of Corporate Development effective 17 April 2023. Dr. Keeney will be a member of Biogen\u2019s Executive Committee reporting to Christopher A. Viehbacher, President and Chief Executive Officer. \u201cWe welcome Adam Keeney to our executive leadership team in this important role at this pivotal time for Biogen. Adam brings considerable expe""}, {""date"": ""20230404124000"", ""headline"": ""Biogen Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Biogen Inc. shed 0.75% to $275.25 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230404181510"", ""headline"": ""Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know"", ""summary"": ""In the latest trading session, Biogen Inc. (BIIB) closed at $275.25, marking a -0.75% move from the previous day.""}, {""date"": ""20230404230919"", ""headline"": ""U.S. Wide-Moat Stocks On Sale - The April 2023 Heat Map"", ""summary"": ""We believe that the most widely used valuation multiples are terribly flawed. Click here for a complete analysis.""}, {""date"": ""20230405020800"", ""headline"": ""JPMorgan sees favorable risk/rewards for Eli Lilly, Biogen into data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230405062131"", ""headline"": ""Eli Lilly says experimental Alzheimer's drug reduces brain plaque in early study"", ""summary"": ""Eli Lilly said a higher dose of the up-and-coming Alzheimer's treatment remternetug had a larger effect on clearing amyloid plaque. ""}, {""date"": ""20230405091009"", ""headline"": ""Top Insider Picks For March 2023"", ""summary"": ""The month of March had a couple of very interesting insider purchases. In this article, we discuss some of the biggest insider purchases by value. Read more here.""}, {""date"": ""20230405124000"", ""headline"": ""Biogen Inc. stock underperforms Wednesday when compared to competitors despite daily gains"", ""summary"": ""Shares of Biogen Inc. rose 3.18% to $283.99 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""20230406022802"", ""headline"": ""Biogen And Eisai, Cassava Sciences, And Anavex: Clinical Trial Results In Need Of Revisions"", ""summary"": ""Biogen, Eisai, Cassava Sciences, and Anavex have all provided data for their Alzheimer\u00e2\u0080\u0099s drugs that hide a deeper reality. See why AVXL stock is a Buy.""}, {""date"": ""20230406073800"", ""headline"": ""FDA forces pre-term birth drug off the market after 12 years"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230406075132"", ""headline"": ""Ionis And Biogen: Tofersen PDUFA Looms - Positive Outcome May Kick Off Bull Run For Both Stocks"", ""summary"": ""Ionis and Biogen have been partnering on antisense drug development for a decade. Read why significant growth could be ahead for this alliance.""}, {""date"": ""20230406100019"", ""headline"": ""The 35% return delivered to Biogen's (NASDAQ:BIIB) shareholders actually lagged YoY earnings growth"", ""summary"": ""These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But if you pick...""}, {""date"": ""20230406124000"", ""headline"": ""Biogen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Biogen Inc. inched 0.99% higher to $286.80 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""20230406132035"", ""headline"": ""Alzheimer\u2019s patients retain the benefits of Leqembi even when they stop the drug, Eisai says"", ""summary"": ""Alzheimer's patients who take Leqembi retain the benefits of the treatment even when they stop taking it, new research by Eisai and Biogen shows. ""}, {""date"": ""20230406233000"", ""headline"": ""The 3 Best Millionaire-Maker Stocks to Buy for April 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230407044600"", ""headline"": ""RBC Capital Sticks to Their Buy Rating for Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230407073400"", ""headline"": ""Steven Cohen Loads Up on Esperion Therapeutics as Shares Slide"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]","{""assetTurnoverTTM"": 0.4079, ""bookValue"": 13796, ""cashRatio"": 0.9611940298507463, ""currentRatio"": 3.2381, ""ebitPerShare"": 3.4966, ""eps"": 2.6715, ""ev"": 43556.344, ""fcfMargin"": 0.1558, ""fcfPerShareTTM"": 9.7993, ""grossMargin"": 0.7309, ""inventoryTurnoverTTM"": 1.7526, ""longtermDebtTotalAsset"": 0.2554, ""longtermDebtTotalCapital"": 0.3129, ""longtermDebtTotalEquity"": 0.4554, ""netDebtToTotalCapital"": 0.1686, ""netDebtToTotalEquity"": 0.2453, ""netMargin"": 0.1575, ""operatingMargin"": 0.2061, ""pb"": 2.9118, ""peTTM"": 12.8302, ""pfcfTTM"": 23.8646, ""pretaxMargin"": 0.178, ""psTTM"": 3.9756, ""ptbv"": 3.3524, ""quickRatio"": 2.8133, ""receivablesTurnoverTTM"": 4.9912, ""roaTTM"": 0.1264, ""roeTTM"": 0.2416, ""roicTTM"": 0.1606, ""rotcTTM"": 0.2036, ""salesPerShare"": 16.9628, ""sgaToSale"": 0.2691, ""tangibleBookValue"": 11983, ""totalDebtToEquity"": 0.4554, ""totalDebtToTotalAsset"": 0.2554, ""totalDebtToTotalCapital"": 0.3129, ""totalRatio"": 2.2772, ""period"": ""2023-03-31""}"
13,2023-04-09,286.79998779296875,2023-04-16,288.1300048828125,0.004637437749139162,U1,"[{""date"": ""20230409225700"", ""headline"": ""FDA AdCom to convene on June 9th to discuss Biogen/Eisai`s LEQEMBI in AD"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230410073402"", ""headline"": ""Pfizer CEO signs open letter calling for reversal of Texas abortion pill ruling"", ""summary"": ""Pfizer's CEO was among the more than 200 pharmaceutical company executives who signed the letter after a federal judge's controversial ruling on mifepristone.""}, {""date"": ""20230410085600"", ""headline"": ""Biogen, Eisai to face FDA AdCom in June for full approval of Alzheimer`s drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230410100121"", ""headline"": ""US FDA advisers to weigh full approval for Eisai-Biogen's Alzheimer's drug"", ""summary"": ""The U.S. Food and Drug Administration (FDA) plans to hold a meeting of its outside experts in June to discuss full approval of the Alzheimer's drug developed by Eisai Co Ltd and Biogen Inc, according to a federal filing on Monday.""}, {""date"": ""20230410124000"", ""headline"": ""Biogen Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. shed 1.37% to $282.86 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230411005000"", ""headline"": ""Drugmakers call for abortion pill ruling reversal, Reuters reports"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230411040300"", ""headline"": ""US DOJ asks appeals court to block Texas judge abortion pill ruling"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230411045100"", ""headline"": ""3 Biotech Stocks to Watch for Potential Breakthroughs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230411074000"", ""headline"": ""Analysts Have Conflicting Sentiments on These Healthcare Companies: Centene (CNC), Ionis Pharmaceuticals (IONS) and Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230411100013"", ""headline"": ""Is Biogen (NASDAQ:BIIB) Using Too Much Debt?"", ""summary"": ""Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...""}, {""date"": ""20230411124000"", ""headline"": ""Biogen Inc. stock rises Tuesday, outperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.29% higher to $283.69 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...""}, {""date"": ""20230411175220"", ""headline"": ""Needham Reiterates Biogen (BIIB) Buy Recommendation"", ""summary"": """"}, {""date"": ""20230411222628"", ""headline"": ""Why Healthcare Stocks Are A Prescription For Investors In Q2 2023"", ""summary"": ""The recent drop in biopharma stocks presents a buying opportunity for investors. Find out why XLV seems like the best fit.""}, {""date"": ""20230412012800"", ""headline"": ""Biogen price target lowered to $307 from $310 at Barclays"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230412024300"", ""headline"": ""Biogen price target lowered to $349 from $351 at Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230412030700"", ""headline"": ""Biogen exercises option with Denali to develop its ATV:ABeta program"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230412033800"", ""headline"": ""Biogen licenses amyloid beta-related program from Denali"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230412042500"", ""headline"": ""Truist biotechnology analyst to hold an analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230412080000"", ""headline"": ""Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta"", ""summary"": ""Program uses Denali\u2019s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagementCAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that Biogen has exercised the option to license Denali\u2019s Antibody Transport Vehicle (ATV):Amyloid beta program (ATV:A\u03b2). Accumulation of A\u03b2 plaque in the brain is a defining feature of""}, {""date"": ""20230412124300"", ""headline"": ""Biogen exercises option to license Denali treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230412171125"", ""headline"": ""Morgan Stanley Maintains Biogen (BIIB) Overweight Recommendation"", ""summary"": """"}, {""date"": ""20230413000900"", ""headline"": ""Appeals court permits limited access to abortion pill, blocks part of Texas ruling"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230413075200"", ""headline"": ""June 2nd Options Now Available For Biogen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230413124000"", ""headline"": ""Biogen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Biogen Inc. rallied 1.37% to $289.70 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""20230413213700"", ""headline"": ""Earnings Week Ahead: Tesla, AT&T, Charles Schwab, Netflix, and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230414003700"", ""headline"": ""Ghana 1st in world to approve new malaria vaccine by Oxford"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230414044000"", ""headline"": ""Biogen Moves Deeper In Alzheimer`s With Denali"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230414083200"", ""headline"": ""Catalyst Watch: Earnings season picks up steam, housing data due"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230414124000"", ""headline"": ""Biogen Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slid 0.54% to $288.13 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230416013800"", ""headline"": ""7 Sorry Pharma Stocks to Sell in April Before It`s Too Late"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230416090028"", ""headline"": ""Biogen Inc.'s (NASDAQ:BIIB) Intrinsic Value Is Potentially 32% Above Its Share Price"", ""summary"": ""Key Insights Biogen's estimated fair value is US$379 based on 2 Stage Free Cash Flow to Equity Biogen's US$288 share...""}, {""date"": ""20230416120824"", ""headline"": ""3 Stocks to Buy That Could Be the Next Biotech Breakthrough"", ""summary"": ""In general, biotech stocks are not ideal for conservative investors. The companies in search of the next medical breakthrough are inherently risky. If they fail, their stocks can languish at very low prices\u2026 or worse. But if they succeed, shareholders can see outstanding returns. It\u2019s not quite a zero-sum game, but it\u2019s close. That said, there are ways to limit risk when buying biotech stocks. Specifically, I look for undervalued companies that have already produced positive clinical trial data.""}]","{""assetTurnoverTTM"": 0.4079, ""bookValue"": 13796, ""cashRatio"": 0.9611940298507463, ""currentRatio"": 3.2381, ""ebitPerShare"": 3.4966, ""eps"": 2.6715, ""ev"": 43556.344, ""fcfMargin"": 0.1558, ""fcfPerShareTTM"": 9.7993, ""grossMargin"": 0.7309, ""inventoryTurnoverTTM"": 1.7526, ""longtermDebtTotalAsset"": 0.2554, ""longtermDebtTotalCapital"": 0.3129, ""longtermDebtTotalEquity"": 0.4554, ""netDebtToTotalCapital"": 0.1686, ""netDebtToTotalEquity"": 0.2453, ""netMargin"": 0.1575, ""operatingMargin"": 0.2061, ""pb"": 2.9118, ""peTTM"": 12.8302, ""pfcfTTM"": 23.8646, ""pretaxMargin"": 0.178, ""psTTM"": 3.9756, ""ptbv"": 3.3524, ""quickRatio"": 2.8133, ""receivablesTurnoverTTM"": 4.9912, ""roaTTM"": 0.1264, ""roeTTM"": 0.2416, ""roicTTM"": 0.1606, ""rotcTTM"": 0.2036, ""salesPerShare"": 16.9628, ""sgaToSale"": 0.2691, ""tangibleBookValue"": 11983, ""totalDebtToEquity"": 0.4554, ""totalDebtToTotalAsset"": 0.2554, ""totalDebtToTotalCapital"": 0.3129, ""totalRatio"": 2.2772, ""period"": ""2023-03-31""}"
14,2023-04-16,288.1300048828125,2023-04-23,293.989990234375,0.020337990671765782,U3,"[{""date"": ""20230416013800"", ""headline"": ""7 Sorry Pharma Stocks to Sell in April Before It`s Too Late"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230416090028"", ""headline"": ""Biogen Inc.'s (NASDAQ:BIIB) Intrinsic Value Is Potentially 32% Above Its Share Price"", ""summary"": ""Key Insights Biogen's estimated fair value is US$379 based on 2 Stage Free Cash Flow to Equity Biogen's US$288 share...""}, {""date"": ""20230416120824"", ""headline"": ""3 Stocks to Buy That Could Be the Next Biotech Breakthrough"", ""summary"": ""In general, biotech stocks are not ideal for conservative investors. The companies in search of the next medical breakthrough are inherently risky. If they fail, their stocks can languish at very low prices\u2026 or worse. But if they succeed, shareholders can see outstanding returns. It\u2019s not quite a zero-sum game, but it\u2019s close. That said, there are ways to limit risk when buying biotech stocks. Specifically, I look for undervalued companies that have already produced positive clinical trial data.""}, {""date"": ""20230416233600"", ""headline"": ""What You Missed On Wall Street On Monday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230416233800"", ""headline"": ""Biogen upgraded to overweight at Piper Sandler on bullish Leqembi outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230417000300"", ""headline"": ""Analysts Have Conflicting Sentiments on These Healthcare Companies: Prometheus Biosciences (RXDX), Staar Surgical (STAA) and Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230417000300"", ""headline"": ""Biogen upgraded to Overweight from Neutral at Piper Sandler"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230417042600"", ""headline"": ""Biogen price target raised to $320 from $315 at Argus"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230417045900"", ""headline"": ""Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230417050700"", ""headline"": ""Biogen`s Leqembi has questionable efficacy, cost effectiveness, ICER says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230417070700"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230417072700"", ""headline"": ""Wedbush Sticks to Their Hold Rating for Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230417195654"", ""headline"": ""Wedbush Maintains Biogen (BIIB) Neutral Recommendation"", ""summary"": """"}, {""date"": ""20230417195704"", ""headline"": ""Piper Sandler Upgrades Biogen (BIIB)"", ""summary"": """"}, {""date"": ""20230417221930"", ""headline"": ""Argus Research Maintains Biogen (BIIB) Buy Recommendation"", ""summary"": """"}, {""date"": ""20230417222800"", ""headline"": ""Notable Tuesday Option Activity: BIIB, NKE, SBUX"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230418095300"", ""headline"": ""Is Biogen Stock a Buy Now?"", ""summary"": ""Biotech giant Biogen (NASDAQ: BIIB) has been trying to develop a successful therapy for Alzheimer's disease (AD) for a long time, and its efforts seem to be about to pay off.  Earlier this year, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Leqembi, a treatment for AD that Biogen co-markets with Japan-based drug company Esai.  Accelerated approval currently comes with severe restrictions in the U.S., but Leqembi is under consideration for full approval by the FDA.""}, {""date"": ""20230418100102"", ""headline"": ""Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline"", ""summary"": ""Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.""}, {""date"": ""20230418124000"", ""headline"": ""Biogen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Biogen Inc. inched 0.56% higher to $293.83 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...""}, {""date"": ""20230419020800"", ""headline"": ""Agios Pharmaceuticals appoints Capello to board of directors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230419053700"", ""headline"": ""Four Biotech Stocks for Parkinson's Disease Awareness Month"", ""summary"": ""Anyone whose life has been touched by Parkinson's disease knows the importance of awareness and the development of more effective treatments. Every six minutes, someone in the U.S. is diagnosed with Parkinson's.""}, {""date"": ""20230419102902"", ""headline"": ""Biogen (BIIB) to Report Q1 Earnings: Here's What to Expect"", ""summary"": ""Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of multiple sclerosis drugs, while sales of Spinraza are likely to have improved.""}, {""date"": ""20230419124000"", ""headline"": ""Biogen Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. dropped 0.53% to $292.27 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...""}, {""date"": ""20230419153200"", ""headline"": ""Supreme Court Extends Decision on Abortion Pills to Friday"", ""summary"": ""The court\u2019s decision has broad implications for reproductive rights, for the power of the judicial system, and for the pharmaceutical industry.""}, {""date"": ""20230420100302"", ""headline"": ""Amgen (AMGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?"", ""summary"": ""Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.""}, {""date"": ""20230420124000"", ""headline"": ""Biogen Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. slid 0.68% to $290.27 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230420140000"", ""headline"": ""Better Big Biotech Buy: Biogen vs. Vertex"", ""summary"": ""Two great examples are Biogen (NASDAQ: BIIB) and Vertex Pharmaceuticals (NASDAQ: VRTX).  Biogen is known for its blockbuster multiple sclerosis drugs, including top seller Tecfidera.  Biogen's immunology drug, Rituxan, has also seen sales slip due to biosimilars in the market.""}, {""date"": ""20230420220000"", ""headline"": ""Biopharma Deals Are Hot. There\u2019s More to Come\u2014and These Stocks Can Benefit."", ""summary"": ""In the first quarter of this year, total healthcare and life sciences M&A in the U.S. was about $71 billion, according to KPMG.""}, {""date"": ""20230420220200"", ""headline"": ""Catalyst watch: Earnings blitz, Mobileye lockup expiration and the new one-day VIX debut"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230421030100"", ""headline"": ""Analysts Are Bullish on These Healthcare Stocks: AmerisourceBergen (ABC), Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230421031100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: AmerisourceBergen (ABC), Biogen (BIIB) and Elevance Health (ELV)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230421040400"", ""headline"": ""Biogen price target raised to $300 from $295 at BofA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230421073300"", ""headline"": ""Biogen To Report Q1 Earnings: Here`s What To Expect"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230421083200"", ""headline"": ""Earnings Week Ahead: Amazon, Meta Platforms, Alphabet, Coca-Cola, Boeing, and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230421114236"", ""headline"": ""B of A Securities Maintains Biogen (BIIB) Neutral Recommendation"", ""summary"": """"}, {""date"": ""20230421124000"", ""headline"": ""Biogen Inc. stock rises Friday, outperforms market"", ""summary"": ""Shares of Biogen Inc. advanced 1.28% to $293.99 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""20230421140315"", ""headline"": ""Will US Medicare Fully Cover Alzheimer's Drugs? Eli Lilly Thinks Yes!"", ""summary"": ""Eli Lilly And Co (NYSE: LLY) expects the U.S. Medicare health plan to loosen its grip on the coverage limits on new Alzheimer's drugs, as more data emerging in coming weeks show that clearing amyloid brain plaques can help patients. Lilly plans to release results from a trial of its experimental amyloid-targeting drug donanemab before the end of June. More study data on Leqembi from Eisai Co Ltd (OTC: ESALY)/Biogen Inc (NASDAQ: BIIB) is also expected in the coming months. FDA granted accelerated""}, {""date"": ""20230423070100"", ""headline"": ""What is behind biotech M&A resurgence?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
15,2023-04-23,293.989990234375,2023-04-30,304.2300109863281,0.03483118844893185,U4,"[{""date"": ""20230423070100"", ""headline"": ""What is behind biotech M&A resurgence?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230423233900"", ""headline"": ""FDA PDUFA Date for Ionis Pharmaceuticals & Biogen Tofersen is April 25, 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230424020927"", ""headline"": ""Weekly Biotech Pulse: Vaxxinity results, Biogen's FDA review, and more | Pro Recap"", ""summary"": ""By Vlad Schepkov""}, {""date"": ""20230424052600"", ""headline"": ""Notable earnings before Tuesday`s open"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230424065400"", ""headline"": ""Biogen Q1 results in focus amid Leqembi conundrum, ALS drug future"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230424122100"", ""headline"": ""Biogen Earnings Beat Expectations. All Eyes Are on the Alzheimer\u2019s Drug."", ""summary"": ""The biotch said it was dropping a number of drug-development initiatives, but is open to M&A. The CFO said the company could spend up to $10 billion.""}, {""date"": ""20230424124000"", ""headline"": ""Biogen Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. shed 0.33% to $293.03 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230424180200"", ""headline"": ""Biogen Reports Earnings Tuesday. Watch for Alzheimer\u2019s Drug Updates"", ""summary"": ""Investors already know that the biotech company's base business is shrinking, so few are looking there for growth.""}, {""date"": ""20230424214800"", ""headline"": ""FDA grants accelerated approval to Biogen treatment for rare form of ALS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230424220800"", ""headline"": ""Biogen confirms FDA grants accelerated approval for Qalsody"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230424233100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Cognetivity Neurosciences (OtherCGNSF)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230425005900"", ""headline"": ""Biogen price target raised to $371 from $349 at Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230425010600"", ""headline"": ""Biogen (BIIB) Gets a Buy from Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230425020500"", ""headline"": ""Biogen reports Q1 EPS $3.40, consensus $3.28"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230425020600"", ""headline"": ""Biogen backs FY23 EPS view $15.00-$16.00, consensus $15.48"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230425020900"", ""headline"": ""Biogen Non-GAAP EPS of $3.40 beats by $0.12, revenue of $2.46B beats by $120M"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230425021300"", ""headline"": ""FDA approves Ionis Pharma/Biogen`s QALSODY as first treatment in ALS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230425030500"", ""headline"": ""Biogen trims down R&D programs, Q1 revenue dips but reaffirms FY23 outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230425030500"", ""headline"": ""Biogen (BIIB) Gets a Buy from Mizuho Securities"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230425032500"", ""headline"": ""Biogen tops estimates as revenue slides 3% from a year ago"", ""summary"": ""Biogen Inc. said Tuesday it had net income of $387.9 million, or $2.67 a share, for the first quarter, up from $303.8 million, or $2.06 a share, in the...""}, {""date"": ""20230425040947"", ""headline"": ""PepsiCo, McDonald's and Spotify rise premarket; First Republic slumps"", ""summary"": ""Investing.com -- Stocks in focus in premarket trade on Tuesday, April 25th. Please refresh for updates.""}, {""date"": ""20230425054000"", ""headline"": ""Biogen Inc. Beats Q1 Earnings And Revenue Estimates"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230425070243"", ""headline"": ""Biogen beats profit estimates on strong Spinraza sales"", ""summary"": ""The drugmaker said it would terminate the late and mid-stage studies for an experimental neurological drug due to operational challenges that would help reduce full-year research expenses modestly.  Biogen will also put on hold a mid-stage study of an ischemic stroke drug candidate and scrap its early-stage trial of an experimental treatment for a rare neurodegenerative disease.  The company's new CEO, Christopher Viehbacher, has been looking for ways to keep costs low as Biogen prepares for high-profile launches of its second Alzheimer's disease treatment, Leqembi, and depression drug zuranolone.""}, {""date"": ""20230425072100"", ""headline"": ""Cantor thinks M&A premium `baked into` TG Therapeutics shares will increase"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230425073112"", ""headline"": ""UPDATE 1-Biogen beats profit estimates on strong Spinraza sales"", ""summary"": ""Biogen Inc on Tuesday beat expectations for quarterly profit on strong sales of spinal muscular atrophy drug Spinraza, but said it would pause or discontinue some studies to cut costs.  Biogen will also put on hold a mid-stage study of an ischemic stroke drug candidate and scrap its early-stage trial of an experimental treatment for a rare neurodegenerative disease.  The company's new CEO, Christopher Viehbacher, has been looking for ways to keep costs low as Biogen prepares for high-profile launches of its second Alzheimer's disease treatment, Leqembi, and depression drug zuranolone.""}, {""date"": ""20230425073200"", ""headline"": ""Biogen On The Hunt"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230425081300"", ""headline"": ""FDA approves Biogen`s Qalsody for ALS patients with SOD1 gene mutation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230425082500"", ""headline"": ""BTIG Reaffirms Their Hold Rating on Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230425082512"", ""headline"": ""Biogen Inc. (BIIB) Beats Q1 Earnings and Revenue Estimates"", ""summary"": ""Biogen Inc. (BIIB) delivered earnings and revenue surprises of 4.62% and 5%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?""}, {""date"": ""20230425082700"", ""headline"": ""Biogen touts development pipeline despite quarterly revenue decline"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230425083713"", ""headline"": ""Biogen Inc. (BIIB) Q1 2023 Earnings Call Transcript"", ""summary"": ""Biogen Inc. (NASDAQ:NASDAQ:BIIB) Q1 2023 Earnings Conference Call April 25, 2023 8:00 AM ETCompany ParticipantsChuck Triano - Head of Investor RelationsChristopher Viehbacher - President...""}, {""date"": ""20230425084900"", ""headline"": ""Biogen, Ionis win FDA nod for ALS therapy Qalsody"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230425085300"", ""headline"": ""FDA grants accelerated approval to Biogen`s treatment for rare form of ALS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230425092041"", ""headline"": ""FDA grants accelerated approval for Biogen ALS drug that treats rare form of the disease"", ""summary"": ""The FDA's approval requires Biogen to further study its ALS drug tofersen to further verify its clinical benefits. ""}, {""date"": ""20230425093001"", ""headline"": ""Biogen Inc. (BIIB) Reports Q1 Earnings: What Key Metrics Have to Say"", ""summary"": ""The headline numbers for Biogen Inc. (BIIB) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.""}, {""date"": ""20230425094018"", ""headline"": ""Biogen isn't concerned about competing with Eli Lilly in the Alzheimer\u2019s drug space, CEO says"", ""summary"": ""Biogen CEO Christopher Viehbacher said during an earnings call that Eli Lilly needs to consider maintenance doses its Alzheimer's treatment donanemab. ""}, {""date"": ""20230425095200"", ""headline"": ""FDA grants accelerated approval to Biogen\u2019s treatment for rare form of ALS"", ""summary"": ""The U.S. Food and Drug Administration said Tuesday it has granted accelerated approval to Biogen Inc.\u2019s torferson, a treatment for a rare form of amyotrophic...""}, {""date"": ""20230425095742"", ""headline"": ""Biogen tops 1Q forecast despite sales slip for key products"", ""summary"": ""Biogen beat Wall Street\u2019s first-quarter expectations even as revenue from the drugmaker\u2019s biggest product group tumbled.  Sales of Biogen's multiple sclerosis treatments, which include Tecfidera and Tysabri, fell 19% to $1.12 billion compared to last year\u2019s quarter, the company said Tuesday.  Sales of the drugmaker\u2019s spinal muscular atrophy treatment Spinraza also dropped 6% to $443 million in the quarter.""}, {""date"": ""20230425110247"", ""headline"": ""Biogen trims pipeline programs to cut costs, focus on Alzheimer's drug launch"", ""summary"": ""Biogen Inc said on Tuesday it will pause or discontinue at least four studies of experimental drugs to focus on more potentially lucrative options including its second Alzheimer's treatment, Leqembi, in the latest attempt by the new CEO to trim costs.""}, {""date"": ""20230425113603"", ""headline"": ""Biogen (BIIB) Beats on Q1 Earnings, Ends Some Research Programs"", ""summary"": ""Biogen (BIIB) beats first-quarter estimates for earnings and sales. It maintains its 2023 guidance. Stock drops in pre-market trading.""}, {""date"": ""20230425120207"", ""headline"": ""Biogen Announces Additional Cost Cutting Initiatives, Chops Certain Stroke, Gene Therapy Programs"", ""summary"": ""Biogen Inc (NASDAQ: BIIB) posted Q1 FY23 sales of $2.46 billion, beating the consensus of $2.34 billion, down 3% Y/Y and flat% at constant currency (CC). Multiple sclerosis revenue of $1.125 billion decreased by 19% (down 17% CC). Multiple sclerosis drug Tysabri sales are down to $472.8 million from $520.8 million. Spinraza's revenue of $443.3 million decreased by 6.2% in actual currency (decreased by 2.5% at CC). Biosimilars' revenue of $192.4 million decreased by 1%. Adjusted EPS of $3.40 decr""}, {""date"": ""20230425124000"", ""headline"": ""Biogen Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. shed 3.62% to $282.41 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230425133349"", ""headline"": ""UPDATE 2-US FDA approves Biogen's ALS drug"", ""summary"": ""The U.S. Food and Drug Administration said on Tuesday it had approved Biogen Inc's drug for treating a form of amyotrophic lateral sclerosis (ALS), making it the first available treatment targeting a genetic cause of the disease.  Biogen will be required to provide more data on the drug's effectiveness for it to remain on the market and for the FDA to grant traditional approval.  Qalsody's approval is based on data that showed it reduced levels of neurofilament protein, an indicator of nerve cell degeneration believed to be tied with progression of the symptoms of the disease.""}, {""date"": ""20230425133828"", ""headline"": ""Drug for rare form of Lou Gehrig\u2019s disease OK'd by FDA"", ""summary"": ""Food and Drug Administration regulators on Tuesday approved a first-of-a-kind drug for a rare form of Lou Gehrig\u2019s disease, though they are requiring further research to confirm it truly helps patients.  The FDA approved Biogen's injectable drug for patients with a rare genetic mutation that's estimated to affect less than 500 people in the U.S. It's the first drug for an inherited form of ALS, or amyotrophic lateral sclerosis, a deadly disease that destroys nerve cells needed for basic functions like walking, talking and swallowing.  Approval came via FDA\u2019s accelerated pathway, which allows drugs to launch based on promising early results, before they\u2019re confirmed to benefit patients.""}, {""date"": ""20230425135406"", ""headline"": ""Biogen's ALS drug granted accelerated approval by the FDA"", ""summary"": ""On Tuesday, Biogen said the FDA had approved the drug \u2014 which will be marketed under the name Qalsody \u2014 to treat ALS patients with a mutation in SOD1 gene.""}, {""date"": ""20230425143939"", ""headline"": ""Biogen shifts gene therapy focus as it builds $200M facility in RTP"", ""summary"": ""Biogen is shifting its focus away from certain gene therapy programs as it builds out a nearly $200 million gene therapy manufacturing facility in Research Triangle Park.""}, {""date"": ""20230425150400"", ""headline"": ""FDA Grants Accelerated Approval for QALSODY\u2122\u00a0(tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS"", ""summary"": ""FDA granted accelerated approval of QALSODY based on a reduction of neurofilament, a marker of neurodegeneration1Superoxide dismutase 1 (SOD1)-amyotrophic lateral sclerosis (ALS) is a devastating, uniformly fatal,2 and ultra-rare genetic form of ALS3-4 with approximately 330 people in the U.S. living with the disease5 CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has approved QALSODY\u2122 (tofersen) 10""}, {""date"": ""20230425160238"", ""headline"": ""US FDA approves Biogen's ALS drug"", ""summary"": ""The U.S. Food and Drug Administration said on Tuesday it had approved Biogen Inc's drug for treating a form of amyotrophic lateral sclerosis (ALS), making it the first available treatment targeting a genetic cause of the disease.""}, {""date"": ""20230425160357"", ""headline"": ""Biogen Wins Speedy Approval For ALS Drug, But Shares Hamstrung On 'Low-Quality' Beat"", ""summary"": ""The FDA approved Biogen's new ALS drug on Tuesday, but Biogen stock remained hamstrung on a \""low-quality earnings beat.\""""}, {""date"": ""20230425220500"", ""headline"": ""RBC says CMS clarity on Leqembi reimbursement should reduce Biogen overhang"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230425230800"", ""headline"": ""Biogen gains as Medicare to cover new Alzheimer`s drug with full FDA approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230425233757"", ""headline"": ""Q1 2023 Biogen Inc Earnings Call"", ""summary"": ""Q1 2023 Biogen Inc Earnings Call""}, {""date"": ""20230426001100"", ""headline"": ""Analysts` Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Centene (CNC) and Danaher (DHR)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230426001800"", ""headline"": ""Biogen price target lowered to $302 from $307 at Barclays"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230426012000"", ""headline"": ""Biogen price target raised to $325 from $310 at Oppenheimer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230426012100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Lineage Therap (LCTX) and Laboratory (LH)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230426012500"", ""headline"": ""Biogen wins accelerated FDA approval for treatment for rare form of ALS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230426021100"", ""headline"": ""Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Amylyx Pharmaceuticals Inc (AMLX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230426023200"", ""headline"": ""Biogen price target lowered to $346 from $347 at UBS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230426024300"", ""headline"": ""Biogen price target lowered to $321 from $325 at Needham"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230426024700"", ""headline"": ""Biogen price target raised to $330 from $325 at Canaccord"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230426033100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Harvard Bioscience (HBIO) and Disc Medicine (IRON)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230426033600"", ""headline"": ""Jefferies Remains a Buy on Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230426034000"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Boston Scientific (BSX) and Danaher (DHR)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230426041900"", ""headline"": ""Biogen price target lowered to $340 from $344 at RBC Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230426043200"", ""headline"": ""EU publishes proposed reforms for pharma industry"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230426062418"", ""headline"": ""Barclays Maintains Biogen (BIIB) Equal-Weight Recommendation"", ""summary"": """"}, {""date"": ""20230426062420"", ""headline"": ""Atlantic Equities Maintains Biogen (BIIB) Neutral Recommendation"", ""summary"": """"}, {""date"": ""20230426062422"", ""headline"": ""Morgan Stanley Maintains Biogen (BIIB) Overweight Recommendation"", ""summary"": """"}, {""date"": ""20230426062424"", ""headline"": ""Needham Maintains Biogen (BIIB) Buy Recommendation"", ""summary"": """"}, {""date"": ""20230426063700"", ""headline"": ""Lilly to report Q1 2023 results with pipeline updates in spotlight"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230426070611"", ""headline"": ""Biotech Stock Roundup: BIIB's Q1 Results, ARWR Up on Data, INCY & BLUE Offer Updates"", ""summary"": ""Earnings and pipeline updates from Biogen (BIIB) and Arrowhead (ARWR) are they key highlights of the biotech sector.""}, {""date"": ""20230426094414"", ""headline"": ""Alzheimer's: Medicare will cover Leqembi for all patients if FDA approves drug, CMS chief says"", ""summary"": ""Medicare has severely restricted access to the medication Leqembi, which costs $26,500 per year, because the FDA approved it just on an expedited basis.""}, {""date"": ""20230426123000"", ""headline"": ""Eli Lilly Earnings Are Soon. All Eyes Are on Its Diabetes Drug, Mounjaro."", ""summary"": ""Expectations for first-quarter sales of its diabetes treatment, Mounjaro, are $433 million.""}, {""date"": ""20230426124000"", ""headline"": ""Biogen Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Biogen Inc. rose 1.99% to $288.04 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230426135320"", ""headline"": ""Biogen's Amyotrophic Lateral Sclerosis Drug Scores Conditional Approval From FDA"", ""summary"": ""The FDA approved Biogen Inc's (NASDAQ: BIIB) Qalsody (tofersen) for amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval based on a reduction in plasma neurofilament light chain (NfL) observed in patients treated with Qalsody. Neurofilaments are proteins released from neurons when damaged, making them a marker of neurodegeneration. Continued approval for this indication may be contingen""}, {""date"": ""20230426215447"", ""headline"": ""Canaccord Genuity Maintains Biogen (BIIB) Buy Recommendation"", ""summary"": """"}, {""date"": ""20230426215447"", ""headline"": ""RBC Capital Maintains Biogen (BIIB) Outperform Recommendation"", ""summary"": """"}, {""date"": ""20230426215449"", ""headline"": ""Wedbush Reiterates Biogen (BIIB) Neutral Recommendation"", ""summary"": """"}, {""date"": ""20230426215451"", ""headline"": ""Oppenheimer Maintains Biogen (BIIB) Outperform Recommendation"", ""summary"": """"}, {""date"": ""20230426215453"", ""headline"": ""HC Wainwright & Co. Reiterates Biogen (BIIB) Buy Recommendation"", ""summary"": """"}, {""date"": ""20230427033727"", ""headline"": ""Wall Street Breakfast Podcast: Meta Platforms Soars"", ""summary"": ""Meta earnings call: Never mind the ad beat, here's the AI future (and present). Disney sues Florida Gov. DeSantis after district clampdown. Biogen gains as Medicare to cover Alzheimer's drug""}, {""date"": ""20230427061010"", ""headline"": ""The Zacks Analyst Blog Highlights Biogen, Incyte, Morphic Therapeutic and bluebird bio"", ""summary"": ""Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog.""}, {""date"": ""20230427061100"", ""headline"": ""Biotech Alert: Searches spiking for these stocks today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230427062000"", ""headline"": ""Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Lineage Therap (LCTX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230427100058"", ""headline"": ""Drugmakers brace for serious headwinds ahead"", ""summary"": ""Yahoo Finance\u2019s Anjalee Khemlanin joins the Live show to discuss quarterly earnings for Abbvie, Merck & Company, and Biogen, the headwinds facing drugmakers, and what they mean for investors watching the pharmaceuticals space.""}, {""date"": ""20230427220000"", ""headline"": ""PureTech Announces Annual Results for Year Ended December 31, 2022"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230428012900"", ""headline"": ""The 3\ufffd\ufffdMost Promising Biotech Innovations in 2023 and the Stocks to Buy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230428040500"", ""headline"": ""Buy Biogen For Runups To\ufffd\ufffdImminent Regulatory Decisions"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230428050026"", ""headline"": ""Buy Biogen For Runups To\u00a0Imminent Regulatory Decisions"", ""summary"": ""Advisory Committee meeting for Biogen's LEQEMBI is set for June 9 and the Prescription Drug User Fee Act action date is on July 6. Read why BIIB stock is a buy.""}, {""date"": ""20230428062631"", ""headline"": ""The 3\u00a0Most Promising Biotech Innovations in 2023 and the Stocks to Buy"", ""summary"": ""The biotech sector is up 4.76% so far in 2023. This continues the nice run that biotech stocks had in 2022. The gains in biotech were in stark contrast to the broader market. All the major exchanges were down last year with growth investors finding few places to hide. But growth-oriented investors don\u2019t have to look back too far to see how quickly things can change. In 2021, biotech stocks were down 25% and even the most innovative biotech stocks found it hard to get a bid. There are many reason""}, {""date"": ""20230428065453"", ""headline"": ""Biogen Inc. 2023 Q1 - Results - Earnings Call Presentation"", ""summary"": ""The following slide deck was published by Biogen Inc.""}, {""date"": ""20230428100106"", ""headline"": ""Biogen Inc. (NASDAQ:BIIB) is favoured by institutional owners who hold 87% of the company"", ""summary"": ""Key Insights Institutions' substantial holdings in Biogen implies that they have significant influence over the...""}, {""date"": ""20230428124000"", ""headline"": ""Biogen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Biogen Inc. rallied 3.58% to $304.23 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""20230429215306"", ""headline"": ""27 Largest Biotech Companies in the US"", ""summary"": ""In this article, we take a look at 27 largest biotech companies in the US. You can skip our detailed analysis of the biotech industry and go directly to the 5 Largest Biotech Companies in the US. The largest biotech companies in the US have a total market cap of $88 trillion. Latest Developments in [\u2026]""}]",{}
16,2023-04-30,304.2300109863281,2023-05-07,318.05999755859375,0.04545898193090214,U5,"[{""date"": ""20230429215306"", ""headline"": ""27 Largest Biotech Companies in the US"", ""summary"": ""In this article, we take a look at 27 largest biotech companies in the US. You can skip our detailed analysis of the biotech industry and go directly to the 5 Largest Biotech Companies in the US. The largest biotech companies in the US have a total market cap of $88 trillion. Latest Developments in [\u2026]""}, {""date"": ""20230501011900"", ""headline"": ""Biogen upgraded to Buy from Neutral at Guggenheim"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230501033500"", ""headline"": ""Morgan Stanley`s Wilson screens for stocks as earnings stabilize but data disappoints"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230501035300"", ""headline"": ""Biogen up as Guggenheim upgrades citing full approval for Leqembi"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230501042100"", ""headline"": ""Biogen upgraded to Buy at Guggenheim on potential for growth"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230501050001"", ""headline"": ""Bipartisan attorneys general call on Medicare to cover Alzheimer's treatments "", ""summary"": ""Attorneys general from 23 states, the District of Columbia, and two U.S. territories called on Medicare to cover Alzheimer's treatments without restrictions. ""}, {""date"": ""20230501082700"", ""headline"": ""Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230501090454"", ""headline"": ""Guggenheim Upgrades Biogen (BIIB)"", ""summary"": """"}, {""date"": ""20230501124000"", ""headline"": ""Biogen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Biogen Inc. advanced 2.26% to $311.11 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...""}, {""date"": ""20230502005411"", ""headline"": ""Biogen Inc. (NASDAQ:BIIB) Q1 2023 Earnings Call Transcript"", ""summary"": ""Biogen Inc. (NASDAQ:BIIB) Q1 2023 Earnings Call Transcript April 25, 2023 Biogen Inc. beats earnings expectations. Reported EPS is $3.4, expectations were $3.28. Operator: Good morning. My name is Bettina and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen First Quarter 2023 Earnings Call [\u2026]""}, {""date"": ""20230502064200"", ""headline"": ""Biogen prices ALS therapy Qalsody at $14K a dose - report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230502081400"", ""headline"": ""Biogen prices new ALS treatment at $14,230 per vial"", ""summary"": ""Biogen Inc. has priced its recently approved ALS treatment Qalsody at $14,230 per vial, a spokesperson confirmed to MarketWatch on Tuesday. The drug, also...""}, {""date"": ""20230502124000"", ""headline"": ""Biogen Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. slipped 0.59% to $309.28 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...""}, {""date"": ""20230502220200"", ""headline"": ""Eli Lilly`s positive results from a Alzheimer`s trial seen as \ufffd\ufffd\ufffdpotentially very important`"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230502222600"", ""headline"": ""Notable Wednesday Option Activity: BIIB, GPRE, CHK"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230502224000"", ""headline"": ""Lilly sends Alzheimer`s drug developers higher after trial data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230503020100"", ""headline"": ""Biogen price target raised to $340 from $315 at Mizuho"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230503021400"", ""headline"": ""Eli Lilly stock jumps 5% after Alzheimer's treatment slows disease progression in major trial"", ""summary"": ""After one year, nearly half of the trial's participants showed no disease progression, Lilly said.""}, {""date"": ""20230503021800"", ""headline"": ""Eli Lilly stock jumps 8% after Alzheimer`s treatment slows disease progression in major trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230503023400"", ""headline"": ""Eli Lilly Drug Aids Alzheimer\u2019s Patients but Safety Is an Issue"", ""summary"": ""The company says a Phase 3 study shows that donanemab 'significantly slowed cognitive and functional decline' in people with early symptomatic Alzheimer\u2019s.""}, {""date"": ""20230503025700"", ""headline"": ""Lilly`s Gain Is Biogen`s Pain After Promising Alzheimer`s Data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230503031100"", ""headline"": ""Biogen slips after competitor Eli Lilly`s Alzheimer`s trial hits target"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230503041334"", ""headline"": ""Stocks making the biggest moves premarket: Starbucks, AMD, Pearson, PacWest & more"", ""summary"": ""These are the stocks posting the largest moves in premarket trading. ""}, {""date"": ""20230503045000"", ""headline"": ""Another Sucess In Alzheimer`s Disease"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230503050900"", ""headline"": ""Biogen wins EU exclusivity for Tecfidera until 2025"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230503053900"", ""headline"": ""Lilly`s New Donanemab Data For Alzheimer`s"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230503062100"", ""headline"": ""Eli Lilly Surges On Promising Data From Late-Stage Alzheimer's Drug Trial"", ""summary"": ""\""This is the first Phase 3 trial of any investigational medicine for Alzheimer's disease to deliver 35% slowing of clinical and functional decline,\"" Eli Lilly said.""}, {""date"": ""20230503070100"", ""headline"": ""Eli Lilly stock jumps 5% after Alzheimer`s treatment slows disease progression in major trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230503082300"", ""headline"": ""Biogen says EC extends Tecfidera regulatory market protection to February 2025"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230503101600"", ""headline"": ""Eli Lilly Results Signal Arrival of Blockbuster New Drug Class"", ""summary"": ""Its Alzheimer\u2019s treatment results might look better than Biogen\u2019s, but both companies will likely benefit.""}, {""date"": ""20230503124000"", ""headline"": ""Biogen Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.56% higher to $311.00 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P...""}, {""date"": ""20230503132256"", ""headline"": ""Eli Lilly Hits A Record-Smashing $400 Billion Market Cap Following Its Alzheimer's Win"", ""summary"": ""Eli Lilly stock popped Wednesday after the company said its experimental Alzheimer's treatment significantly slowed cognitive decline.""}, {""date"": ""20230503145516"", ""headline"": ""Obesity drug could be a 'big upside' for Eli Lilly, says Wells Fargo's Mohit Bansal"", ""summary"": ""Mohit Bansal, Wells Fargo managing director, joins 'Fast Money' to talk Eli Lilly drug trials, it's competition with Biogen for an alzheimer's drug, and more.""}, {""date"": ""20230503165823"", ""headline"": ""Eli Lilly: Positive results on its new Alzheimer's drug"", ""summary"": ""Eli Lilly stock is up on news that its new Alzheimer's drug showed reduction in cognitive decline.""}, {""date"": ""20230503183500"", ""headline"": ""Lilly's New Donanemab Data For Alzheimer's"", ""summary"": ""Eli Lilly made headlines on May 3, 2023 with an announcement that their anti-amyloid antibody donanemab hit its endpoints in a Phase III clinical trial.""}, {""date"": ""20230504000005"", ""headline"": ""AstraZeneca chair says it is paying CEO enough to ward off US rivals"", ""summary"": ""The new chair of AstraZeneca believes the drugmaker has extinguished the threat of chief executive Pascal Soriot quitting for lucrative roles in the US, saying that the benefit of increasing his pay in recent years outweighed the criticism from some shareholders.  Under Soriot, who has led AstraZeneca for more than a decade, the group has become the most valuable company on the London market, with a market capitalisation of \u00a3185bn.  Sales of its innovative cancer drugs has helped propel the group to three times the size of UK rival GSK.""}, {""date"": ""20230504020200"", ""headline"": ""Eli Lilly price target raised to $490 from $420 at Credit Suisse"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230504021000"", ""headline"": ""Eli Lilly price target raised to $475 from $430 at JPMorgan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230504041004"", ""headline"": ""Q1 2023 Ionis Pharmaceuticals Inc Earnings Call"", ""summary"": ""Q1 2023 Ionis Pharmaceuticals Inc Earnings Call""}, {""date"": ""20230504042700"", ""headline"": ""Biogen price target raised to $320 from $300 at BofA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230504045200"", ""headline"": ""Eli Lilly price target raised to $505 from $430 at BMO Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230504053000"", ""headline"": ""Good results from Alzheimer`s drug trial seen as \ufffd\ufffd\ufffdpotentially very important`"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230504055400"", ""headline"": ""Ionis Pharma upgraded at Citi after quarterly update"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230504080019"", ""headline"": ""Is Biogen Inc.'s (NASDAQ:BIIB) Recent Stock Performance Influenced By Its Fundamentals In Any Way?"", ""summary"": ""Biogen's (NASDAQ:BIIB) stock is up by a considerable 12% over the past month. As most would know, fundamentals are what...""}, {""date"": ""20230504085812"", ""headline"": ""Ionis (IONS) Q1 Earnings Surpass Estimates, Sales Match"", ""summary"": ""Ionis (IONS) reports a narrower-than-expected Q1 loss. Sales come in line with estimates. The company re-affirms its previously issued financial guidance for 2023.""}, {""date"": ""20230504121135"", ""headline"": ""B of A Securities Maintains Biogen (BIIB) Neutral Recommendation"", ""summary"": """"}, {""date"": ""20230504124000"", ""headline"": ""Biogen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Biogen Inc. inched 0.83% higher to $313.57 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...""}, {""date"": ""20230504224900"", ""headline"": ""Buy/Sell: Wall Street`s top 10 stock calls this week"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230504231200"", ""headline"": ""New Alzheimer`s drug trial seen as \ufffd\ufffd\ufffdpotentially very important`"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230505124000"", ""headline"": ""Biogen Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. advanced 1.43% to $318.06 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""20230505210200"", ""headline"": ""Eli Lilly`s Donanemab: The Anti-Amyloid Saga Continues"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230506031500"", ""headline"": ""Mizuho Securities Reaffirms Their Buy Rating on Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
17,2023-05-07,318.05999755859375,2023-05-14,309.6000061035156,-0.02659872829031129,D3,"[{""date"": ""20230507222700"", ""headline"": ""Fly Insider: Zions Bancorp, Albertsons among week`s notable insider trades"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230508000027"", ""headline"": ""Two Alzheimer\u2019s drugs offer hope to patients after decades of waiting"", ""summary"": ""In clinical trials, the medications slowed the progress of the degenerative disease that affects 50mn worldwide""}, {""date"": ""20230508024500"", ""headline"": ""Elliott Wave Technical Analysis: Biogen Inc. - Monday, May 8"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230508040000"", ""headline"": ""Coya Therapeutics: Developing Treatments For Serious Neurodegenerative And Autoimmune Diseases"", ""summary"": ""Coya\u00e2\u0080\u0099s pipeline candidates have undergone initial human trials depicting efficacy and safety of its Treg-modulating therapies. Read why COYA stock is a buy.""}, {""date"": ""20230508102900"", ""headline"": ""Lilly and Biogen Want Medicare to Cover New Alzheimer\u2019s Drugs. It\u2019s Not Happening."", ""summary"": ""Even after the latest Lilly data showing that its drug slowed the disease, the agency that runs the program isn't budging.""}, {""date"": ""20230508124000"", ""headline"": ""Biogen Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. shed 1.16% to $314.37 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230508220500"", ""headline"": ""Cassava Sciences adds 14% most since September"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230509025100"", ""headline"": ""Vigil Neuroscience appoints Haeberlein to board of directors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230509085000"", ""headline"": ""See How Biogen Ranks Among Analysts` Top Picks With Strong Buyback Activity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230509124000"", ""headline"": ""Biogen Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Biogen Inc. slumped 0.12% to $314.00 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...""}, {""date"": ""20230509132405"", ""headline"": ""Denali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus"", ""summary"": ""Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.""}, {""date"": ""20230509160959"", ""headline"": ""15 Biggest Immunotherapy Companies in the World"", ""summary"": ""In this article, we will take a look at the 15 biggest immunotherapy companies in the world. If you want to see more companies in this selection, go to the 5 Biggest Immunotherapy Companies in the World. The immunotherapy industry is a rapidly growing field that is focused on developing treatments that harness the power [\u2026]""}, {""date"": ""20230509221000"", ""headline"": ""Meta Platforms Takes Center Stage Among Moat Stocks"", ""summary"": ""A punishing 2022 for Meta Platforms created a valuation opportunity - one that has paid off as it becomes the top contributor year-to-date for the Morningstar Wide Moat Focus Index.""}, {""date"": ""20230510030551"", ""headline"": ""PTC Therapeutics: A Gem In The Rare Diseases Treatment Market"", ""summary"": ""PTC Therapeutics specializes in developing and subsequently commercializing next-generation drugs to treat orphan diseases. Find out why PTCT stock is a Buy.""}, {""date"": ""20230510124000"", ""headline"": ""Biogen Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Biogen Inc. sank 0.24% to $313.26 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230511005900"", ""headline"": ""Lundbeck, Otsuka`s Rexulti wins FDA approval for agitation linked with Alzheimer`s"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230511034800"", ""headline"": ""Biogen price target raised to $350 from $320 at Argus"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230511080027"", ""headline"": ""Biogen's (NASDAQ:BIIB) investors will be pleased with their favorable 64% return over the last year"", ""summary"": ""Passive investing in index funds can generate returns that roughly match the overall market. But you can significantly...""}, {""date"": ""20230511100700"", ""headline"": ""Here's Why Eli Lilly's Alzheimer's Drug Could Be the Real Deal"", ""summary"": ""Eli Lilly stock may look expensive, but there's still plenty of value here for long-term investors.""}, {""date"": ""20230511101233"", ""headline"": ""Argus Research Maintains Biogen (BIIB) Buy Recommendation"", ""summary"": """"}, {""date"": ""20230511124000"", ""headline"": ""Biogen Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Biogen Inc. shed 0.86% to $310.56 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230511153500"", ""headline"": ""Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up to $5 bln a year, study finds"", ""summary"": ""Wide coverage of Alzheimer's drug Leqembi would raise future costs for the U.S. Medicare health plan by $2 billion to $5 billion a year, according to a study led by researchers at the University of California, Los Angeles (UCLA).  Leqembi, sold by partners Eisai Co Ltd and Biogen Inc at an annual list price of $26,500, was approved this year under the U.S. Food and Drug Administration's accelerated pathway.  The Centers for Medicare and Medicaid Services (CMS), the agency that runs the health plan for people age 65 and older, currently covers the medication only for patients enrolled in clinical trials.""}, {""date"": ""20230511171538"", ""headline"": ""Eisai, Biogen Alzheimer's drug Leqembi would cost US Medicare up to $5 billion a year, study finds"", ""summary"": ""Wide coverage of Alzheimer's drug Leqembi would raise future costs for the U.S. Medicare health plan by $2 billion to $5 billion a year, according to a study led by researchers at the University of California, Los Angeles (UCLA).""}, {""date"": ""20230512032500"", ""headline"": ""BiomX appoints Jason Marks, Michael Dambach to board of directors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230512101500"", ""headline"": ""3 Reasons to Buy Biogen Stock (and 1 to Sell)"", ""summary"": ""The stock has been rallying but how it performs from here will likely depend on the fate of its Alzheimer's treatment, Leqembi.""}, {""date"": ""20230512105357"", ""headline"": ""Alzheimer's treatment Leqembi could cost Medicare up to $5 billion per year, study estimates"", ""summary"": ""The authors said the estimated costs of Leqembi to Medicare are conservative and spending on the Alzheimer's treatment may increase more than anticipated. ""}, {""date"": ""20230512124000"", ""headline"": ""Biogen Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slid 0.31% to $309.60 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230514070500"", ""headline"": ""Biogen`s new Alzheimer`s drug to raise annual Medicare costs by up to $5B \ufffd\ufffd\ufffd study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230514081500"", ""headline"": ""These 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win"", ""summary"": ""Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) are both keen to compete in the market for Alzheimer's disease therapies.  Biogen's prior attempt at an Alzheimer's medicine to hit the market was a train wreck, but its latest drug seems to be avoiding a repeat.  Meanwhile, Eli Lilly has yet to submit its candidate for regulatory review.""}]",{}
18,2023-05-14,309.6000061035156,2023-05-21,308.4800109863281,-0.0036175552167561076,D1,"[{""date"": ""20230514070500"", ""headline"": ""Biogen`s new Alzheimer`s drug to raise annual Medicare costs by up to $5B \ufffd\ufffd\ufffd study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230514081500"", ""headline"": ""These 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win"", ""summary"": ""Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) are both keen to compete in the market for Alzheimer's disease therapies.  Biogen's prior attempt at an Alzheimer's medicine to hit the market was a train wreck, but its latest drug seems to be avoiding a repeat.  Meanwhile, Eli Lilly has yet to submit its candidate for regulatory review.""}, {""date"": ""20230515021100"", ""headline"": ""Canadian Solar subsidiary signs aggregation deal for 100MW in Texas"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230515021500"", ""headline"": ""Biogen (BIIB) Receives a Hold from Bank of America Securities"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230515030000"", ""headline"": ""Recurrent Energy Signs Aggregation Deal for 100 MW of Solar Energy in Texas with Industry Consortium"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230515034400"", ""headline"": ""Eli Lilly price target raised to $507 from $478 at Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230515124000"", ""headline"": ""Biogen Inc. stock rises Monday, outperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.73% higher to $311.87 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""20230515151059"", ""headline"": ""Jim Cramer compares market conditions to 2011 as debt ceiling showdown continues"", ""summary"": ""'Mad Money' host Jim Cramer talks market performance after the Dow breaks its losing streak and compares market conditions to 2011.""}, {""date"": ""20230515152700"", ""headline"": ""Jim Cramer expects defensive stocks to be resilient as debt ceiling talks drag on"", ""summary"": ""CNBC's Jim Cramer is looking to 2011 for investing guidance during the ongoing debt ceiling uncertainty. ""}, {""date"": ""20230515160559"", ""headline"": ""Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says."", ""summary"": ""Lilly's Alzheimer's treatment could reach blockbuster status by 2025, an analyst said Monday. Eli Lilly stock is trading near a record high.""}, {""date"": ""20230515193000"", ""headline"": ""Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer\u2019s Disease"", ""summary"": ""TOKYO and CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \""Eisai\"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \""Biogen\"") announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (brand name in the U.S.: LEQEMBI\u2122), an investigational anti-amyloid beta (A\u03b2) protofibril* antibody, for the treatment of early Alzheimer\u2019s disease (mild cogniti""}, {""date"": ""20230516001600"", ""headline"": ""Health Canada accepts Biogen's submission for Alzheimer's drug Leqembi"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230516095601"", ""headline"": ""Here's Why Biogen (BIIB) Stock is Up 12.6% This Year So Far"", ""summary"": ""Biogen (BIIB) is set to launch three potential new drugs across four indications in 2023, all in areas of high unmet need.""}, {""date"": ""20230516124000"", ""headline"": ""Biogen Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. shed 1.37% to $307.61 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230517071700"", ""headline"": ""Prothena adds former FDA neuro chief Billy Dunn to director board"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230517124000"", ""headline"": ""Biogen Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Biogen Inc. dropped 0.44% to $306.25 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""20230517223500"", ""headline"": ""Sen. Wyden presses HHS, CMS on access to new Alzheimer`s therapies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230518061600"", ""headline"": ""Supreme Court rules against Amgen in Rapatha patent dispute with Sanofi/ Regeneron"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230518062200"", ""headline"": ""Supreme Court rules against Amgen in Repatha patent dispute with Sanofi/ Regeneron"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230518063400"", ""headline"": ""Cognition Therapeutics stock rises after CT1812 shows promise in Alzheimer`s study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230518080033"", ""headline"": ""Biogen Inc.'s (NASDAQ:BIIB) Intrinsic Value Is Potentially 29% Above Its Share Price"", ""summary"": ""Key Insights Biogen's estimated fair value is US$394 based on 2 Stage Free Cash Flow to Equity Biogen's US$306 share...""}, {""date"": ""20230518124000"", ""headline"": ""Biogen Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Biogen Inc. shed 0.26% to $305.45 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230519081500"", ""headline"": ""1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market"", ""summary"": ""Analysts are bullish on Biogen's Alzheimer's drug, Leqembi, projecting it may generate over $10 billion in sales at its peak.""}, {""date"": ""20230519100052"", ""headline"": ""3 Biotech Stocks That Are Revolutionizing Healthcare in 2023"", ""summary"": ""The biotechnology (or biotech) sector is a crystal-clear illustration of risk and reward. Many biotech companies work on drugs and therapeutics for some of the most pernicious conditions affecting our society and healthcare system. But finding the best biotech stocks to buy is not always simple. Many biotech companies work on drugs for years. And these biotech stocks will swing wildly on the news. Positive results from a clinical trial can send stocks soaring. Conversely, disappointing results c""}, {""date"": ""20230519124000"", ""headline"": ""Biogen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Biogen Inc. inched 0.99% higher to $308.48 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""20230521070100"", ""headline"": ""Billions of dollars at stake as FDA shortcut allows half-proven drugs - report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
19,2023-05-21,308.4800109863281,2023-05-28,298.6600036621094,-0.031833528833263625,D4,"[{""date"": ""20230521070100"", ""headline"": ""Billions of dollars at stake as FDA shortcut allows half-proven drugs - report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230521222900"", ""headline"": ""Biogen collaborator Eisai submits marketing application for Lecanemab"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230522022900"", ""headline"": ""Biogen reports Eisai submitted MAA for lecanemab for early Alzheimer's to MHRA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230522080032"", ""headline"": ""Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?"", ""summary"": ""Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...""}, {""date"": ""20230522124000"", ""headline"": ""Biogen Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Biogen Inc. shed 0.52% to $306.87 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230523033100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Biogen (BIIB) and Blueprint Medicines (BPMC)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230523034100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Blueprint Medicines (BPMC) and Cerevel Therapeutics Holdings (CERE)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230523112647"", ""headline"": ""Wedbush Reiterates Biogen (BIIB) Neutral Recommendation"", ""summary"": """"}, {""date"": ""20230523124000"", ""headline"": ""Biogen Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. shed 1.21% to $303.15 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230524042000"", ""headline"": ""Wednesday\u2019s Top Analyst Upgrades and Downgrades: Chevron, Microsoft, Nucor, Salesforce, Wheaton Precious Metals and More"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230524124000"", ""headline"": ""Biogen Inc. stock outperforms market despite losses on the day"", ""summary"": ""Shares of Biogen Inc. sank 0.52% to $301.56 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230524134633"", ""headline"": ""10 Dementia Medications that are Approved or in Clinical Trials"", ""summary"": ""In this article, we will be taking a look at the 10 dementia medications that are approved or in clinical trials. To skip our detailed analysis, you can go directly to see the 5 dementia medications that are approved or in clinical trials. Advancements in medicine have absolutely changed the way we live right now, [\u2026]""}, {""date"": ""20230525040352"", ""headline"": ""14 Best Biotech Stocks To Buy According To Hedge Funds"", ""summary"": ""In this piece, we will take a look at 14 best biotechnology stocks to buy according to hedge funds. For more stocks, head on over to 5 Best Biotech Stocks To Buy According To Hedge Funds. Biotechnology is one of the hottest sectors these days. A handful of industries, such as space exploration, artificial intelligence, [\u2026]""}, {""date"": ""20230525065200"", ""headline"": ""New Alzheimer\u2019s drug could bring hope to patients, but could be out of reach for people on Medicare"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230525113100"", ""headline"": ""Biogen Inc. (BIIB) Up 4.7% Since Last Earnings Report: Can It Continue?"", ""summary"": ""Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.""}, {""date"": ""20230525124000"", ""headline"": ""Biogen Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slid 1.47% to $297.13 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230525153630"", ""headline"": ""Roche, With Ocrevus And Fenebrutinib Advancement, Should Be Top MS Contender"", ""summary"": ""Biggest sales growth driver for Roche Holding AG is Vabysmo, approved for wet age-related macular degeneration and other uses. Click here for our RHHBF stock review.""}, {""date"": ""20230526014200"", ""headline"": ""Elon Musk's Neuralink gets FDA nod to start human trial of brain implant"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230526070800"", ""headline"": ""Biogen Unusual Options Activity For May 26"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230526113141"", ""headline"": ""Alkermes (ALKS) Up 3.7% Since Last Earnings Report: Can It Continue?"", ""summary"": ""Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.""}, {""date"": ""20230526124000"", ""headline"": ""Biogen Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.51% higher to $298.66 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}]",{}
20,2023-05-28,298.6600036621094,2023-06-04,300.20001220703125,0.005156393645076696,U1,"[{""date"": ""20230529100016"", ""headline"": ""Biogen Inc. (NASDAQ:BIIB) is favoured by institutional owners who hold 88% of the company"", ""summary"": ""Key Insights Given the large stake in the stock by institutions, Biogen's stock price might be vulnerable to their...""}, {""date"": ""20230530081600"", ""headline"": ""Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230530124000"", ""headline"": ""Biogen Inc. stock rises Tuesday, outperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.01% higher to $298.69 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...""}, {""date"": ""20230531124000"", ""headline"": ""Biogen Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Biogen Inc. shed 0.76% to $296.41 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230531213500"", ""headline"": ""Medicare unveils plan for coverage of new Alzheimer\u2019s drugs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230601033300"", ""headline"": ""Biogen price target raised to $360 from $346 at Piper Sandler"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230601053900"", ""headline"": ""Medicare to cover Alzheimer's drugs granted full FDA approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230601070600"", ""headline"": ""Biogen (BIIB) Receives a Buy from Mizuho Securities"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230601075600"", ""headline"": ""Goldman Sachs Remains a Buy on Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230601090704"", ""headline"": ""Medicare to cover new Alzheimer's drug after full approval "", ""summary"": ""The Centers for Medicare & Medicaid Services said on Thursday that the U.S. Medicare health plan would cover new Alzheimer's drugs such as Eisai Co Ltd and Biogen Inc's Leqembi if they gain full U.S. approval.""}, {""date"": ""20230601100407"", ""headline"": ""15 Best Healthcare Stocks To Buy Now"", ""summary"": ""In this article, we will take a look at the 15 best healthcare stocks to buy now. For more stocks, head on over to 5 Best Healthcare Stocks To Buy Now. In the midst of uncertain economic conditions globally, the healthcare sector has displayed a notable degree of resilience. Historically, the demand for healthcare products [\u2026]""}, {""date"": ""20230601103932"", ""headline"": ""Piper Sandler Maintains Biogen (BIIB) Overweight Recommendation"", ""summary"": """"}, {""date"": ""20230601120900"", ""headline"": ""Medicare Will Pay for Biogen\u2019s Alzheimer\u2019s Drug, With a Caveat"", ""summary"": ""The agency that oversees the medical program for seniors will pick up the bill only if doctors submit treatment data to a nationwide registry.""}, {""date"": ""20230601121710"", ""headline"": ""Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump"", ""summary"": ""Biogen stock jumped into a buy zone Thursday after Medicare officials said they would pay for some Alzheimer's treatments.""}, {""date"": ""20230601124000"", ""headline"": ""Biogen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Biogen Inc. rallied 2.02% to $302.41 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""20230601142900"", ""headline"": ""Medicare Plans to Cover Alzheimer\u2019s Drugs"", ""summary"": ""Medicare plans to widen coverage of Alzheimer\u2019s drugs that could win full approval as soon as this summer.  The Centers for Medicare and Medicaid Services on Thursday said it would cover Biogen and Eisai\u2019s treatment Leqembi if the drug wins full approval and patients and doctors contribute to a registry that collects evidence on how the medication works.  Most Alzheimer\u2019s patients in the U.S. are Medicare enrollees.""}, {""date"": ""20230602011800"", ""headline"": ""Medicare will cover Biogen, Eisai's Alzheimer's drug, WSJ reports"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230602073100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Stericycle (SRCL), Biogen (BIIB) and Acadia Healthcare (ACHC)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230602123500"", ""headline"": ""Ionis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study"", ""summary"": ""Data from a mid-stage study shows that treatment with Ionis' (IONS) donidalorsen over a two-year period resulted in consistent and sustained protection from HAE attacks.""}, {""date"": ""20230602125100"", ""headline"": ""Biogen Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slumped 0.73% to $300.20 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""20230602170128"", ""headline"": ""RBC Capital Reiterates Biogen (BIIB) Outperform Recommendation"", ""summary"": """"}]",{}
21,2023-06-04,300.20001220703125,2023-06-11,308.8800048828125,0.028914031721608113,U3,"[{""date"": ""20230604210200"", ""headline"": ""$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230604222500"", ""headline"": ""Biotech stocks could soon get a M&A boost. Here are 3 likely takeover plays."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230605035700"", ""headline"": ""Biogen, Denali shift focus of Parkinson's Disease clinical development program"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230605041000"", ""headline"": ""Denali's LRRK2 program changes 'unsurprising but negative,' says Stifel"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230605082100"", ""headline"": ""IN BRIEF: Biogen revises development program of BIIB122 in Parkinson's"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230605125200"", ""headline"": ""Biogen Inc. stock underperforms Monday when compared to competitors despite daily gains"", ""summary"": ""Shares of Biogen Inc. inched 0.64% higher to $302.13 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...""}, {""date"": ""20230605181515"", ""headline"": ""Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure"", ""summary"": ""In its ongoing R&D reorganization, Biogen Inc (NASDAQ: BIIB) will discontinue a Phase 3 program evaluating BIIB122 as a treatment for patients with Parkinson\u2019s disease related to LRRK2 mutations with partner Denali Therapeutics Inc (NASDAQ: DNLI). Before the planned revisions, the BIIB122 development program encompassed the following: The Phase 2b LUMA study in participants with early-stage Parkinson\u2019s disease commenced in May 2022. The Phase 3 LIGHTHOUSE study in participants with Parkinson\u2019s d""}, {""date"": ""20230605231000"", ""headline"": ""Biogen withdraws from Jefferies Healthcare Conference"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230605233400"", ""headline"": ""Notable Tuesday Option Activity: BIIB, OZK, TRUP"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230606105800"", ""headline"": ""Biogen (BIIB) to End One of Two Parkinson's Studies on BIIB122"", ""summary"": ""Biogen (BIIB) is now set to focus on the LUMA study on its and partner Denali Therapeutics' (DNLI) small molecule LRRK2 inhibitor, BIIB122, for Parkinson's""}, {""date"": ""20230606125100"", ""headline"": ""Biogen Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. dropped 0.77% to $299.79 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230606211600"", ""headline"": ""Biogen (BIIB) Receives a Buy from Goldman Sachs"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230607061200"", ""headline"": ""FDA posts briefing document ahead of review of Biogen and Eisai's Leqembi"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230607064600"", ""headline"": ""Mizuho Securities Reaffirms Their Buy Rating on Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230607071400"", ""headline"": ""Biogen briefing docs 'super clean' with no surprises, says Mizuho"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230607073200"", ""headline"": ""Novo Nordisk and Golden Entertainment have been highlighted as Zacks Bull and Bear of the Day"", ""summary"": ""Novo Nordisk and Golden Entertainment are part of the Zacks Bull and Bear of the Day article.""}, {""date"": ""20230607074200"", ""headline"": ""FDA briefing docs 'appear largely supportive' of Biogen's Leqembi, says Wedbush"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230607075800"", ""headline"": ""Biogen's Lequembi likely to be granted full approval by FDA, says Baird"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230607081000"", ""headline"": ""Biogen gains on \u201csuper clean\u201d FDA docs on Alzheimer\u2019s drug ahead of AdCom vote"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230607100017"", ""headline"": ""Do Its Financials Have Any Role To Play In Driving Biogen Inc.'s (NASDAQ:BIIB) Stock Up Recently?"", ""summary"": ""Biogen's (NASDAQ:BIIB) stock is up by a considerable 14% over the past three months. We wonder if and what role the...""}, {""date"": ""20230607103023"", ""headline"": ""Bernie Sanders says price of Alzheimer's treatment is unconscionable, calls on HHS to take action "", ""summary"": ""Sen. Bernie Sanders said the $26,500 annual price for Alzheimer's treatment Leqembi would financially burden on Medicare and increase premiums for seniors.""}, {""date"": ""20230607110635"", ""headline"": ""FDA staff say Eisai's Alzheimer's drug may get full approval despite concerns"", ""summary"": ""Staff reviewers of the U.S. Food and Drug Administration (FDA) said on Wednesday that Eisai and Biogen's Alzheimer's drug, Leqembi, may still be eligible for a full approval despite concerns of brain hemorrhage from using blood thinners along with the drug.  The FDA staff's comments about the drug were made in documents released ahead of a meeting of the panel of external advisers on Friday to discuss the Japanese company's application for a traditional approval.""}, {""date"": ""20230607122810"", ""headline"": ""Eisai-Biogen Alzheimer's drug data confirms benefits, FDA staff says"", ""summary"": ""Staff reviewers of the U.S. drug regulator said trial data on Eisai and Biogen's Leqembi confirmed benefits of the early Alzheimer's drug and the prospects of a full approval were unaffected by higher risks of brain hemorrhage.""}, {""date"": ""20230607125100"", ""headline"": ""Biogen Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Biogen Inc. rallied 1.70% to $304.90 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""20230607133713"", ""headline"": ""Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near"", ""summary"": ""Biogen stock rose Wednesday after the FDA posted documents that suggest the agency will approve Alzheimer's treatment Leqembi.""}, {""date"": ""20230607134937"", ""headline"": ""Thinking Of Buying Boston Properties? Here Are The Properties And Tenants You'd Add To Your Portfolio"", ""summary"": ""When investors consider the purchase of a real estate investment trust (REIT), along with performance and dividends, they need to consider the properties and tenants that accompany that REIT. Several questions must be answered: Are the tenants long-term and stable? Are they strong enough to survive recessions and market downturns? Is the portfolio diversified by location, type and annualized base rent (ABR)? Take a look at one of the largest office REITs today to see whether it answers the above""}, {""date"": ""20230607181400"", ""headline"": ""Mastering the Double-Bottom Pattern (Unveiling 3 Intriguing Setups in Today's Market)"", ""summary"": ""A double-bottom base is a chart pattern commonly used in technical analysis to identify a solid reward-to-risk zone in a stock. Stock Strategist Andrew Rocco walks you through the pattern and unveils 3 juicy setups.""}, {""date"": ""20230607190834"", ""headline"": ""Baird Reiterates Biogen (BIIB) Prior Recommendation"", ""summary"": """"}, {""date"": ""20230607215304"", ""headline"": ""Eisai and Biogen\u2019s Alzheimer\u2019s Drug Moves Closer to Full US Approval"", ""summary"": ""(Bloomberg) -- Eisai Co. and Biogen Inc. moved closer to full US approval for their Alzheimer\u2019s drug Leqembi after the Food and Drug Administration posted documents indicating it sees no barriers to clearance, setting the product up for likely government health-plan coverage. Most Read from BloombergMystery Bet Before SEC Crypto Crackdown May Mint Trader MillionsThese Are the World\u2019s 20 Most Expensive Cities for Expats in 2023Messi Spurns $400 Million Saudi Offer to Join Beckham\u2019s MiamiFlights t""}, {""date"": ""20230607233400"", ""headline"": ""Biogen notes Eisai files marketing authorisation for Alzheimer's drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230608000100"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Avita Medical (RCEL), 4D Molecular Therapeutics (FDMT) and Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230608003100"", ""headline"": ""Biogen briefing documents 'appear benign,' says Barclays"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230608013300"", ""headline"": ""Biogen briefing documents bode well for full approval, says Canaccord"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230608023100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Paycor HCM (PYCR), Crispr Therapeutics AG (CRSP) and Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230608033100"", ""headline"": ""Analysts\u2019 Top Healthcare Picks: HashiCorp (HCP), Astria Therapeutics (ATXS)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230608040600"", ""headline"": ""Expert Ratings for Biogen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230608063700"", ""headline"": ""Interesting BIIB Put And Call Options For July 28th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230608081900"", ""headline"": ""Eisai submits marketing authorization application for lecanemab in South Korea"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230608100241"", ""headline"": ""Needham Reiterates Biogen (BIIB) Buy Recommendation"", ""summary"": """"}, {""date"": ""20230608103450"", ""headline"": ""FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval"", ""summary"": ""FDA Peripheral and Central Drugs Advisory Committee is meeting Friday (June 9) to discuss a supplemental marketing application for Leqembi (lecanemab) submitted by Eisai Co Ltd (OTC: ESALY) for Alzheimer's disease, initiated in patients with mild cognitive impairment or mild dementia stage of the disease. The Leqembi application has been granted Priority Review, with a Prescription Drug User Fee Act action date of July 6. Eisai is collaborating with Biogen Inc (NASDAQ: BIIB) for lecanemab. The A""}, {""date"": ""20230608123800"", ""headline"": ""Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More"", ""summary"": ""Regulatory and pipeline updates from GSK plc (GSK) and Biogen (BIIB) are in focus in the biotech sector.""}, {""date"": ""20230608124100"", ""headline"": ""Biogen (BIIB), Eisai's Alzheimer Drug Likely to Get Full FDA Nod"", ""summary"": ""Based on briefing documents issued by the FDA, a full regulatory approval is expected on Biogen (BIIB)/Eisai's Alzheimer's disease antibody. The final decision is expected in the early next month.""}, {""date"": ""20230608125100"", ""headline"": ""Biogen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Biogen Inc. advanced 1.31% to $308.88 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""20230608132715"", ""headline"": ""Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'"", ""summary"": ""Senator Bernie Sanders urged the U.S. Department of Health and Human Services (HHS) to immediately address the exorbitant cost of Eisai Co Ltd (OTC: ESALY)/Biogen Inc (NASDAQ: BIIB) Alzheimer's treatment Leqembi (lecanemab). Wednesday, the FDA released briefing documents ahead of the meeting that appears to support a full FDA approval for Leqembi. In a letter to HHS Secretary Xavier Becerra, Sanders, who chairs the Senate Health Committee, expressed his deep concern over the annual price for Leq""}, {""date"": ""20230608165237"", ""headline"": ""Barclays Maintains Biogen (BIIB) Overweight Recommendation"", ""summary"": """"}, {""date"": ""20230608225400"", ""headline"": ""FDA panel votes 6-0 to back Biogen, Eisai's Leqembi"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230608230600"", ""headline"": ""FDA panel recommends full approval for Biogen, Esai Alzheimer's drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230608232400"", ""headline"": ""FDA panel recommends full approval for Biogen, Eisai Alzheimer's drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230609001300"", ""headline"": ""FDA advisers vote in favor of Biogen and Eisai\u2019s collaborative Alzheimer\u2019s treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230609015000"", ""headline"": ""Eisai, Biogen: FDA panel votes unanimously to confirm benefit of Leqembi"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230609020000"", ""headline"": ""Biogen Takes Alzheimer\u2019s Drug to FDA Advisers. The Last Time Was a Disaster."", ""summary"": ""The agency's Peripheral and Central Nervous System Drugs Advisory Committee will consider whether a Phase 3 study confirms the drug's clinical benefit.""}, {""date"": ""20230609024200"", ""headline"": ""Biogen on hold for trading ahead of FDA AdCom vote on Alzheimer\u2019s drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230609035300"", ""headline"": ""Biogen trading on Nasdaq halted as US FDA probes Alzheimer's drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230609040900"", ""headline"": ""Biogen Stock in Focus on Key Vote on Lequembi"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230609044700"", ""headline"": ""SVB Securities Sticks to Its Buy Rating for Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230609045100"", ""headline"": ""Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), Zimmer Biomet Holdings (ZBH) and Innate Pharma SA (OtherIPHYF)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230609060442"", ""headline"": ""Biogen shares halted as FDA advisory panel meets to discuss Alzheimer's drug"", ""summary"": ""Investing.com -- Biogen Inc. (NASDAQ:BIIB) announced that the Nasdaq (NASDAQ:NDAQ) exchange had halted trading of its stock on Friday.""}, {""date"": ""20230609060703"", ""headline"": ""FDA advisors weigh whether Alzheimer's drug Leqembi should receive full approval"", ""summary"": ""Medicare has promised to broadly cover Leqembi, which costs $26,500 per year, if the FDA grants full approval of the treatment.""}, {""date"": ""20230609070000"", ""headline"": ""FDA panel to debate US approval for Alzheimer's drug from Eisai and Biogen "", ""summary"": ""A panel of experts on Friday will discuss whether to recommend traditional U.S. regulatory approval for Eisai and Biogen's new Alzheimer's drug Leqembi, a move expected to expand Medicare payment for the treatment.""}, {""date"": ""20230609070000"", ""headline"": ""FDA panel to debate US approval for Alzheimer's drug from Eisai and Biogen"", ""summary"": ""A panel of experts on Friday will discuss whether to recommend traditional U.S. regulatory approval for Eisai and Biogen's new Alzheimer's drug Leqembi, a move expected to expand Medicare payment for the treatment.  Leqembi won accelerated approval by the Food and Drug Administration in January based on its ability to remove toxic amyloid plaques from the brain.""}, {""date"": ""20230609105038"", ""headline"": ""UPDATE 1-FDA panel weighs US approval for Alzheimer's drug from Eisai and Biogen"", ""summary"": ""A panel of expert advisers on Friday began their meeting to discuss whether to recommend traditional U.S. regulatory approval for Eisai and Biogen's new Alzheimer's drug Leqembi, a move expected to expand Medicare payment for the treatment.  Leqembi won accelerated approval by the Food and Drug Administration in January based on its ability to remove toxic amyloid plaques from the brain.""}, {""date"": ""20230609112645"", ""headline"": ""Biogen Stock Halted as FDA Committee Considers Alzheimer\u2019s Drug"", ""summary"": ""Trading in shares of Biogen remains halted Friday morning as a Food and Drug Administration advisory committee meets to discuss whether the Alzheimer's drug Leqembi from the company and partner Eisai merits full approval.""}, {""date"": ""20230609120200"", ""headline"": ""Eisai shares jump on FDA advisers vote on Alzheimer\u2019s treatment"", ""summary"": ""Eisai Co. Ltd. shares were up 9.4% Friday after advisers to the U.S. Food and Drug Administration voted unanimously in favor of the Eisai and Biogen...""}, {""date"": ""20230609120846"", ""headline"": ""Biogen Stock Halted As It Faces Make-Or-Break Moment For Alzheimer's Treatment"", ""summary"": ""Biogen stock was halted Friday as a panel of experts to the FDA debated the merits of its Alzheimer's treatment, Leqembi.""}, {""date"": ""20230609122200"", ""headline"": ""NEW YORK MARKET CLOSE: Stocks rise on growing optimism of rate pause"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230609131137"", ""headline"": ""Here's what the FDA's endorsement of the Alzheimer's drug Leqembi means for Biogen"", ""summary"": ""Matt Herper, Stat News senior writer, joins 'Closing Bell: Overtime' to discuss the FDA advisers' unanimous vote to recommend Biogen Alzheimer's drug.""}, {""date"": ""20230609144500"", ""headline"": ""FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI\u00ae (lecanemab-irmb) for the Treatment of Alzheimer's Disease"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230609152700"", ""headline"": ""Biogen stock rallies after full-day halt as FDA panel recommends Alzheimer\u2019s drug for approval"", ""summary"": ""Biogen Inc. shares rallied in the extended session late Friday following a full-day halt after the biotech company received a recommendation from a Food and...""}, {""date"": ""20230609155421"", ""headline"": ""US FDA panel back traditional approval for Eisai-Biogen's Alzheimer's drug Leqembi"", ""summary"": ""A panel of expert advisers on Friday unanimously agreed that a late-stage clinical trial of Eisai and Biogen's Leqembi verified the benefit of the treatment for Alzheimer's disease, clearing the way for traditional U.S. regulatory approval.""}, {""date"": ""20230609161546"", ""headline"": ""Biogen Remains Halted After Panelists Vote Unanimously In Favor Of Its Alzheimer's Drug"", ""summary"": ""Biogen stock remained halted Friday after a panel of advisors to the FDA voted unanimously in favor of its newest Alzheimer's treatment.""}, {""date"": ""20230609161546"", ""headline"": ""Biogen Halted After Panelists Vote Unanimously In Favor Of Its Alzheimer's Drug"", ""summary"": ""Biogen stock remained halted Friday after a panel of advisors to the FDA voted unanimously in favor of its newest Alzheimer's treatment.""}, {""date"": ""20230609171800"", ""headline"": ""FDA Advisory Committee Votes in Favor of Biogen Alzheimer\u2019s Drug, Clears Path to Full Approval"", ""summary"": ""The vote came two and a half years after the same panel dealt a decisive blow to Aduhelm, another drug from Biogen and Eisai.""}, {""date"": ""20230609182055"", ""headline"": ""US FDA panel backs approval for Eisai-Biogen Alzheimer's drug Leqembi"", ""summary"": ""A panel of expert advisers on Friday unanimously agreed that a late-stage trial of Eisai and Biogen's Alzheimer's drug Leqembi verified the benefit of the treatment for those at an early stage of the disease, clearing the way for traditional U.S. approval.""}, {""date"": ""20230609184500"", ""headline"": ""FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI\u00ae (lecanemab-irmb) for the Treatment of Alzheimer\u2019s Disease"", ""summary"": ""Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer\u2019s disease The PDUFA action date for traditional approval of LEQEMBI has been set for July 6, 2023, with designation of priority review LEQEMBI received accelerated approval from the FDA for the treatment of early Alzheimer\u2019s disease on January 6, 2023 TOKYO and CAMBRIDGE, Mass., June 09, 2023 (GLOBE NEWSWIRE) -""}, {""date"": ""20230611014300"", ""headline"": ""FDA AdComm votes to confirm clinical benefit of LEQEMBI in Alzheimer's disease"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230611070100"", ""headline"": ""Alzheimer\u2019s disease market expected to reach $14B globally in 2030"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
22,2023-06-11,308.8800048828125,2023-06-18,297.4800109863281,-0.03690751656394686,D4,"[{""date"": ""20230611014300"", ""headline"": ""FDA AdComm votes to confirm clinical benefit of LEQEMBI in Alzheimer's disease"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230611070100"", ""headline"": ""Alzheimer\u2019s disease market expected to reach $14B globally in 2030"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230611202240"", ""headline"": ""Eisai, Biogen Clinch FDA Advisers\u2019 Support for Alzheimer\u2019s Drug"", ""summary"": ""(Bloomberg) -- Eisai Co.\u2019s Alzheimer\u2019s disease drug developed with Biogen Inc. gained support from advisers to US regulators, paving the way for a likely full regulatory approval that could lead to broader insurance coverage. Most Read from BloombergOil Traders Are Daring to Defy Market Kingpin Saudi ArabiaAs Fed Signals Rate Pause, Powell Will Have to Placate HawksUBS Completes Credit Suisse Takeover to Create Bank TitanJeff Bezos Has Gained $10 on Mystery Purchase of One Amazon ShareUK Politic""}, {""date"": ""20230611210300"", ""headline"": ""Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230611212400"", ""headline"": ""Tech Sector Powers S&P 500 To 10-Month High, While Oil Stocks Struggle: What's Driving Markets Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230611213000"", ""headline"": ""Tech Sector Powers S&P 500 To 10-Month High While Oil Stocks Struggle: What's Driving Markets Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230611215300"", ""headline"": ""Macro Muddle Coming Up As Market Exceeds Expectations, Small Caps Gain Ground"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230611215600"", ""headline"": ""US FDA confirms clinical benefit of Biogen's leqembi for Alzheimer's"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230611232100"", ""headline"": ""What You Missed On Wall Street On Monday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230612002900"", ""headline"": ""These Stocks Are Moving the Most Today: Tesla, Carnival, Nasdaq, SoFi, and More"", ""summary"": ""Tesla is rising for a 12th consecutive day, Carnival trades higher after Wall Street upgrades the stock, and Nasdaq falls after agreeing to acquire software...""}, {""date"": ""20230612010800"", ""headline"": ""Biogen price target raised to $360 from $350 at Oppenheimer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230612012700"", ""headline"": ""Biogen announces board changes, new date for annual meeting"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230612013100"", ""headline"": ""Wall Street Analysts Are Bullish on Top Healthcare Picks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230612013800"", ""headline"": ""Biogen, Carnival and Oracle post solid gains, while Nasdaq and KeyCorp slump"", ""summary"": ""Here are some of the biggest movers on Monday.""}, {""date"": ""20230612020000"", ""headline"": ""Here\u2019s Why Biogen Stock (NASDAQ:BIIB) is Trending Higher"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230612020800"", ""headline"": ""Nasdaq, S&P 500 Futures Signal Strong Start To Week On Hopes Of Fed Pause: Why This Analyst Is Pricing In A 20% Gain From Bear Market Low"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230612023700"", ""headline"": ""Biogen price target raised to $350 from $330 at Canaccord"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230612025401"", ""headline"": ""Biogen shares jump after FDA advisory panel backs Alzheimer's drug"", ""summary"": ""Investing.com -- Shares in Biogen Inc (NASDAQ:BIIB) surged in premarket trading on Monday after an advisory panel to U.S. regulators gave their support to the early-stage usage of an Alzheimer's drug co-developed by the biotech group.""}, {""date"": ""20230612031100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230612033000"", ""headline"": ""S&P 500 Futures Rise in Premarket Trading; Nasdaq, Globant Lag"", ""summary"": ""With U.S. stock markets set to open in two hours, (CCL) was up 5.4% in pre-market trading, and (ZBH) was up 5.1%. (ORCL), (PLNT), and (BIIB) were all posting...""}, {""date"": ""20230612033200"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: ImmunoGen (IMGN), Humacyte (HUMA) and Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230612035100"", ""headline"": ""Analysts\u2019 Top Healthcare Picks: Keros Therapeutics (KROS), Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230612035500"", ""headline"": ""Fly Intel: Pre-market Movers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230612053700"", ""headline"": ""Stocks Higher, Fed Decision, Inflation In Focus, Biogen Surges, Oracle Earnings, Silvio Berlusconi Dies - 5 Things To Know"", ""summary"": ""Stock futures higher ahead of key market tests; Week Ahead: Fed, inflation, retail sales in focus; Biogen surges as FDA panel gives final nod to Alzheimer's treatment; Oracle set for new record high ahead of Q4 earnings and Silvio Berlusconi, billionaire media mogul and former prime minister of Italy, dies at 86.""}, {""date"": ""20230612054800"", ""headline"": ""BIIB Stock Alert: Biogen Resumes Trading With New FDA Backing"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230612060000"", ""headline"": ""Biogen stock doesn't see big boost from FDA panel endorsement of Leqembi"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230612061400"", ""headline"": ""Why Are Cruise Stocks CCL, RCL, NCLH Up Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230612065000"", ""headline"": ""Global company events calendar - next 7 days"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230612070200"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230612070548"", ""headline"": ""HC Wainwright & Co. Reiterates Biogen (BIIB) Buy Recommendation"", ""summary"": """"}, {""date"": ""20230612072252"", ""headline"": ""5 Things to Know Before Markets Open"", ""summary"": ""UBS completes its takeover of Credit Suisse and Biogen wins key FDA support for its Alzheimer's disease treatment. Here\u2019s what investors need to know today.""}, {""date"": ""20230612081352"", ""headline"": ""Stocks to Watch Monday: Biogen, Illumina, Oracle"", ""summary"": ""**\u2197\ufe0f** [**Biogen (BIIB)**](https://www.wsj.com/market-data/quotes/BIIB): The biotech company's shares rose 1.3% after an advisory committee [recommended the Food and Drug Administration approve Leqembi](https://investors.""}, {""date"": ""20230612092500"", ""headline"": ""Biogen (BIIB), Eisai Alzheimer Drug Gets FDA Panel Endorsement"", ""summary"": ""An FDA advisory committee supports granting full approval to Biogen (BIIB)/Eisai's Alzheimer's disease antibody. NASDAQ halts BIIB's common stock trading on Jun 9.""}, {""date"": ""20230612092946"", ""headline"": ""Biogen Jumps After Panelists Vote Unanimously In Favor Of Its Alzheimer's Drug"", ""summary"": ""Biogen stock jumped Monday after a panel of advisors to the FDA voted unanimously in favor of its newest Alzheimer's treatment.""}, {""date"": ""20230612095841"", ""headline"": ""FDA recommends Biogen's Alzheimer's drug for approval"", ""summary"": ""Shares of biotech company Biogen are rising this morning after an FDA panel recommended its Alzheimer's treatment drug for approval. Yahoo Finance Live takes a look at the stock action.""}, {""date"": ""20230612101657"", ""headline"": ""CORRECTED-Biogen rises as FDA panel backs Alzheimer's drug, easing safety concerns "", ""summary"": ""Shares of Biogen Inc rose 4% in premarket trade on Monday as an unanimous backing of the company's Alzheimer's drug Leqembi by the U.S. regulator's advisers eased concerns that a traditional approval for the treatment will come with major new safety warnings.""}, {""date"": ""20230612103000"", ""headline"": ""Trading the Alzheimer's Space: Here's My Plan as Companies Try to Slay the Beast"", ""summary"": ""This will obviously be a huge market. It's time for me to diversify my exposure after positive news on Biogen and Eisai's Leqembi.""}, {""date"": ""20230612103743"", ""headline"": ""These Stocks Are Moving the Most Today: Tesla, Carnival, Nasdaq, NIO, and More"", ""summary"": ""Tesla is rising for a 12th consecutive day, Carnival trades higher after Wall Street upgrades the stock, and Nasdaq falls after agreeing to acquire software company Adenza for $10.5 billion in cash and shares.""}, {""date"": ""20230612104840"", ""headline"": ""Biogen rises as FDA panel backs Alzheimer's drug, easing safety concerns"", ""summary"": ""Biogen's shares rose 2% on Monday as a unanimous backing of its Alzheimer's drug by the U.S. health regulator's advisers strengthened the case for a traditional approval with no major new safety warnings.""}, {""date"": ""20230612110715"", ""headline"": ""3-Stock Lunch: Oracle, Biogen and SentinelOne"", ""summary"": ""Eva Ados, ERShares chief operations officer, joins \u2018Power Lunch\u2019 to discuss three stocks: Oracle, Biogen and SentinelOne.""}, {""date"": ""20230612120646"", ""headline"": ""Biogen Rises After 'Drama-Free' Panel Votes Unanimously In Support Of Alzheimer's Drug"", ""summary"": ""Biogen stock rose Monday after a panel of advisors to the FDA voted unanimously in favor of its newest Alzheimer's treatment.""}, {""date"": ""20230612125000"", ""headline"": ""Biogen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Biogen Inc. rose 1.47% to $313.41 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230612130000"", ""headline"": ""Biogen's Charts So Far Appear Free of Major Side Effects"", ""summary"": ""Biotechnology firm Biogen  has pushed up to a new 52-week high Monday on the heels of a Food and Drug Administration panel voting unanimously in favor of its newest Alzheimer's treatment.  The daily On-Balance-Volume (OBV) line shows a rise for the past twelve months.  The 40-week moving average line is rising, The weekly OBV line is bullish and so is the MACD oscillator.""}, {""date"": ""20230612131711"", ""headline"": ""Canaccord Genuity Maintains Biogen (BIIB) Buy Recommendation"", ""summary"": """"}, {""date"": ""20230612131711"", ""headline"": ""Oppenheimer Maintains Biogen (BIIB) Outperform Recommendation"", ""summary"": """"}, {""date"": ""20230612131714"", ""headline"": ""Needham Reiterates Biogen (BIIB) Buy Recommendation"", ""summary"": """"}, {""date"": ""20230612133100"", ""headline"": ""Biogen Makes Board Changes Ahead of Shareholder Meeting"", ""summary"": ""By Denny Jacob Biogen on Monday made several changes to its board, part of its efforts to achieve sustainable growth. The biopharmaceutical company said...""}, {""date"": ""20230612171400"", ""headline"": ""Biogen Announces Changes to Its Board of Directors"", ""summary"": ""Biogen Will Adjourn Its Annual Meeting of Stockholders Until June 26, 2023, to Give All Stockholders Sufficient Time to Review and Vote on Proposed Slate CAMBRIDGE, Mass., June 12, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced several changes to its Board of Directors today. The changes will refresh the composition of the Board and follow the Board\u2019s continual interaction with company stockholders to solicit their perspective on a range of issues around the company\u2019s performance""}, {""date"": ""20230613020700"", ""headline"": ""Biogen's Leqembi may not be widely used for Alzheimer's in Europe - report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230613030000"", ""headline"": ""FOCUS-European Alzheimer's experts unconvinced by new Eisai, Biogen drug"", ""summary"": ""Alzheimer's disease experts in Europe weighing potential use of a new drug from Eisai and Biogen say its ability to slow cognitive decline may not outweigh its health risks, or be worth the toll on scarce healthcare resources.  Lecanemab, branded Leqembi in the U.S., is under regulatory review in Europe and likely poised for traditional U.S. approval next month based on trial data showing it slowed cognitive decline by 27% in patients with early Alzheimer's.  In Europe, where cost-conscious countries rigorously weigh new drugs before adopting their use, nine neurologists and researchers across six countries told Reuters lecanemab is unlikely to be widely used if approved.""}, {""date"": ""20230613042044"", ""headline"": ""European Alzheimer's experts unconvinced by new Eisai, Biogen drug"", ""summary"": ""Alzheimer's disease experts in Europe weighing potential use of a new drug from Eisai and Biogen say its ability to slow cognitive decline may not outweigh its health risks, or be worth the toll on scarce healthcare resources.""}, {""date"": ""20230613042900"", ""headline"": ""Biogen in pact with NeuroSense for ALS biomarker study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230613050400"", ""headline"": ""FTC Sues To Block Microsoft-Activision Blizzard Deal, Netflix's First Sports Streaming Debut, European Mulls Antitrust Case Against Google's Ad-Tech Business: Today's Top Stories"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230613051000"", ""headline"": ""FTC Sues To Block Microsoft-Activision Blizzard Deal, Netflix's First Sports Streaming Debut, EU Mulls Antitrust Case Against Google's Ad-Tech Business: Today's Top Stories"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230613054200"", ""headline"": ""Methode Electronics, Brookfield Renewable Partners And Other Big Stocks Moving Lower On Tuesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230613065215"", ""headline"": ""Top 20 Most Profitable Pharmaceutical Companies In The World"", ""summary"": ""In this article, we will be covering the top 20 most profitable pharmaceutical companies in the world. If you wish to see the top ones, head straight to the Top 5 Most Profitable Pharmaceutical Companies In The World. Undoubtedly, the pharmaceutical industry stands as one of the most financially rewarding and essential sectors worldwide, leading [\u2026]""}, {""date"": ""20230613071700"", ""headline"": ""Video: Nasdaq 100 Movers: BIIB, JD"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230613075600"", ""headline"": ""SVB Securities Sticks to Its Buy Rating for Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230613083801"", ""headline"": ""Stocks making the biggest moves midday: JD.com, Biogen, Oracle and more"", ""summary"": ""These are some of the stocks posting the largest moves in midday trading. ""}, {""date"": ""20230613103017"", ""headline"": ""Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources"", ""summary"": ""Experts in Europe considering the potential use of a new Alzheimer's disease drug developed by Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) say Leqembi (lecanemab)'s ability to slow cognitive decline may not outweigh its health risks or justify the strain it would place on limited healthcare resources. The drug is currently undergoing regulatory review in Europe and is likely to receive traditional approval in the U.S. next month after the FDA adcomm unanimously voted to favor the dru""}, {""date"": ""20230613122056"", ""headline"": ""Markets Rise Midday as Inflation News Raises Expectations of a Rate Hike Pause"", ""summary"": ""U.S. equities gained at midday on Tuesday, June 13, 2023 as lower inflation raised optimism the Fed could pause its rate hike cycle.""}, {""date"": ""20230613135233"", ""headline"": ""Sarissa's Denner quits Biogen board as firm seeks seats at Alkermes"", ""summary"": ""Activist investor Sarissa Capital may have cleared a stumbling block in its push for board seats at Alkermes when one of its candidates resigned from the board of a company that has a commercial relationship with the drugmaker.  The hedge fund's founder, Alex Denner, one of three Sarissa candidates running for seats on Alkermes' 11-member board, said this week that he will give up his board seat at biotech Biogen.""}, {""date"": ""20230613135400"", ""headline"": ""Biogen Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slipped 2.81% to $304.60 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""20230613141705"", ""headline"": ""Biogen has been an 'uninvestable' stock for awhile, says Mizuho's Jared Holz"", ""summary"": ""Jared Holz, Mizuho Securities healthcare sector specialist, joins 'Fast Money' to talk controversy brewing at Biogen, Alzheimer's drug approval roadblocks in Europe, and more.""}, {""date"": ""20230613191402"", ""headline"": ""UPDATE 1-Sarissa's Denner quits Biogen board as firm seeks seats at Alkermes"", ""summary"": ""Activist investor Sarissa Capital may have cleared a stumbling block in its push for board seats at Alkermes when one of its candidates resigned from the board of a company that has a commercial relationship with the drugmaker.  The hedge fund's founder, Alex Denner, 53, one of three Sarissa candidates running for seats on Alkermes' 11-member board, on Monday said he would give up his board seat at biotech company Biogen.""}, {""date"": ""20230613202900"", ""headline"": ""GLOBAL BRIEFING: US judge temporarily blocks Microsoft-Activision deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230614085500"", ""headline"": ""Senator Bernie Sanders Puts Brakes on Health Agency Nominees Until Drug Pricing Issue is Addressed"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230614125100"", ""headline"": ""Biogen Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slid 1.51% to $299.99 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230614225600"", ""headline"": ""Notable Thursday Option Activity: BIIB, UA, MET"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230615024900"", ""headline"": ""Sage Therapeutics price target raised to $66 from $61 at BofA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230615102100"", ""headline"": ""Biotech Stock Roundup: KDNY Up on NVS Buyout, BIIB & Eisai's AD Drug Update & More"", ""summary"": ""Acquisition and regulatory updates from Chinook Therapeutics (KDNY) and Biogen (BIIB) are in focus in the biotech sector.""}, {""date"": ""20230615125200"", ""headline"": ""Biogen Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Biogen Inc. dropped 0.72% to $297.83 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""20230615142923"", ""headline"": ""UPDATE 1-ISS backs election of Langer to replace former Biogen director Denner"", ""summary"": ""Proxy advisory firm Institutional Shareholder Services on Thursday recommended that Biogen shareholders elect Susan Langer to replace long-standing director Alex Denner, who abruptly left the board earlier this week.  Biogen said Langer, a former corporate strategy chief at the biotech company, would stand for election to replace Denner.  ISS issued its recommendation after the unexpected announcement on Monday that three directors -- Denner, William Jones and Richard Mulligan -- would not stand for reelection.""}, {""date"": ""20230615143217"", ""headline"": ""ISS backs election of Langer to replace former Biogen director Denner"", ""summary"": ""Proxy advisory firm Institutional Shareholder Services on Thursday recommended that Biogen  shareholders elect Susan Langer to replace long-standing director Alex Denner, who abruptly left the board earlier this week.  Biogen said Langer, a former corporate strategy chief at the biotech company, would stand for election to replace Denner.  ISS issued its recommendation after the unexpected announcement on Monday that three directors -- Denner, William Jones and Richard Mulligan -- would not stand for reelection.""}, {""date"": ""20230615185508"", ""headline"": ""Clene's ALS drug shows reduction in disease indicator levels in trial"", ""summary"": ""Clene said on Thursday its experimental amyotrophic lateral sclerosis (ALS) drug showed reduction in levels of an indicator believed to be tied with the disease progression in a mid-stage trial.""}, {""date"": ""20230615213550"", ""headline"": ""7 Undervalued S&P 500 Stocks to Buy in June"", ""summary"": ""When attempting to build a portfolio of reliable entities, you probably can\u2019t go wrong with undervalued S&P 500 stocks. Featuring the market performance of 500 of the largest companies listed on stock exchanges in the U.S., you\u2019re dealing with proven winners. To be fair, you might not receive a blistering performance. At the same time, these ideas are less likely to leave you stranded on the road. In addition, ChatGPT points out that the best S&P 500 stocks to buy offer diversification. Specific""}, {""date"": ""20230616045100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Grifols SA (GRFS)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230616125200"", ""headline"": ""Biogen Inc. stock outperforms market despite losses on the day"", ""summary"": ""Shares of Biogen Inc. slipped 0.12% to $297.48 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230616153600"", ""headline"": ""A Schwab Wealth Survey Reveals a Paradox"", ""summary"": ""Nearly half of the respondents averaging $560,000 in net worth said they were wealthy, when including nonfinancial factors like health and family. But when...""}, {""date"": ""20230617090013"", ""headline"": ""Biogen Inc. (NASDAQ:BIIB) Shares Could Be 24% Below Their Intrinsic Value Estimate"", ""summary"": ""Key Insights Biogen's estimated fair value is US$392 based on 2 Stage Free Cash Flow to Equity Current share price of...""}, {""date"": ""20230617100700"", ""headline"": ""2 Market-Beating Stocks With Major Catalysts on the Way"", ""summary"": ""For those seeking stocks that have trounced the market over the past year, the biotech sector might be an excellent place to start.  Two drugmakers that have done particularly well for themselves are Vertex Pharmaceuticals (NASDAQ: VRTX) and Biogen (NASDAQ: BIIB).  Vertex Pharmaceuticals has a rich portfolio of cystic fibrosis (CF) drugs that generates growing revenue.""}, {""date"": ""20230618165610"", ""headline"": ""How to Retire Rich: Biotech Stocks Edition"", ""summary"": ""Among the most difficult endeavors when it comes to deciphering the best retirement planning stocks is to identify companies that will remain relevant for years, if not decades to come. While no guarantees exist for anything, those who focus on investing in biotech own a clear advantage. Almost surely, the underlying sector \u2013 which falls under the broad healthcare industry \u2013 is permanently relevant. Further, I submitted a query on ChatGPT to extract key reasons why biotech stocks for retirement""}]",{}
23,2023-06-18,297.4800109863281,2023-06-25,284.5199890136719,-0.04356602626739814,D5,"[{""date"": ""20230618165610"", ""headline"": ""How to Retire Rich: Biotech Stocks Edition"", ""summary"": ""Among the most difficult endeavors when it comes to deciphering the best retirement planning stocks is to identify companies that will remain relevant for years, if not decades to come. While no guarantees exist for anything, those who focus on investing in biotech own a clear advantage. Almost surely, the underlying sector \u2013 which falls under the broad healthcare industry \u2013 is permanently relevant. Further, I submitted a query on ChatGPT to extract key reasons why biotech stocks for retirement""}, {""date"": ""20230619011646"", ""headline"": ""PBE: Healthcare Dashboard For June"", ""summary"": ""Pharma/biotechnology and healthcare providers are slightly undervalued relative to 11-year averages. Click here for the June edition of the Healthcare Dashboard.""}, {""date"": ""20230619053000"", ""headline"": ""Does This Signal Trouble for Biogen's New Alzheimer's Drug?"", ""summary"": ""Biogen (NASDAQ: BIIB) recently got some good news in the U.S. An advisory committee for the Food and Drug Administration (FDA) unanimously confirmed the clinical benefit of its Alzheimer's drug, Leqembi.  The FDA earlier granted Leqembi accelerated approval and now is considering it for traditional approval.""}, {""date"": ""20230619070000"", ""headline"": ""Alzheimer\u2019s Blockbuster Is Coming, but Slowly"", ""summary"": ""As any patient or family member dealing with cognitive impairment knows, getting diagnosed with Alzheimer\u2019s disease isn\u2019t simple.  With  Eisai  and  Biogen  anti-amyloid treatment Leqembi likely to receive full Food and Drug Administration approval and subsequent Medicare coverage next month, the focus will shift to tackling the hurdles to patient access.  For Eisai and Biogen, the challenge isn\u2019t just convincing patients and doctors that the drug provides real clinical benefits.""}, {""date"": ""20230620002000"", ""headline"": ""5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230620025824"", ""headline"": ""Ionis: Potential Advancement Into HAE Space Makes This A Must Watch"", ""summary"": ""Ionis Pharmaceuticals should be watched closely because it is advancing a drug for the prevention of hereditary angioedema attacks. Find out why IONS stock is a Buy.""}, {""date"": ""20230620092438"", ""headline"": ""ISS recommends one of Sarissa's three nominees for Alkermes board"", ""summary"": ""Proxy advisory firm Institutional Investor Services urged Alkermes shareholders to elect one of three director candidates proposed by activist hedge fund Sarissa Capital, arguing more outside pressure on management is needed right now.  ISS said Sarah Schlesinger, a physician with experience serving on public company boards, should be elected to Alkermes' 11-member board at next week's annual meeting.""}, {""date"": ""20230620125200"", ""headline"": ""Biogen Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Biogen Inc. shed 1.24% to $293.79 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230620213200"", ""headline"": ""$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230621040700"", ""headline"": ""Wednesday\u2019s Top Analyst Upgrades and Downgrades: ADM, Baidu, Melco Resorts, Palantir, Peabody Energy, Philip Morris, Shopify and More"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230621060800"", ""headline"": ""Top pharma lobby sues U.S. govt. over Medicare drug pricing negotiations"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230621125200"", ""headline"": ""Biogen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Biogen Inc. inched 0.19% higher to $294.36 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P...""}, {""date"": ""20230622125200"", ""headline"": ""Biogen Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. sank 0.14% to $293.95 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230623004500"", ""headline"": ""Mizuho Securities Remains a Buy on Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230623020100"", ""headline"": ""CMS update 'incremental positive' for Biogen, says William Blair"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230623022600"", ""headline"": ""Bank of America Securities Keeps Their Hold Rating on Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230623073000"", ""headline"": ""Is This a Sign That Biogen's Leqembi Could Obtain FDA Approval Next Month?"", ""summary"": ""It was two years ago that\u00a0Biogen's (NASDAQ: BIIB) stock soared to more than $400 on news that its Alzheimer's treatment, Aduhelm (aducanumab), had obtained accelerated approval from the Food and Drug Administration (FDA).  Today, however, the company has given up on Aduhelm and is instead focusing on a potentially more promising Alzheimer's drug, Leqembi.  It has already obtained accelerated approval and next month it could hit a much more important milestone: full, traditional approval.""}, {""date"": ""20230623125200"", ""headline"": ""Biogen Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. slid 3.21% to $284.52 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230624142640"", ""headline"": ""10 Personalized Medicine Stocks Billionaires Are Loading Up On"", ""summary"": ""In this article, we will take a look at the 10 personalized medicine stocks billionaires are purchasing. If you want to skip our detailed analysis of the industry and its growth prospects, go to the 5 Personalized Medicine Stocks Billionaires Are Loading Up On. According to Allied Market Research, the global personalized medicine industry is set [\u2026]""}]",{}
24,2023-06-25,284.5199890136719,2023-07-02,284.8500061035156,0.0011599082756463819,U1,"[{""date"": ""20230625204700"", ""headline"": ""GLOBAL BRIEFING: Vladimir Putin weakened by attempted Wagner revolt"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230625214600"", ""headline"": ""Biogen (BIIB) Receives a Buy from Robert W. Baird"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230626125200"", ""headline"": ""Biogen Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Biogen Inc. slipped 1.03% to $281.58 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230626125945"", ""headline"": ""UPDATE 1-Biogen shareholders back Susan Langer as director"", ""summary"": ""Biogen shareholders elected former company executive Susan Langer as a director on Monday, weeks after her romantic partner, Alex Denner, vacated the seat and the board nominated her to replace him.  Langer, 32, had served in various roles at the biotech company from 2013 to 2019.  Denner was a hedge fund manager, who had been a Biogen director since 2009 and headed the company's nominating and governance committee.""}, {""date"": ""20230626130745"", ""headline"": ""Biogen shareholders back Susan Langer as director"", ""summary"": ""Langer, 32, had served in various roles at the biotech company from 2013 to 2019.  Denner was a hedge fund manager, who had been a Biogen director since 2009 and headed the company's nominating and governance committee.""}, {""date"": ""20230626210600"", ""headline"": ""A Look Into Biogen Inc's Price Over Earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230627011431"", ""headline"": ""Biogen: Highs, Lows, And Mounting Expectations Ahead Of Leqembi Decision"", ""summary"": ""Biogen's problem has always been that its products target very difficult-to-treat diseases where signs of success are difficult to establish. Find out why BIIB stock is a Hold.""}, {""date"": ""20230627012100"", ""headline"": ""Biogen: Mounting Expectations Ahead Of Leqembi Decision"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230627020500"", ""headline"": ""Alcyone Therapeutics gets FDA IDE to initiate study of ThecaFlex DRx System"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230627030000"", ""headline"": ""Alcyone Therapeutics Receives FDA IDE Approval to Initiate Clinical Study of the ThecaFlex DRxTM System for Administration of SPINRAZA\u00ae (nusinersen)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230627042300"", ""headline"": ""Tuesday\u2019s Top Analyst Upgrades and Downgrades: Advance Auto Parts, Alphabet, Micron Technology, Ross Stores, Tesla and More"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230627125200"", ""headline"": ""Biogen Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.49% higher to $282.95 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""20230628125300"", ""headline"": ""Biogen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Biogen Inc. inched 0.38% higher to $284.02 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P...""}, {""date"": ""20230628233000"", ""headline"": ""A Drug for Itchy Dogs Costs $1,200. Why Is the Human Equivalent $43,000?"", ""summary"": ""What a shot that treats pet eczema reveals about how pharma companies actually price their drugs.""}, {""date"": ""20230628233800"", ""headline"": ""Piper Sandler pharmaceuticals analysts to hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230629050500"", ""headline"": ""How Is The Market Feeling About Biogen?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230629100028"", ""headline"": ""Biogen's (NASDAQ:BIIB) underlying earnings growth outpaced the favorable return generated for shareholders over the past year"", ""summary"": ""The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...""}, {""date"": ""20230629125300"", ""headline"": ""Biogen Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. slid 0.67% to $282.13 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""20230629220500"", ""headline"": ""Catalyst Watch: BorgWarner, Biogen, iRobot and Coty are in the spotlight during holiday-shortened week"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230629231300"", ""headline"": ""Biogen announces new SPINRAZA data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230630000300"", ""headline"": ""Amgen Inc. Dividend Stock Analysis"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230630074500"", ""headline"": ""Medicare revises guidance on drug price negotiations amid lawsuits"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230630084200"", ""headline"": ""10 Health Care Stocks With Whale Alerts In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230630091502"", ""headline"": ""Sage Therapeutics: Zuranolone August Approval Likely, Opportunity Uncertain"", ""summary"": ""Sage Therapeutics should find out in August whether its drug, zuranolone, will be approved. Click here to see our take on SAGE stock.""}, {""date"": ""20230630125300"", ""headline"": ""Biogen Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.96% higher to $284.85 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""20230630160600"", ""headline"": ""New Data at Cure SMA Highlight Potential Benefit of SPINRAZA\u00ae (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy"", ""summary"": ""Interim results from the RESPOND study show improved motor function in most participants treated with SPINRAZA after Zolgensma\u00ae (onasemnogene abeparvovec)Biogen also reported new real-world evidence and progress on the development of a novel device to enhance the patient treatment experience CAMBRIDGE, Mass., June 30, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced new SPINRAZA\u00ae (nusinersen) data aimed at answering critical questions for the spinal muscular atrophy (SMA) community.""}, {""date"": ""20230630230300"", ""headline"": ""Lilly, Vertex top pharma performers in H1; Moderna, Pfizer the worst"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]","{""assetTurnoverTTM"": 0.4022, ""bookValue"": 14467, ""cashRatio"": 0.8214621901474741, ""currentRatio"": 3.2733, ""ebitPerShare"": 4.0337, ""eps"": 4.066, ""ev"": 44896.863, ""fcfMargin"": 0.1629, ""fcfPerShareTTM"": 7.7462, ""grossMargin"": 0.7587, ""inventoryTurnoverTTM"": 1.7473, ""longtermDebtTotalAsset"": 0.2498, ""longtermDebtTotalCapital"": 0.3029, ""longtermDebtTotalEquity"": 0.4344, ""netDebtToTotalCapital"": 0.1767, ""netDebtToTotalEquity"": 0.2535, ""netMargin"": 0.2409, ""operatingMargin"": 0.239, ""pb"": 2.8499, ""peTTM"": 15.4732, ""pfcfTTM"": 29.756, ""pretaxMargin"": 0.2883, ""psTTM"": 4.1348, ""ptbv"": 3.2487, ""quickRatio"": 2.8547, ""receivablesTurnoverTTM"": 4.8312, ""roaTTM"": 0.1075, ""roeTTM"": 0.1958, ""roicTTM"": 0.134, ""rotcTTM"": 0.1563, ""salesPerShare"": 16.8797, ""sgaToSale"": 0.2413, ""tangibleBookValue"": 12691, ""totalDebtToEquity"": 0.4344, ""totalDebtToTotalAsset"": 0.2498, ""totalDebtToTotalCapital"": 0.3029, ""totalRatio"": 2.3533, ""period"": ""2023-06-30""}"
25,2023-07-02,284.8500061035156,2023-07-09,275.07000732421875,-0.03433385490517693,D4,"[{""date"": ""20230703033800"", ""headline"": ""Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230703210000"", ""headline"": ""FDA set to make decisions on several drug applications in July"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230704080059"", ""headline"": ""Biogen Inc. (NASDAQ:BIIB) is largely controlled by institutional shareholders who own 88% of the company"", ""summary"": ""Key Insights Given the large stake in the stock by institutions, Biogen's stock price might be vulnerable to their...""}, {""date"": ""20230705125300"", ""headline"": ""Biogen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Biogen Inc. inched 0.16% higher to $285.89 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P...""}, {""date"": ""20230705232300"", ""headline"": ""Biogen trading halted, news pending"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230705234400"", ""headline"": ""3 Biotech Stocks to Make Your \u2018Get Rich\u2019 Dreams Come True"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230705234500"", ""headline"": ""FDA converts Biogen Alzheimer's treatment to full approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230706001600"", ""headline"": ""Biogen, Eisai win full FDA approval for Alzheimer's drug Leqembi"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230706005400"", ""headline"": ""FDA approves Alzheimer\u2019s treatment Leqembi, clearing the way for Medicare coverage"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230706013200"", ""headline"": ""Quanterix launches LucentAD biomarker test for early Alzheimer's disease"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230706030600"", ""headline"": ""Mizuho Securities Sticks to Their Buy Rating for Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230706033400"", ""headline"": ""Top 5 Trending Stocks: Prestige Wealth's IPO, Rivian's Lawsuit, Meta's New Platform, Tesla's Dip, And Biogen's FDA Approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230706053103"", ""headline"": ""U.S. Wide-Moat Stocks On Sale - The July 2023 Heat Map"", ""summary"": ""Our 3-step process focuses on wide-moat stocks. We're only interested in targets attractively valued in historical comparison. Read what investors need to know.""}, {""date"": ""20230706102757"", ""headline"": ""Biogen's Make-Or-Break Moment Is Here In Alzheimer's Treatment"", ""summary"": ""The FDA could fully approve Biogen's Alzheimer's treatment, Leqembi, on Thursday. The decision could give a lift to Biogen stock.""}, {""date"": ""20230706124419"", ""headline"": ""FDA approves Alzheimer\u2019s drug Leqembi, paving way for broader Medicare coverage"", ""summary"": ""Leqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.""}, {""date"": ""20230706125300"", ""headline"": ""Biogen Inc. stock outperforms market despite losses on the day"", ""summary"": ""Shares of Biogen Inc. sank 0.31% to $284.99 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230706125305"", ""headline"": ""US FDA grants standard approval of Eisai/Biogen Alzheimer's drug"", ""summary"": ""The U.S. Food and Drug\nAdministration on Thursday granted standard approval to Eisai\nand Biogen's Leqembi for patients with\nAlzheimer's disease, clearing the way for wider insurance\ncoverage of the...""}, {""date"": ""20230706125500"", ""headline"": ""FDA approves Biogen and Eisai Alzheimer\u2019s treatment Leqembi"", ""summary"": ""The U.S. Food and Drug Administration on Thursday granted full approval to the Biogen and Eisai Co. Ltd. Alzheimer\u2019s treatment Leqembi, a step that secures...""}, {""date"": ""20230706130637"", ""headline"": ""FDA approves Alzheimer's drug Leqembi, paving way for broader Medicare coverage"", ""summary"": ""'Closing Bell Overtime' breaks latest from the FDA concerning Biogen's Alzheimer's drug.""}, {""date"": ""20230706132042"", ""headline"": ""Who is eligible for the new FDA-approved Alzheimer's drug?"", ""summary"": ""July 6 - The U.S. Food and Drug Administration on\nThursday granted standard approval to Eisai and\nBiogen's Leqembi for patients with Alzheimer's disease.\n             ...""}, {""date"": ""20230706144216"", ""headline"": ""Many health systems are already ready for 'Leqembi' roll out, says Eisai CEO Ivan Cheung"", ""summary"": ""Ivan Cheung, Eisai U.S. CEO, joins 'Fast Money' to discuss the FDA approving Biogen's 'Leqembi' Alzheimer's drug.""}, {""date"": ""20230706160000"", ""headline"": ""FDA Grants Traditional Approval for LEQEMBI\u00ae (lecanemab-irmb) for the Treatment of Alzheimer\u2019s Disease"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230706164601"", ""headline"": ""Eisai-Biogen Alzheimer's drug gets standard approval in US"", ""summary"": ""The U.S. Food and Drug Administration on Thursday granted standard approval to Eisai and Biogen's Leqembi that has slowed cognitive decline in Alzheimer's patients at an early stage of the memory-robbing disease.  It is the first traditional approval for a drug shown to modify the course of Alzheimer's and is expected to increase use among U.S. patients who have had limited access to the treatment since it received accelerated FDA approval in January.""}, {""date"": ""20230706165305"", ""headline"": ""UPDATE 5-US FDA grants standard approval of Eisai/Biogen Alzheimer's drug"", ""summary"": ""Eisai and Biogen's Leqembi won a coveted standard approval nod from the U.S. Food and Drug Administration on Thursday, the first Alzheimer's treatment to achieve that goal, clearing the way for wider insurance coverage of the drug.  The FDA decision marks a new milestone for a fatal disease that has eluded drugmakers' efforts for decades.  Trial data showed that the treatment slows progression of the brain-wasting disease by 27% for patients in the earliest stages of Alzheimer's.""}, {""date"": ""20230706170357"", ""headline"": ""Biogen Snags Full Approval For Alzheimer's Treatment; Shares Halted"", ""summary"": ""The FDA fully approved Biogen's Alzheimer's treatment, Leqembi, on Thursday. Biogen stock was halted in late trading.""}, {""date"": ""20230706171310"", ""headline"": ""Levi Strauss & Co., Costco, Biogen: After-hours movers"", ""summary"": ""Levi Strauss & Co. shares drop as the company slashes 2023 guidance. Costco reports a 0.4% increase in net sales for June. The FDA approves Eisai and Biogen's Alzheimer's drug Leqembi. Yahoo Finance Live's Seana Smith breaks down the after-hours movers.""}, {""date"": ""20230706173355"", ""headline"": ""US regulators approve first drug to slow progression of Alzheimer\u2019s"", ""summary"": ""The US Food and Drug Administration has approved the first Alzheimer\u2019s drug to slow the progression of the neurodegenerative disease, paving the way for millions of American patients to access the treatment.  The regulator said on Thursday it would grant full approval to lecanemab, now known by the brand name Leqembi, which was developed by Japanese drugmaker Eisai and US biotech Biogen.  Teresa Buracchio, acting director of the Office of Neuroscience in the FDA\u2019s Center for Drug Evaluation and Research, said a confirmatory study had shown that Leqembi was a \u201csafe and effective treatment\u201d for patients with Alzheimer\u2019s.""}, {""date"": ""20230706174608"", ""headline"": ""Dow Jones Futures: Jobs Report On Tap; Threads Off To Record Start As Elon Musk Rips 'Cheating'"", ""summary"": ""Stocks retreated as Treasury yields jumped on hot economic data ahead of Friday's jobs report. Meta's Threads had record first-day downloads as Elon Musk decried \""cheating.\""""}, {""date"": ""20230706181000"", ""headline"": ""FDA Gives Full Approval to Alzheimer\u2019s Drug"", ""summary"": ""Federal approval for the treatment marks a major step forward in making the drug accessible. The Centers for Medicare and Medicaid Services said in January it would cover much of the cost.""}, {""date"": ""20230706185700"", ""headline"": ""FDA Approves Leqembi, Extending Alzheimer\u2019s Treatment to More Patients"", ""summary"": ""A treatment for Alzheimer\u2019s disease is on its way to many more patients across the U.S.  The Food and Drug Administration on Thursday granted full approval to Leqembi, allowing Medicare enrollees to get fully covered treatment with the drug if they qualify and agree to report data to a registry.  Most of the six million people in the U.S. with Alzheimer\u2019s are eligible for Medicare.""}, {""date"": ""20230706200000"", ""headline"": ""FDA Grants Traditional Approval for LEQEMBI\u00ae (lecanemab-irmb) for the Treatment of Alzheimer's Disease"", ""summary"": ""Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \""Eisai\"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \""Biogen\"") announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI\u00ae (lecanemab-irmb) 100 mg/mL injection for intravenous use, making LEQEMBI the first and only approved treatment shown to reduce the r""}, {""date"": ""20230706202505"", ""headline"": ""Trending : Eisai, Biogen's Alzheimer's Treatment Gets Full FDA Approval"", ""summary"": ""0408 GMT - Eisai is one of the most mentioned companies in the news over the past 12 hours, according to Factiva data, after its Alzheimer's drug Leqembi secured traditional approval from the U.S....""}, {""date"": ""20230706204800"", ""headline"": ""TOP NEWS: US FDA approves Biogen's Alzheimer's treatment Leqembi"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230706210200"", ""headline"": ""If You Invested $1000 In This Stock 15 Years Ago, You Would Have $4,900 Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230706221300"", ""headline"": ""Notable Two Hundred Day Moving Average Cross - BIIB"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230706222400"", ""headline"": ""Noteworthy Friday Option Activity: BIIB, LLY, AVGO"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230706222700"", ""headline"": ""Biogen, Eisai\u2019s Alzheimer\u2019s Drug Scores Big With FDA\u2019s Full Approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230706225400"", ""headline"": ""Mixed Jobs Data; Fed Governors Want More Interest Rate Hikes; US, China Spat Rattles Semiconductor Sector: The Week In The Markets"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230706231100"", ""headline"": ""What You Missed On Wall Street On Friday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230706235500"", ""headline"": ""Piper Sandler pharmaceuticals analysts to hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230707001100"", ""headline"": ""Analysts\u2019 Opinions Are Mixed on These Healthcare Stocks: Thermo Fisher (TMO), Biogen (BIIB) and Boston Scientific (BSX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230707011500"", ""headline"": ""Biogen set up nicely to generate upside, says Canaccord"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230707012600"", ""headline"": ""H.C. Wainwright Remains a Buy on Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230707013400"", ""headline"": ""Black box warning on Leqembi  'bit if a surprise,' says Piper Sandler"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230707014300"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Biogen (BIIB) and Crinetics Pharmaceuticals (CRNX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230707014600"", ""headline"": ""Label for Biogen's Leqembi generally as expected, says Mizuho"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230707015800"", ""headline"": ""Stock Futures Dip As Traders Eye Friday Jobs Report: Analyst Says Q3 Returns Hinge More On This Catalyst Than Fed Move"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230707020007"", ""headline"": ""Japanese pharma Eisai slides 4% despite FDA approval for Alzheimer's drug"", ""summary"": ""Leqembi is the first Alzheimer's antibody treatment to receive full FDA approval.""}, {""date"": ""20230707020500"", ""headline"": ""BMO Capital Sticks to Their Buy Rating for Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230707020800"", ""headline"": ""Label for Biogen's Leqembi not barrier to treatment, says William Blair"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230707022200"", ""headline"": ""Biogen shares little changed after resumption of trade"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230707025100"", ""headline"": ""Analysts\u2019 Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Simulations Plus (SLP)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230707030600"", ""headline"": ""Jefferies Remains a Buy on Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230707032900"", ""headline"": ""Biogen\u2019s stock slides premarket as analysts take mixed view of Alzheimer\u2019s disease drug approval"", ""summary"": ""Biogen Inc.\u2019s stock rose about 2% before paring those gains premarket Friday, after the U.S. Food and Drug Administration on Thursday granted full approval...""}, {""date"": ""20230707040200"", ""headline"": ""What 29 Analyst Ratings Have To Say About Biogen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230707042233"", ""headline"": ""Stocks making the biggest premarket moves: Levi Strauss, Biogen, Alibaba and more"", ""summary"": ""These are the stocks posting the largest moves in the premarket.""}, {""date"": ""20230707050300"", ""headline"": ""BIIB Stock Alert: What to Know as FDA Approves Biogen\u2019s Alzheimer\u2019s Drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230707053000"", ""headline"": ""Why Is Alibaba (BABA) Stock Up Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230707054829"", ""headline"": ""EISAI - FDA GRANTS TRADITIONAL APPROVAL FOR LEQEMBI FOR THE TREATMENT OF ALZHEIMER'S DISEASE"", ""summary"": ""TOKYO - Eisai Co., Ltd.  and Biogen Inc.  announced today that the U.S. Food and Drug Administration  has approved the supplemental Biologics License Application  supporting the traditional approval...""}, {""date"": ""20230707060700"", ""headline"": ""FSLR Stock Alert: The $1 Billion Reason First Solar Is Up Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230707062040"", ""headline"": ""Will Watershed Moment For Alzheimer's Propel Biogen Stock Higher?"", ""summary"": ""Esai and Biogen's Alzheimer's Disease therapeutic, Leqembi, received full FDA approval on July 6th. Read more here.""}, {""date"": ""20230707064649"", ""headline"": ""Demand for Biogen's new Alzheimer's drug will surprise to the upside, says Piper Sandler analyst"", ""summary"": ""Christopher Raymond, Piper Sandler, joins 'Squawk on the Street' to discuss the market's reaction to Biogen's FDA approval, what demand will look like for Biogen's new drug and the serious side effects of the Alzheimer's drug.""}, {""date"": ""20230707064900"", ""headline"": ""Biogen\u2019s big Alzheimer\u2019s drug win fails to boost the stock as analysts see slow Leqembi rollout"", ""summary"": ""Milestone Leqembi approval is \u201ca mixed bag,\u201d analysts say, given drug label's risk warnings and infusion-center bottlenecks.""}, {""date"": ""20230707072423"", ""headline"": ""Why The Market Is Likely Wrong About Cassava Sciences, Again"", ""summary"": ""Cassava Sciences stock crashed in reaction to top-line data from a Phase 2 trial. Click here to find out why SAVA stock is rated a strong buy.""}, {""date"": ""20230707074000"", ""headline"": ""These Stocks Are Moving the Most Today: Rivian, Tesla, Levi Strauss, Paramount, and More"", ""summary"": ""Analysts boost their price targets on Rivian and Tesla, Levi Strauss cuts its revenue outlook for the fiscal year, and Paramount shares are downgraded.""}, {""date"": ""20230707074127"", ""headline"": ""Needham Reiterates Biogen (BIIB) Buy Recommendation"", ""summary"": """"}, {""date"": ""20230707074131"", ""headline"": ""HC Wainwright & Co. Reiterates Biogen (BIIB) Buy Recommendation"", ""summary"": """"}, {""date"": ""20230707081308"", ""headline"": ""Dow Jones Futures Fall With Jobs Report Due; Meta Leads 7 Resilient Stocks"", ""summary"": ""The jobs report looms with Treasury yields soaring. Meta is among stocks holding up as Threads had record first-day downloads.""}, {""date"": ""20230707082700"", ""headline"": ""Stocks Rebound, Dollar Tumbles As June Jobs Data Eases Fed Hike Wagers: What's Driving Markets Friday?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230707082700"", ""headline"": ""Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230707084500"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230707085242"", ""headline"": ""Stocks making the biggest moves midday: Rivian, Levi Strauss, Biogen, First Solar and more"", ""summary"": ""These are the stocks posting the largest moves in midday trading. ""}, {""date"": ""20230707095100"", ""headline"": ""Biogen (BIIB), Eisai Get Full FDA Nod for Leqembi in Alzheimer's"", ""summary"": ""Following the full approval, Biogen (BIIB)/Eisai's Leqembi is the first approved treatment to slow progression of Alzheimer's disease. This also paves the way for a broader Medicare coverage.""}, {""date"": ""20230707095751"", ""headline"": ""Eisai-Biogen's Alzheimer's treatment drug receives FDA approval"", ""summary"": ""Shares of Biogen and Eisai are lower amid news of label updates to the FDA officially approved the Alzheimer's treatment drug Leqembi. Yahoo Finance Live breaks down the story.""}, {""date"": ""20230707095937"", ""headline"": ""Sales of Alzheimer\u2019s drug Leqembi may be slow initially but could pick up in 2024"", ""summary"": ""Analysts believe the Medicare registry requirement and new guidance on Leqembi's prescription label could potentially weigh on sales in the near term. ""}, {""date"": ""20230707111213"", ""headline"": ""Three-Stock Lunch: Meta, Biogen and Levi Strauss"", ""summary"": ""Gina Sanchez, chief market strategist at Lido Advisors, joins \u2018Power Lunch\u2019 to discuss her thoughts on three stocks: Meta, Biogen and Levi Strauss.""}, {""date"": ""20230707125300"", ""headline"": ""Biogen Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slid 3.48% to $275.07 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230707130023"", ""headline"": ""More Eisai/Biogen Alzheimer's drug approvals seen likely despite safety warning"", ""summary"": ""With U.S. approval of Eisai's and Biogen's Alzheimer's drug Leqembi secured, Wall Street analysts said they expect other region's health regulators to follow suit even if they share similar concerns about a potentially severe side effect.  Leqembi won standard approval from the U.S. Food and Drug Administration (FDA) on Thursday, but the FDA placed its strongest \""boxed\"" safety warning on the drug's label, flagging the risk of potentially dangerous brain swelling in it and similar drugs.  Outside the United States, Eisai and Biogen are seeking approval for Leqembi, whose chemical name is lecanemab, in Japan, the European Union, China, Canada, Great Britain and South Korea.""}, {""date"": ""20230707131411"", ""headline"": ""These Stocks Are Moving the Most Today: Rivian, Tesla, Alibaba, Levi Strauss, and More"", ""summary"": ""Analysts boost their price targets on Rivian and Tesla, Alibaba stock rises after Chinese authorities fine Ant Group\u2014a fintech company of which Alibaba owns a third\u2014almost $1 billion, and Levi Strauss cuts its fiscal-year outlook.""}, {""date"": ""20230707131700"", ""headline"": ""Biogen\u2019s Alzheimer\u2019s Drug Rollout Could Be Slow"", ""summary"": ""Biogen has said it doesn't expect to clear a profit on Alzheimer's treatment Leqembi, which was approved by the FDA Thursday, until late 2024.""}, {""date"": ""20230707144008"", ""headline"": ""New Alzheimer's drug from Biogen, Eisai gets government approval, but faces long road ahead"", ""summary"": ""Biogen and Eisai's second attempt at a new class of Alzheimer's treatments faces pressure despite regulatory and CMS greenlight.""}, {""date"": ""20230707160257"", ""headline"": ""Biogen Skids As Analysts Debate Uptake For Newly Approved Alzheimer's Drug"", ""summary"": ""Biogen stock skidded Friday after the Food and Drug Administration fully approved its Alzheimer's treatment, Leqembi.""}, {""date"": ""20230707162100"", ""headline"": ""Rivian, Tesla, Alibaba, Levi Strauss, First Solar, and More Stock Market Movers"", ""summary"": ""Analysts boosted their price targets on Rivian and Tesla, Alibaba stock rose after Chinese authorities fine Ant Group\u2014a fintech company of which Alibaba owns a third\u2014almost $1 billion, and Levi Strauss cut its fiscal-year outlook.""}, {""date"": ""20230707162214"", ""headline"": ""Biogen, Eisai stocks fall despite receiving FDA approval for Alzheimer's drug"", ""summary"": ""Shares of pharmaceutical developers Biogen and Eisai are falling in the after-hours session. This comes following the companies received official FDA approval for their Alzheimer's treatment drug, Leqembi. Yahoo Finance Healthcare Reporter Anjalee Khemlani joins the Live show to detail the treatment plan.""}, {""date"": ""20230707210100"", ""headline"": ""Biogen/Eisai's Leqembi set to become Medicare's single highest drug spend"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230707231600"", ""headline"": ""Needham Reaffirms Their Buy Rating on Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230708030001"", ""headline"": ""Medicare will pay for Alzheimer's drug Leqembi. What patients and doctors should know"", ""summary"": ""Patients with early Alzheimer's disease could still pay more than $5,000 in out-of-pocket costs for Leqembi even with Medicare coverage.""}, {""date"": ""20230709060000"", ""headline"": ""Eisai: Looking To Upside Targets Following Leqembi Full Approval"", ""summary"": ""FDA approved Eisai's Leqembi label last week, developed with Biogen, for treatment of adult patients with Alzheimer's Disease. Find out why ESALF stock is a Buy.""}, {""date"": ""20230709060000"", ""headline"": ""Biogen Just Reached a Big Milestone. Why Isn't the Stock Rising?"", ""summary"": ""Biogen (NASDAQ: BIIB) once stood out as one of the most successful biotech companies.  Biogen turned its attention to Alzheimer's disease.  Along with partner Eisai, Biogen advanced Leqembi -- and the companies just reached a major milestone.""}, {""date"": ""20230709070000"", ""headline"": ""Goldman Sachs sees rays of hope in underperforming health sector"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230709195219"", ""headline"": ""Biogen And Alzheimer's Disease: Too Early To Celebrate"", ""summary"": ""The FDA granted full approval to Biogen and Eisai\u00e2\u0080\u0099s anti-amyloid antibody drug Leqembi. Click here to read why BIIB stock is a Hold.""}]","{""assetTurnoverTTM"": 0.4022, ""bookValue"": 14467, ""cashRatio"": 0.8214621901474741, ""currentRatio"": 3.2733, ""ebitPerShare"": 4.0337, ""eps"": 4.066, ""ev"": 44896.863, ""fcfMargin"": 0.1629, ""fcfPerShareTTM"": 7.7462, ""grossMargin"": 0.7587, ""inventoryTurnoverTTM"": 1.7473, ""longtermDebtTotalAsset"": 0.2498, ""longtermDebtTotalCapital"": 0.3029, ""longtermDebtTotalEquity"": 0.4344, ""netDebtToTotalCapital"": 0.1767, ""netDebtToTotalEquity"": 0.2535, ""netMargin"": 0.2409, ""operatingMargin"": 0.239, ""pb"": 2.8499, ""peTTM"": 15.4732, ""pfcfTTM"": 29.756, ""pretaxMargin"": 0.2883, ""psTTM"": 4.1348, ""ptbv"": 3.2487, ""quickRatio"": 2.8547, ""receivablesTurnoverTTM"": 4.8312, ""roaTTM"": 0.1075, ""roeTTM"": 0.1958, ""roicTTM"": 0.134, ""rotcTTM"": 0.1563, ""salesPerShare"": 16.8797, ""sgaToSale"": 0.2413, ""tangibleBookValue"": 12691, ""totalDebtToEquity"": 0.4344, ""totalDebtToTotalAsset"": 0.2498, ""totalDebtToTotalCapital"": 0.3029, ""totalRatio"": 2.3533, ""period"": ""2023-06-30""}"
26,2023-07-09,275.07000732421875,2023-07-16,278.92999267578125,0.014032738025897551,U2,"[{""date"": ""20230709060000"", ""headline"": ""Eisai: Looking To Upside Targets Following Leqembi Full Approval"", ""summary"": ""FDA approved Eisai's Leqembi label last week, developed with Biogen, for treatment of adult patients with Alzheimer's Disease. Find out why ESALF stock is a Buy.""}, {""date"": ""20230709060000"", ""headline"": ""Biogen Just Reached a Big Milestone. Why Isn't the Stock Rising?"", ""summary"": ""Biogen (NASDAQ: BIIB) once stood out as one of the most successful biotech companies.  Biogen turned its attention to Alzheimer's disease.  Along with partner Eisai, Biogen advanced Leqembi -- and the companies just reached a major milestone.""}, {""date"": ""20230709070000"", ""headline"": ""Goldman Sachs sees rays of hope in underperforming health sector"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230709195219"", ""headline"": ""Biogen And Alzheimer's Disease: Too Early To Celebrate"", ""summary"": ""The FDA granted full approval to Biogen and Eisai\u00e2\u0080\u0099s anti-amyloid antibody drug Leqembi. Click here to read why BIIB stock is a Hold.""}, {""date"": ""20230709221100"", ""headline"": ""Wall Street Analysts Are Bullish on Top Healthcare Picks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230710014400"", ""headline"": ""Icahn Enterprises shares jump on loan agreement and other stocks on the move"", ""summary"": ""Icahn Enterprises, Alibaba and Northern Trust are stocks on the move.""}, {""date"": ""20230710032100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV), Galapagos (GLPG) and Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230710040500"", ""headline"": ""Monday\u2019s Top Analyst Upgrades and Downgrades: Biogen, Bloom Energy, ConocoPhillips, DraftKings, Humana, IBM, JP Morgan Chase, Newmont, Playtika, Williams-Sonoma and More"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230710045800"", ""headline"": ""Biogen shares \u2018an under-owned turnaround story,\u2019 Jefferies analysts say"", ""summary"": ""Shares of Biogen Inc. which last week received a milestone U.S. Food and Drug Administration approval for Alzheimer\u2019s treatment Leqembi, \u201cremain an...""}, {""date"": ""20230710112200"", ""headline"": ""Biogen (BIIB) Stock Down Despite FDA Nod to Alzheimer's Drug"", ""summary"": ""Biogen (BIIB) stock falls despite Leqembi getting the traditional nod for the treatment of Alzheimer's Disease.""}, {""date"": ""20230710121206"", ""headline"": ""BIOGEN : TO REPORT SECOND QUARTER 2023 FINANCIAL RESULTS JULY 25, 2023"", ""summary"": ""Cambridge, Mass.- Biogen Inc.  today announced it will report second quarter 2023 financial results Tuesday, July 25, 2023, before the financial markets open.\n      \n      \n       ...""}, {""date"": ""20230710125400"", ""headline"": ""Biogen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Biogen Inc. rose 2.37% to $281.58 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230710155200"", ""headline"": ""Why Biotech Stocks Keep Falling on Good News"", ""summary"": ""It\u2019s a sign that investors are increasingly wary of the biopharma sector.  It happened in late June, when  Sarepta Therapeutics  (ticker: SRPT) dropped 16% over the course of a few days after the FDA approved its new gene therapy for Duchenne muscular dystrophy.  On June 29, the FDA approved another gene therapy, this one a hemophilia A treatment from  BioMarin Pharmaceutical  (BMRN); BioMarin shares fell 3.6% that day and 2.5% the following day.""}, {""date"": ""20230711031700"", ""headline"": ""ADC Therapeutics falls after pausing mid-stage trial for lead asset"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230711032200"", ""headline"": ""Biogen price target raised to $341 from $332 at RBC Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230711094000"", ""headline"": ""Ionis (IONS) Posts Encouraging Data From Amyloidosis Drug Study"", ""summary"": ""Ionis (IONS) reports positive 85-week phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).""}, {""date"": ""20230711112122"", ""headline"": ""RBC Capital Maintains Biogen (BIIB) Outperform Recommendation"", ""summary"": """"}, {""date"": ""20230711112122"", ""headline"": ""Morgan Stanley Maintains Biogen (BIIB) Overweight Recommendation"", ""summary"": """"}, {""date"": ""20230711125300"", ""headline"": ""Biogen Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. dropped 0.62% to $279.84 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""20230711132324"", ""headline"": ""We've only seen the beginning of Moderna's story, says Goldman Sachs' Salveen Richter"", ""summary"": ""Salveen Richter, Goldman Sachs lead biotech analyst, joins 'Closing Bell Overtime' to discuss the biotech sector and how investors should play in the space.""}, {""date"": ""20230712070037"", ""headline"": ""Biogen Inc. (NASDAQ:BIIB) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?"", ""summary"": ""With its stock down 11% over the past month, it is easy to disregard Biogen (NASDAQ:BIIB). But if you pay close...""}, {""date"": ""20230712072100"", ""headline"": ""P/E Ratio Insights for Biogen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230712121012"", ""headline"": ""Why Biogen Inc. (BIIB) is Poised to Beat Earnings Estimates Again"", ""summary"": ""Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.""}, {""date"": ""20230712125400"", ""headline"": ""Biogen Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. sank 0.79% to $277.62 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230712175018"", ""headline"": ""Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know"", ""summary"": ""Biogen Inc. (BIIB) closed the most recent trading day at $277.41, moving -0.87% from the previous trading session.""}, {""date"": ""20230713040358"", ""headline"": ""Acumen Pharmaceuticals: A Risky Bet Through Upcoming Data Readout"", ""summary"": ""Acumen will present Phase 1 topline data on its Alzheimer\u00e2\u0080\u0099s therapeutic candidate, ACU193, at the annual AAIC. Check out our recommendation on ABOS stock.""}, {""date"": ""20230713044100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Silence Therapeutics (SLN) and Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230713081500"", ""headline"": ""Why Isn't Biogen Stock Soaring After This Major FDA Approval?"", ""summary"": ""Investors in Biogen (NASDAQ: BIIB) got some great news last week as the Food and Drug Administration (FDA) approved the company's Alzheimer's drug Leqembi.  Here's why investors might still be hesitant about buying the stock despite the approval.  The FDA previously approved Leqembi on an accelerated basis.""}, {""date"": ""20230713083000"", ""headline"": ""7 Stocks That AI Says Will Make You a Millionaire by 2025"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230713092200"", ""headline"": ""Biotech Stock Roundup: BIIB, Eisai's Drug Update, NVAX Gains on Deal Amendment"", ""summary"": ""Regulatory and key pipeline updates from Biogen (BIIB) and Novavax (NVAX) are in focus in the biotech sector.""}, {""date"": ""20230713125500"", ""headline"": ""Biogen Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.13% higher to $277.97 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""20230714125400"", ""headline"": ""Biogen Inc. stock underperforms Friday when compared to competitors despite daily gains"", ""summary"": ""Shares of Biogen Inc. inched 0.35% higher to $278.93 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""20230716070100"", ""headline"": ""Eli Lilly, Merck among top pharma picks in Barclays Q2 preview"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230716071500"", ""headline"": ""These 2 Numbers Should Scare Every Biogen Shareholder"", ""summary"": ""Most Biogen (NASDAQ: BIIB) shareholders are probably excited about the company's newly approved Alzheimer's drug Leqembi right about now, and it's no surprise why.  As a pharma company, Biogen needs to consistently use its research and development (R&D) capabilities to discover, test, and commercialize new medicines over time.  For the business to grow, and for shareholders to earn a return, it needs to make more money from selling its medicines than it costs to develop them.""}, {""date"": ""20230716090024"", ""headline"": ""Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?"", ""summary"": ""Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...""}]","{""assetTurnoverTTM"": 0.4022, ""bookValue"": 14467, ""cashRatio"": 0.8214621901474741, ""currentRatio"": 3.2733, ""ebitPerShare"": 4.0337, ""eps"": 4.066, ""ev"": 44896.863, ""fcfMargin"": 0.1629, ""fcfPerShareTTM"": 7.7462, ""grossMargin"": 0.7587, ""inventoryTurnoverTTM"": 1.7473, ""longtermDebtTotalAsset"": 0.2498, ""longtermDebtTotalCapital"": 0.3029, ""longtermDebtTotalEquity"": 0.4344, ""netDebtToTotalCapital"": 0.1767, ""netDebtToTotalEquity"": 0.2535, ""netMargin"": 0.2409, ""operatingMargin"": 0.239, ""pb"": 2.8499, ""peTTM"": 15.4732, ""pfcfTTM"": 29.756, ""pretaxMargin"": 0.2883, ""psTTM"": 4.1348, ""ptbv"": 3.2487, ""quickRatio"": 2.8547, ""receivablesTurnoverTTM"": 4.8312, ""roaTTM"": 0.1075, ""roeTTM"": 0.1958, ""roicTTM"": 0.134, ""rotcTTM"": 0.1563, ""salesPerShare"": 16.8797, ""sgaToSale"": 0.2413, ""tangibleBookValue"": 12691, ""totalDebtToEquity"": 0.4344, ""totalDebtToTotalAsset"": 0.2498, ""totalDebtToTotalCapital"": 0.3029, ""totalRatio"": 2.3533, ""period"": ""2023-06-30""}"
27,2023-07-16,278.92999267578125,2023-07-23,276.739990234375,-0.007851441217911037,D1,"[{""date"": ""20230716070100"", ""headline"": ""Eli Lilly, Merck among top pharma picks in Barclays Q2 preview"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230716071500"", ""headline"": ""These 2 Numbers Should Scare Every Biogen Shareholder"", ""summary"": ""Most Biogen (NASDAQ: BIIB) shareholders are probably excited about the company's newly approved Alzheimer's drug Leqembi right about now, and it's no surprise why.  As a pharma company, Biogen needs to consistently use its research and development (R&D) capabilities to discover, test, and commercialize new medicines over time.  For the business to grow, and for shareholders to earn a return, it needs to make more money from selling its medicines than it costs to develop them.""}, {""date"": ""20230716090024"", ""headline"": ""Does Biogen (NASDAQ:BIIB) Have A Healthy Balance Sheet?"", ""summary"": ""Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...""}, {""date"": ""20230717050200"", ""headline"": ""Acumen stock rallies over 60% on Alzheimer's drug data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230717061503"", ""headline"": ""Eli Lilly expects FDA decision on Alzheimer's treatment donanemab by the end of the year"", ""summary"": ""Eli Lilly is racing to market donanemab for Alzheimer's after Eisai and Biogen's drug for the disease, Leqembi, won FDA approval this month.""}, {""date"": ""20230717082700"", ""headline"": ""Eli Lilly full phase 3 data confirms benefit of Alzheimer's asset donanemab"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230717094500"", ""headline"": ""Should You Buy the Dip With Biogen Stock Right Now?"", ""summary"": ""With shares of Biogen (NASDAQ: BIIB) falling by 11% in the last 30 days, and by 20% in the last five years, could there be an opportunity for enterprising investors to buy the dip on this struggling biotech stock?  On the positive side, the company's new Alzheimer's drug Leqembi secured full approval from the Food and Drug Administration (FDA) on July 6.  For people with early-stage Alzheimer's disease, Leqembi slows the rate of progression by around 27%, such that their cognitive capabilities remain relatively more intact for longer than they would otherwise.""}, {""date"": ""20230717125600"", ""headline"": ""Biogen Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Biogen Inc. slumped 0.19% to $278.40 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230718002200"", ""headline"": ""Eli Lilly\u2019s (NYSE:LLY) Alzheimer\u2019s Drug Inches Closer to FDA Approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230718020100"", ""headline"": ""Biogen price target lowered to $357 from $380 at BMO Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230718022800"", ""headline"": ""The Tech Stock Rally Has Reached a Critical Moment. Watch Tesla, Netflix Earnings."", ""summary"": ""AT&T hit by report about lead on cables, Eli Lilly\u2019s Alzheimer\u2019s drug shows promise in latest trial, and other news to start your day.""}, {""date"": ""20230718031706"", ""headline"": ""5 things to know before the stock market opens Tuesday"", ""summary"": ""Here are the most important news items that investors need to start their trading day.""}, {""date"": ""20230718043440"", ""headline"": ""Acumen: A First In Targeting, May Lead To Improvement For Early AD Patients"", ""summary"": ""Acumen reported positive topline results from its phase 1 INTERCEPT-AD study, which used ACU193 for the treatment of patients with early Alzheimer's Disease. Read more here.""}, {""date"": ""20230718043900"", ""headline"": ""Biogen, Eli Lilly likely to split the Alzheimer\u2019s drug market, analysts say"", ""summary"": ""Eli Lilly and Co. and Biogen Inc. are likely to reach an \u201cequitable split\u201d of the Alzheimer\u2019s drug market after Lilly on Monday released more details on its...""}, {""date"": ""20230718062900"", ""headline"": ""Sanofi expands collaboration with Scribe on CRISPR genome editing"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230718100122"", ""headline"": ""Earnings Preview: Biogen Inc. (BIIB) Q2 Earnings Expected to Decline"", ""summary"": ""Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.""}, {""date"": ""20230718102218"", ""headline"": ""New Alzheimer's drug success 'was built on failures': Eisai exec"", ""summary"": ""Eisai just reached the finish line with its long-fought battle to gain Medicare approval for Alzheimer's drug Leqembi. But the company says more work remains.""}, {""date"": ""20230718113000"", ""headline"": ""Lilly's (LLY) Donanemab Slows Alzheimer's Disease Progression"", ""summary"": ""Data from a phase III study shows that treatment with Eli Lilly's (LLY) donanemab slowed cognitive and functional decline by 60% in study participants at the earliest stage of Alzheimer's disease.""}, {""date"": ""20230718125500"", ""headline"": ""Biogen Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slid 0.80% to $276.17 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""20230718131120"", ""headline"": ""IBD Stock Of The Day Eli Lilly: How Alzheimer's And Weight Loss Are Driving A New Breakout"", ""summary"": ""Eli Lilly stock is Tuesday's IBD Stock Of The Day. Shares are rising as Lilly's Alzheimer's treatment appears \""very competitive\"" with Biogen's.""}, {""date"": ""20230718141300"", ""headline"": ""Alzheimer\u2019s Drugs May Be a Big-Pharma Payday. Lilly and Biogen Are Facing Off."", ""summary"": ""Two similar Alzheimer\u2019s drugs are likely to be on the market and accessible for Medicare patients sometime in 2024.""}, {""date"": ""20230718173600"", ""headline"": ""The Fight Against Alzheimer\u2019s Goes Beyond Plaque. Tangles Are a Target, Too."", ""summary"": ""Several companies at an Amsterdam conference reported progress in going after tau protein tangles. Prothena probably has the most at stake.""}, {""date"": ""20230718173600"", ""headline"": ""The Fight Against Alzheimer Goes Beyond Plaque. Tangles Are a Target Too."", ""summary"": ""Several companies at an Amsterdam conference reported progress in going after tau protein tangles. Prothena probably has the most at stake.""}, {""date"": ""20230718175020"", ""headline"": ""Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know"", ""summary"": ""In the latest trading session, Biogen Inc. (BIIB) closed at $276.17, marking a -0.8% move from the previous day.""}, {""date"": ""20230719031500"", ""headline"": ""At-home Alzheimer\u2019s testing is on the horizon, researchers say"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230719053000"", ""headline"": ""Prediction: This Beaten-Down Stock Will Be a Biotech Giant by 2030"", ""summary"": ""When you think of biotech giants, you may think of Amgen or Biogen. These companies have brought significant treatments to market over time -- and have generated billions of dollars in earnings, too. Most investors would be happy to find the next company set to follow in their footsteps.""}, {""date"": ""20230719083000"", ""headline"": ""Is Biogen Stock a Buy Now?"", ""summary"": ""Over the past few years, Biogen (NASDAQ: BIIB) has been engaged in a much-talked-about journey to develop an effective Alzheimer's disease (AD) medicine.  On July 6, the company announced that along with its longtime partner, Japan-based Esai, it had earned traditional approval for Leqembi, a therapy that targets patients with early AD.  Leqembi had previously earned accelerated approval in January.""}, {""date"": ""20230719100146"", ""headline"": ""GSK (GSK) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release"", ""summary"": ""Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.""}, {""date"": ""20230719105600"", ""headline"": ""Biogen (BIIB) to Report Q2 Earnings: Here's What to Expect"", ""summary"": ""Biogen's sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have improved.""}, {""date"": ""20230719125400"", ""headline"": ""Biogen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Biogen Inc. inched 0.26% higher to $276.89 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""20230719153000"", ""headline"": ""Eisai Presents Latest Analysis of Lecanemab\u2019s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer\u2019s Association International Conference (AAIC) 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230719193000"", ""headline"": ""Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023"", ""summary"": ""Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \""Eisai\"") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \""Biogen\"") announced today that the results of a detailed analysis of the Phase 3 Clarity AD study demonstrated that lecanemab-irmb (generic name, U.S. brand name: LEQEMBI\u00ae) treatment showed reductions in amyloid-beta (A\u03b2) pathology and downstream biomarker changes. This analysis, and the latest findings on the lecanemab""}, {""date"": ""20230720033932"", ""headline"": ""EISAI PRESENTS LATEST ANALYSIS OF LECANEMAB'S EFFECT ON BIOMARKER CHANGES AND SUBCUTANEOUS DOSING AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE 2023"", ""summary"": ""TOKYO - Eisai Co., Ltd. and Biogen Inc.  announced today that the results of a detailed analysis of the Phase 3 Clarity AD study demonstrated that lecanemab-irmb  treatment showed reductions in...""}, {""date"": ""20230720053200"", ""headline"": ""(BIIB) - Analyzing Biogen's Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230720065600"", ""headline"": ""Robert W. Baird Sticks to Their Buy Rating for Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230720070029"", ""headline"": ""Are Investors Undervaluing Biogen Inc. (NASDAQ:BIIB) By 31%?"", ""summary"": ""Key Insights Using the 2 Stage Free Cash Flow to Equity, Biogen fair value estimate is US$402 Biogen is estimated to be...""}, {""date"": ""20230720125500"", ""headline"": ""Biogen Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slid 0.79% to $274.70 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""20230720125940"", ""headline"": ""Final Trades: Charles Schwab, Biogen & more"", ""summary"": ""The \""Halftime Report\"" traders give their top picks to watch for the second half.""}, {""date"": ""20230720225900"", ""headline"": ""Eisai hopes to start new Alzheimer's drug trials in 2024, Nikkei Asia says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230720233000"", ""headline"": ""Earnings week ahead: Microsoft, Google, Meta, Boeing, Coca-Cola and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230720235600"", ""headline"": ""Biogen Inc. stock underperforms Friday when compared to competitors despite daily gains"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230721072500"", ""headline"": ""Biogen Unusual Options Activity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230723035418"", ""headline"": ""4 Ideal Barron's Mid-Year 2023 Dividend Dog Buys"", ""summary"": ""Barron\u00e2\u0080\u0099s Mid-Year Roundtable, Published July 17, listed 40 stocks of note for 2023; 38 of those were unduplicated US publicly-listed companies. Read more here.""}]",{}
28,2023-07-23,276.739990234375,2023-07-30,265.2300109863281,-0.0415913118964083,D5,"[{""date"": ""20230723035418"", ""headline"": ""4 Ideal Barron's Mid-Year 2023 Dividend Dog Buys"", ""summary"": ""Barron\u00e2\u0080\u0099s Mid-Year Roundtable, Published July 17, listed 40 stocks of note for 2023; 38 of those were unduplicated US publicly-listed companies. Read more here.""}, {""date"": ""20230723221500"", ""headline"": ""Analyst Favorites With Strong Buyback Activity: Biogen Ranks As a Top Pick"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230723235700"", ""headline"": ""Biogen Inc. stock rises Monday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230724015100"", ""headline"": ""Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Biogen (BIIB) and Johnson & Johnson (JNJ)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230724020500"", ""headline"": ""Editas Medicine appoints Burkly as Chief Scientific Officer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230724032500"", ""headline"": ""Notable companies reporting before tomorrow's open"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230724062600"", ""headline"": ""Notable earnings before Tuesday's open"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230724071900"", ""headline"": ""Biogen Q2 2023 Earnings Preview"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230724100927"", ""headline"": ""Better Big Biotech Buy: Vertex vs. Biogen"", ""summary"": ""When you think of biotech companies, you may think of up-and-coming players with exciting pipelines, but zero marketed products.  Two top examples are Vertex Pharmaceuticals (NASDAQ: VRTX) and Biogen (NASDAQ: BIIB).  Vertex brings in billions of dollars in earnings annually thanks to its cystic fibrosis (CF) portfolio.""}, {""date"": ""20230724110824"", ""headline"": ""Eli Lilly: Does 'Miracle' Weight Loss Franchise Justify Rising Price Tag?"", ""summary"": ""Eli Lilly's share price won't stop climbing on the promise of its miracle diabetes and weight loss drug, tirzepatide. Learn more about LLY stock here.""}, {""date"": ""20230724174651"", ""headline"": ""All Eyes On Biogen's Alzheimer's Drug, A Big Potential Payday, Ahead Of Earnings"", ""summary"": ""Biogen stock is trading flat in 2023 ahead of earnings as analysts await news from biotechnology firm about its Alzheimer's drug, Leqembi.""}, {""date"": ""20230724203400"", ""headline"": ""GLOBAL BRIEFING: Beijing pledges support for faltering economy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230724235700"", ""headline"": ""Biogen Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725020400"", ""headline"": ""Biogen reports Q2 EPS $4.02, consensus $3.77"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725020700"", ""headline"": ""Biogen backs FY23 EPS view of $15.00-$16.00, consensus $15.43"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725021600"", ""headline"": ""Biogen Non-GAAP EPS of $4.02 beats by $0.26, revenue of $2.46B beats by $100M"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725023700"", ""headline"": ""Biogen tops earnings estimates and says it will shift resources to higher value areas"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725024500"", ""headline"": ""Nasdaq Futures Rise Ahead Of Microsoft, Alphabet Earnings: Analyst Warns Of Volatility From Fed's Message 'Crafting'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725030203"", ""headline"": ""Biogen : Q2 2023 Biogen Earnings Presentation"", ""summary"": ""Second Quarter 2023\n        \n        \n          Financial Results and Business Update\n        \n      \n      \n        \n          \n            \n              \n               ...""}, {""date"": ""20230725030203"", ""headline"": ""Biogen : Reports Q2 2023 Earnings"", ""summary"": ""Press Release\n      \n      \n        Cambridge, Mass. - July 25, 2023\n      \n      \n        Biogen reports second quarter 2023 results and reaffirms full year 2023 guidance;\n      \n    ...""}, {""date"": ""20230725030600"", ""headline"": ""Biogen (NASDAQ:BIIB) Gains On Q2 Beat"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725030703"", ""headline"": ""Biogen : reports second quarter 2023 results and reaffirms full year 2023 guidance; LEQEMBI launched in the U.S - Form 8-K"", ""summary"": ""Biogen reports second quarter 2023 results and reaffirms full year 2023 guidance;\n    \n    \n      LEQEMBI launched in the U.S.\n    \n    \n      \n    \n    \n      Second quarter revenue $2,456...""}, {""date"": ""20230725030703"", ""headline"": ""Biogen : Reports Second Quarter 2023 Results"", ""summary"": ""Press Release\n      \n      \n        Cambridge, Mass. - July 25, 2023\n      \n      \n        Biogen reports second quarter 2023 results and reaffirms full year 2023 guidance;\n      \n    ...""}, {""date"": ""20230725032100"", ""headline"": ""Biogen sees saving about $1B in gross operating expenses from 'Fit for Growth'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725032123"", ""headline"": ""GE, General Motors, Verizon rise premarket; Goldman Sachs, Dow fall"", ""summary"": ""Investing.com -- U.S. futures edged higher Tuesday, as investors digest a deluge of corporate earnings ahead of a key Federal Reserve meeting.""}, {""date"": ""20230725033100"", ""headline"": ""Analysts\u2019 Top Healthcare Picks: Alnylam Pharma (ALNY), Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725033200"", ""headline"": ""Biogen announces layoffs as focus turns to new products"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725033800"", ""headline"": ""Biogen Q2 Earnings Tops Expectations, Shift Resources To Higher Value Area(s), Layoff 1K Staff"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725035700"", ""headline"": ""Fly Intel: Pre-market Movers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725041100"", ""headline"": ""Tuesday\u2019s Top Analyst Upgrades and Downgrades: American Express, Apple, Conagra, Estee Lauder, Livent, Microsoft, Netflix, Nvidia, Shopify, Tesla and More"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725043300"", ""headline"": ""Biogen backs yearly guidance after second-quarter revenue fall"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725043700"", ""headline"": ""Biogen Layoffs 2023: What to Know About the Latest BIIB Job Cuts"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725043948"", ""headline"": ""Biogen to cut 1,000 jobs to save costs as company prepares for Leqembi launch "", ""summary"": ""Biogen, in its second-quarter earnings report, said the plan will result in $700 million in net operating expense savings by 2025.\u00a0""}, {""date"": ""20230725045300"", ""headline"": ""MBLY Stock Alert: Morgan Stanley Restarts Mobileye Coverage"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725045500"", ""headline"": ""Biogen Inc. Tops Q2 Earnings And Revenue Estimates"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725050900"", ""headline"": ""WMT Stock Alert: Is Walmart Really Worth $210?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725053300"", ""headline"": ""Ron DeSantis Escapes Car Accident Unhurt En Route To Campaign Event, TikTok Takes On Twitter, Analysts Expect Nvidia's AI Revenues To Reach $300B In Five Years: Today's Top Stories"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725054500"", ""headline"": ""Biogen to slash 1,000 jobs as it looks to save $700 million"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725055100"", ""headline"": ""Biogen price target lowered to $320 from $324 at Stifel"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725062246"", ""headline"": ""Biogen, Eisai, And Eli Lilly: Goldilocks-Like Treatments For Alzheimer's May Hurt"", ""summary"": ""Biogen, Eisai, and Eli Lilly's Alzheimer's drugs have shown little efficacy, particularly in non-APOE4 carriers. Read more here.""}, {""date"": ""20230725063400"", ""headline"": ""Wolfe says Biogen 'struck a more cautious tone' on possible Tysabri biosimilar"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725070004"", ""headline"": ""Biogen to cut 1,000 jobs to save costs as Alzheimer's drug launch gathers pace"", ""summary"": ""Biogen Inc said on Tuesday it expects to slash about 1,000 jobs, or about 11% of its workforce, to save costs as the company ramps up the launch of a new Alzheimer's disease drug in efforts to return to growth.  Investors have pinned their hopes on Leqembi, which Biogen sells with Eisai, to power growth as money spinner multiple sclerosis and spinal muscular atrophy (SMA) treatments face fierce competition from cheaper versions and rival drugs.  \""Biogen's business is in transition,\"" CEO Christopher Viehbacher said in a statement.""}, {""date"": ""20230725070456"", ""headline"": ""Biogen announces job cuts, turns focus to Alzheimer's drug launch"", ""summary"": ""(Reuters) -Biogen Inc said on Tuesday it expects to slash about 1,000 jobs, or 11% of its workforce, in a fresh round of cost-cutting as it looks to the launch of a new Alzheimer's drug to help it return to growth.  The company said its costs are elevated compared to rivals and that it would focus on higher-growth products such as the recently approved Alzheimer's drug Leqembi, which it sells with partner Eisai.  \""I don't think we as a company have really made the changes in our ... cost base to really reflect that transition,\"" Viehbacher said after the job cuts were announced.""}, {""date"": ""20230725072100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725081651"", ""headline"": ""Stocks making the biggest moves midday: Spotify, RTX, General Electric and more"", ""summary"": ""These are the stocks posting the largest moves in midday trading. ""}, {""date"": ""20230725082507"", ""headline"": ""Biogen Inc. (BIIB) Tops Q2 Earnings and Revenue Estimates"", ""summary"": ""Biogen Inc. (BIIB) delivered earnings and revenue surprises of 6.63% and 3.32%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?""}, {""date"": ""20230725084310"", ""headline"": ""Biogen Inc. (BIIB) Q2 2023 Earnings Call Transcript"", ""summary"": ""Biogen Inc. (NASDAQ:NASDAQ:BIIB) Q2 2023 Earnings Conference Call July 25, 2023 8:00 AM ETCompany ParticipantsChuck Triano - Head of Investor RelationsChristopher Viehbacher - President and...""}, {""date"": ""20230725085400"", ""headline"": ""US Stocks Climb Before Big Tech Earnings, Fed Meeting As China Stimulus Boosts Excitement: What's Driving Markets Tuesday?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725093027"", ""headline"": ""Compared to Estimates, Biogen Inc. (BIIB) Q2 Earnings: A Look at Key Metrics"", ""summary"": ""While the top- and bottom-line numbers for Biogen Inc. (BIIB) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.""}, {""date"": ""20230725100141"", ""headline"": ""Biogen to cut another 1,000 jobs in 'complete redesign'"", ""summary"": ""Biogen Inc. is making sweeping cuts again as it works to offset declining revenue due to competition from generic drugs.  The Cambridge drugmaker (Nasdaq: BIIB) said in its second-quarter earnings report Tuesday morning that it would cut another 1,000 jobs, part of an overhaul that also includes the elimination of some early-stage R&D programs.  Biogen shares were down 2.4% at market close, giving the company a market capitalization of $39.1 billion.""}, {""date"": ""20230725104851"", ""headline"": ""Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates"", ""summary"": ""Biogen stock dropped Tuesday after the biotechnology firm said it's eliminating 1,000 jobs as part of a strategy to cut operating expenses.""}, {""date"": ""20230725112100"", ""headline"": ""Biogen (BIIB) Beats on Q2 Earnings & Sales, Announces Job Cuts"", ""summary"": ""Biogen (BIIB) beats second-quarter estimates for earnings and sales. It maintains 2023 guidance. Stock up in pre-market.""}, {""date"": ""20230725114100"", ""headline"": ""A Surprising Beneficiary of New Alzheimer\u2019s Drugs: GE HealthCare"", ""summary"": ""With a new drug for Alzheimer\u2019s disease set to unleash a massive new market, attention is now shifting to the imaging needs likely to be created by this patient group.  For patients to be put on Eisai and  Biogen  Leqembi, they will likely need to undergo at least one PET scan to confirm they have the disease and then repeated MRI scans to assess them for safety.  While those requirements might create a bottleneck for the drugmakers given the limited number of PET machines in the country, they represent a growth opportunity for developers of imaging equipment such as  GE HealthCare Siemens Healthineers  and Philips.""}, {""date"": ""20230725115639"", ""headline"": ""Biogen to cut 1,000 jobs as focus turns to Alzheimer's drug Leqembi launch"", ""summary"": ""Biogen said on Tuesday it expects to eliminate roughly 1,000 positions in the U.S. to save money ahead of launching a new drug to treat Alzheimer's disease.""}, {""date"": ""20230725123100"", ""headline"": ""Biogen Stock Drops Despite News of Layoffs as Company Rolls Out Alzheimer\u2019s Drug"", ""summary"": ""The company is reducing its staff by about 11%, in a cost-cutting effort it expects it will save $1 billion a year in gross operating expenses.""}, {""date"": ""20230725132000"", ""headline"": ""Biogen to Lay Off Roughly 11% of Workforce to Focus on Big-Return Drugs"", ""summary"": ""The biotech company cited the launch of Alzheimer\u2019s drug Leqembi as part of its new focus on big-return products.""}, {""date"": ""20230725153045"", ""headline"": ""Biogen (BIIB) Q2 2023 Earnings Call Transcript"", ""summary"": ""BIIB earnings call for the period ending June 30, 2023.""}, {""date"": ""20230725180946"", ""headline"": ""Why Biogen Stock Got Sick Today"", ""summary"": ""While the company has won approval for a promising drug, it's cutting costs in the wake of that regulatory green light.""}, {""date"": ""20230725192734"", ""headline"": ""Stifel Maintains Biogen (BIIB) Buy Recommendation"", ""summary"": """"}, {""date"": ""20230725192734"", ""headline"": ""Needham Reiterates Biogen (BIIB) Buy Recommendation"", ""summary"": """"}, {""date"": ""20230725225100"", ""headline"": ""Analysts\u2019 Opinions Are Mixed on These Healthcare Stocks: ImmunoGen (IMGN) and Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230725235700"", ""headline"": ""Biogen Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230726002111"", ""headline"": ""Q2 2023 Biogen Inc Earnings Call"", ""summary"": ""Q2 2023 Biogen Inc Earnings Call""}, {""date"": ""20230726012100"", ""headline"": ""Analysts Are Bullish on These Healthcare Stocks: MoonLake Immunotherapeutics (MLTX), Abbott Labs (ABT)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230726015500"", ""headline"": ""Biogen price target lowered to $310 from $320 at BofA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230726021100"", ""headline"": ""Analysts Are Bullish on These Healthcare Stocks: Biogen (BIIB), Terns Pharmaceuticals (TERN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230726023400"", ""headline"": ""Biogen price target raised to $323 from $320 at Needham"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230726032600"", ""headline"": ""GLOBAL BROKER RATINGS: HSBC cuts Glencore; LBBW likes Adidas"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230726042200"", ""headline"": ""Biogen price target raised to $379 from $341 at RBC Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230726052600"", ""headline"": ""Truist Financial Reaffirms Their Buy Rating on Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230726084200"", ""headline"": ""Sage hits eight-month low as FDA decision on depression therapy nears"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230726100800"", ""headline"": ""Biotech Stock Roundup: BIIB, GSK's Q2 Earnings, KOD Faces Setback & More"", ""summary"": ""Earnings updates from Biogen (BIIB) and GSK (GSK) are in focus in the biotech sector.""}, {""date"": ""20230726110100"", ""headline"": ""Biogen\u2019s CEO Didn\u2019t Mention an Impending FDA Decision. Investors Got Spooked."", ""summary"": ""Despite generally positive earnings and a cost-savings plan that will reduce the company\u2019s head count by 1,000, shares of Biogen have traded down sharply since Tuesday's earnings call.""}, {""date"": ""20230726140857"", ""headline"": ""12 Out of Favor Stocks That Hedge Funds Love"", ""summary"": ""In this article, we will be taking a look at 12 out of favor stocks that hedge funds love. To skip our detailed analysis of investing moves today, you can go directly to see the 5 Out of Favor Stocks That Hedge Funds Love. Investing in stocks will always be a tricky exercise. The market [\u2026]""}, {""date"": ""20230726154600"", ""headline"": ""Why Sage Therapeutics Stock Is Tumbling Today"", ""summary"": ""A partner's perceived lack of enthusiasm for an upcoming regulatory decision is spooking investors today.""}, {""date"": ""20230726180907"", ""headline"": ""RBC Capital Maintains Biogen (BIIB) Outperform Recommendation"", ""summary"": """"}, {""date"": ""20230726180908"", ""headline"": ""Morgan Stanley Maintains Biogen (BIIB) Overweight Recommendation"", ""summary"": """"}, {""date"": ""20230726180916"", ""headline"": ""Wedbush Maintains Biogen (BIIB) Neutral Recommendation"", ""summary"": """"}, {""date"": ""20230726180949"", ""headline"": ""BMO Capital Maintains Biogen (BIIB) Outperform Recommendation"", ""summary"": """"}, {""date"": ""20230726180953"", ""headline"": ""HC Wainwright & Co. Reiterates Biogen (BIIB) Buy Recommendation"", ""summary"": """"}, {""date"": ""20230726181001"", ""headline"": ""Needham Maintains Biogen (BIIB) Buy Recommendation"", ""summary"": """"}, {""date"": ""20230726235700"", ""headline"": ""Biogen Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230727032500"", ""headline"": ""Biogen initiated with an Outperform at Scotiabank"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230727040800"", ""headline"": ""Thursday\u2019s Top Analyst Upgrades and Downgrades: Alphabet, Disney, Eli Lilly, Etsy, Microsoft, Mosaic, NetApp, RTX, Spotify and More"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230727060000"", ""headline"": ""I Was Concerned About Biogen Until I Heard These 11 Words From Its CEO"", ""summary"": ""When you think about biotech leaders, the name Biogen (NASDAQ: BIIB) may come to mind.  As a result, revenue has been on the decline, and the share price has stagnated.  Biogen prepared for the loss of exclusivity by developing new products, most specifically one to treat Alzheimer's disease.""}, {""date"": ""20230727095633"", ""headline"": ""Meta Platforms upgraded, Estee Lauder downgraded: Wall Street's top analyst call"", ""summary"": ""Meta Platforms upgraded, Estee Lauder downgraded: Wall Street's top analyst call""}, {""date"": ""20230727191004"", ""headline"": ""Scotiabank Initiates Coverage of Biogen (BIIB) with Sector Outperform Recommendation"", ""summary"": """"}, {""date"": ""20230727213100"", ""headline"": ""Buy/Sell: Wall Street's top 10 stock calls this week"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230727231100"", ""headline"": ""Reata Pharmaceuticals downgraded to Hold from Buy at Jefferies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230727233700"", ""headline"": ""What You Missed On Wall Street On Friday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230727235800"", ""headline"": ""Biogen Inc. stock rises Friday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230728004400"", ""headline"": ""Intel is chipper, Boston Beer fizzes, and other movers"", ""summary"": ""Roku shares rally after the streamer's results beat expectations""}, {""date"": ""20230728010700"", ""headline"": ""Reata downgraded to Market Perform from Outperform at SVB Securities"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230728020900"", ""headline"": ""Biogen to acquire Reata Pharmaceuticals for $172.50 per share in cash"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230728021800"", ""headline"": ""Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion in cash"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230728022400"", ""headline"": ""Biogen agrees to buy Reata Pharmaceuticals for $172.50 a share in cash"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230728023100"", ""headline"": ""Biogen agrees to buy Reata Pharmaceuticals in deal valued at $7.3B"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230728030131"", ""headline"": ""Biogen considering takeover of biotech Reata - Bloomberg Law"", ""summary"": ""Biogen is exploring an\nacquisition of biotech firm Reata Pharmaceuticals,\nBloomberg Law reported on Friday, citing people familiar with\nthe matter.\n              Shares of Reata surged about 13% in...""}, {""date"": ""20230728031600"", ""headline"": ""Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering"", ""summary"": ""Biogen's all-cash deal is a rare-disease play.""}, {""date"": ""20230728033210"", ""headline"": ""Biogen : Business Update"", ""summary"": ""Reata acquisition expected to meaningfully advance Biogen's\n        \n        \n          return to growth objective\n        \n      \n      \n        \n          \n           ...""}, {""date"": ""20230728035616"", ""headline"": ""Stocks making the biggest moves premarket: Intel, Roku, Procter & Gamble and more "", ""summary"": ""These are the stocks posting the largest moves in premarket trading. ""}, {""date"": ""20230728040700"", ""headline"": ""Friday\u2019s Top Analyst Upgrades and Downgrades: Apple, Boeing, Carvana, Coty, Meta, RTX, Southwest Airlines, SunPower and More"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230728044800"", ""headline"": ""Biogen Snaps Up Reata Pharma In $7.3B Deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230728052400"", ""headline"": ""Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230728052700"", ""headline"": ""Intel, Reata Pharma and Roku rally, and other movers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230728055200"", ""headline"": ""Reata Pharmaceuticals Shares Soar on Takeover by Biogen >RETA"", ""summary"": ""By Colin Kellaher Reata Pharmaceuticals shares surged to a multi-year high Friday after the biopharmaceutical company struck a $7.3 billion deal to be...""}, {""date"": ""20230728061100"", ""headline"": ""Health Care Company Biogen Announces Acquisition of Reata Pharmaceuticals"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230728064100"", ""headline"": ""Biogen bolsters rare disease treatments with USD7 billion Reata buy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230728064600"", ""headline"": ""Reata Pharmaceuticals downgraded to Hold from Buy at Stifel"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230728070100"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230728070500"", ""headline"": ""Biogen to Acquire Reata Pharmaceuticals"", ""summary"": ""SKYCLARYS\u00ae recently approved in US as the only treatment indicated for patients with Friedreich\u2019s ataxia Proposed acquisition represents meaningful step forward in Biogen\u2019s strategy for sustainable growth, adding a highly complementary innovative product in an area of high unmet medical needExpected to be significantly accretive to Biogen\u2019s Non-GAAP diluted EPS beginning in 2025Biogen to host investor conference call today at 9:00 a.m. ET. CAMBRIDGE, Mass. and PLANO, Texas, July 28, 2023 (GLOBE""}, {""date"": ""20230728070919"", ""headline"": ""UPDATE 4-Biogen to buy Reata for $6.5 bln to bulk up rare disease portfolio"", ""summary"": ""Biogen agreed to buy biotech firm Reata Pharmaceuticals for nearly $6.5 billion to bolster its position in the rare disease drugs market while its older multiple sclerosis drugs face intense competition.  Through the deal, Biogen said it will gain Plano, Texas-based Reata's recently approved drug Skyclarys to treat a rare genetic disorder that causes progressive damage to the nervous system.  Biogen has said it has been hunting for deals, especially in areas such as rare diseases and immunology, to expand beyond its multiple sclerosis drugs portfolio that is under pressure from competition.""}, {""date"": ""20230728072140"", ""headline"": ""Biogen to buy Reata for $6.5 billion to bulk up rare disease portfolio"", ""summary"": ""(Reuters) -Biogen agreed to buy rare disease drugmaker Reata Pharmaceuticals for nearly $6.5 billion, the first large acquisition under new CEO Christopher Viehbacher as he seeks to return the drugmaker to growth.  Viehbacher was hired in November to put Biogen back on a growth path after a series of missteps around the controversial Alzheimer's drug Aduhelm hurt the company, which was already grappling with intense competition to its top-selling drugs.  Through the deal, Biogen said it will gain Texas-based Reata's recently approved drug Skyclarys to treat a rare genetic disorder that causes progressive damage to the nervous system.""}, {""date"": ""20230728075715"", ""headline"": ""Biogen to bulk up rare disease treatments with $7 billion Reata acquisition"", ""summary"": ""Biogen is spending more than $7 billion to buy Reata Pharmaceuticals and bolster its rare disease treatments.  The Alzheimer\u2019s treatment developer said Friday it will pay $172.50 in cash for each share of Reata in a deal it expects to close by the end of this year.  Plano, Texas-based Reata focuses on developing treatments that regulate cellular metabolism and deal with inflammation in serious neurologic diseases.""}, {""date"": ""20230728082800"", ""headline"": ""Larimar, Design higher as they benefit from Biogen deal for Reata"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230728084321"", ""headline"": ""Will Biogen's Deal Splash Give Biotech a Lift?"", ""summary"": ""It\u2019s a merger Friday, and that means payday for shareholders of Reata Pharmaceuticals. Shares of Reata, which specializes in developing drugs to treat rare neurologic diseases, are up 51% in premarket trading.""}, {""date"": ""20230728103118"", ""headline"": ""Biogen to buy a Texas-based rare disease firm for $7.2B"", ""summary"": ""Biogen is paying $7.2 billion to buy a Texas-based biotech as new CEO makes good on his promise to expand into the rare disease space.""}, {""date"": ""20230728103547"", ""headline"": ""Biogen to Buy Reata for $7.3 Billion in Rare-Disease Deal"", ""summary"": ""(Bloomberg) -- Biogen Inc. agreed to acquire Reata Pharmaceuticals Inc. for $7.3 billion, including debt, to expand its rare disease treatments in one of its biggest-ever acquisitions. Most Read from BloombergLargest US Grid Declares Emergency Alert For July 27BOJ Sends Yields Soaring With Surprise Change to Rate LimitSubway Offers Free Sandwiches That Come With a Lifetime CommitmentChina\u2019s Push to Expand BRICS Membership FaltersS&P 500 Up 1% as \u2018Goldilocks\u2019 Data Embolden Bulls: Markets WrapThe""}, {""date"": ""20230728103900"", ""headline"": ""Reata Stock Surges. Biogen Is Buying It for $7.3 Billion in Cash."", ""summary"": ""Biogen will acquire Reata for $172.50 a share in cash, expanding its portfolio of neuromuscular disease treatments.""}, {""date"": ""20230728105059"", ""headline"": ""Biogen Announces $7.3 Billion Acquisition After Outlining Plans To Cut 11% Of Workforce"", ""summary"": ""Biogen announced Friday it has agreed to acquire Reata Pharmaceuticals for about $7.3 billion, boosting biopharmaceutical company Biogen's drug offerings for serious neurological diseases.  Reata stock surged early as Biogen stock slid.  RETA stock skyrocketed 52.4% to 165.24 early Friday during market trade after Biogen reported it plans to pay $172.50 per share in cash for Reata.""}, {""date"": ""20230728105319"", ""headline"": ""Enphase Energy outlook, Biogen-Reata deal, Boston Beer stock: Top stocks"", ""summary"": ""Enphase Energy shares slide on a cloudy outlook stemming from an elevated interest rate environment. Biogen is set to acquire Reata Pharmaceuticals in a $7.3 billion deal. Boston Beer Company stock soars on increased demand for its Twisted Tea. Yahoo Finance Live's Brad Smith, Julie Hyman, and Rachelle Akuffo take a look at several stocks trending in the morning session.""}, {""date"": ""20230728111124"", ""headline"": ""Biogen's Alzheimer's drug is the biggest growth catalyst for the stock, says Jefferies' Yee"", ""summary"": ""Michael Yee, Jefferies biotech analyst, joins 'Power Lunch' to discuss what Biogen's purchase of Reata means for the former, the biggest catalyst for Biogen stock, and more.""}, {""date"": ""20230728120000"", ""headline"": ""Eli Lilly: There Is No Logic To This Over Optimism"", ""summary"": ""Mounjaro may rake in $25B of annualized sales by 2026, exceeding ABBV's Humira. This naturally explains Mr. Market's optimism surrounding the LLY's stock thus far.""}, {""date"": ""20230728122300"", ""headline"": ""NEW YORK MARKET CLOSE: Tech stars as stocks end winning week on high"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230728124100"", ""headline"": ""Biogen Buying Rare-Disease Drugmaker In $7.3 Billion Deal"", ""summary"": ""The deal would bolster the biotech company\u2019s portfolio of treatments for neuromuscular and rare diseases.""}, {""date"": ""20230728132010"", ""headline"": ""Biogen's Bold $7.3B Acquisition Of Reata: Analyzing The Impact On Investors"", ""summary"": ""Biogen Inc. now plans to acquire Reata Pharmaceuticals, Inc. for $7.3 billion, validating the potential of Skyclarys. Click for my updated take on RETA shares.""}, {""date"": ""20230728142127"", ""headline"": ""Why Biogen Agreed to Acquire Reata for $7.3 Billion"", ""summary"": ""Biogen agreed to acquire\u00a0Reata Pharmaceuticals for $7.3 billion, including debt, to expand its rare disease treatments. Michelle Davis reports on \""Bloomberg Markets.\"" Follow Bloomberg for business news & analysis, up-to-the-minute market data, features, profiles and more: http://www.bloomberg.com Connect with us on... Twitter: https://twitter.com/business Facebook: https://www.facebook.com/bloombergbusiness/ Instagram: https://www.instagram.com/quicktake/?hl=en""}, {""date"": ""20230728160747"", ""headline"": ""Biogen to buy rare-disease drugmaker Reata in $7.3B deal"", ""summary"": ""Biogen will pay $7.3 billion to buy Reata Pharmaceuticals, company that makes a drug for a rare neurological condition. Analysts have been generally positive on the deal, with one calling it \""low-risk.\"" Yahoo Finance Health Care Reporter Anjalee Khemlani recaps some of the biggest stories from the health industry.""}, {""date"": ""20230728162401"", ""headline"": ""Biogen Buys Reata Pharmaceuticals, Expanding Its Lineup of Rare Disease Drugs"", ""summary"": ""Biogen said it was buying Reata Pharmaceuticals for $7.3 billion, expanding its rare disease treatment portfolio.""}, {""date"": ""20230728164524"", ""headline"": ""S&P 500 Gains and Losses Today: Stocks Jump as Inflation Cools"", ""summary"": ""U.S. equities rallied on Friday, July 28, 2023 after a report showing inflation cooled in June, and the S&P 500 rose 1%.""}, {""date"": ""20230729090821"", ""headline"": ""Biotech Battlefields: 3 Stocks to Watch Amid Wall Street Turmoil"", ""summary"": ""As biotech stock prices have fallen, Wall Street and biotech boards have grown increasingly unfriendly. Amid the turmoil, key biotech stocks have become the targets of activist investors demanding new executives, new boards and new strategies. The specifics of each case vary, but the biotech stocks in sharpest focus have been those whose earnings and revenue have disappointed investors. Of course, it\u2019s no accident this happens. Investors want to protect their investments. And if the company isn\u2019""}, {""date"": ""20230729220500"", ""headline"": ""3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230730070101"", ""headline"": ""Biogen's (NASDAQ:BIIB) underlying earnings growth outpaced the return generated for shareholders over the past year"", ""summary"": ""It hasn't been the best quarter for Biogen Inc. ( NASDAQ:BIIB ) shareholders, since the share price has fallen 15% in...""}]",{}
29,2023-07-30,265.2300109863281,2023-08-06,268.9200134277344,0.013912461970966294,U2,"[{""date"": ""20230729220500"", ""headline"": ""3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230730070101"", ""headline"": ""Biogen's (NASDAQ:BIIB) underlying earnings growth outpaced the return generated for shareholders over the past year"", ""summary"": ""It hasn't been the best quarter for Biogen Inc. ( NASDAQ:BIIB ) shareholders, since the share price has fallen 15% in...""}, {""date"": ""20230730233300"", ""headline"": ""TOP NEWS: Biogen to acquire Reata Pharmaceuticals in USD7 billion deal"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230731010000"", ""headline"": ""Promising new Alzheimer's drugs may benefit whites more than Blacks"", ""summary"": ""Groundbreaking treatments\nfor Alzheimer's disease that work by removing a toxic protein\ncalled beta amyloid from the brain may benefit whites more than\nBlack Americans, whose disease may be driven by...""}, {""date"": ""20230731014400"", ""headline"": ""Reata Pharmaceuticals downgraded to Neutral from Buy at Ladenburg"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230731021800"", ""headline"": ""Reata Pharmaceuticals price target raised to $173 from $85 at Baird"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230731032300"", ""headline"": ""Quest Diagnostics launches first at-home blood test to assess risk of developing Alzheimer\u2019s disease"", ""summary"": ""Quest Diagnostics Inc. said Monday it has brought the first blood-based biomarker test to assess the risk of developing Alzheimer\u2019s disease to market and...""}, {""date"": ""20230731051541"", ""headline"": ""US announces trial payment program for care providers of dementia patients"", ""summary"": ""The U.S. government said on Monday\nit would trial a new payment program for people who provide\ndementia care coordination services for patients covered by the\nMedicare health plan.\n              The...""}, {""date"": ""20230731061100"", ""headline"": ""Biotech Alert: Searches spiking for these stocks today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230731062400"", ""headline"": ""Rising Stars, Falling Trends: July's Industry ETF Winners And Losers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230731070000"", ""headline"": ""Biogen\u2019s New Boss Is Delivering, but Stock Isn\u2019t Pricing It in Yet"", ""summary"": ""The decision to buy Reata signals a new era under CEO Chris Viehbacher, and Wall Street\u2019s skepticism presents an opportunity.""}, {""date"": ""20230731074500"", ""headline"": ""Better Alzheimer's Drug Stock: Eli Lilly vs. Biogen"", ""summary"": ""Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) will soon likely be going head to head in the market for therapies that treat Alzheimer's disease.  Both drug developers see the market for such medicines as being a major one in the coming years, and their candidates are set up to duel for the first leg of growth.  Let's dive in and evaluate the case for each on the basis of how their medicines seem to perform so far.""}, {""date"": ""20230731131108"", ""headline"": ""10 Most Oversold S&P 500 Stocks Right Now"", ""summary"": ""In this article, we will take a look at 10 most oversold S&P 500 stocks right now. To skip our analysis of the recent market activity, you can go directly to see the 5 Most Oversold S&P 500 Stocks Right Now. The stock markets have been through the wringer in the recent past especially since [\u2026]""}, {""date"": ""20230731235511"", ""headline"": ""RBC Capital Maintains Biogen (BIIB) Outperform Recommendation"", ""summary"": """"}, {""date"": ""20230731235511"", ""headline"": ""Needham Reiterates Biogen (BIIB) Buy Recommendation"", ""summary"": """"}, {""date"": ""20230731235700"", ""headline"": ""Biogen Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230801054500"", ""headline"": ""Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know."", ""summary"": ""Biogen's (NASDAQ: BIIB) biggest problem in recent times has been growth.  The biotech giant's multiple sclerosis (MS) portfolio is facing more and more generic competition, and that's resulted in declining sales.  All this has weighed on share performance too, as investors wonder about what the company and its earnings will look like in the future.""}, {""date"": ""20230801094600"", ""headline"": ""For Dementia Patients and Their Caregivers, Help Could Be Coming Next Year"", ""summary"": ""A voluntary nationwide program starting next year aims to improve care for the more than 6.7 million Americans living with dementia and their unpaid caregivers.""}, {""date"": ""20230801145901"", ""headline"": ""Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points"", ""summary"": ""The biotechnology sector is huge and growing. Grand View Research forecasts that the industry will reach $3.88 trillion by 2030, growing at a compound annual growth rate of 14%. Despite the massive amount of revenue being generated, most biotech companies remain small and medium-sized enterprises. Many of the companies operating in the space are start-ups. Yet they are performing cutting-edge research and developing life-saving innovations that are in high demand. This presents an opportunity fo""}, {""date"": ""20230801223700"", ""headline"": ""Biogen Unusual Options Activity For August 02"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230802020215"", ""headline"": ""Larimar: Friedreich's Ataxia Drug With Significant Potential"", ""summary"": ""Larimar therapeutics has been making significant progress in advancing its drug known as CTI-1601. Read more about LRMR here.""}, {""date"": ""20230802042300"", ""headline"": ""Earnings Insight: Analysts Raising Full-Year 2023 Estimates For U.S. And European Equities"", ""summary"": ""We\u00e2\u0080\u0099ve seen a shift in analyst sentiment over the last two weeks when looking at data in This Week in Earnings and STOXX 600 Earnings Outlook report.""}, {""date"": ""20230802151756"", ""headline"": ""3 \u2018Strong Buy\u2019 Biotech Stocks You Should Be Loading Up On Now"", ""summary"": ""Medical stocks, in general, aren\u2019t enjoying the market-wide reversal we\u2019re seeing in the back half of 2023. The Morningstar US Healthcare Index, which measures a range of biotech, pharma, medical device and healthcare facility companies, has returned less than 1% since January. Compare that performance to the S&P 500\u2019s rapid mid-March reversal and 20% jump since then, and healthcare stockholders\u2019 woes are understandable. Despite strained supply chains and an industry-wide inability to readapt to""}, {""date"": ""20230802235700"", ""headline"": ""Biogen Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230803024200"", ""headline"": ""Goldman in, Microsoft out of BofA Alpha Surprise Portfolio"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230803080124"", ""headline"": ""Biogen Inc. (NASDAQ:BIIB) is a favorite amongst institutional investors who own 88%"", ""summary"": ""Key Insights Institutions' substantial holdings in Biogen implies that they have significant influence over the...""}, {""date"": ""20230803235700"", ""headline"": ""Biogen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230804013800"", ""headline"": ""Biogen trading halted, news pending"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230804015800"", ""headline"": ""FDA approves Zurzuvae for postpartum depression"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230804025500"", ""headline"": ""Sage, Biogen postpartum depression pill zuranolone wins FDA approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230804064000"", ""headline"": ""Eli Lilly Stock Is on a Tear. Expect More Gains After Earnings."", ""summary"": ""Despite its strong start to the year, the drugmaker\u2019s report on Tuesday should lift shares even further.""}, {""date"": ""20230804080900"", ""headline"": ""5 Healthcare Stocks to Buy Now, According to Analysts \u2013 August 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230804154000"", ""headline"": ""FDA approves first-ever pill\u00a0for postpartum depression in new mothers"", ""summary"": ""Biogen and Sage Therapeutics are behind the first FDA-approved pill for treating postpartum depression.""}, {""date"": ""20230804163300"", ""headline"": ""The Biotech Game Is Changing. Watch for Disruptions, Says RBC."", ""summary"": ""SECTORFOCUS BLOG  The rules of the biotech game could change dramatically if several trends play out in science and regulation. Investors should be on alert, say analysts from RBC Capital Markets. Government programs could command deep discounts.""}, {""date"": ""20230804184214"", ""headline"": ""FDA Approves ZURZUVAE\u2122\u00a0(zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder"", ""summary"": ""Postpartum depression  approval based on results from two Phase 3 clinical trials; in the SKYLARK Study treatment with ZURZUVAE rapidly improved symptoms of PPD at Day 15 and as early as Day 3 with...""}, {""date"": ""20230804191109"", ""headline"": ""US FDA approves Biogen-Sage Therapeutics pill for postpartum depression"", ""summary"": ""The companies had sought the FDA's approval for the drug, Zurzuvae, to treat major depressive disorder (MDD), or clinical depression, as well as postpartum depression, which affect millions of people.  PPD severely affects a woman's ability to return to normal functioning, while also potentially affecting the mother's relationship with her child.""}, {""date"": ""20230804192400"", ""headline"": ""First Pill for Postpartum Depression Is Approved by FDA"", ""summary"": ""The pill, to be taken daily for at least two weeks, significantly reduced postpartum depression among new mothers in a recent trial.""}, {""date"": ""20230804201304"", ""headline"": ""UPDATE 1-US FDA approves Biogen-Sage Therapeutics pill for postpartum depression"", ""summary"": ""The U.S. Food and Drug Administration on Friday approved Biogen and Sage Therapeutics' oral pill to treat postpartum depression (PPD) in adults.  The companies had sought the FDA's approval for the drug, Zurzuvae, to treat major depressive disorder), or clinical depression, as well as postpartum depression (PPD), which affect millions of people.  Analysts were anticipating the stocks of both companies to fall if the drug was approved only for postpartum depression due to the smaller patient population.""}, {""date"": ""20230804204433"", ""headline"": ""Postpartum depression drug developed by Sage, Biogen approved by FDA"", ""summary"": ""A new depression drug has received the green light from the U.S. Food and Drug Administration after years of development by two Cambridge drugmakers. Zuranolone, a new drug co-developed by Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics Inc. (Nasdaq: SAGE), scored an FDA approval late Friday \u2014 but the approval was only for postpartum depression, not major depressive disorder. The companies had applied to market the drug as a treatment for both.""}, {""date"": ""20230804224200"", ""headline"": ""FDA Approves ZURZUVAE\u2122 (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder"", ""summary"": ""CAMBRIDGE, Mass., August 05, 2023--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) approved ZURZUVAETM (zuranolone) 50 mg for adults with postpartum depression (PPD). ZURZUVAE is the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms for women with PPD. ZURZUVAE is expected to launch and be commercially available in the fourth quarter of 2023 shortly following sch""}, {""date"": ""20230805224100"", ""headline"": ""2023 shaping up to be biggest year for biopharma M&A since pandemic"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230806000812"", ""headline"": ""DiaMedica Therapeutics: Risk-Reward Favors Following Insider Optimism"", ""summary"": ""DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on recombinant proteins to treat life-threatening diseases. Read more here.""}, {""date"": ""20230806051700"", ""headline"": ""Biogens, Sage Therapeutics postpartum depression treatment approved"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230806080700"", ""headline"": ""CORRECT: Biogens, Sage Therapeutics postpartum depression drug okayed"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
30,2023-08-06,268.9200134277344,2023-08-13,273.67999267578125,0.017700353303477634,U2,"[{""date"": ""20230805224100"", ""headline"": ""2023 shaping up to be biggest year for biopharma M&A since pandemic"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230806000812"", ""headline"": ""DiaMedica Therapeutics: Risk-Reward Favors Following Insider Optimism"", ""summary"": ""DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on recombinant proteins to treat life-threatening diseases. Read more here.""}, {""date"": ""20230806051700"", ""headline"": ""Biogens, Sage Therapeutics postpartum depression treatment approved"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230806080700"", ""headline"": ""CORRECT: Biogens, Sage Therapeutics postpartum depression drug okayed"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230806235200"", ""headline"": ""Sage, Biogen receive CRL for zuranolone in major depressive disorder"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230806235700"", ""headline"": ""Biogen Inc. stock rises Monday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807001700"", ""headline"": ""Biogen (BIIB) Receives a Hold from Barclays"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807002100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Becton Dickinson (BDX) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807004600"", ""headline"": ""Wedbush cuts Sage to neutral, questions Biogen's future funding of zuranolone"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807010600"", ""headline"": ""J.P. Morgan Sticks to Its Hold Rating for Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807012100"", ""headline"": ""RBC Capital cuts Sage to sector perform, calls FDA decision \""major setback\"""", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807012100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Foghorn Therapeutics (FHTX), Aurinia Pharmaceuticals (AUPH) and Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807013500"", ""headline"": ""Sage sees cash and equivalentes enough to support operations into 2025"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807024400"", ""headline"": ""Biogen price target lowered to $333 from $340 at Baird"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807024500"", ""headline"": ""Sage plummets 46% after FDA declines zuranolone in major depression"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807025200"", ""headline"": ""Wedbush downgrades Sage Therapeutics to Neutral, lowers price target to $22"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807025400"", ""headline"": ""Biogen price target lowered to $269 from $276 at Wedbush"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807025600"", ""headline"": ""Biogen price target lowered to $290 from $310 at BofA"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807030200"", ""headline"": ""Sage Therapeutics\u2019 stock craters 49% after FDA approves zuranolone for postpartum depression, but not major depressive disorder"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807030400"", ""headline"": ""Biogen price target lowered to $290 from $360 at Oppenheimer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807030900"", ""headline"": ""Biogen price target lowered to $350 from $380 at Piper Sandler"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807031100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Horizon Therapeutics (HZNP) and Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807032900"", ""headline"": ""Biogen, Sage face uphill battle with postpartum depression pill"", ""summary"": ""The U.S. drug regulator's approval of\nBiogen and Sage Therapeutics'\nfirst-of-its-kind postpartum depression  pill is unlikely\nto allay the drugmakers' growth concerns, analysts said on\nMonday.\n       ...""}, {""date"": ""20230807034800"", ""headline"": ""Sage Therapeutics Shares Slide Premarket After Zurzuvae MDD Setback >SAGE"", ""summary"": ""By Colin Kellaher Shares of Sage Therapeutics tumbled more than 45% in premarket trading Monday after the U.S. Food and Drug Administration rejected a key...""}, {""date"": ""20230807040200"", ""headline"": ""Biogen price target lowered to $343 from $350 at Wells Fargo"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807040300"", ""headline"": ""Fly Intel: Pre-market Movers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807040500"", ""headline"": ""Biogen price target lowered to $294 from $311 at Barclays"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807043400"", ""headline"": ""Biogen price target lowered to $354 from $374 at RBC Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807053800"", ""headline"": ""PayPal Unveils USD-Backed Stablecoin, Trucking Firm Yellow Corp Files For Bankruptcy, FDA Approves First Oral Treatment For Postpartum Depression: Today's Top Stories"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807055000"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Pharvaris (PHVS)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807055620"", ""headline"": ""Biogen, Sage face challenges as FDA rejects pill for clinical depression"", ""summary"": ""The approval of Biogen and\nSage Therapeutics' depression pill for a\nsmaller-than-expected patient cohort has fueled concerns over\nits growth prospects, analysts said on Monday.\n              The U.S....""}, {""date"": ""20230807060000"", ""headline"": ""Major US health systems expect to offer Alzheimer's drug Leqembi in a few months"", ""summary"": ""Five major U.S. health systems said they would offer Eisai and Biogen's promising new Alzheimer's drug Leqembi after working out payment and administrative policies, and how to assess and monitor patients, most likely in the next month or two.  Leqembi, which won full U.S. regulatory approval last month, is the first treatment proven to slow progression of the mind-robbing disease for people in the earliest stages of Alzheimer's.  The disease affects an estimated 6.5 million people, most of whom are part of the U.S. government\u2019s Medicare plan for people 65 and older.""}, {""date"": ""20230807060000"", ""headline"": ""Retirees' Biggest Social Security News of the Year Is Less Than 10 Weeks Away"", ""summary"": ""Retirees don't only have cooler temperatures to look forward to.  The Social Security Administration (SSA) hasn't officially announced when it will reveal the cost-of-living adjustment (COLA) for 2024.  SSA provided its update for the 2022 COLA on Oct. 13, 2021.""}, {""date"": ""20230807060418"", ""headline"": ""Sage Therapeutics' Zuranolone Is A Lost Cause In Depression Market"", ""summary"": ""Sage Therapeutics faces challenges with declining cash, rising expenses, and limited market potential despite FDA approval for Zurzuvae in PPD treatment.""}, {""date"": ""20230807065226"", ""headline"": ""Sage Therapeutics stock plunges more than 50% after FDA denies wider use of postpartum depression drug"", ""summary"": ""The FDA approved the pill zuranolone, developed by Sage and Biogen, for postpartum depression but declined to approve it for major depressive disorder. ""}, {""date"": ""20230807071300"", ""headline"": ""FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807071500"", ""headline"": ""Dow Rises Over 300 Points To Start The Week"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807071800"", ""headline"": ""Sage Therapeutics downgraded to Neutral at BofA after MDD CRL"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807080609"", ""headline"": ""Sage Tumbles as Depression Pill Approval Omits Major Disorder"", ""summary"": ""(Bloomberg) -- Sage Therapeutics Inc. slumped in early trading after regulators granted approval to its fast-acting pill only for postpartum depression, denying the drug clearance for major depressive disorder.Most Read from BloombergMusk Says He May Need Surgery, Will Get MRI on Back and NeckTexas Power Prices to Surge 800% on Sunday Amid Searing HeatPayPal Launches a Stablecoin in Latest Crypto Payments PushUkraine Black Sea Drone Attacks Signal Rapidly Expanding WarHSBC Executive Slams \u2018Weak\u2019""}, {""date"": ""20230807080900"", ""headline"": ""Sage Stock Tumbles After FDA Decision on Depression Drug"", ""summary"": ""Sage Therapeutics says it's 'evaluating resource allocation, including pipeline prioritization and a workforce reorganization with a goal of extending our cash runway.'""}, {""date"": ""20230807084417"", ""headline"": ""Sage tumbles to record low on clinical depression pill setback"", ""summary"": ""Shares of Sage Therapeutics slumped to a record low on Monday after the U.S. health regulator approved the company and partner Biogen's pill for postpartum depression, but rejected it as a...""}, {""date"": ""20230807085000"", ""headline"": ""What More Can Support Biogen/Sage's Zuranolone Resubmission: Analysts See Uncertain Road Ahead"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230807100400"", ""headline"": ""Split FDA Call on Depression Drug Upsets Strategies for Biogen, Sage"", ""summary"": ""Sage Therapeutics says it is 'evaluating resource allocation, including pipeline prioritization and a workforce reorganization with a goal of extending our cash runway.'""}, {""date"": ""20230807101411"", ""headline"": ""FDA approves first postpartum depression pill from Biogen, Sage"", ""summary"": ""The U.S. Food and Drug Administration has approved the first pill to help treat postpartum depression. The pill was co-developed by Biogen (BIIB) and Sage Therapeutics (SAGE). The approval was a mixed bag for the companies. It was not approved to treat for major depressive disorder, which would have been made the pill marketable to more patients. Also, there was a surprise warning from the FDA about not driving for 12 hours after taking the pill. The drugmakers say the pill should be ready for launch in the fourth quarter of 2023. Yahoo Finance Health Care Reporter Anjalee Khemlani explains the pill's approval.""}, {""date"": ""20230807103246"", ""headline"": ""Sage shares cut in half after postpartum drug approval. Here's what happened."", ""summary"": ""The Cambridge drugmaker saw its market value drop by about $1 billion in the first minutes of trading Monday, following a partial approval of a new depression drug late Friday. Cambridge-based Sage had applied to market the depression drug, zuranolone, as a treatment for both major depressive disorder (MDD) and postpartum depression (PPD). The U.S. Food and Drug Administration approved zuranolone, now marketed under the name Zurzuvae, for PPD but rejected it as a treatment for MDD, citing a lack""}, {""date"": ""20230807114432"", ""headline"": ""Why Sage Therapeutics Stock Is Crashing Today"", ""summary"": ""The huge sell-off came after the company and its partner, Biogen, announced following the market close on Friday that the U.S. Food and Drug Administration (FDA) didn't approve Zurzuvae (zuranolone) for major depressive disorder (MDD).  The FDA did approve Zurzuvae for treating postpartum depression (PPD).  The big problem for Sage -- and the main reason the biotech stock is plunging -- is that Zurzuvae will have a much smaller market size to target now.""}, {""date"": ""20230807134422"", ""headline"": ""Future Prospects For Johnson & Johnson Following Strong Q2 Performance"", ""summary"": ""Johnson & Johnson, the mastodon of the healthcare sector, released its financial results for the 2nd quarter of 2023. Read why JNJ stock is a hold.""}, {""date"": ""20230807155029"", ""headline"": ""Sage Therapeutics Shares Plummet Following FDA Decision on Depression Drug"", ""summary"": ""Sage Therapeutic shares fell to an all-time low after the FDA rejected use of its treatment for major depressive disorder.""}, {""date"": ""20230807172200"", ""headline"": ""Eli Lilly to Report Earnings as Hope Soars for Weight-Loss Drug Mounjaro"", ""summary"": ""Things couldn't be going much better for the drugmaker. The stock is up about 50% over the past 12 months and nearly 25% so far this year.""}, {""date"": ""20230807235700"", ""headline"": ""Biogen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230808011400"", ""headline"": ""BofA upgrades Axome to neutral, cites improved outlook for MDD drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230808024800"", ""headline"": ""DraftKings To Rally Over 38%? Here Are 10 Other Analyst Forecasts For Tuesday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230808032200"", ""headline"": ""Biogen price target lowered to $336 from $347 at BMO Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230808040400"", ""headline"": ""Looking Into Biogen's Recent Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230808040500"", ""headline"": ""Needham cuts Sage Therapeutics to Hold on reduced zuranalone opportunity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230808043500"", ""headline"": ""Biogen price target lowered to $340 from $3500 at Truist"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230808044502"", ""headline"": ""RBC Capital Maintains Biogen (BIIB) Outperform Recommendation"", ""summary"": """"}, {""date"": ""20230808044502"", ""headline"": ""Wells Fargo Maintains Biogen (BIIB) Overweight Recommendation"", ""summary"": """"}, {""date"": ""20230808044522"", ""headline"": ""Oppenheimer Maintains Biogen (BIIB) Outperform Recommendation"", ""summary"": """"}, {""date"": ""20230808052900"", ""headline"": ""Lilly reaches all-time high on Q2 results, 2023 guidance boost"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230808090000"", ""headline"": ""Is Sage Therapeutics a Contrarian Buy?"", ""summary"": ""Monday was a dark day for Sage Therapeutics (NASDAQ: SAGE), a company that focuses on developing therapies for brain disorders.  The stock plummeted by more than 53% after the company revealed that its blockbuster drug candidate, zuranolone, failed to win approval from the U.S. Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD).  Zuranolone, which Sage Therapeutics developed in collaboration with Biogen (NASDAQ: BIIB), is a novel antidepressant designed to offer fast and durable relief from depressive symptoms, with a short course of treatment and minimal side effects.""}, {""date"": ""20230808102600"", ""headline"": ""Eli Lilly Stock Is Flying After Strong Results. Obesity Drugs Delivered the Goods."", ""summary"": ""Things couldn't be going much better for the drugmaker. The stock is up about 50% over the past 12 months and nearly 25% so far this year.""}, {""date"": ""20230808123612"", ""headline"": ""Is Biogen Inc (BIIB) Modestly Overvalued? A Comprehensive Valuation Analysis"", ""summary"": ""Exploring the intrinsic value and financial health of Biogen Inc (BIIB)""}, {""date"": ""20230808225000"", ""headline"": ""Regional Bank U.S. Bancorp Tops Moat Stocks In July"", ""summary"": ""While U.S. equities extended their rally, Morningstar\u00e2\u0080\u0099s Moat Index extended its year-to-date lead over the S&P 500 to nearly 800 basis points. U.S. Bancorp stood out as the top contributor.""}, {""date"": ""20230808235700"", ""headline"": ""Biogen Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230809025900"", ""headline"": ""Denali Therapeutics price target lowered to $31 from $37 at Wedbush"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230809054300"", ""headline"": ""Needham Maintains Biogen (BIIB) Buy Recommendation"", ""summary"": """"}, {""date"": ""20230809054300"", ""headline"": ""Truist Securities Maintains Biogen (BIIB) Buy Recommendation"", ""summary"": """"}, {""date"": ""20230809054303"", ""headline"": ""Atlantic Equities Maintains Biogen (BIIB) Neutral Recommendation"", ""summary"": """"}, {""date"": ""20230809054304"", ""headline"": ""Barclays Maintains Biogen (BIIB) Equal-Weight Recommendation"", ""summary"": """"}, {""date"": ""20230809061500"", ""headline"": ""Biotech Alert: Searches spiking for these stocks today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230809072100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Caliber Imaging & Diagnostic (OtherLCDX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230809080042"", ""headline"": ""Eli Lilly Has A Big Stake In Weight Loss And Alzheimer's Drugs; But Is The Stock A Buy?"", ""summary"": ""Eli Lilly surged 15% in one day on enthusiasm for weight-loss and Alzheimer\u2019s drugs. But is LLY stock a buy now? Here's what you should know.""}, {""date"": ""20230809083000"", ""headline"": ""With an Acquisition on the Way, Is Biogen Stock a Buy?"", ""summary"": ""Biotech giant Biogen (NASDAQ: BIIB) can't seem to keep its name out of the news.  After a recent major approval for its Alzheimer's disease (AD) medicine Leqembi, the company just announced that it would acquire Reata Pharmaceuticals, a company that focuses on developing treatments for serious and life-threatening diseases.  Biogen has been a relatively volatile stock to own over the past few years, but could this new acquisition move help the company turn things around?""}, {""date"": ""20230809095300"", ""headline"": ""More Alzheimer's Treatments Are Coming: This Company Can Help With Early Detection"", ""summary"": ""Alzheimer's patients could soon have more treatment options available.  Biogen's Leqembi obtained approval from the U.S. Food and Drug Administration earlier this year, and another treatment from Eli Lilly, donanemab, may not be far behind.  The one drawback, however, is that those drugs treat Alzheimer's when the disease is in its\u00a0early stages, and thus, many people won't be able to benefit from them.""}, {""date"": ""20230809135816"", ""headline"": ""U.S. Wide-Moat Stocks On Sale - The August 2023 Heat Map"", ""summary"": ""Discover our 3-step process for identifying undervalued wide-moat stocks, including a heat map of top investable candidates. Click here to read our picks.""}, {""date"": ""20230809235700"", ""headline"": ""Biogen Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230810070615"", ""headline"": ""Wall Street Analysts Trim Price Targets for These 10 Stocks"", ""summary"": ""In this article, we will discuss the 10 stocks whose price targets were recently trimmed by analysts. If you want to see more such stocks on the list, go directly to Wall Street Analysts Trim Price Targets for These 5 Stocks. A series of daily 1% changes in the S&P 500, whether it goes up [\u2026]""}, {""date"": ""20230810090000"", ""headline"": ""Could This $6.5 Billion Acquisition Help Turn Biogen's Business Around?"", ""summary"": ""Biogen (NASDAQ: BIIB) is an intriguing stock right now.  For starters, the company's Alzheimer's treatment, Leqembi, obtained approval from the Food and Drug Administration (FDA) earlier this year.  Plus, it announced a significant $6.5 billion acquisition last month that could bolster its portfolio of drugs.""}, {""date"": ""20230810113100"", ""headline"": ""Ionis (IONS) Q2 Loss Narrows Y/Y, Sales Surpass Estimates"", ""summary"": ""Ionis (IONS) Q2 loss narrows from the year-ago levels. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.""}, {""date"": ""20230810120200"", ""headline"": ""Denali (DNLI) Q2 Earnings Beat on Higher Collaboration Revenues"", ""summary"": ""Denali's (DNLI) second-quarter results are better than expected due to an increase in collaboration revenues under its agreement with Biogen.""}, {""date"": ""20230810225600"", ""headline"": ""Biotech Duo Sage (NASDAQ:SAGE) and BioGen (NASDAQ:BIIB) Jump on Pricing Data"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230810235700"", ""headline"": ""Biogen Inc. stock rises Friday, outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230811061100"", ""headline"": ""Insurers won't cover new Alzheimer's treatment for some customers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230811073200"", ""headline"": ""Biogen/ Sage expected to hike price for new depression drug after narrow label"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230811080035"", ""headline"": ""Should Weakness in Biogen Inc.'s (NASDAQ:BIIB) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?"", ""summary"": ""It is hard to get excited after looking at Biogen's (NASDAQ:BIIB) recent performance, when its stock has declined 13...""}, {""date"": ""20230811102356"", ""headline"": ""Biogen Q2 2023 Analysis: Reata Acquisition, Financials, And Alzheimer's Prospects"", ""summary"": ""Biogen focuses on neurological therapies, recently acquired Reata Pharmaceuticals, and shows mixed financial performance. Click here to read more.""}, {""date"": ""20230811120514"", ""headline"": ""15 Most Important Medical Discoveries in History"", ""summary"": ""In this article, we take a look at the 15 most important medical discoveries in history. You can skip our detailed analysis of the global medicine industry and go directly to the 5 Most Important Medical Discoveries in History. Medical discoveries have done wonders for civilizations and helped humans to thrive. Since the evolution of [\u2026]""}, {""date"": ""20230812050000"", ""headline"": ""INSIGHT-What happens when a $2 million gene therapy is not enough"", ""summary"": ""Baby Ben Kutschke was diagnosed at three months with spinal muscular atrophy, a rare inherited disorder which is the leading genetic cause of death in infancy globally.  It leaves children too weak to walk, talk, swallow or even breathe.  So when in 2021 his parents heard about Zolgensma \u2013 a one-time therapy costing millions of dollars that promises to replace genes needed for the body to control muscles \u2013 they had high hopes.""}, {""date"": ""20230813091248"", ""headline"": ""13 Best Wide Moat Stocks To Buy According To Hedge Funds"", ""summary"": ""In this piece, we will take a look at the 13 best wide moat stocks to buy according to hedge funds. If you want to skip our primer on wide moat investing, then head on over to 5 Best Wide Moat Stocks To Buy According To Hedge Funds. Among the countless ways in which companies [\u2026]""}]",{}
31,2023-08-13,273.67999267578125,2023-08-20,261.1499938964844,-0.04578339343256532,D5,"[{""date"": ""20230813091248"", ""headline"": ""13 Best Wide Moat Stocks To Buy According To Hedge Funds"", ""summary"": ""In this piece, we will take a look at the 13 best wide moat stocks to buy according to hedge funds. If you want to skip our primer on wide moat investing, then head on over to 5 Best Wide Moat Stocks To Buy According To Hedge Funds. Among the countless ways in which companies [\u2026]""}, {""date"": ""20230813235700"", ""headline"": ""Biogen Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230814014530"", ""headline"": ""Capitalizing On Inflammation's Role In Neurological Disease Part 1: Coya Therapeutics"", ""summary"": ""Coya Therapeutics aims to target inflammation-related diseases, like ALS, with Treg-enhancing therapeutics. Click here to read my analysis of COYA stock.""}, {""date"": ""20230814015300"", ""headline"": ""Biogen price target lowered to $335 from $340 at Mizuho"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230814030000"", ""headline"": ""Second Half Outlook For Biotech Stocks"", ""summary"": ""Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%. Click here to read my thoughts.""}, {""date"": ""20230814101729"", ""headline"": ""Mizuho Maintains Biogen (BIIB) Buy Recommendation"", ""summary"": """"}, {""date"": ""20230814123810"", ""headline"": ""Sage Therapeutics: Undeserving Selloff Presents A Buying Opportunity"", ""summary"": ""Sage Therapeutics, Inc. is revolutionizing the treatment of postpartum depression, while also tackling CNS disorders. Click here to read more on SAGE stock.""}, {""date"": ""20230814223800"", ""headline"": ""Sanofi was second bidder for Reata, Bloombreg reports"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230814224400"", ""headline"": ""Sanofi was second bidder for Reata, Bloomberg reports"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230814232200"", ""headline"": ""Sanofi was mystery bidder in Reata Pharma bidding war - report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230814233400"", ""headline"": ""Sanofi was mystery suitor in Reata Pharma bidding war - report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230814235700"", ""headline"": ""Biogen Inc. stock falls Tuesday, still outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230815100039"", ""headline"": ""Is Biogen (NASDAQ:BIIB) A Risky Investment?"", ""summary"": ""Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...""}, {""date"": ""20230815211400"", ""headline"": ""BofA upgrades Axsome to neutral, cites improved outlook for MDD drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230815235700"", ""headline"": ""Biogen Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230816070300"", ""headline"": ""Wells Fargo starts GE HealthCare at overweight, sees increased imaging demand"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230816110828"", ""headline"": ""CORRECTED-INSIGHT-What happens when a $2 million gene therapy is not enough"", ""summary"": ""Baby Ben Kutschke was diagnosed at three months with spinal muscular atrophy, a rare inherited disorder which is the leading genetic cause of death in infancy globally.  It leaves children too weak to walk, talk, swallow or even breathe.  So when in 2021 his parents heard about Zolgensma \u2013 a one-time therapy costing millions of dollars that promises to replace genes needed for the body to control muscles \u2013 they had high hopes.""}, {""date"": ""20230816235700"", ""headline"": ""Biogen Inc. stock falls Thursday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230817165410"", ""headline"": ""Biogen's 1,000-person layoff begins in Cambridge"", ""summary"": ""Cambridge-based Biogen (Nasdaq: BIIB) employees began posting about the changes on LinkedIn on Thursday. Some offered help to departing colleagues, while others announced that they were open to work.""}, {""date"": ""20230818125600"", ""headline"": ""Biogen Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slumped 0.13% to $261.15 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""20230819080026"", ""headline"": ""Is There An Opportunity With Biogen Inc.'s (NASDAQ:BIIB) 47% Undervaluation?"", ""summary"": ""Key Insights Biogen's estimated fair value is US$496 based on 2 Stage Free Cash Flow to Equity Current share price of...""}]",{}
32,2023-08-20,261.1499938964844,2023-08-27,264.42999267578125,0.01255982713366266,U2,"[{""date"": ""20230821125600"", ""headline"": ""Biogen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Biogen Inc. rallied 1.50% to $265.07 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230822125600"", ""headline"": ""Biogen Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Biogen Inc. slumped 0.79% to $262.98 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230822211200"", ""headline"": ""Biogen's Leqembi set for strong uptake based on Baird physician survey"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230823125600"", ""headline"": ""Biogen Inc. stock rises Wednesday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.69% higher to $264.80 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the...""}, {""date"": ""20230823222026"", ""headline"": ""Bristol-Myers Squibb: Top Defensive Pick During Recessions With A Value Proposition"", ""summary"": ""Discover why Bristol-Myers is a strong investment, undervalued with a promising dividend yield. After a slow start, expect a bullish turnaround.""}, {""date"": ""20230824022000"", ""headline"": ""FDA approves Sandoz's biosimilar of Biogen's blockbuster MS drug Tysabri"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230824043300"", ""headline"": ""Insider Richard Barry Just Doubled Down on Cassava (SAVA) Stock"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230824044600"", ""headline"": ""Drugs picked for Medicare price negotiations to be announced on Tuesday \u2013 Politico"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230824070400"", ""headline"": ""October 6th Options Now Available For Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230824113041"", ""headline"": ""Biogen Inc. (BIIB) Down 0.2% Since Last Earnings Report: Can It Rebound?"", ""summary"": ""Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.""}, {""date"": ""20230824125600"", ""headline"": ""Biogen Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. slid 0.90% to $262.43 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230824140700"", ""headline"": ""Biogen stock slips after FDA approves first biosimilar to Tysabri MS treatment"", ""summary"": ""Biogen Inc. shares slipped in the extended session Thursday after the Food and Drug Administration granted a soon-to-be Novartis AG spinoff approval for the...""}, {""date"": ""20230825015100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Stericycle (SRCL), Biogen (BIIB) and Cooper Co (COO)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230825015500"", ""headline"": ""Novartis\u2019 (NYSE:NVS) Sandoz Bags FDA Approval for Tyruko in Multiple Sclerosis"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230825121753"", ""headline"": ""Novartis comes for a Biogen MS drug with new biosimilar"", ""summary"": ""On Thursday, the U.S. Food and Drug Administration approved a new biosimilar designed to mimic Tysabri, one of Biogen's (Nasdaq: BIIB) MS products. Biosimilars, like generics, are typically more affordable versions of brand-name drugs.""}, {""date"": ""20230825130200"", ""headline"": ""Biogen Inc. stock rises Friday, outperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.76% higher to $264.43 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""20230825210400"", ""headline"": ""Crohn's disease drugmakers set to benefit from expected rise in cases"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
33,2023-08-27,264.42999267578125,2023-09-03,267.1700134277344,0.0103619892895912,U2,"[{""date"": ""20230828043100"", ""headline"": ""Wall Street Analysts Are Bullish on Top Healthcare Picks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230828093925"", ""headline"": ""12 Undervalued Wide Moat Stocks To Invest In"", ""summary"": ""In this piece, we will take a look at 12 undervalued wide moat stocks to invest in. If you want to skip our primer on wide moat investing, then check out 5 Undervalued Wide Moat Stocks To Invest In. The strategy of wide moat investing has gained a lot of traction over the past few [\u2026]""}, {""date"": ""20230828105700"", ""headline"": ""Novartis' (NVS) Sandoz Gets FDA Nod for Tysabri's Biosimilar"", ""summary"": ""Novartis' (NVS) generic division, Sandoz, wins FDA approval for a biosimilar of the leading MS drug Tysabri.""}, {""date"": ""20230828125600"", ""headline"": ""Biogen Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.23% higher to $265.05 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""20230828222800"", ""headline"": ""RBC Capital sees Biogen stock undervaluing Leqembi prospects"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230828225800"", ""headline"": ""Gingko Bioworks (NASDAQ:DNA) Blasts Up on New Alphabet (NASDAQ:GOOG) Partnership"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230828225900"", ""headline"": ""Ginkgo Bioworks (NASDAQ:DNA) Blasts Up on New Alphabet (NASDAQ:GOOG) Partnership"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230828232800"", ""headline"": ""Ginkgo Bioworks (NASDAQ:DNA) Blasts Up on New Alphabet Partnership"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230829012100"", ""headline"": ""Biogen price target raised to $357 from $354 at RBC Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230829012600"", ""headline"": ""RBC Capital Remains a Buy on Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230829100700"", ""headline"": ""Better Buy: Biogen vs. Eli Lilly"", ""summary"": ""Biogen (NASDAQ: BIIB) and Eli Lilly (NYSE: LLY) have a lot in common. Both companies are among the leaders in the biotech industry. Both have deep lineups and pipelines. And both are looking to dominate an area with a severe and growing need for new therapies: Alzheimer's disease (AD).""}, {""date"": ""20230829113900"", ""headline"": ""Roche's (RHHBY) Evrysdi Gets Label Expansion in EU for Newborns"", ""summary"": ""Following the label expansion, Roche's (RHHBY) Evrysdi is now approved to treat people of all ages with SMA in the European Union.""}, {""date"": ""20230829125600"", ""headline"": ""Biogen Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. rose 1.11% to $268.00 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""20230829181154"", ""headline"": ""RBC Capital Maintains Biogen (BIIB) Outperform Recommendation"", ""summary"": """"}, {""date"": ""20230830002500"", ""headline"": ""The 3 Most Promising Pharma Stocks to Own Now"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230830121002"", ""headline"": ""Biogen : to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference"", ""summary"": ""Cambridge, MA, - - Biogen Inc. announced today that Christopher Viehbacher, CEO, will participate in the Morgan Stanley 21st Annual Global Healthcare Conference. The webcast will be...""}, {""date"": ""20230830175019"", ""headline"": ""Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know"", ""summary"": ""Biogen Inc. (BIIB) closed the most recent trading day at $267.18, moving -0.31% from the previous trading session.""}, {""date"": ""20230831022700"", ""headline"": ""Sage cuts 40% of staff in portfolio shake-up ahead of Zurzuvae launch"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230831033100"", ""headline"": ""The 7 Most Promising Momentum Stocks to Own Now"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230831035900"", ""headline"": ""Sage Therapeutics to lay off 40% of staff as it gears up for launch of postpartum-depression treatment"", ""summary"": ""Sage Therapeutics Inc. said Thursday it is reorganizing its business operations and workforce as it gears up for the launch of its postpartum-depression...""}, {""date"": ""20230831040000"", ""headline"": ""Sage Therapeutics (NASDAQ:SAGE) Slashes 40% Positions with Zurzuvae Launch in Mind"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230831042100"", ""headline"": ""Sage Therapeutics (NASDAQ:SAGE) Slashes 40% of Positions with Zurzuvae Launch in Mind"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230831070011"", ""headline"": ""UPDATE 1-Sage Therapeutics to cut about 188 jobs after depression drug setback"", ""summary"": ""Sage Therapeutics said on Thursday it plans to lay off about 188 people, or about 40% of its workforce, weeks after the U.S. health regulator declined to approve its drug to treat major depressive disorder.  The U.S. Food and Drug Administration (FDA) in early August approved the company and partner Biogen's pill for postpartum depression (PDD), but rejected it as a treatment for clinical depression, which is a much larger market.  Sage said the job cuts, which are part of a reorganization plan, will help it launch the drug for women with PDD and also position the company for long-term growth.""}, {""date"": ""20230831101059"", ""headline"": ""Sage cuts nearly half its staff in wake of partial FDA rejection"", ""summary"": ""Sage Therapeutics is letting go of around 276 workers following some mixed news from the U.S. Food and Drug Administration.""}, {""date"": ""20230831125600"", ""headline"": ""Biogen Inc. stock rises Thursday, outperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.07% higher to $267.36 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...""}, {""date"": ""20230831160734"", ""headline"": ""FDA Documents Suggest Sage's Battle In Depression Drugs Will Be Trickier Than Expected"", ""summary"": ""Sage said Thursday it will cut about 40% of its workforce following a setback for depression treatment Zurzuvae. Sage stock edged higher.""}, {""date"": ""20230831174517"", ""headline"": ""Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know"", ""summary"": ""Biogen Inc. (BIIB) closed the most recent trading day at $267.36, moving +0.07% from the previous trading session.""}, {""date"": ""20230901013400"", ""headline"": ""Biogen in $1.5B unsecured loan facility for Reata acquisition"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230901042000"", ""headline"": ""(BIIB) - Analyzing Biogen's Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230901125600"", ""headline"": ""Biogen Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Biogen Inc. slipped 0.07% to $267.17 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""20230902090017"", ""headline"": ""Biogen Inc. (NASDAQ:BIIB) is favoured by institutional owners who hold 89% of the company"", ""summary"": ""Key Insights Significantly high institutional ownership implies Biogen's stock price is sensitive to their trading...""}, {""date"": ""20230903050312"", ""headline"": ""U.S. Wide-Moat Stocks On Sale - The September 2023 Heat Map"", ""summary"": ""Our 3-step process focuses on wide-moat stocks (as per Morningstar\u00e2\u0080\u0099s rating). Find out the heat map of the most investable candidates.""}]",{}
34,2023-09-03,267.1700134277344,2023-09-10,258.989990234375,-0.030617295288537183,D4,"[{""date"": ""20230903050312"", ""headline"": ""U.S. Wide-Moat Stocks On Sale - The September 2023 Heat Map"", ""summary"": ""Our 3-step process focuses on wide-moat stocks (as per Morningstar\u00e2\u0080\u0099s rating). Find out the heat map of the most investable candidates.""}, {""date"": ""20230903213500"", ""headline"": ""$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230903224700"", ""headline"": ""The 3 Best Biotech Stocks to Buy Now: September 2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230904220200"", ""headline"": ""EOG and Livent Have Pleasingly Plump Profit Margins"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230904235700"", ""headline"": ""Biogen Inc. stock outperforms market despite losses on the day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230905031100"", ""headline"": ""Biogen price target raised to $381 from $363 at Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230905031100"", ""headline"": ""Eli Lilly price target raised to $640 from $617 at Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230905042758"", ""headline"": ""Biogen: Leqembi Could Boost Prospects Until Acquisition Comes Into Play"", ""summary"": ""Biogen receives FDA approval for Leqembi, a treatment for Alzheimer's Disease, providing a large market opportunity. Read more here.""}, {""date"": ""20230905094000"", ""headline"": ""Biogen's (BIIB) Stock Outperforms Industry YTD: Here's Why"", ""summary"": ""While most of Biogen's (BIIB) key drugs are facing declining sales, new products, like Leqembi in Alzheimer's disease, Qalsody in amyotrophic lateral sclerosis and zuranolone in depression, can help revive growth.""}, {""date"": ""20230905212700"", ""headline"": ""3 Healthcare Stocks to Sell in September Before They Crash & Burn"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230905215200"", ""headline"": ""Denali Therapeutics Breakthrough Blood-Brain Barrier Platform A Game-Changer in Neurodegenerative Diseases: Analyst"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230905222928"", ""headline"": ""Morgan Stanley Maintains Biogen (BIIB) Overweight Recommendation"", ""summary"": """"}, {""date"": ""20230905234400"", ""headline"": ""Biogen initiated with a Buy at HSBC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230905235700"", ""headline"": ""Biogen Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230906023700"", ""headline"": ""Biogen appoints Jane Grogan as Executive Vice President"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230906030800"", ""headline"": ""GLOBAL BROKER RATINGS: Shore Capital raises B&M; HSBC likes Amgen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230906031100"", ""headline"": ""Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector \u2013 What To Look For"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230906034000"", ""headline"": ""Biogen names Dr. Jane Grogan head of research effective Oct. 2"", ""summary"": ""Biogen Inc. said Wednesday it has appointed Dr. Jane Grogan as head of research, effective Oct. 2. Grogan was most recently chief scientific officer at...""}, {""date"": ""20230906035100"", ""headline"": ""Biogen Names Jane Grogan Head of Research >BIIB"", ""summary"": ""By Colin Kellaher Biogen has tapped industry veteran Jane Grogan as executive vice president and head of research of the biotechnology company. Biogen on...""}, {""date"": ""20230906050000"", ""headline"": ""Octave\u00ae Bioscience, Inc. Announces Real-World Study Using its Multimodal Precision Care Solution for Multiple Sclerosis Patient Management"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230906073000"", ""headline"": ""Biogen Appoints Jane Grogan as Head of Research"", ""summary"": ""CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research effective 2 October 2023. Dr. Grogan will be a member of Biogen\u2019s Executive Committee reporting to Christopher A. Viehbacher, President and Chief Executive Officer. \u201cDr. Grogan is a pioneering scientist whose groundbreaking discoveries at Genentech helped pave the way for development of targeted autoimmune and oncology ther""}, {""date"": ""20230906111651"", ""headline"": ""Octave Bioscience Releases Multiple Sclerosis Study in Biogen Partnership"", ""summary"": ""By Karen E. Roman Octave Bioscience, Inc., a company offering treatment for multiple sclerosis and other neurodegenerative diseases, said it will conduct a real-world study with its sponsor Biogen (Nasdaq: BIIB) evaluating 150 patients using the Octave Precision Care Solution. Octave\u2019s Solution includes the first and only multivariate blood test to measure MS Disease Activity [\u2026]""}, {""date"": ""20230906140000"", ""headline"": ""Biogen Inc. Announces the Appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research Effective 2 October 2023"", ""summary"": ""Biogen Inc. announced the appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research effective 2 October 2023. Dr. Grogan will be a member of Biogens Executive Committee...""}, {""date"": ""20230906175021"", ""headline"": ""Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know"", ""summary"": ""Biogen Inc. (BIIB) closed at $263.72 in the latest trading session, marking a -0.97% move from the prior day.""}, {""date"": ""20230906224937"", ""headline"": ""HSBC Initiates Coverage of Biogen (BIIB) with Buy Recommendation"", ""summary"": """"}, {""date"": ""20230906235700"", ""headline"": ""Biogen Inc. stock falls Thursday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230907060800"", ""headline"": ""Researchers study weight loss drugs in dementia and addiction"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230907063055"", ""headline"": ""The Petri Dish: Biogen secures $1.5B loan; Mersana CEO departs after trial failure"", ""summary"": ""Biogen is acquiring Reata Pharmaceuticals with the help of a hefty loan, Novo Nordisk teams up with the Broad Institute and other life sciences news you may have missed.""}, {""date"": ""20230907070802"", ""headline"": ""7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth"", ""summary"": ""Pharma stocks can be a great way to add profits to your investment account. Companies that make lifesaving medications or develop treatments to ease symptoms can be true moneymakers. Finding the best pharma stocks to buy is well worth your time and effort. But finding the right pharma stocks to buy can be tricky. You have to be comfortable with some fundamental truths about pharma stocks before you can decide if this is a good investment for you. Pharma stocks are heavily affected by regulation.""}, {""date"": ""20230907171700"", ""headline"": ""Top Analyst Reports for Humana, Cintas & Biogen"", ""summary"": ""Today's Research Daily features new research reports on 16 major stocks, including Humana Inc. (HUM), Cintas Corporation (CTAS) and Biogen Inc. (BIIB).""}, {""date"": ""20230907220600"", ""headline"": ""Catalyst Watch: Arm IPO, Apple event, and Senate AI Forum with Musk, Zuckerberg, and Gates"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230907235700"", ""headline"": ""Biogen Inc. stock falls Friday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230908092400"", ""headline"": ""The Zacks Analyst Blog Highlights Humana, Cintas, Biogen, Royal Caribbean Cruises and Markel Group"", ""summary"": ""Humana, Cintas, Biogen, Royal Caribbean Cruises and Markel Group are part of the Zacks top Analyst Blog.""}, {""date"": ""20230908121000"", ""headline"": ""Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study"", ""summary"": ""Alector (ALEC) completes enrolment in a mid-stage study evaluating its investigational monoclonal antibody in patients with early Alzheimer's disease. Data from the study is expected before year-end.""}, {""date"": ""20230908123142"", ""headline"": ""Is Eli Lilly Stock A Buy Now That It Has Hit A Profit-Taking Zone?"", ""summary"": ""Eli Lilly surged 15% in one day on enthusiasm for weight-loss and Alzheimer\u2019s drugs. But is LLY stock a buy now? Here's what you should know.""}, {""date"": ""20230909063000"", ""headline"": ""Stocks To Watch: Eyes On CPI, New iPhones, And Google Vs. U.S. Trial"", ""summary"": ""Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week.""}, {""date"": ""20230909074500"", ""headline"": ""Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy?"", ""summary"": ""As you may have heard this summer, Biogen (NASDAQ: BIIB) is taking out a $1.5 billion-dollar loan to fund its acquisition of rare disease drug developer Reata Pharmaceuticals (NASDAQ: RETA) for $7.3 billion in cash.  Buying Reata Pharmaceuticals will accomplish a couple of things for Biogen.  First, it'll gain control of Reata's newly approved drug Skyclarys, which is the only medicine approved to treat Friedreich's ataxia.""}, {""date"": ""20230909222400"", ""headline"": ""HSBC bullish on IQVIA, Zoetis, bluebird, Actinium; bearish on Gilead"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
35,2023-09-10,258.989990234375,2023-09-17,254.7899932861328,-0.01621683117730288,D2,"[{""date"": ""20230909222400"", ""headline"": ""HSBC bullish on IQVIA, Zoetis, bluebird, Actinium; bearish on Gilead"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230910235700"", ""headline"": ""Biogen Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230911031920"", ""headline"": ""Latest U.S. Zombie Firms With The Highest Potential Credit Risks, Plus 6-Month Update"", ""summary"": ""The zombie label was used by Federal Reserve researchers to assess market risks during Covid-19. Read for a review of the 6-month performance of top zombie firms.""}, {""date"": ""20230911041933"", ""headline"": ""Amylyx Pharmaceuticals: A High Risk/High Reward Stock"", ""summary"": ""Amylyx is focused on developing therapies for neurodegenerative diseases. Click here to read a full investment analysis of AMLX stock.""}, {""date"": ""20230911070600"", ""headline"": ""Sandoz to commercialize biosimilar to J&J blockbuster drug Stelara"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230911104709"", ""headline"": ""Biogen Inc. (BIIB) Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)"", ""summary"": ""Biogen Inc. (NASDAQ:NASDAQ:BIIB) Morgan Stanley 21st Annual Global Healthcare Conference September 11, 2023 10:40 AM ETCompany ParticipantsChristopher Viehbacher - CEOConference Call...""}, {""date"": ""20230911225200"", ""headline"": ""Intas reportedly readying bid of up to $1B for Biogen biosimilars unit"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230911235700"", ""headline"": ""Biogen Inc. stock falls Tuesday, still outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230912022100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230912082300"", ""headline"": ""Reata says waiting period related to merger under Hart-Scott-Rodino act expired"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230912083000"", ""headline"": ""Reata Pharmaceuticals climbs as HSR waiting period for sale to Biogen expired"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230912175017"", ""headline"": ""Biogen Inc. (BIIB) Stock Moves -0.19%: What You Should Know"", ""summary"": ""In the latest trading session, Biogen Inc. (BIIB) closed at $258.44, marking a -0.19% move from the previous day.""}, {""date"": ""20230912235700"", ""headline"": ""Biogen Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230913090019"", ""headline"": ""Biogen Inc.'s (NASDAQ:BIIB) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?"", ""summary"": ""With its stock down 14% over the past three months, it is easy to disregard Biogen (NASDAQ:BIIB). But if you pay close...""}, {""date"": ""20230913120203"", ""headline"": ""Why Did GE HealthCare Excel Beyond The COVID-19 Crisis?"", ""summary"": ""GE HealthCare's Q2\u00e2\u0080\u009923 revenue was $4.82 billion, 2.3% more than Q1\u00e2\u0080\u009923 and 7.6% more than Q2\u00e2\u0080\u009922 and raised 2023 adjusted EPS guidance. Find out why GEHC stock is a Buy.""}, {""date"": ""20230913235800"", ""headline"": ""Biogen Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230914220000"", ""headline"": ""Catalyst watch: Microsoft, Amazon, Oracle, and Intel to Hold High-Profile Events"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230914235800"", ""headline"": ""Biogen Inc. stock falls Friday, still outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230915003900"", ""headline"": ""Novartis shareholders approve 100% spinout of Sandoz unit"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230915083300"", ""headline"": ""$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
36,2023-09-17,254.7899932861328,2023-09-24,257.67999267578125,0.011342672262654174,U2,"[{""date"": ""20230917235800"", ""headline"": ""Biogen Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230918235800"", ""headline"": ""Biogen Inc. stock outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230919074600"", ""headline"": ""Scholar Rock gains as Phase 3 trial for SMA drug hits milestone"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230920052000"", ""headline"": ""(BIIB) - Analyzing Biogen's Short Interest"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230920055200"", ""headline"": ""Jefferies biotechnology analyst to hold an analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230920100214"", ""headline"": ""GE Healthcare: Why it's still waiting on its Leqembi windfall"", ""summary"": ""GE Healthcare's potential windfall from Leqembi approval is being hampered by CMS coverage of PET scans.""}, {""date"": ""20230920125700"", ""headline"": ""Biogen Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Biogen Inc. rose 1.50% to $260.53 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230921033300"", ""headline"": ""Analysts Are Bullish on These Healthcare Stocks: Boston Scientific (BSX), Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230921051100"", ""headline"": ""Reata stockholders approve merger transaction with Biogen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230921053900"", ""headline"": ""Reta shareholders clear buyout deal with Biogen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230921055100"", ""headline"": ""Reata shareholders clear buyout deal with Biogen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230921063100"", ""headline"": ""Interesting BIIB Put And Call Options For November 3rd"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230921124100"", ""headline"": ""Biogen notes Reata Pharma shareholders OK takeover by Biogen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230921125600"", ""headline"": ""Biogen Inc. stock falls Thursday, still outperforms market"", ""summary"": ""Shares of Biogen Inc. slid 0.61% to $258.93 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230922025900"", ""headline"": ""California Attorney General Cracks Down On Deceptive Abortion Pill Reversal Claims"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230922125600"", ""headline"": ""Biogen Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slumped 0.48% to $257.68 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230922230500"", ""headline"": ""These companies set to benefit from sales of Biogen Alzheimer's med Leqembi"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
37,2023-09-24,257.67999267578125,2023-10-01,257.010009765625,-0.002600057936974709,D1,"[{""date"": ""20230924232900"", ""headline"": ""Biogen gets approval in Japan for Leqembi to slow Alzheimer's"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230925005600"", ""headline"": ""Biogen, Eisai announce LEQEMBI Intravenous Infusion approved in Japan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230925010200"", ""headline"": ""LEQEMBI\u00ae Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer\u2019s Disease in Japan"", ""summary"": ""TOKYO and CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, \u201cEisai\u201d) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, \u201cBiogen\u201d) announced today that humanized anti- soluble aggregated amyloid-beta (A\u03b2) monoclonal antibody LEQEMBI\u00ae Intravenous Infusion (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment (MC""}, {""date"": ""20230925011317"", ""headline"": ""Japan approves Alzheimer treatment Leqembi by Eisai and Biogen"", ""summary"": ""Japan's Eisai said on Monday the country's health ministry had approved its Alzheimer treatment Leqembi, co-developed with U.S.-based Biogen .  The drug is the first treatment shown to slow progression of the disease for people in the earlier stages of Alzheimer's.  An Eisai executive said in August the company expected to begin marketing Leqembi in Japan within  about 60 days of receiving insurance reimbursement approval from the country's national health system.""}, {""date"": ""20230925020200"", ""headline"": ""Biogen/ Eisai Alzheimer\u2019s therapy Leqembi approved in Japan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230925054400"", ""headline"": ""Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230925060000"", ""headline"": ""Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230925095728"", ""headline"": ""UPDATE 1-Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen"", ""summary"": ""Japan's Eisai said on Monday its Alzheimer's treatment developed with Biogen , Leqembi, was approved by the country's health ministry, making it the second nation after the United States to clear its use.  It can now be used in Japan as a treatment for slowing progression of mild cognitive impairment and mild dementia due to Alzheimer's disease.  The drug is the first treatment shown to slow progression of the disease for people in the earlier stages of Alzheimer's.""}, {""date"": ""20230925113909"", ""headline"": ""Unveiling Biogen (BIIB)'s Value: Is It Really Priced Right? A Comprehensive Guide"", ""summary"": ""An in-depth analysis of Biogen's intrinsic value and financial performance""}, {""date"": ""20230925125500"", ""headline"": ""Biogen Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. slipped 1.03% to $255.02 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230925175019"", ""headline"": ""Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know"", ""summary"": ""In the latest trading session, Biogen Inc. (BIIB) closed at $255.02, marking a -1.03% move from the previous day.""}, {""date"": ""20230926021859"", ""headline"": ""After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen"", ""summary"": ""Japan's health ministry has approved Leqembi, a drug for Alzheimer\u2019s disease that was jointly developed by Japanese and U.S. pharmaceutical companies.  Developed by Japanese drugmaker Eisai Co. and U.S. biotechnology firm Biogen Inc., the drug's approval in Japan comes two months after it was endorsed by the U.S. Food and Drug Administration.  Leqembi is for patients with mild dementia and other symptoms in the early stages of Alzheimer's disease, and the first medicine that can modestly slow their cognitive decline.""}, {""date"": ""20230926085900"", ""headline"": ""Biogen Completes Acquisition of Reata Pharmaceuticals"", ""summary"": ""Reata acquisition bolsters Biogen\u2019s rare disease portfolio with the addition of SKYCLARYS\u00ae (omaveloxolone), the first and only FDA approved treatment for Friedreich\u2019s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) \u2013 has completed the acquisition of Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of the transact""}, {""date"": ""20230926125600"", ""headline"": ""Biogen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Biogen Inc. rallied 1.19% to $258.05 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230926131711"", ""headline"": ""Biogen Inc. (BIIB) Management presents at Decentralized Clinical Trials in Focus Conference (Transcript)"", ""summary"": ""Biogen Inc. (NASDAQ:NASDAQ:BIIB) Decentralized Clinical Trials in Focus Conference September 26, 2023 10:00 AM ETCompany ParticipantsStephanie Manson Brown - Head of Clinical Development...""}, {""date"": ""20230927054600"", ""headline"": ""First Week of BIIB April 2024 Options Trading"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230927095800"", ""headline"": ""Ionis (IONS) Meets Rare Disease Drug Study Goal, Stock Up 8.5%"", ""summary"": ""Ionis (IONS) reports positive phase III study results, supporting the benefits of olezarsen to treat familial chylomicronemia syndrome (FCS), a rare genetic disorder.""}, {""date"": ""20230927125600"", ""headline"": ""Biogen Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Biogen Inc. slid 0.21% to $257.52 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230928013700"", ""headline"": ""Prospects of Biogen\u2019s Leqembi in Alzheimer\u2019s Market: A Buy Rating Justification"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230928054500"", ""headline"": ""First Week of November 17th Options Trading For Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230928062727"", ""headline"": ""The Petri Dish: Ginkgo, Pfizer sign $331M deal; Leqembi OK'd in Japan"", ""summary"": ""Pfizer is partnering up with Boston synthetic biology firm Ginkgo Bioworks, plus other life sciences news you may have missed.""}, {""date"": ""20230928063300"", ""headline"": ""Interesting BIIB Put And Call Options For November 10th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230928100600"", ""headline"": ""Ionis (IONS) Inks New Deal With Roche to Develop Novel RNA Drugs"", ""summary"": ""Per the agreement, Ionis (IONS) will grant exclusive global rights to Roche to develop and market two novel RNA-therapeutics for Alzheimer's and Huntington's diseases.""}, {""date"": ""20230928100700"", ""headline"": ""Is Biogen Stock a Buy Now?"", ""summary"": ""It has been one of the most talked about biotechs in recent years, but that's not enough to make its shares a buy.""}, {""date"": ""20230928125500"", ""headline"": ""Biogen Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.12% higher to $257.83 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""20230928225300"", ""headline"": ""Biogen's Tofidence biosimilar granted FDA approval"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230928230800"", ""headline"": ""Biogen says FDA approves TOFIDENCE"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230928235000"", ""headline"": ""FDA approves Biogen\u2019s biosimilar to Roche's arthritis drug Actemra"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20230929121900"", ""headline"": ""Biogen's Tofidence Intravenous Formulation Gets FDA Approval"", ""summary"": ""By Denny Jacob Biogen's tofidence intravenous formulation was approved by the U.S. Food and Drug Administration, the biopharmaceutical company said Friday....""}, {""date"": ""20230929122500"", ""headline"": ""Biogen gets FDA approval for biotech treatment similar to Roche\u2019s Actemra"", ""summary"": ""Biogen Inc. said late Friday the Food and Drug Administration approved its biosimilar version of Roche \u2018s arthritis treatment Actemra. Biogen said its...""}, {""date"": ""20230929124622"", ""headline"": ""Biogen - Revised Revenue Forecasting To 2030 - New CEO Faces Major Challenges"", ""summary"": ""Biogen's stock increased post-approval of its Alzheimer's drug, Leqembi. Click here to find out why BIIB stock is rated as a hold.""}, {""date"": ""20230929125500"", ""headline"": ""Biogen Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Biogen Inc. shed 0.32% to $257.01 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20230929160600"", ""headline"": ""FDA Approves Biogen\u2019s TOFIDENCE\u2122 (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA\u00ae"", ""summary"": ""TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United StatesFDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA.""}]","{""assetTurnoverTTM"": 0.39, ""bookValue"": 14484, ""cashRatio"": 0.4555953803265631, ""currentRatio"": 1.6834, ""ebitPerShare"": 1.0967, ""eps"": -0.4703, ""ev"": 41618.027, ""fcfMargin"": 0.1995, ""fcfPerShareTTM"": 7.0766, ""grossMargin"": 0.7393, ""inventoryTurnoverTTM"": 1.1412, ""longtermDebtTotalAsset"": 0.2407, ""longtermDebtTotalCapital"": 0.3117, ""longtermDebtTotalEquity"": 0.4685, ""netDebtToTotalCapital"": 0.2296, ""netDebtToTotalEquity"": 0.3451, ""netMargin"": -0.0269, ""operatingMargin"": 0.0628, ""pb"": 2.5283, ""peTTM"": 25.0513, ""pfcfTTM"": 28.4207, ""pretaxMargin"": -0.0558, ""psTTM"": 3.6645, ""ptbv"": 5.1296, ""quickRatio"": 1.0896, ""receivablesTurnoverTTM"": 4.7655, ""roaTTM"": 0.057, ""roeTTM"": 0.1041, ""roicTTM"": 0.0711, ""rotcTTM"": 0.095, ""salesPerShare"": 17.4744, ""sgaToSale"": 0.2607, ""tangibleBookValue"": 7139, ""totalDebtToEquity"": 0.503, ""totalDebtToTotalAsset"": 0.2584, ""totalDebtToTotalCapital"": 0.3347, ""totalRatio"": 2.0565, ""period"": ""2023-09-30""}"
38,2023-10-01,257.010009765625,2023-10-08,263.25,0.024279172006045346,U3,"[{""date"": ""20231002125500"", ""headline"": ""Biogen Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slid 1.61% to $252.86 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231002175019"", ""headline"": ""Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know"", ""summary"": ""Biogen Inc. (BIIB) closed at $252.86 in the latest trading session, marking a -1.61% move from the prior day.""}, {""date"": ""20231002233700"", ""headline"": ""Quant Ratings Updated on 74 Stocks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231002235600"", ""headline"": ""Biogen Inc. stock outperforms market despite losses on the day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231003085800"", ""headline"": ""ProMIS Neuro draws Buy at BTIG on lead Alzheimer\u2019s asset"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231003230443"", ""headline"": ""U.S. Wide-Moat Stocks On Sale - The October 2023 Heat Map"", ""summary"": ""Discover the 3-step process of selecting wide-moat stocks, with a focus on attractively valued candidates. See a heat map of investment candidates here.""}, {""date"": ""20231004053000"", ""headline"": ""How Much Will Your Medicare Part B Premiums Increase Next Year?"", ""summary"": ""Many retirees are no doubt anxiously awaiting to find out how much their Social Security benefits will increase in 2024.  There's another question for which they still don't have an answer: How much will Medicare Part B premiums increase next year?  The Centers for Medicare and Medicaid Services (CMS) typically announces the Medicare Part B premiums for the next year sometime between mid-October and early November.""}, {""date"": ""20231004134442"", ""headline"": ""Is Eli Lilly Stock A Buy Following Its $1.4 Billion Point Biopharma Takeover In Cancer Treatment?"", ""summary"": ""Eli Lilly agreed to buy Point Biopharma for $1.4 billion to bolster its cancer drugs business. Is LLY stock a buy right now?""}, {""date"": ""20231005044600"", ""headline"": ""Biogen (BIIB) Receives a Buy from RBC Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231005050300"", ""headline"": ""An Oversold Gold Miner With Strong Fundamentals--Its Relative Strength Index Is Below 20, And Its Piotroski F-Score Is 8"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231005063700"", ""headline"": ""Interesting BIIB Put And Call Options For November 24th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231005213800"", ""headline"": ""Biotech Sector: On The Verge Of Triumph Or Turmoil?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231005235600"", ""headline"": ""Biogen Inc. stock outperforms market on strong trading day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231006080028"", ""headline"": ""Biogen Inc. (NASDAQ:BIIB) is favoured by institutional owners who hold 89% of the company"", ""summary"": ""Key Insights Given the large stake in the stock by institutions, Biogen's stock price might be vulnerable to their...""}, {""date"": ""20231008054000"", ""headline"": ""Week In Review: QYuns Plans Hong Kong IPO For Autoimmune/Allergic Disease Portfolio"", ""summary"": ""Jiangsu QYuns Therapeutics filed for a Hong Kong IPO to underwrite development of its portfolio of clinical-stage biologic antibody drugs for autoimmune and allergic diseases. Read more here""}]","{""assetTurnoverTTM"": 0.39, ""bookValue"": 14484, ""cashRatio"": 0.4555953803265631, ""currentRatio"": 1.6834, ""ebitPerShare"": 1.0967, ""eps"": -0.4703, ""ev"": 41618.027, ""fcfMargin"": 0.1995, ""fcfPerShareTTM"": 7.0766, ""grossMargin"": 0.7393, ""inventoryTurnoverTTM"": 1.1412, ""longtermDebtTotalAsset"": 0.2407, ""longtermDebtTotalCapital"": 0.3117, ""longtermDebtTotalEquity"": 0.4685, ""netDebtToTotalCapital"": 0.2296, ""netDebtToTotalEquity"": 0.3451, ""netMargin"": -0.0269, ""operatingMargin"": 0.0628, ""pb"": 2.5283, ""peTTM"": 25.0513, ""pfcfTTM"": 28.4207, ""pretaxMargin"": -0.0558, ""psTTM"": 3.6645, ""ptbv"": 5.1296, ""quickRatio"": 1.0896, ""receivablesTurnoverTTM"": 4.7655, ""roaTTM"": 0.057, ""roeTTM"": 0.1041, ""roicTTM"": 0.0711, ""rotcTTM"": 0.095, ""salesPerShare"": 17.4744, ""sgaToSale"": 0.2607, ""tangibleBookValue"": 7139, ""totalDebtToEquity"": 0.503, ""totalDebtToTotalAsset"": 0.2584, ""totalDebtToTotalCapital"": 0.3347, ""totalRatio"": 2.0565, ""period"": ""2023-09-30""}"
39,2023-10-08,263.25,2023-10-15,262.260009765625,-0.003760646664292544,D1,"[{""date"": ""20231008054000"", ""headline"": ""Week In Review: QYuns Plans Hong Kong IPO For Autoimmune/Allergic Disease Portfolio"", ""summary"": ""Jiangsu QYuns Therapeutics filed for a Hong Kong IPO to underwrite development of its portfolio of clinical-stage biologic antibody drugs for autoimmune and allergic diseases. Read more here""}, {""date"": ""20231009125400"", ""headline"": ""Biogen Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.36% higher to $264.21 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""20231009175020"", ""headline"": ""Biogen Inc. (BIIB) Advances But Underperforms Market: Key Facts"", ""summary"": ""In the most recent trading session, Biogen Inc. (BIIB) closed at $264.21, indicating a +0.36% shift from the previous trading day.""}, {""date"": ""20231010125400"", ""headline"": ""Biogen Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Biogen Inc. dropped 0.03% to $264.14 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231010212900"", ""headline"": ""Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231011060500"", ""headline"": ""Analyst Ratings for Biogen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231011121011"", ""headline"": ""Will Biogen Inc. (BIIB) Beat Estimates Again in Its Next Earnings Report?"", ""summary"": ""Biogen Inc. (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.""}, {""date"": ""20231011122242"", ""headline"": ""Eli Lilly Sparks As Rival Novo Says Diabetes Drug Could Treat Kidney Disease \u2014 But Is Lilly Stock A Buy?"", ""summary"": ""Is Eli Lilly stock a buy after rival Novo Nordisk said its diabetes drug showed promise in kidney disease treatment? Is LLY stock a buy?""}, {""date"": ""20231011125500"", ""headline"": ""Biogen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Biogen Inc. inched 0.90% higher to $266.52 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""20231011164012"", ""headline"": ""7 Low-Volatility Stocks to Buy if You\u2019re a Concerned Investor"", ""summary"": ""Immediately following the initial shock of the COVID-19 pandemic, the narrative of low-volatility stocks admittedly didn\u2019t make much sense. With the benefit of hindsight, we can see that the additional influx of cash that retail investors had poured into higher-risk ventures. As a result, the traditional safe stocks fell by the wayside, replaced with a hunger for robust capital gains. Well, that paradigm shifted rather abruptly, hasn\u2019t it? Now, it\u2019s true that certain catalysts \u2013 most notably a h""}, {""date"": ""20231011171223"", ""headline"": ""Morgan Stanley Maintains Biogen (BIIB) Overweight Recommendation"", ""summary"": """"}, {""date"": ""20231012063500"", ""headline"": ""December 1st Options Now Available For Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231012125500"", ""headline"": ""Biogen Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. slid 2.07% to $260.99 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231012221300"", ""headline"": ""Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231013014400"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Bioline RX Ltd Sponsored ADR (BLRX), Biogen (BIIB) and Walgreens Boots Alliance (WBA)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231013070109"", ""headline"": ""The past five years for Biogen (NASDAQ:BIIB) investors has not been profitable"", ""summary"": ""For many, the main point of investing is to generate higher returns than the overall market. But in any portfolio...""}, {""date"": ""20231013080600"", ""headline"": ""U.S. to expand access to PET imaging scans for Alzheimer's disease diagnosis"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231013095505"", ""headline"": ""Wall Street Analysts See a 25.44% Upside in Biogen Inc. (BIIB): Can the Stock Really Move This High?"", ""summary"": ""The mean of analysts' price targets for Biogen Inc. (BIIB) points to a 25.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.""}, {""date"": ""20231013125500"", ""headline"": ""Biogen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Biogen Inc. inched 0.49% higher to $262.26 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...""}, {""date"": ""20231014005500"", ""headline"": ""BIIB Stock Price Analysis: To Bet Or To Fold The Cards"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]","{""assetTurnoverTTM"": 0.39, ""bookValue"": 14484, ""cashRatio"": 0.4555953803265631, ""currentRatio"": 1.6834, ""ebitPerShare"": 1.0967, ""eps"": -0.4703, ""ev"": 41618.027, ""fcfMargin"": 0.1995, ""fcfPerShareTTM"": 7.0766, ""grossMargin"": 0.7393, ""inventoryTurnoverTTM"": 1.1412, ""longtermDebtTotalAsset"": 0.2407, ""longtermDebtTotalCapital"": 0.3117, ""longtermDebtTotalEquity"": 0.4685, ""netDebtToTotalCapital"": 0.2296, ""netDebtToTotalEquity"": 0.3451, ""netMargin"": -0.0269, ""operatingMargin"": 0.0628, ""pb"": 2.5283, ""peTTM"": 25.0513, ""pfcfTTM"": 28.4207, ""pretaxMargin"": -0.0558, ""psTTM"": 3.6645, ""ptbv"": 5.1296, ""quickRatio"": 1.0896, ""receivablesTurnoverTTM"": 4.7655, ""roaTTM"": 0.057, ""roeTTM"": 0.1041, ""roicTTM"": 0.0711, ""rotcTTM"": 0.095, ""salesPerShare"": 17.4744, ""sgaToSale"": 0.2607, ""tangibleBookValue"": 7139, ""totalDebtToEquity"": 0.503, ""totalDebtToTotalAsset"": 0.2584, ""totalDebtToTotalCapital"": 0.3347, ""totalRatio"": 2.0565, ""period"": ""2023-09-30""}"
40,2023-10-15,262.260009765625,2023-10-22,257.45001220703125,-0.018340568060270845,D2,"[{""date"": ""20231016070200"", ""headline"": ""Inquiry Into Biogen's Competitor Dynamics In Biotechnology Industry"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231016125500"", ""headline"": ""Biogen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Biogen Inc. advanced 2.17% to $267.94 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""20231016233500"", ""headline"": ""Quant Ratings Updated on 92 Stocks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231017023200"", ""headline"": ""Gamida Cell rises after Phase 1 data for NK cell therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231017125500"", ""headline"": ""Biogen Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Biogen Inc. shed 0.19% to $267.43 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""20231017175020"", ""headline"": ""Biogen Inc. (BIIB) Falls More Steeply Than Broader Market: What Investors Need to Know"", ""summary"": ""In the closing of the recent trading day, Biogen Inc. (BIIB) stood at $267.43, denoting a -0.19% change from the preceding trading day.""}, {""date"": ""20231017233000"", ""headline"": ""ClearBridge All Cap Value Strategy Q3 2023 Portfolio Manager Commentary"", ""summary"": ""The transition to a higher rate environment has increased risks and concerns over companies accustomed to low-cost capital, but which now lack the profitability to self-fund.""}, {""date"": ""20231018000400"", ""headline"": ""$1000 Invested In Biogen 20 Years Ago Would Be Worth This Much Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231018082300"", ""headline"": ""3 Struggling Stocks Investors Shouldn't Buy on the Dip"", ""summary"": ""These stocks have been brutal investments to own in recent years -- and investors shouldn't expect things to get better.""}, {""date"": ""20231018084903"", ""headline"": ""Incyte: One Of The Most Undervalued Pharmaceuticals"", ""summary"": ""Incyte stock declined nearly 60% from all-time highs in 2017 due to market volatility, regulatory challenges, and increased competition. Read more about INCY here.""}, {""date"": ""20231018112000"", ""headline"": ""5 Biotech Stocks Set to Outpace Q3 Earnings Estimates"", ""summary"": ""Let us look at some biotech stocks, AMGN, BIIB, GSK, PRTA and VRTX, which are poised to beat on third-quarter earnings.""}, {""date"": ""20231018125500"", ""headline"": ""Biogen Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slipped 1.47% to $263.50 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...""}, {""date"": ""20231018145203"", ""headline"": ""Sage Therapeutics: Several Neuropsychiatric Disorder Data Readouts In 2024"", ""summary"": ""Sage Therapeutics, Inc. receives FDA approval for postpartum depression treatment. Ongoing studies for new drugs in pipeline. Click for my full update of SAGE.""}, {""date"": ""20231019024100"", ""headline"": ""Biogen to present new data on Alzheimer's disease portfolio"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231019040300"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Bio-Rad Laboratories (BIO), Biogen (BIIB) and REPRO-MED Systems (KRMD)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231019073000"", ""headline"": ""Biogen to Present New Data at the Clinical Trials on Alzheimer\u2019s Disease (CTAD) 2023 Meeting"", ""summary"": ""Late-breaking Phase 1b data assesses the clinical outcomes of reducing tau in patients with early-stage Alzheimer\u2019s diseaseAdditional late-breaking presentations from the CLARITY AD study explore predictive biomarkers and novel subcutaneous administration of LEQEMBI\u00ae (lecanemab-irmb) CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from its Alzheimer\u2019s disease portfolio at the upcoming Clinical Trials on Alzheimer\u2019s Disease (CTAD) meeting takin""}, {""date"": ""20231019125500"", ""headline"": ""Biogen Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slipped 2.35% to $257.30 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...""}, {""date"": ""20231020055200"", ""headline"": ""Interesting BIIB Put And Call Options For December 15th"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231020125500"", ""headline"": ""Biogen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Biogen Inc. inched 0.06% higher to $257.45 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...""}]",{}
41,2023-10-22,257.45001220703125,2023-10-29,234.52000427246094,-0.08906586462357946,D5+,"[{""date"": ""20231023083800"", ""headline"": ""10 Health Care Stocks With Whale Alerts In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231023100020"", ""headline"": ""Biogen Inc.'s (NASDAQ:BIIB) Intrinsic Value Is Potentially 97% Above Its Share Price"", ""summary"": ""Key Insights The projected fair value for Biogen is US$508 based on 2 Stage Free Cash Flow to Equity Biogen is...""}, {""date"": ""20231023125500"", ""headline"": ""Biogen Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. slipped 1.58% to $253.39 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231023152501"", ""headline"": ""Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug"", ""summary"": ""Swiss pharmaceutical company Roche has settled a patent lawsuit against U.S. biotech firm Biogen over its biosimilar version of Roche's blockbuster rheumatoid arthritis drug Actemra, according to a filing on Monday in Massachusetts federal court.  Roche and its subsidiaries Genentech and Chugai Pharmaceutical jointly told the court without providing further details that they, Biogen and its manufacturer Bio-Thera had agreed to settle the case.""}, {""date"": ""20231023175019"", ""headline"": ""Here's Why Biogen Inc. (BIIB) Fell More Than Broader Market"", ""summary"": ""The latest trading day saw Biogen Inc. (BIIB) settling at $253.39, representing a -1.58% change from its previous close.""}, {""date"": ""20231024074500"", ""headline"": ""An Oversold Small Cap Industrial That Insiders Are Buying Ahead Of Earnings This Week"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231024093000"", ""headline"": ""LEQEMBI\u00ae (lecanemab-irmb) NAMED ONE OF TIME's BEST INVENTIONS OF 2023"", ""summary"": ""Eisai Inc. and Biogen Inc. are honored to announce today that TIME has selected LEQEMBI\u00ae (lecanemab-irmb) as one of the Best Inventions of 2023 in the Medical Care category.""}, {""date"": ""20231024125500"", ""headline"": ""Biogen Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. slipped 0.51% to $252.11 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231024210200"", ""headline"": ""Cassava Sciences gains after safety data for Alzheimer\u2019s candidate"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231024235700"", ""headline"": ""Positive Outlook for Biogen\u2019s Leqembi subQ: An Analysis of Its Potential and Investment Opportunity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231025005700"", ""headline"": ""Biogen says new Leqembi formulation better than IV version"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231025055400"", ""headline"": ""Biogen says Phase 1b data on BIIB080 in Alzheimer's showed 'favorable trends'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231025070600"", ""headline"": ""Biogen updates Phase 1 data for Ionis-partnered Alzheimer\u2019s drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231025072700"", ""headline"": ""Biogen Says New Data Shows Promise For Potential New Generation Of Treatments In Early Alzheimer's Disease"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231025105100"", ""headline"": ""New Data from Biogen\u2019s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer\u2019s Disease"", ""summary"": ""In the Phase 1b study, favorable trends were reported for the high-dose groups on multiple measures of cognition and function.First study of a tau targeting drug that shows reduction of aggregated tau pathology and favorable trends on clinical outcomes.Recruitment is underway for the Phase 2 CELIA study further investigating clinical efficacy and safety. CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) reported new Phase 1b clinical data from the study of BIIB080, a""}, {""date"": ""20231025125500"", ""headline"": ""Biogen Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Biogen Inc. shed 2.14% to $246.72 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231025132500"", ""headline"": ""EISAI PRESENTS NEW LEQEMBI\u00ae (LECANEMAB-IRMB) INVESTIGATIONAL SUBCUTANEOUS FORMULATION INTERIM STUDY RESULTS AND CLINICAL IMPROVEMENT DATA IN EARLIER STAGES OF EARLY ALZHEIMER'S DISEASE FROM ADDITIONAL ANALYSES OF CLARITY AD AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE (CTAD) CONFERENCE"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231025132800"", ""headline"": ""Biogen and Eisai release new Alzheimer\u2019s drug data that may support wider uptake"", ""summary"": ""Eisai plans to apply for FDA approval of subcutaneous Leqembi by early next year.""}, {""date"": ""20231025172500"", ""headline"": ""Injected version of Eisai/Biogen Alzheimer's drug effective, side effects higher"", ""summary"": ""An injected version of Eisai and Biogen's Alzheimer's drug Leqembi works as well as the current intravenous administration at removing toxic brain plaques, but rates of serious side effects were higher, according to an analysis presented by Eisai on Wednesday.  The Japanese drugmaker's review compared data for 72 patients with early Alzheimer's given Leqembi by subcutaneous injection to prior pivotal trial results from 898 patients who received the drug by infusion.""}, {""date"": ""20231025172600"", ""headline"": ""Eisai Presents New LEQEMBI\u00ae (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer\u2019s Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzheimer\u2019s Disease (CTAD) Conference"", ""summary"": ""Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Patients Showed No Decline And 60% Showed Clinical Improvement At 18 Months in Low-Tau Subpopulation in Additional Analysis of Clarity AD Dual-Acting LEQEMBI Supports Brain Neuron Function by Removing Highly Toxic Proteins (Protofibrils) That Can Continue to Cause Neuronal Injury and Death Even After Plaque Removal, Offering Early AD Patients the Opportu""}, {""date"": ""20231026004000"", ""headline"": ""Hold Rating on Biogen Amid Uncertainties in Alzheimer\u2019s Treatment Market \u2013 An Analysis of Lecanemab\u2019s Clinical Prospects"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026014200"", ""headline"": ""Hold Rating on Biogen\u2019s Leqembi: SubQ Formulation Shows Promising Results but Further Evaluation Needed"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026014900"", ""headline"": ""Promising Alzheimer\u2019s Drug Drives Morgan Stanley\u2019s Buy Rating for Biogen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026020600"", ""headline"": ""Hold Rating for Biogen: Evaluating the Potential and Challenges of SC Lecanemab and BIIB80"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026025000"", ""headline"": ""Biogen\u2019s Stock Promising Future: Efficacy, Competitive Edge, and Convenience Bolster Buy Rating"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026032600"", ""headline"": ""Needham Reaffirms Their Buy Rating on Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026033000"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Biogen (BIIB) and Universal Health (UHS)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026040400"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Alimera (ALIM) and Align Tech (ALGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026042200"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Community Health (CYH), Biogen (BIIB) and Roche Holding AG (OtherRHHVF)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026064200"", ""headline"": ""December 8th Options Now Available For Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026085300"", ""headline"": ""Prothena, BioVie among decliners after Biogen data for new Alzheimer\u2019s therapy"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026103500"", ""headline"": ""Biogen and Eisai\u2019s Revised Alzheimer\u2019s Drug Works, but Safety Questions Linger"", ""summary"": ""Wall Street analysts say Biogen and Eisai could secure Food and Drug Administration approval for their injected Alzheimer\u2019s drug.""}, {""date"": ""20231026125600"", ""headline"": ""Biogen Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. slid 2.29% to $241.08 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231026160932"", ""headline"": ""Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment"", ""summary"": ""Biogen stock tumbled Thursday \u2014 pulling Prothena stock down \u2014 on mixed test results for an updated version of its Alzheimer's treatment.""}, {""date"": ""20231026220000"", ""headline"": ""Buy Rating for Biogen Upheld Based on Positive Leqembi Subcutaneous Formulation Results & Potential Commercial Opportunities"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026224200"", ""headline"": ""Promising Developments Boost Biogen\u2019s Prospects: An In-depth Analysis of Leqembi\u2019s Position in Alzheimer\u2019s Treatment Market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231026225603"", ""headline"": ""Needham Reiterates Biogen (BIIB) Buy Recommendation"", ""summary"": """"}, {""date"": ""20231026225603"", ""headline"": ""Wedbush Maintains Biogen (BIIB) Neutral Recommendation"", ""summary"": """"}, {""date"": ""20231026225900"", ""headline"": ""Promising Leqembi Data and Undervalued Stock: A Case for Buying Biogen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231027022900"", ""headline"": ""Positive Outlook on Biogen\u2019s Stock: Leqembi\u2019s Promising Data and Strategic Management Decisions Fuel Buy Rating"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231027070115"", ""headline"": ""Should Weakness in Biogen Inc.'s (NASDAQ:BIIB) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?"", ""summary"": ""With its stock down 9.1% over the past three months, it is easy to disregard Biogen (NASDAQ:BIIB). However, the...""}, {""date"": ""20231027083054"", ""headline"": ""Alzheimer's drug Leqembi: The twice-monthly infusion could be available in injection form"", ""summary"": ""An Alzheimer's drug in injectable form could be the key for Biogen, Eisai to ease pressures and concerns of a limited market and revenue.""}, {""date"": ""20231027124542"", ""headline"": ""Eli Lilly Gives Back Its Recent Weight-Loss Gains \u2014 Is Lilly Stock A Buy?"", ""summary"": ""Novo Nordisk said its GLP-1 drug showed promise in kidney disease treatment. But Lilly stock has since fallen.""}, {""date"": ""20231027125600"", ""headline"": ""Biogen Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Biogen Inc. shed 2.72% to $234.52 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231029070500"", ""headline"": ""Pharma, PBMs spar over rising drug costs amid public scrutiny"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
42,2023-10-29,234.52000427246094,2023-11-05,249.5,0.06387512985943666,U5+,"[{""date"": ""20231029070500"", ""headline"": ""Pharma, PBMs spar over rising drug costs amid public scrutiny"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231030005100"", ""headline"": ""Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231030070200"", ""headline"": ""Assessing Biogen's Performance Against Competitors In Biotechnology Industry"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231030125700"", ""headline"": ""Biogen Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. rallied 1.15% to $237.21 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""20231030174520"", ""headline"": ""Biogen Inc. (BIIB) Rises But Trails Market: What Investors Should Know"", ""summary"": ""The latest trading day saw Biogen Inc. (BIIB) settling at $237.30, representing a +1.19% change from its previous close.""}, {""date"": ""20231030235800"", ""headline"": ""Biogen Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231031213400"", ""headline"": ""Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231101014100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Biogen (BIIB) and Vertex Pharmaceuticals (VRTX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231101100119"", ""headline"": ""Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release"", ""summary"": ""Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.""}, {""date"": ""20231101125600"", ""headline"": ""Biogen Inc. stock rises Wednesday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.88% higher to $239.62 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""20231101220000"", ""headline"": ""This New Pain Pill Could Replace Opioids. It\u2019s an Opportunity for Investors."", ""summary"": ""The new Vertex drug is in trials now. Investors might want to make their bets soon.""}, {""date"": ""20231102023800"", ""headline"": ""Prothena price target lowered to $43 from $60 at RBC Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231102125700"", ""headline"": ""Biogen Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.93% higher to $241.86 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""20231102220500"", ""headline"": ""Catalyst Watch: Disney earnings, Moderna AI event, Powell IMF speech and Las Vegas strike threat"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231103050951"", ""headline"": ""Q3 2023 Ionis Pharmaceuticals Inc Earnings Call"", ""summary"": ""Q3 2023 Ionis Pharmaceuticals Inc Earnings Call""}, {""date"": ""20231103094400"", ""headline"": ""Ionis (IONS) Q3 Loss Wider Than Expected, Sales Beat Estimates"", ""summary"": ""Ionis (IONS) incurs a wider-than-expected third-quarter loss. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.""}, {""date"": ""20231103125700"", ""headline"": ""Biogen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Biogen Inc. advanced 3.16% to $249.50 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""20231105055000"", ""headline"": ""Earnings week ahead: Disney, AMC, Plug Power, Lucid, Realty Income and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
43,2023-11-05,249.5,2023-11-12,224.7899932861328,-0.09903810306159189,D5+,"[{""date"": ""20231105055000"", ""headline"": ""Earnings week ahead: Disney, AMC, Plug Power, Lucid, Realty Income and more"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231106005600"", ""headline"": ""3 Biotech Moonshots to Bet on the Future of Health"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231106015000"", ""headline"": ""Biogen appoints Patolawala to board of directors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231106023400"", ""headline"": ""NeuroSense completes dosing in Phase 2b ALS clinical trial of PrimeC"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231106071900"", ""headline"": ""Potential Growth for Biogen: Exploring Upside Opportunities and Anticipating Skyclarys Success"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231106073000"", ""headline"": ""Biogen Appoints Monish Patolawala to its Board of Directors"", ""summary"": ""Accomplished executive brings deep expertise leading global financial organizations and overseeing successful business transformationCAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Monish Patolawala, currently President and Chief Financial Officer of 3M Company (\u201c3M\u201d), to the Company\u2019s Board of Directors (the \u201cBoard\u201d), effective January 1, 2024. As an accomplished financial executive, Mr. Patolawala is qualified as an Audit Commit""}, {""date"": ""20231106082600"", ""headline"": ""Biogen (BIIB) to Report Q3 Earnings: Will It Beat Estimates?"", ""summary"": ""Biogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have improved.""}, {""date"": ""20231106115700"", ""headline"": ""Biogen Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. slumped 0.35% to $248.63 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""20231106120200"", ""headline"": ""Countdown to Biogen Inc. (BIIB) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS"", ""summary"": ""Evaluate the expected performance of Biogen Inc. (BIIB) for the quarter ended September 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.""}, {""date"": ""20231107010000"", ""headline"": ""Eisai sees a sharp rise in patients on Biogen-partnered Alzheimer\u2019s drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231107023500"", ""headline"": ""Sage Therapeutics falls after stock offering, Q3 miss"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231107054500"", ""headline"": ""Biogen Q3 2023 Earnings Preview"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231107063000"", ""headline"": ""Biogen, Sage set price of postpartum depression pill at $15,900"", ""summary"": ""The price is below what some analysts had predicted and significantly less then $34,000 Sage initially set for its earlier postpartum infusion, Zulresso.""}, {""date"": ""20231107074200"", ""headline"": ""Notable companies reporting before tomorrow's open"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231107083200"", ""headline"": ""Why Biogen (BIIB) Might Surprise This Earnings Season"", ""summary"": ""Biogen (BIIB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.""}, {""date"": ""20231107084412"", ""headline"": ""Biogen-Sage Therapeutics postpartum depression pill priced at $15,900"", ""summary"": ""Biogen and Sage Therapeutics' oral pill to treat postpartum depression (PPD) in adults is expected to cost U.S. wholesalers $15,900 for a full 14-day treatment, Sage Therapeutics said on Tuesday.  The companies had sought U.S. approval for Zurzuvae to treat major depressive disorder (MDD), or clinical depression, and postpartum depression, but the Food and Drug Administration in August approved it only for PPD.  Jefferies had estimated peak sales of more than $1 billion for the drug if it was approved to treat clinical depression, and $250 million to $500 million for postpartum depression.""}, {""date"": ""20231107090011"", ""headline"": ""Positive week for Biogen Inc. (NASDAQ:BIIB) institutional investors who lost 13% over the past year"", ""summary"": ""Key Insights Institutions' substantial holdings in Biogen implies that they have significant influence over the...""}, {""date"": ""20231107115700"", ""headline"": ""Biogen Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slid 1.21% to $245.61 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""20231107124054"", ""headline"": ""UPDATE 1-Biogen-Sage Therapeutics postpartum depression pill priced at $15,900"", ""summary"": ""Sage Therapeutics has priced the oral postpartum depression (PPD) pill it developed with partner Biogen at $15,900 for a full 14-day course of treatment, the company said on Tuesday, months after the drug was approved by the U.S. health regulator.  The companies had sought U.S. approval for Zurzuvae to treat clinical depression, a much larger market, and postpartum depression, but the Food and Drug Administration in August approved it only for PPD.  Zurzuvae is the first oral pill for the condition that affects one in seven mothers after childbirth.""}, {""date"": ""20231107174100"", ""headline"": ""Biogen Reports Earnings Wednesday. Here\u2019s What to Expect."", ""summary"": ""Wall Street will likely be more interested in updates on future developments, rather than the latest quarter's numbers.""}, {""date"": ""20231107192300"", ""headline"": ""GLOBAL BRIEFING: Rivian raises guidance; eBay's outlook disappoints"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231107231300"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Bluebird Bio (BLUE), Biogen (BIIB) and Johnson & Johnson (JNJ)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108010300"", ""headline"": ""Biogen reports Q3 EPS $4.36, consensus $3.99"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108010600"", ""headline"": ""Biogen lowers FY23 adjusted EPS view to $14.50-$15.00, consensus $15.29"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108010900"", ""headline"": ""Biogen Non-GAAP EPS of $4.36 beats by $0.37, revenue of $2.53B beats by $130M"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108011300"", ""headline"": ""Biogen quarterly results top estimates despite complex launch of new Alzheimer\u2019s treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108011700"", ""headline"": ""US Stocks Set To Open Flat After Hot 7-Day Rally: Traders Sharpen Focus On Powell's Speech, Disney Earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108014400"", ""headline"": ""Biogen swings to Q3 growth after Reata acquisition"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108021000"", ""headline"": ""Biogen quarterly results top estimates despite complex launch of new Alzheimer's treatment"", ""summary"": ""Company focuses on new products in Alzheimer's, postpartum depression as multiple sclerosis product revenues decline""}, {""date"": ""20231108030500"", ""headline"": ""Biogen downgrades guidance as Reata expenses hit quarterly earnings"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108031316"", ""headline"": ""Biogen Inc. 2023 Q3 - Results - Earnings Call Presentation"", ""summary"": ""The following slide deck was published by Biogen Inc.""}, {""date"": ""20231108035200"", ""headline"": ""Hold Rating for Biogen: Revenue Decrease, Patent Expiry, and Delayed FDA Application Add Complexity to Financial Outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108035400"", ""headline"": ""Hold Rating on Biogen: Balancing Prospects of Leqembi and Skyclarys Against Slow Alzheimer\u2019s Market Build and Limited Growth Drivers"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108040100"", ""headline"": ""Compared To Estimates, Biogen Inc. Q3 Earnings: A Look At Key Metrics"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108040800"", ""headline"": ""Biogen price target lowered to $255 from $294 at Barclays"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108041000"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108042000"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Immatics (IMTX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108063000"", ""headline"": ""Biogen says growth is coming, but won\u2019t specify when"", ""summary"": ""CEO Chris Viehbacher said the company has \u201cthe elements to think about a return to topline growth.\u201d Yet, that goal hinges on the successful commercialization of multiple new products.""}, {""date"": ""20231108063900"", ""headline"": ""10 Health Care Stocks Whale Activity In Today's Session"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108070018"", ""headline"": ""Biogen Tops Earnings Forecasts, But Cuts Profit Outlook As Leqembi Expenses Mount"", ""summary"": ""Biogen reported better-than-expected sales and earnings on Wednesday, but Biogen stock could slide on the earnings guidance haircut.""}, {""date"": ""20231108070304"", ""headline"": ""Biogen cuts profit view on higher M&A costs, Alzheimer's drug expense"", ""summary"": ""To drive future growth, the drugmaker is leaning on newer products including Leqembi, postpartum depression drug Zurzuvae and the rare disease treatments acquired through its $6.5  billion buyout of Reata.  \""We now have the elements to grow sustainably so our focus is no longer on doing anything of significance in M&A at least for the time being,\"" CEO Christopher Viehbacher said on a media call.  Viehbacker said Biogen plans to \""branch out\"" more into immunology and rare disease treatments by investing in research as well as through collaborations.""}, {""date"": ""20231108070900"", ""headline"": ""Biogen swings to Q3 growth after Reata acquisition (update)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108072900"", ""headline"": ""US Stocks Set To Snap Winning Streak, Treasuries Rally, Oil Tumbles: What's Driving Markets Wednesday?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108075900"", ""headline"": ""Biogen\u2019s Earnings Top Estimates. Wall Street Still Has Questions About Growth."", ""summary"": ""Wall Street is interested in updates on future developments, rather than the latest quarter's numbers.""}, {""date"": ""20231108080303"", ""headline"": ""Biogen Inc. (BIIB) Q3 2023 Earnings Call Transcript"", ""summary"": ""Biogen Inc. (NASDAQ:NASDAQ:BIIB) Q3 2023 Results Earnings Conference Call November 8, 2023 8:00 AM ETCompany ParticipantsChuck Triano - Head of Investor...""}, {""date"": ""20231108084006"", ""headline"": ""Biogen Expects Sales of Alzheimer\u2019s Drug Leqembi to Start Growing Next Year"", ""summary"": ""Biogen expects sales of the Alzheimer's drug Leqembi to start ramping up in the first quarter of next year.  The company\u2019s partner Eisai reported $2 million in third quarter sales of Leqembi.  \u201cThis was always going to be a gradual launch,\u201d said Biogen CEO Chris Viehbacher on a conference call with analysts Wednesday.""}, {""date"": ""20231108093026"", ""headline"": ""Compared to Estimates, Biogen Inc. (BIIB) Q3 Earnings: A Look at Key Metrics"", ""summary"": ""Although the revenue and EPS for Biogen Inc. (BIIB) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.""}, {""date"": ""20231108103100"", ""headline"": ""Biogen (BIIB) Beats on Q3 Earnings & Sales, Cuts EPS View"", ""summary"": ""Biogen (BIIB) beats third-quarter estimates for earnings and sales. It lowers its 2023 EPS guidance range to include the impact of dilution from the Reata acquisition. Stock rises in pre-market.""}, {""date"": ""20231108104200"", ""headline"": ""Pre-Markets Keep Streak Alive; RL, BIIB Beat"", ""summary"": ""The Dow rides its longest winning streak since July of this year, while the S&P and Nasdaq are enjoying their strongest moves since 2021.""}, {""date"": ""20231108110341"", ""headline"": ""Biogen's Uncertain Strategic Pivots Amidst MS Market Challenges"", ""summary"": ""Biogen faces MS market challenges, shifts focus to rare diseases/Alzheimer\u00e2\u0080\u0099s drugs like Skyclarys and Leqembi. Read my earnings analysis of BIIB stock here.""}, {""date"": ""20231108115700"", ""headline"": ""Biogen Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slipped 5.67% to $231.69 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...""}, {""date"": ""20231108141520"", ""headline"": ""Biogen (BIIB) Q3 2023 Earnings Call Transcript"", ""summary"": ""Image source: The Motley Fool.  Biogen (NASDAQ: BIIB)Q3 2023 Earnings CallNov 08, 2023, 8:00 a.m. ETContents:  Prepared Remarks Questions and Answers Call Participants  Prepared Remarks:  OperatorGood morning.""}, {""date"": ""20231108150615"", ""headline"": ""Biogen Inc (BIIB) Reports Mixed Q3 2023 Results and Revises Full-Year Guidance"", ""summary"": ""Challenges Persist as Biogen Navigates Market Dynamics and Strategic Acquisitions""}, {""date"": ""20231108160418"", ""headline"": ""Biogen Skids On 'Low-Quality' Beat, Cuts Profit Guidance Following Reata Buyout"", ""summary"": ""Biogen stock skidded Wednesday on a \""low-quality\"" sales beat that relied on other revenue. But analysts noted Skyclarys' strong launch.""}, {""date"": ""20231108200700"", ""headline"": ""Buy Recommendation for Biogen Amid Satisfactory 3Q23 Results and Strategic Accounting Adjustments"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108201000"", ""headline"": ""Analysts Have Conflicting Sentiments on These Healthcare Companies: Adicet Bio (ACET), Biogen (BIIB) and Ikena Oncology (IKNA)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108220400"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Acrivon Therapeutics, Inc. (ACRV)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108231244"", ""headline"": ""Q3 2023 Biogen Inc Earnings Call"", ""summary"": ""Q3 2023 Biogen Inc Earnings Call""}, {""date"": ""20231108231400"", ""headline"": ""Thoughts For Thursday: Staying On Top - Barely"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231108233000"", ""headline"": ""Biogen price target lowered to $290 from $300 at JPMorgan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231109001200"", ""headline"": ""Biogen price target raised to $365 from $343 at Wells Fargo"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231109002200"", ""headline"": ""Best Stocks to Buy Now, 11/9/2023, According to Top Analysts"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231109003100"", ""headline"": ""Analyst Projects Robust Sales Growth for Biogen Amid Rising Leqembi Demand and Upcoming Market Expansions"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231109004200"", ""headline"": ""Fein\u2019s Buy Rating on Biogen: Leqembi\u2019s Potential Growth and Market Penetration"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231109012200"", ""headline"": ""Biogen price target lowered to $310 from $350 at Canaccord"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231109012800"", ""headline"": ""Biogen price target raised to $363 from $351 at RBC Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231109013700"", ""headline"": ""Biogen price target lowered to $295 from $314 at BMO Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231109023700"", ""headline"": ""Analysts\u2019 Top Healthcare Picks: Biogen (BIIB), Stryker (SYK)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231109034940"", ""headline"": ""Top 20 Drug Companies in the US by Revenue"", ""summary"": ""In this article, we will be taking a look at the top 20 drug companies in the US by revenue. To skip our detailed analysis, you can go directly to see the Top 5 Drug Companies in the US by Revenue. Following the Covid-19 pandemic, which drastically altered the way of living, the top pharmaceutical [\u2026]""}, {""date"": ""20231109060400"", ""headline"": ""Expert Ratings for Biogen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231109075300"", ""headline"": ""These Analysts Revise Their Forecasts On Biogen After Q3 Results"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231109115900"", ""headline"": ""Biogen Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. slid 3.04% to $224.65 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231109162703"", ""headline"": ""Biogen Inc. (NASDAQ:BIIB) Q3 2023 Earnings Call Transcript"", ""summary"": ""Biogen Inc. (NASDAQ:BIIB) Q3 2023 Earnings Call Transcript November 8, 2023 Biogen Inc. beats earnings expectations. Reported EPS is $4.36, expectations were $3.97. Operator: Good morning. My name is Ally and I\u2019ll be your conference operator today. At this time, I\u2019d like to welcome everyone to the Biogen Third Quarter 2023 Earnings Call and Business [\u2026]""}, {""date"": ""20231110001600"", ""headline"": ""Strong Financial Performance and Cost Savings Potential: A Buy Rating for Biogen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231110021600"", ""headline"": ""Barclays Reaffirms Their Hold Rating on Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231110022300"", ""headline"": ""GLOBAL BROKER RATINGS: UBS cuts Worldline to 'sell'"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231110065000"", ""headline"": ""The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?"", ""summary"": ""It's a no-brainer to invest in businesses that are making headway in the growth markets of the future.  In biopharma, therapies to treat or prevent Alzheimer's disease constitute one such growth market.  Let's survey the competitive landscape as it is today, and think through how it's likely to develop.""}, {""date"": ""20231110110535"", ""headline"": ""U.S. Wide-Moat Stocks On Sale - The November 2023 Heat Map"", ""summary"": ""Discover our 3-step process for identifying attractive, undervalued stocks with wide economic moats - Morningstar approved. Click here to read more.""}, {""date"": ""20231110115900"", ""headline"": ""Biogen Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.06% higher to $224.79 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""20231111060026"", ""headline"": ""Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly"", ""summary"": ""Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...""}, {""date"": ""20231112031100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), Biogen (BIIB) and Becton Dickinson (BDX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
44,2023-11-12,224.7899932861328,2023-11-19,228.0,0.014280024955475756,U2,"[{""date"": ""20220720083705"", ""headline"": ""Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks"", ""summary"": ""Build and maintain your watch list with the latest news and analysis of the market's top-rated growth stocks.""}, {""date"": ""20231112031100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO), Biogen (BIIB) and Becton Dickinson (BDX)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231112230400"", ""headline"": ""PRIMECAP Management Adjusts Portfolio, Notably Trims Eli Lilly Stake"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231112234700"", ""headline"": ""Ionis says Angelman syndrome drug well tolerated in study"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231113120000"", ""headline"": ""Biogen Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slipped 0.98% to $222.59 Monday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""20231113184122"", ""headline"": ""Anavex Alzheimer's And Parkinson's Drug Underappreciated By Investors"", ""summary"": ""Anavex's Alzheimer's drug Blarcamesine demonstrates strong statistical significance in improving cognition among dementia patients. Read why AVXL stock is a Buy.""}, {""date"": ""20231114040400"", ""headline"": ""Mark Hillman Bolsters Portfolio with Baxter International Inc, Impacting 3.19%"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231114115900"", ""headline"": ""Biogen Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. rallied 1.20% to $225.26 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""20231115111610"", ""headline"": ""Biogen : to Participate in the 6th Annual Evercore ISI HealthCONx Conference"", ""summary"": ""Cambridge, MA, - - Biogen.com announced today that Priya Sighal, M.D., M.P.H., Head of Development, will participate in the 6th Annual Evercore ISI HealthCONx Conference. The webcast...""}, {""date"": ""20231115115900"", ""headline"": ""Biogen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Biogen Inc. advanced 1.94% to $229.63 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""20231115210500"", ""headline"": ""Here's How Much $1000 Invested In Biogen 20 Years Ago Would Be Worth Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231116025100"", ""headline"": ""Analysts\u2019 Opinions Are Mixed on These Healthcare Stocks: Cigna (CI), Agilon Health (AGL) and Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231116115900"", ""headline"": ""Biogen Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. slumped 0.07% to $229.46 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...""}, {""date"": ""20231117050900"", ""headline"": ""Interesting BIIB Put And Call Options For July 2024"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231117081510"", ""headline"": ""Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning"", ""summary"": ""Biogen and Eisai scored key victories in the quest for an Alzheimer's cure. But the race is just getting started.""}, {""date"": ""20231117090019"", ""headline"": ""The past five years for Biogen (NASDAQ:BIIB) investors has not been profitable"", ""summary"": ""For many, the main point of investing is to generate higher returns than the overall market. But every investor is...""}, {""date"": ""20231117115900"", ""headline"": ""Biogen Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slumped 0.64% to $228.00 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""20231119060200"", ""headline"": ""M&A, GLP-1s to dominate healthcare themes in 2024 as COVID fades: survey"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
45,2023-11-19,228.0,2023-11-26,231.9499969482422,0.017324548018606167,U2,"[{""date"": ""20231119060200"", ""headline"": ""M&A, GLP-1s to dominate healthcare themes in 2024 as COVID fades: survey"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231119222900"", ""headline"": ""Biogen Inc (BIIB) 2022 CEO Christopher A. ..."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231120120000"", ""headline"": ""Biogen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Biogen Inc. inched 0.93% higher to $230.11 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...""}, {""date"": ""20231121015100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Agilent (A), Henry Schein (HSIC) and Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231121115900"", ""headline"": ""Biogen Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. shed 0.23% to $229.57 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231122033100"", ""headline"": ""Analysts Are Bullish on These Healthcare Stocks: IQVIA Holdings (IQV), Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231122115900"", ""headline"": ""Biogen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Biogen Inc. inched 0.73% higher to $231.25 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""20231123230000"", ""headline"": ""Biogen Inc. stock rises Friday, outperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
46,2023-11-26,231.9499969482422,2023-12-03,234.63999938964844,0.011597337688288523,U2,"[{""date"": ""20231127115900"", ""headline"": ""Biogen Inc. stock falls Monday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slid 1.36% to $228.79 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231128022100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Exact Sciences (EXAS) and Regeneron (REGN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231128050300"", ""headline"": ""Comparative Study: Biogen And Industry Competitors In Biotechnology Industry"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231128071206"", ""headline"": ""Biogen Inc. (BIIB) Evercore ISI 6th Annual HealthCONx Conference (Transcript)"", ""summary"": ""Biogen Inc. (NASDAQ:NASDAQ:BIIB) Evercore ISI 6th Annual HealthCONx Conference November 28, 2023 9:10 AM ETCompany ParticipantsPriya Singhal - Head of...""}, {""date"": ""20231128115900"", ""headline"": ""Biogen Inc. stock underperforms Tuesday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. slipped 0.60% to $227.41 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""20231129002800"", ""headline"": ""RBC starts Lexeo at outperform, cites Friedreich's ataxia drug opportunity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231129100001"", ""headline"": ""Biogen: LAQEMBI's $10 Billion Potential"", ""summary"": ""Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval. Click here to read why we still rate the BIIB stock as a 'Strong Buy'.""}, {""date"": ""20231129120000"", ""headline"": ""Biogen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Biogen Inc. rose 2.04% to $232.06 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""20231130075400"", ""headline"": ""Noteworthy Thursday Option Activity: BIIB, ADM, TMUS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231130090049"", ""headline"": ""Are Biogen Inc.'s (NASDAQ:BIIB) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?"", ""summary"": ""With its stock down 13% over the past three months, it is easy to disregard Biogen (NASDAQ:BIIB). It is possible that...""}, {""date"": ""20231130115900"", ""headline"": ""Biogen Inc. stock underperforms Thursday when compared to competitors despite daily gains"", ""summary"": ""Shares of Biogen Inc. inched 0.87% higher to $234.08 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the...""}, {""date"": ""20231201020300"", ""headline"": ""Analysts\u2019 Opinions Are Mixed on These Healthcare Stocks: Cybin (CYBN), Nevro Corp (NVRO) and Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231201111200"", ""headline"": ""Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why"", ""summary"": ""Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.""}, {""date"": ""20231201115900"", ""headline"": ""Biogen Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.24% higher to $234.64 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""20231203060400"", ""headline"": ""Biotechs post record gains in November amid improving outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
47,2023-12-03,234.63999938964844,2023-12-10,239.2899932861328,0.019817566947579524,U2,"[{""date"": ""20231203060400"", ""headline"": ""Biotechs post record gains in November amid improving outlook"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231204120000"", ""headline"": ""Biogen Inc. stock underperforms Monday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. slumped 0.76% to $232.85 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231204225810"", ""headline"": ""Alzheimer's Disease Drug Development: Another Lost Year"", ""summary"": ""Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Click here for a detailed review.""}, {""date"": ""20231205030500"", ""headline"": ""NeuroSense ALS candidate meets key study goals"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231205110137"", ""headline"": ""Billionaire Louis Bacon\u2019s 10 Stock Picks with Huge Upside Potential"", ""summary"": ""In this article, we discuss billionaire Louis Bacon\u2019s 10 stock picks with huge upside potential. To skip the details about Mr. Bacon\u2019s life, portfolio performance, and investment strategy, go directly to Billionaire Louis Bacon\u2019s 5 Stock Picks with Huge Upside Potential. Louis Bacon is a macro-trading legend on Wall Street. Macro traders capitalize on financial [\u2026]""}, {""date"": ""20231205115900"", ""headline"": ""Biogen Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slid 1.41% to $229.57 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231205225500"", ""headline"": ""Biogen management to meet with Oppenheimer"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231205231200"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL), Mayne Pharma Group (OtherMAYNF) and Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231206002400"", ""headline"": ""Biogen price target lowered to $315 from $365 at Wells Fargo"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231206081608"", ""headline"": ""U.S. Wide-Moat Stocks On Sale - The December 2023 Heat Map"", ""summary"": ""We share the heat map of the most investable candidates that may be worth your time for further analysis. Explore more details here.""}, {""date"": ""20231206211100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Crispr Therapeutics AG (CRSP) and Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231206211500"", ""headline"": ""Biogen named a best idea for 2024 at Cowen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231206223000"", ""headline"": ""What You Missed On Wall Street On Thursday"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231206233200"", ""headline"": ""Biogen upgraded to Outperform from Market Perform at Raymond James"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231206234800"", ""headline"": ""Biogen\u2019s Turnaround: Projecting Growth and Outperformance with New Therapies"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231207001714"", ""headline"": ""UNH, HUM, BIIB: 3 Healthcare Stocks to Buy, Say Analysts"", ""summary"": ""As the market rally enters a more advanced stage, many investors may be at risk of assuming we\u2019ll be in for an economic \u201csoft landing\u201d just because of the latest cooler-than-expected inflation report and the prospect of 2024 rate cuts. In many ways, 2024 could be a good year, but investors ought to always be prepared for a broader range of scenarios (including a hard landing) with more defensively-focused firms like healthcare stocks (UNH, BIIB, and HUM will be covered in this piece). Therefore,""}, {""date"": ""20231207005400"", ""headline"": ""Raymond James upgrades Biogen to Outperform on attractive 2024 setup"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231207020500"", ""headline"": ""The Latest Analyst Ratings for Biogen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231207055800"", ""headline"": ""What You Missed On Wall Street This Morning"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231207062100"", ""headline"": ""Why This Biogen Analyst Is Turning Bullish On Alzheimer's Treatment Prospects"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231207073200"", ""headline"": ""S&P 500's Hidden Gems: 27 Stocks With 30%+ Upside Potential According To Wall Street Analysts Targets"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231207094935"", ""headline"": ""Biogen upgraded, Take-Two downgraded: Wall Street's top analyst calls"", ""summary"": ""Biogen upgraded, Take-Two downgraded: Wall Street's top analyst calls""}, {""date"": ""20231207115900"", ""headline"": ""Biogen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Biogen Inc. advanced 2.24% to $239.12 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""20231207205200"", ""headline"": ""Buy/Sell: Wall Street's top 10 stock calls this week"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231208000616"", ""headline"": ""Raymond James Upgrades Biogen (BIIB)"", ""summary"": """"}, {""date"": ""20231208014100"", ""headline"": ""Wall Street Analysts Are Bullish on Top Healthcare Picks"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231208113042"", ""headline"": ""Why Is Biogen Inc. (BIIB) Up 6.4% Since Last Earnings Report?"", ""summary"": ""Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.""}, {""date"": ""20231208115900"", ""headline"": ""Biogen Inc. stock rises Friday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.07% higher to $239.29 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""20231209135200"", ""headline"": ""2 Popular Stocks to Avoid Like the Plague in 2024 and Beyond"", ""summary"": ""Take, for instance, Aurora Cannabis (NASDAQ: ACB), a leader in the Canadian pot market, and Biogen (NASDAQ: BIIB), a notable biotech.  Aurora Cannabis has consistently been one of the most talked-about stocks in the Canadian pot market since recreational adult use became legal some five years ago.  Aurora Cannabis looks to be turning the corner, at least on the surface.""}]",{}
48,2023-12-10,239.2899932861328,2023-12-17,248.1300048828125,0.03694267142257468,U4,"[{""date"": ""20231210223800"", ""headline"": ""$1000 Invested In This Stock 20 Years Ago Would Be Worth $7,200 Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231210233200"", ""headline"": ""Biotech Is Coming Back, Can The Run Last?"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231211115900"", ""headline"": ""Biogen Inc. stock outperforms market on strong trading day"", ""summary"": ""Shares of Biogen Inc. advanced 2.85% to $246.11 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""20231211224929"", ""headline"": ""Diving Into Denali Therapeutics"", ""summary"": """"}, {""date"": ""20231211225600"", ""headline"": ""Tuesday Talk: CPI Data And FOMC Meeting Hold Back Market Breakout"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231212014800"", ""headline"": ""Biogen price target lowered by $9 at Morgan Stanley, here's why"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231212021200"", ""headline"": ""Analysts\u2019 Top Healthcare Picks: Biogen (BIIB), Penumbra (PEN)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231212032549"", ""headline"": ""Corvus Pharmaceuticals: Ahead Of The Clinical-Stage Curve"", ""summary"": ""Corvus is a clinical-stage company with potential investment opportunities and a focus on ITK inhibitor soquelitinib. Read why I'm bullish on CRVS stock.""}, {""date"": ""20231212044400"", ""headline"": ""The biopharma stocks to own in 2024, according to Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231212075400"", ""headline"": ""QQQ ETF Update, 12/12/2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231212115900"", ""headline"": ""Biogen Inc. stock rises Tuesday, outperforms market"", ""summary"": ""Shares of Biogen Inc. rallied 1.19% to $249.04 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""20231212150448"", ""headline"": ""30 Largest Pharmaceutical Companies in the World"", ""summary"": ""In this article, we will be taking a look at the 30 largest pharmaceutical companies in the world. To skip our detailed analysis, you can go directly to see the 10 Largest Pharmaceutical Companies in the World. The world\u2019s leading pharmaceutical companies became the center of attention for people all over the world as a [\u2026]""}, {""date"": ""20231212161904"", ""headline"": ""Biogen : \u201cLEQEMBI\u00ae Intravenous Infusion\u201d (Lecanemab) for the Treatment of Alzheimer\u2019s Disease to be Launched in Japan on December 20"", ""summary"": ""TOKYO and CAMBRIDGE, Mass., December 12, 2023 - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta monoclonal antibody LEQEMBI\u00ae...""}, {""date"": ""20231212200600"", ""headline"": ""Biogen (NASDAQ:BIIB) Ticks Up on New Alzheimer\u2019s Treatment in Japan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231212200700"", ""headline"": ""Biogen (NASDAQ:BIIB) Ticks Up on New Alzheimer\u2019s Drug in Japan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231212222700"", ""headline"": ""Biogen's Leqembi launches in Japan next week for Alzheimer's treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231213005000"", ""headline"": ""Biogen sees Leqembi Intravenous Infusion for AD launched in Japan on Dec 20"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231213040800"", ""headline"": ""Is Biogen Inc (BIIB) Set to Underperform? Analyzing the Factors Limiting Growth"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231213050200"", ""headline"": ""Industry Comparison: Evaluating Biogen Against Competitors In Biotechnology Industry"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231213060800"", ""headline"": ""Biogen, Eisai to launch new Alzheimer therapy in Japan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231213073900"", ""headline"": ""Biogen (NASDAQ:BIIB) Ticks Up With New Alzheimer\u2019s Treatment in Japan"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231213104030"", ""headline"": ""Big Pharma: Why the drug industry faces a 3-front battle with the FTC, Medicare, and the White House"", ""summary"": ""The Biden administration is increasingly focused on finding ways to lower drug prices, putting the drug industry in a three-way battle to defend its ecosystem.""}, {""date"": ""20231213115900"", ""headline"": ""Biogen Inc. stock rises Wednesday, outperforms market"", ""summary"": ""Shares of Biogen Inc. advanced 2.62% to $255.56 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""20231213211100"", ""headline"": ""Biogen (NASDAQ:BIIB) Rolls out Another New Treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214003500"", ""headline"": ""Biogen and Sage's Zurzuvae for postpartum depression now available in the U.S."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214012000"", ""headline"": ""Biogen price target lowered by $28 at Stifel, here's why"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214032900"", ""headline"": ""NeuroSense reports statistically significant efficacy in Phase 2b ALS Trial"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214050622"", ""headline"": ""These 3 stocks are Cowen\u2019s best ideas for 2024 including Amazon and Biogen"", ""summary"": ""It\u2019s only a few weeks to the New Year, so what better time to find out what stocks the major investment banks and research firms are recommending? TD Cowen, the New York-based multinational financial services firm, has been publishing the year-end stock calls from its analysts \u2013 and their choices make interesting reading. These are the \u2018best ideas\u2019 for 2024, from analysts with 5-star ratings from TipRanks; Cowen\u2019s team has the experience and success to back up their recommendations, and investor""}, {""date"": ""20231214063000"", ""headline"": ""ZURZUVAE\u2122 (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S."", ""summary"": ""ZURZUVAE, the first and only oral, once-daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for women with PPD Patient support program, ZURZUVAE For You, and financial assistance available to eligible women with PPD prescribed ZURZUVAE Patients will receive prescriptions directly at home via specialty pharmacy distribution model CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therap""}, {""date"": ""20231214074100"", ""headline"": ""Biogen, Sage launch depression therapy in the U.S."", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231214115800"", ""headline"": ""Biogen Inc. stock underperforms Thursday when compared to competitors despite daily gains"", ""summary"": ""Shares of Biogen Inc. inched 0.38% higher to $256.54 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""20231214165942"", ""headline"": ""Is Eli Lilly Stock A Buy Or A Sell As Shares Seesaw On Recent Obesity Drug Findings?"", ""summary"": ""Is Eli Lilly stock a buy or a sell as shares seesaw in the wake of new Zepbound test results? LLY stock a buy or a sell right now?""}, {""date"": ""20231214194326"", ""headline"": ""Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential"", ""summary"": ""Mental health has been one of the hot topics in the medical industry over the past few years. Widespread awareness was brought to the public eye during the COVID-19 pandemic as people in prolonged lockdowns struggled with isolation as well as the threat of a deadly virus. The World Health Organization has issued statements to emphasize how mental health issues are serious, life-altering conditions not to be downplayed. As a response, various US states raised legislation to legalize psilocybin se""}, {""date"": ""20231215014800"", ""headline"": ""Unveiling Biogen Inc (BIIB)'s Market Value: A Comprehensive Guide to Its Fair Valuation"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231215030800"", ""headline"": ""Biogen reports CHMP issues positive opinion for SKYCLARYS"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231215050100"", ""headline"": ""European regulators push Biogen, CRISPR drugs toward approval"", ""summary"": ""While a positive recommendation for the gene editing treatment Casgevy was expected, a clearance for Biogen\u2019s Skyclarys, acquired through a recent acquisition, has been no sure bet.""}, {""date"": ""20231215063000"", ""headline"": ""EU regulators issue positive opinion for Biogen Friedreich's Ataxia drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231215090500"", ""headline"": ""CHMP Issues Positive Opinion for Biogen\u2019s SKYCLARYS\u00ae (omaveloxolone), the First Therapy to Treat Friedreich\u2019s Ataxia, a Rare Neurodegenerative Disease"", ""summary"": ""Friedreich\u2019s ataxia is a genetic, debilitating and life-shortening neuromuscular disease1Milestone highlights Biogen\u2019s growing portfolio in rare diseases and focus on addressing unmet needs of patients living with neuromuscular diseases CAMBRIDGE, Mass., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended marketing authorization for SKYCLARYS\u00ae (omaveloxolone) for the tr""}, {""date"": ""20231215115800"", ""headline"": ""Biogen Inc. stock falls Friday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slid 3.28% to $248.13 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}]",{}
49,2023-12-17,248.1300048828125,2023-12-24,257.9700012207031,0.03965661606518678,U4,"[{""date"": ""20231217232600"", ""headline"": ""Biogen\u2019s Buy Rating Affirmed: Skyclarys Approval Forecasts Growth and Turnaround by 2024"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231218095700"", ""headline"": ""Biogen's (BIIB) Rare Disease Drug Skyclarys Gets CHMP Nod in EU"", ""summary"": ""Biogen (BIIB) gets positive CHMP opinion recommending marketing authorization to Skyclarys in the EU for the treatment of Friedreich's ataxia in patients aged 16 years and older.""}, {""date"": ""20231218115800"", ""headline"": ""Biogen Inc. stock rises Monday, outperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.89% higher to $250.33 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...""}, {""date"": ""20231219013700"", ""headline"": ""Biogen: EC revokes centralized marketing authorizations for TECFIDERA generics"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231219020500"", ""headline"": ""Europe revokes approvals for generics of Biogen's multiple sclerosis drug Tecfidera"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231219024115"", ""headline"": ""Europe revokes marketing authorization for generic versions of Biogen's MS drug"", ""summary"": ""Biogen Inc said on Tuesdaythe European Commission has revoked the centralized marketingauthorization for generic versions of its drug Tecfidera totreat multiple sclerosis.(Reporting by Khushi...""}, {""date"": ""20231219024200"", ""headline"": ""Biogen: European Commission Revokes Authorization For Generic Versions of Tecfidera Drug"", ""summary"": ""By Will Feuer Biogen said the European Commission has revoked the centralized marketing authorizations for generic versions of Biogen's Tecfidera drug, a...""}, {""date"": ""20231219024900"", ""headline"": ""Biogen \u2018welcomes\u2019 EC decision to revoke CMAs for generic versions of Tecfidera"", ""summary"": ""Biogen Inc. said Tuesday that the European Commission has revoked the centralized marketing authorizations for generic versions of the biotechnology...""}, {""date"": ""20231219043200"", ""headline"": ""IN BRIEF: Biogen Tecfidera receives marketing protection in EU"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231219070200"", ""headline"": ""Biogen holds onto Tecfidera market in Europe for a little longer"", ""summary"": ""A decision by European regulators to revoke approvals for five generic versions of Biogen's multiple sclerosis medicine helps cement the drug's monopoly there through early 2025.""}, {""date"": ""20231219073000"", ""headline"": ""Centralized Marketing Authorizations of Generic Versions of TECFIDERA\u00ae are Revoked by the European Commission"", ""summary"": ""CAMBRIDGE, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission has revoked the centralized marketing authorizations for generic versions of Biogen\u2019s product TECFIDERA\u00ae (dimethyl fumarate) held by Accord, Mylan, Neuraxpharm, Polpharma and Teva. In reaching this decision, the European Commission affirmed that Biogen is entitled to full data protection and marketing protection for TECFIDERA. Biogen welcomes the actions of the European Com""}, {""date"": ""20231219104500"", ""headline"": ""Ionis (IONS) Out Licenses Europe Rights for HAE Drug to Otsuka"", ""summary"": ""Per the agreement, Ionis (IONS) will be responsible for the clinical development of the HAE drug. Otsuka will be responsible for all regulatory filings and commercialization activities in Europe.""}, {""date"": ""20231219111104"", ""headline"": ""Biogen : to Participate in the 42nd Annual J.P. Morgan Healthcare Conference"", ""summary"": ""Cambridge, MA, Biogen, Inc. announced today that Christopher A. Viehbacher, President and Chief Executive Officer, will participate in a fireside chat during the 42nd Annual J.P....""}, {""date"": ""20231219114105"", ""headline"": ""13 Most Promising Healthcare Stocks According to Analysts"", ""summary"": ""In this article, we discuss the 13 most promising healthcare stocks according to analysts. To skip the detailed overview of the healthcare sector, go directly to the 5 Most Promising Healthcare Stocks According to Analysts. The healthcare industry landscape is changing. While the COVID-19 pandemic was one of the most significant events that led to [\u2026]""}, {""date"": ""20231219115900"", ""headline"": ""Biogen Inc. stock rises Tuesday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.54% higher to $251.69 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P...""}, {""date"": ""20231220010100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON), Biogen (BIIB) and Ascendis Pharma (ASND)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231220022400"", ""headline"": ""Biogen initiated with bullish view at Cantor Fitzgerald, here's why"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231220040200"", ""headline"": ""Salesforce downgraded, Starbucks initiated: Wall Street's top analyst calls"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231220044500"", ""headline"": ""JPMorgan pharmaceuticals analysts hold analyst/industry conference call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231220074200"", ""headline"": ""QQQ ETF Update, 12/20/2023"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231220115800"", ""headline"": ""Biogen Inc. stock outperforms competitors despite losses on the day"", ""summary"": ""Shares of Biogen Inc. shed 1.40% to $248.16 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231221115900"", ""headline"": ""Biogen Inc. stock rises Thursday, outperforms market"", ""summary"": ""Shares of Biogen Inc. advanced 2.30% to $253.86 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""20231222093400"", ""headline"": ""Ionis (IONS), AstraZeneca's Eplontersen Receives FDA Nod"", ""summary"": ""FDA approves Ionis (IONS) and partner AstraZeneca's (AZN) Wainua for treating ATTRv-PN. Ionis stock rises on this important milestone.""}, {""date"": ""20231222115800"", ""headline"": ""Biogen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Biogen Inc. rose 1.62% to $257.97 Friday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index...""}]",{}
50,2023-12-24,257.9700012207031,2023-12-31,258.7699890136719,0.0031010884567324037,U1,"[{""date"": ""20231225200500"", ""headline"": ""If You Invested $100 In This Stock 20 Years Ago, You Would Have $800 Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231225201410"", ""headline"": ""Top 3 Healthcare Stock Picks for the New Year"", ""summary"": ""After lagging most sectors in 2023, healthcare stocks could deliver substantial returns in 2024. The market has been overly pessimistic about the sector due to short-term challenges. However, some healthcare stock picks have deep pipelines and trade at bargain valuations. In 2023, only GLP-1 makers Eli Lilly (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) saw substantial gains. Other pharmaceuticals declined due to patent cliffs and Medicare price negotiations. Similarly, medical device companies, es""}, {""date"": ""20231225202700"", ""headline"": ""See How Biogen Ranks Among Analysts' Top Picks With Strong Buyback Activity"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231226115800"", ""headline"": ""Biogen Inc. stock rises Tuesday, outperforms market"", ""summary"": ""Shares of Biogen Inc. rose 1.06% to $260.70 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231227040300"", ""headline"": ""Is Biogen Inc (BIIB) Set to Underperform? Analyzing the Factors Limiting Growth"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231227050200"", ""headline"": ""Understanding Biogen's Position In Biotechnology Industry Compared To Competitors"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231227060600"", ""headline"": ""24 global single name stock longs for 2024 - Morgan Stanley"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231227063400"", ""headline"": ""FDA\u2019s new drug approvals for 2023 rise 51% from last year"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231227115700"", ""headline"": ""Biogen Inc. stock outperforms competitors on strong trading day"", ""summary"": ""Shares of Biogen Inc. inched 0.47% higher to $261.93 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P...""}, {""date"": ""20231227173153"", ""headline"": ""Healthcare Heroes: 3 Stocks Innovating in Medicine and Wellness"", ""summary"": ""The United States leads globally in the healthcare sector, with its innovative healthcare stocks drawing attention from an impressive $4.3 trillion in spending. As the American Medical Association highlights, this expenditure equals nearly $13,000 per person, contributing 18.3% to the nation\u2019s GDP. This level of investment showcases its commitment to health and underscores its role as a frontrunner in medical advancements and innovations. Amidst this landscape, the U.S. emerges as a powerhouse i""}, {""date"": ""20231227195035"", ""headline"": ""12 Best Stocks to Buy for an 18 Year Old"", ""summary"": ""In this article, we discuss the 12 best stocks to buy for an 18 year old. If you want to skip our detailed analysis of these stocks, go directly to 5 Best Stocks to Buy for an 18 Year Old. It is an exciting time to be involved in trading stocks. The Federal Reserve in [\u2026]""}, {""date"": ""20231227211000"", ""headline"": ""Pharma and biotech deal values spike 35% in 2023: report"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231228115700"", ""headline"": ""Biogen Inc. stock falls Thursday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slumped 0.52% to $260.58 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500...""}, {""date"": ""20231228175020"", ""headline"": ""Biogen Inc. (BIIB) Stock Declines While Market Improves: Some Information for Investors"", ""summary"": ""The latest trading day saw Biogen Inc. (BIIB) settling at $260.58, representing a -0.52% change from its previous close.""}, {""date"": ""20231229010800"", ""headline"": ""Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231229115700"", ""headline"": ""Biogen Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. shed 0.69% to $258.77 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20231230060100"", ""headline"": ""Government-Granted Patent Monopolies Are Not The Free Market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20231230230900"", ""headline"": ""Biogen (BIIB) Receives a Hold from BTIG"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
51,2023-12-31,258.7699890136719,2024-01-07,257.8800048828125,-0.003439286504017147,D1,"[{""date"": ""20231230230900"", ""headline"": ""Biogen (BIIB) Receives a Hold from BTIG"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240102031400"", ""headline"": ""BTIG Sticks to Its Hold Rating for Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240102040100"", ""headline"": ""Biogen added to Top 30 Global Ideas for Q1 at RBC Capital"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240102115800"", ""headline"": ""Biogen Inc. stock rises Tuesday, outperforms market"", ""summary"": ""Shares of Biogen Inc. rallied 3.45% to $267.71 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""20240102135742"", ""headline"": ""3\u00a0Biotech Stocks at the Forefront of the Quest for Eternal Youth"", ""summary"": ""Americans live longer than ever, and a handful of biotech stocks stand at the forefront of longevity\u2019s future. Many misconceive anti-aging stocks as peddling some magic pill that inexplicably makes you live longer \u2014 that perception is pure fiction. While many treatments help extend your life if leveraged properly and consistently \u2014 namely, diet and exercise \u2014 the most compelling longevity stocks address specific age-associated ailments instead. As we age, rapid neurological and physical degenera""}, {""date"": ""20240103020000"", ""headline"": ""Biotech Bonanza: 2024 Biotech Outlook As The Fed Turns Dovish"", ""summary"": ""Biotechnology is well-positioned to outperform the broader indexes in 2024, provided the 10-year yield remains below 4%, with potential gains of 20%-25% and likely higher. Read more here.""}, {""date"": ""20240103030000"", ""headline"": ""Alcyone Therapeutics Announces First Patient Implanted in PIERRE IDE Clinical Study of the ThecaFlex DRx\u2122 System for Administration of SPINRAZA\u00ae (nusinersen)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240103115700"", ""headline"": ""Biogen Inc. stock underperforms Wednesday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. slipped 1.60% to $263.43 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...""}, {""date"": ""20240103175020"", ""headline"": ""Biogen Inc. (BIIB) Sees a More Significant Dip Than Broader Market: Some Facts to Know"", ""summary"": ""In the latest trading session, Biogen Inc. (BIIB) closed at $263.43, marking a -1.6% move from the previous day.""}, {""date"": ""20240103210400"", ""headline"": ""Biogen, Neurocrine, and more are Bairds top picks for biotech in 2024"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240104051000"", ""headline"": ""Gingko Bioworks completes gene therapy program with Biogen"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240104115700"", ""headline"": ""Biogen Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. slipped 1.20% to $260.28 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""20240104143642"", ""headline"": ""Is Eli Lilly Stock A Buy As It Battles In Obesity Drugs With A New Direct-To-Consumer Website?"", ""summary"": ""Is Eli Lilly stock a buy after the company launched a website to help patients access its diabetes and weight-loss drugs? Is LLY stock a buy?""}, {""date"": ""20240105031200"", ""headline"": ""Florida to become first state to win FDA nod for mass drug imports from Canada: NYT"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240105042300"", ""headline"": ""Florida wins FDA nod for mass drug imports from Canada (update)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240105090012"", ""headline"": ""Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024"", ""summary"": ""Biotech stocks are heating up as multibillion-dollar deals pile up and new modalities like CRISPR gene-editing hit prime time.""}, {""date"": ""20240105115800"", ""headline"": ""Biogen Inc. stock underperforms Friday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. dropped 0.92% to $257.88 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""20240106233000"", ""headline"": ""BTIG Reaffirms Their Hold Rating on Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}]",{}
52,2024-01-07,257.8800048828125,2024-01-14,248.1199951171875,-0.03784709780062323,D4,"[{""date"": ""20240106233000"", ""headline"": ""BTIG Reaffirms Their Hold Rating on Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240108114808"", ""headline"": ""Biogen Inc. (BIIB) J.P. Morgan 42nd Annual Healthcare Conference (Transcript)"", ""summary"": ""Biogen Inc. (NASDAQ:NASDAQ:BIIB) J.P.""}, {""date"": ""20240108115800"", ""headline"": ""Biogen Inc. stock rises Monday, still underperforms market"", ""summary"": ""Shares of Biogen Inc. inched 0.04% higher to $257.98 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...""}, {""date"": ""20240108130700"", ""headline"": ""Biogen CEO sees progress in launch of Alzheimer\u2019s drug Leqembi"", ""summary"": ""At the J.P. Morgan Healthcare Conference Monday, company head Chris Viehbacher said insurance reimbursement is now \u2018not an issue\u2019 for treatment.""}, {""date"": ""20240108230600"", ""headline"": ""Maintaining Hold on Biogen: Balancing New Product Potential Against Market and Pipeline Uncertainties"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240108231600"", ""headline"": ""Optimistic Buy Rating for Biogen on Robust Drug Launches and Strategic Growth Initiatives"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240108233400"", ""headline"": ""Biogen, Eisai win China approval for Alzheimer's drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240109000500"", ""headline"": ""Biogen, Eisai report Leqembi approved in China for Alzheimer's treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240109032500"", ""headline"": ""Biogen's Leqembi approved in China for Alzheimer's treatment"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240109051833"", ""headline"": ""China approves Alzheimer's treatment Leqembi by Eisai and Biogen"", ""summary"": ""Eisai and Biogen said on Tuesday that their Alzheimer's treatment Leqembi had won approval in China, the third country after the United States and Japan.  The two companies are preparing to launch the drug in the second quarter of Eisai's 2024/25 business year starting in April.  It is the first treatment shown to slow progression of the disease for people in the earlier stages of Alzheimer's.""}, {""date"": ""20240109115800"", ""headline"": ""Biogen Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Biogen Inc. sank 0.83% to $255.84 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20240109172204"", ""headline"": ""Eisai : \""LEQEMBI\"" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in China"", ""summary"": ""- Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta monoclonal antibody LEQEMBI has been approved in China as a treatment of mild cognitive...""}, {""date"": ""20240109175020"", ""headline"": ""Biogen Inc. (BIIB) Registers a Bigger Fall Than the Market: Important Facts to Note"", ""summary"": ""In the latest trading session, Biogen Inc. (BIIB) closed at $255.84, marking a -0.83% move from the previous day.""}, {""date"": ""20240109203500"", ""headline"": ""Analyst Assesses Cell-Programming Focused Ginkgo Bioworks' Positioning Amid Revenue Surge, Program Adjustments"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240110023100"", ""headline"": ""Analysts Offer Insights on Healthcare Companies: Icon (ICLR) and Biogen (BIIB)"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240110050500"", ""headline"": ""Comparing Biogen With Industry Competitors In Biotechnology Industry"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240110115800"", ""headline"": ""Biogen Inc. stock falls Wednesday, underperforms market"", ""summary"": ""Shares of Biogen Inc. shed 0.63% to $254.23 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500...""}, {""date"": ""20240110213500"", ""headline"": ""$1000 Invested In This Stock 20 Years Ago Would Be Worth $6,100 Today"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240110234800"", ""headline"": ""Eisai, Biogen file for EU marketing authorization of Alzheimer's drug"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240111010800"", ""headline"": ""Eisai says SAG to discuss MAA for lecanemab by European Medicines Agency"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240111021300"", ""headline"": ""Acorda regains rights to Fampyra after Biogen terminates license agreement"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240111022000"", ""headline"": ""Acorda to regain global commercialization rights to FAMPYRA by Jan 2025"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240111032300"", ""headline"": ""Acorda Therapeutics: Biogen Ending Fampyra Collaboration"", ""summary"": ""By Colin Kellaher Acorda Therapeutics will regain global commercialization rights to the multiple-sclerosis drug Fampyra after partner Biogen opted to end a...""}, {""date"": ""20240111042900"", ""headline"": ""Video: Nasdaq 100 Movers: BIIB, NFLX"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240111070500"", ""headline"": ""EU regulators to consult advisers in review of Eisai Alzheimer\u2019s drug"", ""summary"": ""As a result of the planned consultation, Eisai now expects an approval decision on Leqembi in Europe by the end of June, rather than March.""}, {""date"": ""20240111115800"", ""headline"": ""Biogen Inc. stock underperforms Thursday when compared to competitors"", ""summary"": ""Shares of Biogen Inc. slid 2.76% to $247.21 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...""}, {""date"": ""20240111214000"", ""headline"": ""IN BRIEF: EMA to hand verdict on Biogen, Eisai's Leqembi by June end"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240112063200"", ""headline"": ""Q2 2023 Biogen Inc Earnings Call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240112063200"", ""headline"": ""Q1 2023 Biogen Inc Earnings Call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240112063200"", ""headline"": ""Q4 2022 Biogen Inc Earnings Call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240112063200"", ""headline"": ""Q3 2022 Biogen Inc Earnings Call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240112063200"", ""headline"": ""Q2 2022 Biogen Inc Earnings Call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240112063200"", ""headline"": ""Q1 2022 Biogen Inc Earnings Call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240112063200"", ""headline"": ""Q4 2021 Biogen Inc Earnings Call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240112063200"", ""headline"": ""Q3 2021 Biogen Inc Earnings Call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240112063200"", ""headline"": ""Q2 2021 Biogen Inc Earnings Call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240112063200"", ""headline"": ""Q1 2021 Biogen Inc Earnings Call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240112063200"", ""headline"": ""Q4 2020 Biogen Inc Earnings Call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240112063200"", ""headline"": ""Q3 2020 Biogen Inc Earnings Call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240112063200"", ""headline"": ""Q2 2020 Biogen Inc Earnings Call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240112063200"", ""headline"": ""Q1 2020 Biogen Inc Earnings Call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240112063200"", ""headline"": ""Q4 2019 Sangamo Therapeutics Inc Earnings and Collaboration Agreement with Biogen Inc Call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240112063200"", ""headline"": ""Q4 2019 Biogen Inc Earnings Call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240112063200"", ""headline"": ""Q3 2019 Biogen Inc Earnings and Update on Aducanumab Call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240112063200"", ""headline"": ""Q2 2019 Biogen Inc Earnings Call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240112063200"", ""headline"": ""Q1 2019 Biogen Inc Earnings Call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240112063200"", ""headline"": ""Q4 2018 Biogen Inc Earnings Call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240112063200"", ""headline"": ""Q3 2023 Biogen Inc Earnings Call"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240112072000"", ""headline"": ""Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240112115900"", ""headline"": ""Biogen Inc. stock underperforms Friday when compared to competitors despite daily gains"", ""summary"": ""Shares of Biogen Inc. inched 0.37% higher to $248.12 Friday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...""}, {""date"": ""20240113140525"", ""headline"": ""BIIB, ZTS, EXAS: Which \u201cStrong Buy\u201d Healthcare Stock is Best?"", ""summary"": ""In 2023, the only thing nearly as hot as generative AI technologies like ChatGPT were GLP-1 injections (weight-loss drugs like Ozempic). GLP-1 may not be the most significant healthcare breakthrough of all time, but it certainly represents one of its most profitable in a while. Further, I believe GLP-1 drugs shined a bright light on the rest of the healthcare industry and its ability to innovate to the degree of an AI firm. Highly-rated healthcare stocks \u2014 like BIIB, ZTS, and EXAS \u2014 look nothing""}]",{}
53,2024-01-14,248.1199951171875,2024-01-21,245.27000427246094,-0.011486340886716961,D2,"[{""date"": ""20240115044600"", ""headline"": ""QQQ ETF Update, 1/16/2024"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240116115900"", ""headline"": ""Biogen Inc. stock falls Tuesday, underperforms market"", ""summary"": ""Shares of Biogen Inc. slumped 0.78% to $246.19 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index...""}, {""date"": ""20240116230000"", ""headline"": ""Biogen Inc. stock outperforms market despite losses on the day"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240117123222"", ""headline"": ""Alector: Q4 2024 Data Release Could Provide Major Shift For Valuation"", ""summary"": ""Alector, Inc. expects results from its phase 2 INVOKE-2 study, using AL002 for Alzheimer's disease treatment. Find out why ALEC stock is a Buy.""}, {""date"": ""20240117175019"", ""headline"": ""Biogen Inc. (BIIB) Stock Moves -0.37%: What You Should Know"", ""summary"": ""Biogen Inc. (BIIB) closed the most recent trading day at $245.27, moving -0.37% from the previous trading session.""}, {""date"": ""20240117230000"", ""headline"": ""Biogen Inc. stock rises Thursday, still underperforms market"", ""summary"": ""Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.""}, {""date"": ""20240118055000"", ""headline"": ""These Could Be the Biggest Nasdaq-100 Winners in 2024, According to Wall Street"", ""summary"": ""Nice gains could be on the way for three stocks if analysts are right.""}, {""date"": ""20240118201007"", ""headline"": ""First Circuit Partially Revives Putative Class Action Against Pharmaceutical Company Alleging Misstatements About Clinical Trial Data"", ""summary"": ""On October 11, 2023, the United States Court of Appeals for the First Circuit affirmed in part and reversed in part the dismissal of a putative class action asserting claims under the Securities...""}, {""date"": ""20240118210500"", ""headline"": ""ClearBridge Aggressive Growth Strategy Q4 2023 Portfolio Manager Commentary"", ""summary"": ""The ClearBridge Aggressive Growth Strategy outperformed its benchmark in the fourth quarter of 2023. Click here to read the full fund letter.""}, {""date"": ""20240119074200"", ""headline"": ""ClearBridge Multi Cap Growth Strategy Q4 2023 Portfolio Manager Commentary"", ""summary"": ""Easing financial conditions sparked an equity rally and led to improving market breadth, with mid-cap stocks outperforming their counterparts. Read more here.""}]",{}
